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Problematic painkiller use is a large and increasing problem worldwide, 
leading to serious physical, psychological and social consequences. Existing 
research indicates that accessibility of painkillers and psychological factors 
could have a role in problematic painkiller use. To clarify, accessibility refers 
to ease of obtaining painkillers, whilst psychological factors refer to individual-
level processes and meanings that influence mental states (Upton, 2013). 
However, there have been few studies conducted, and these studies have 
focused mainly on either clinical samples or women with childbirth pain. 
Hence, the role among the general population is less clear. The aim of the 
present thesis was therefore to focus on the role of accessibility and 
psychological factors in problematic painkiller use among the general 
population.  
Methods 
Three studies were conducted: one study compared the general population of 
the UK (N = 295) and Egypt (N = 420) regarding the role of accessibility of 
painkillers and psychological factors, including attitudes and beliefs towards 
pain, painkillers, self-medication and alternative methods of pain relief; 
another study was a multi-national comparison of these variables among the 
general population of more countries including Germany (N = 217), USA (N = 
146), Australia (N = 93) and China (N = 76); another study focused on the role 
of psychological factors over time among the UK general population (N = 
529), specifically attitudes and beliefs towards painkillers, as well as pain 
catastrophising, pain acceptance, pain self-efficacy and alexithymia. In these 
studies, the role of accessibility and psychological factors was investigated 
using online surveys, with participants aged 18 years or over, who 
experienced pain in the last month, used over-the-counter (OTC) or 
prescription painkillers in the last month, and were residents of the countries 
concerned. An additional study was conducted to develop 14-item versions of 
 xviii 
the Survey of Pain Attitudes-Brief (SOPA-B-14) and the Pain Medication 
Attitudes Questionnaire (PMAQ-14), which also tested the validity of these 
scales. 
Results 
Accessibility of painkillers and psychological factors predicted problematic 
painkiller use. However, there were several differences between the countries 
regarding the particular role of these factors. In the longitudinal study of the 
UK general population, changes in psychological factors were found over 
time, but attitudes and beliefs about withdrawal from painkillers was the only 
psychological factor that predicted problematic painkiller use over time. In 
addition, testing the validity of the SOPA-B-14 and PMAQ-14 showed that 
these scales were valid.  
Conclusion 
The present research provided understanding regarding the role of 
accessibility and psychological factors in problematic painkiller use among the 
general population, and the role of psychological factors over time. Based on 
this understanding, interventions focusing on accessibility and psychological 
factors should be developed to reduce problematic painkiller use, but tailored 
to the particular factors that were predictors for each country. The present 
research also developed a valid SOPA-B-14 and PMAQ-14, therefore these 
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“It is easier to find men who will volunteer to die, than to find those who 
are willing to endure pain with patience”. 
-Julius Caesar (Jones & McCullough, 2012, p. 583) 
Painkiller use is a phenomenon that is receiving increased research attention 
for many reasons including the high prevalence of users and the serious 
consequences to physical, psychological and social functioning if painkillers 
are used in a problematic way1. In general, problematic painkiller use refers to 
misusing and abusing painkillers, which can eventually lead to painkiller 
dependence in the long-term. Some of the consequences associated with 
problematic painkiller use include falls among older persons, respiratory 
depression, decreased memory, decreased attention, co-ordination problems, 
withdrawal from family and friends, and even death (e.g. Leipzig, Cumming & 
Tinetti, 1999; Simoni-Wastila & Yang, 2006).  
The high prevalence of painkiller use can be seen from many different data 
about painkiller use. For example, painkillers were reported as one of the 
most significant sales categories of over-the-counter (OTC) medicines in 
2016, worth £614 million (Euromonitor International, 2016). In another 
example, over 67 million National Health Service (NHS) analgesic and anti-
                                                        
1 Although “analgesics” is the technical term for pain relief medication, recently 
there has been an increasing number of publications referring to analgesics 
as “painkillers” (e.g. Gitay, Zia & Zehra, 2013; Elander, Duarte, Maratos, 
Gilbert, 2014; Shapiro, 2015). The reasons for this might be because 
“painkillers” appears to be a more easily understandable and commonly used 
term, especially among the general population. If publications use the term 
painkillers, this means that they can be easily read, understood and 
appreciated by the general population. Moreover, the general population 
would find these publications easily in their search of literature, because they 
might be more likely to use the term “painkillers” to search. As a result, the 
general population can benefit more than when publications use technical 
language. Therefore, this thesis follows the same approach as recent 
publications by referring to pain relief medication as painkillers. This is 
especially important because of the relevance to the general population of this 
thesis and the increasing open access to scientific publications, including 
theses. 
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inflammatory prescription medications were dispensed in England in 2007 
(Donaldson, 2008; Chief Medical Officer, 2009). Moreover, the number of 
painkiller prescriptions issued has been increasing over time and is continuing 
to increase. In recent surveys, the number of prescriptions in the UK for opioid 
analgesics has increased significantly between 2000 and 2010 (e.g. Zin, Chen 
& Knaggs, 2012; Shapiro, 2015). For tramadol, the increase was ten times 
(e.g. Zin et al., 2012; Shapiro, 2015). In addition, there has been a 6% 
increase of prescriptions of opiates in England alone between 2010 and 2013 
(Health & Social Care Information Centre, 2014).  
The increasing prevalence of painkiller prescriptions is a serious problem that 
has been linked to an increase in deaths involving these strong painkillers in 
the UK. According to a recent report from the Office for National Statistics 
(ONS), deaths related to tramadol alone have “reached an all-time high” and 
the increase “may be partly explained by a 35% increase in tramadol 
prescriptions over the last five years” (ONS, 2013). Importantly, further reports 
have shown that the number of deaths from opioid painkillers has exceeded 
that caused by heroin and cocaine (e.g. Giraudon et al., 2013; Shapiro et al., 
2015). Therefore, problematic use of painkillers appears greater than 
problematic use of drugs such as heroin and cocaine. Also, problematic use 
of painkillers appears greater than problematic use of other medications. 
Specifically, a recent study conducted by Fingleton, Watson, Duncan and 
Matheson (2016) examined the prevalence of misuse, abuse and dependence 
of OTC medication in the UK general population. A high prevalence of 
misuse, abuse and dependence of OTC medication was found generally, but 
painkillers were the most commonly misused, abused and dependent type of 
OTC medication. Thus, the results from the previously mentioned reports and 
this study together show that problematic use of OTC and prescription 
painkillers is a serious problem that should be researched.  
Similar to the UK, high prevalence of painkiller use has also been reported in 
the USA, Canada, Australia and several other countries internationally (e.g. 
Goh et al., 2009; Stannard, 2012; NSDUH, 2013). However, prevalence rates 
are thought to be even higher in some developing countries like Egypt (e.g. 
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Mumtaz et al., 2011; Ghandour, Sayed & Martins, 2012). Also similar to the 
UK, increases in painkiller use over time and problems associated with these 
increases, such as deaths from painkillers, have also been reported 
internationally (e.g. ASAM, 2016). Hence, research should be focused on 
painkiller use internationally. 
1.1.1. Definition of terms 
As mentioned at the beginning of the introduction, problematic painkiller use 
refers to misusing, abusing and dependence on painkillers. In the literature, 
the term “misuse” generally refers to the incorrect use of painkillers for 
managing pain, by either taking more than the recommended dose of 
painkillers or using painkillers for a longer duration than recommended (e.g. 
Orriols, Gaillard, Lapeyre-Mestre & Roussin, 2009). In contrast to misuse, the 
term “abuse” generally refers to the non-medical use of painkillers, which 
involves using painkillers “even once, that was not prescribed for you, or that 
you took only for the experience or feeling it caused” (Orriols et al., 2009, p. 
861). Therefore, painkiller abuse involves using painkillers for reasons other 
than pain such as to “get high” and experience euphoria or to experience 
relaxation. Many organisations and societies accept these definitions of 
painkiller misuse and abuse as accurate (e.g. World Health Organisation, 
1993; ASAM, 2016).   
Definitions for substance dependence have been proposed by the Diagnostic 
and Statistical Manual of Mental Disorders (DSM; American Psychiatric 
Association, 2000) and the International Classification of Diseases (ICD; 
World Health Organisation, 2007). According to the definitions, at least two 
(DSM-IV; American Psychiatric Association, 2000) or one (ICD-10; 10th ed.; 
World Health Organisation, 2007) of the following criteria must be present. In 
terms of painkillers, these criteria are:  
• Using larger amounts of painkillers than recommended or using for a 
longer duration than recommended. 
• Loss of control over use. 
• Craving painkillers. 
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• Spending a lot of time obtaining and using painkillers. 
• Social problems resulting from using painkillers. 
• Persistent or recurrent physical or psychological problems.  
• Using painkillers in physically hazardous situations.  
These criteria can be applied to most races or ethnic groups, so the criteria 
have cultural sensitivity (DSM-IV; American Psychiatric Association, 2000). 
The presence of more criteria indicates more severe dependence (DSM-IV; 
American Psychiatric Association, 2000). Additional criteria for diagnosing 
dependence are tolerance and withdrawal symptoms but these are 
considered to be normal physiological reactions to long-term use of painkillers 
so are not sufficient alone to be evidence of dependence (e.g. Højsted & 
Sjøgren, 2007). Therefore, painkiller dependence can only be diagnosed 
when more criteria than tolerance and withdrawal are present.  
In the most recent DSM (DSM-5; 5th ed.; American Psychiatric Association, 
2013), dependence has been replaced with opioid use disorder and 
substance use disorder because there has been confusion about the 
definition of dependence. However, the same seven criteria of dependence 
are still included in the criteria for opioid use disorder and substance use 
disorder, therefore dependence is still an important part of opioid use disorder 
and substance use disorder. 
The Leeds Dependence Questionnaire (LDQ; Raistrick et al., 1994) is a 10-
item scale designed to measure dependence to substances such as alcohol 
and drugs, but has been adapted to measure painkiller dependence (e.g. 
Ferrari et al., 2006). The LDQ measures dependence using the following 
psychological criteria:  
• Pre-occupation 
• Salience 
• Compulsion to start 
• Planning 
• Maximising effect 
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• Narrowing of repertoire 
• Compulsion to continue 
• Primacy of effect 
• Constancy of state 
• Cognitive set 
The above criteria are similar to the DSM-5 and ICD-10 criteria for 
dependence. However, physiological symptoms such as tolerance and 
withdrawal in the DSM-5 and ICD-10 are not considered in the LDQ since 
dependence is “viewed as a purely psychological phenomenon” (Raistrick et 
al., 1994, p. 564). Much research has supported viewing dependence as a 
purely psychological phenomenon and supported using the LDQ to measure 
dependence. For example, as mentioned by Elander et al. (2017), the LDQ is 
an established measure of painkiller dependence that has good reliability and 
validity.  
In terms of pain, definitions have been proposed by the British Pain Society, 
which are accepted by most researchers as correct. Specifically, pain can be 
defined as acute or chronic, where acute pain refers to “short-term pain of 
less than twelve weeks duration” and chronic pain refers to “continuous, long 
term pain of more than twelve weeks or after the time that healing would have 
been thought to have occurred in pain after trauma or surgery” (British Pain 
Society, 2008). Chronic pain has more negative impact on daily life compared 
to acute pain, including depression, unemployment, activity limitation, poor 
overall health and obesity (e.g. Breivik et al., 2006; Toblin, Mack, Parveen & 
Paulozzi, 2011).  
1.1.2. Factors influencing painkiller use 
One reason for a high prevalence of painkiller use is the high prevalence of 
pain (e.g. Shapiro, 2015). In the UK, it is estimated that 1 in 5 Britons suffer 
from pain on an almost daily basis with a further 1 in 4 Britons experiencing 
pain “most days” or “some days” (British Pain Society, 2008). A general 
population survey of the UK reported that the prevalence of chronic pain is 
48% and is more likely to be found among females who are smokers, older in 
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age, with no qualifications, who are no longer married and living in council 
accommodation (Torrance, Smith, Bennett & Lee, 2006). Repeated surveys 
have found that the prevalence is rising and similar results have been found 
internationally (e.g. Donaldson, 2008; Chief Medical Officer, 2009). Therefore, 
the high prevalence of pain is an increasing problem internationally.   
Although pain is an important factor, it does not fully explain painkiller use 
because people that have similar pain can show differences in painkiller use. 
For example, some people with pain may use painkillers, but other people 
may avoid painkillers. Other than pain, the literature has shown that 
accessibility of painkillers, attitudes and beliefs, and other psychological 
factors could be important (e.g. Christiaens et al., 2010), but more research 
needs to be conducted to clarify the role in painkiller use. The present review 
aims to present literature on the role of accessibility and psychological factors 
in painkiller use.  
1.2. Review methods 
The aim of this literature review was to explore previous research regarding 
problematic painkiller use, focusing on the role of accessibility and 
psychological factors. There were also two research questions that guided 
this literature review. The first research question was “What is the role of 
accessibility in problematic painkiller use?” The second research question 
was “What is the role of psychological factors in problematic painkiller use?” 
The review was conducted by searching journal articles and books in the 
following sources: PsychINFO, PsychARTICLES, Web of Knowledge, Elsevier 
Science Direct, eBook Collection (EBSCOhost), E-journals, University of 
Derby library catalogue, British library catalogue and Google Scholar. These 
databases and library catalogues were searched up to the date of March 
2017. 
The search terms used included: attitudes; beliefs; access, availability; 
source; culture; pain; painkillers; analgesics; pain medication; pain 
management; pain relief; prescription; over-the-counter; complementary 
medicine; alternative medicine; holistic medicine; general population; 
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prevalence; misuse; abuse; dependence; pain catastrophising; pain 
acceptance; alexithymia; pain self-efficacy; and psychological factors.  
1.3. Multi-national comparisons 
The literature has demonstrated that factors such as stoicism and 
expressiveness have an influence on pain (e.g. Nayak, Shiflett, Eshun & 
Levine, 2000; Vlaar et al., 2007). According to Nayak et al. (2000), people 
from stoic cultures prefer to endure their pain independently and may avoid 
seeking treatment for their pain as a result. In contrast, expressive cultures 
prefer to vocalise their pain and seek treatment or support from others. For 
example, it has been claimed that stoic cultures such as the UK have a “stiff 
upper lip” to pain, so may use less painkillers than expressive cultures such 
as Egypt (e.g. Wolf, 1985; Ondeck, 2003). In other words, these differences 
between stoic and expressive cultures have been thought to be linked to 
differences in painkiller use; expressive cultures favor strong and fast acting 
painkillers that can relieve them of pain whereas stoic cultures favor personal 
strength in managing pain (e.g. Wolf, 1985; Ondeck, 2003).  
More multi-national comparisons are needed, however, because there are 
further differences that could influence painkiller use, specifically accessibility 
of painkillers. For example, some painkillers are more freely accessible and 
available in Egypt than the UK for reasons such as less restrictive legislation 
and the lack of law enforcement in Egypt regarding painkillers (e.g. Benjamin, 
Smith & Motawi, 1996; Sallam et al., 2009). As might be expected, the greater 
accessibility of painkillers has been associated with more painkiller use in 
Egypt (Sallam et al., 2009). Surveys in further developing countries such as 
Lebanon and Pakistan show high levels of painkiller use, which is often 
associated with availability of strong painkillers without prescription in these 
countries (e.g. Zafar et al., 2008; Mumtaz et al., 2011; Ghandour et al., 2012). 
For example, almost two-thirds of people in a survey of Lebanon reported that 
prescription painkillers would be easy to obtain without prescription 
(Ghandour et al., 2012). 
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The link between easier access of painkillers and higher painkiller use levels 
has also been shown in developed countries; a comparative study between 
Germany and the USA showed that painkiller use was higher in the USA and 
linked to easier access of painkillers (Hanoch et al., 2007). The easier access 
in the USA is because OTC painkillers are available to buy from outlets such 
as supermarkets, whereas OTC painkillers in Germany are only available 
from the pharmacy after consulting a pharmacist (e.g. Cohen et al., 2005; 
Hanoch et al., 2007). Due to the link between accessibility of painkillers and 
increased painkiller use, accessibility might also be linked with problematic 
use of painkillers. However, further research is required to clarify this link.  
1.4. Psychological factors 
Other than accessibility of painkillers, psychological factors can also play a 
role in painkiller use. Here, the role of attitudes and beliefs towards pain, 
painkillers, self-medication and alternative methods of pain relief will be 
reviewed, followed by the role of pain catastrophising, pain acceptance, pain 
self-efficacy and alexithymia. 
1.4.1. Attitudes and beliefs towards pain, painkillers, self-medication and 
alternative methods of pain relief  
Research has shown that attitudes and beliefs towards pain can have a role in 
painkiller use. Specifically, a study of childbirth pain showed that positive 
attitudes and beliefs towards childbirth pain were associated with less use of 
painkillers, but negative attitudes and beliefs towards childbirth pain were 
associated with more use of painkillers (Christiaens et al., 2010). Similarly, a 
review of the literature on childbirth pain showed that women were less likely 
to use painkillers if the pain was believed to be an important part of the 
childbirth (Callister et al., 2003). In addition to childbirth pain, there have also 
been findings showing that pharmacy students whom believed pain should 
“run its course” were significantly more reluctant to self-medicate with 
painkillers (James & French, 2008).  
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Like attitudes and beliefs towards pain, research has shown that attitudes and 
beliefs towards painkillers and self-medication can also have a role in 
painkiller use. Generally, more negative attitudes and beliefs have been 
associated with using less painkillers. These results have been found in 
chronic pain patients (e.g. McCracken et al., 2006; Rosser, McCracken, 
Velleman & Boichat, 2011) women with childbirth pain (e.g. Van den Bussche 
et al., 2007) and cardiac patients before undergoing surgery (e.g. Cogan et 
al., 2014).  
Some common attitudes and beliefs found in these studies were about 
becoming dependent to the painkillers easily, negative side effects, tolerance 
and needing to save painkillers incase pain worsens (e.g. McCracken et al., 
2006; Van den Bussche et al., 2007; Rosser et al., 2011; Cogan et al., 2014). 
However, these negative attitudes and beliefs towards painkillers have not 
always been associated with less painkiller use. For example, Monsivais and 
McNeill (2007) showed that high levels of negative attitudes and beliefs 
towards painkillers or “concerns” among chronic pain patients were not 
related to less painkiller use if patients perceived the benefits of the painkillers 
as greater than the risks.  
There has also been some research to show that attitudes and beliefs 
towards alternative pain management methods can have a role in painkiller 
use. Specifically, positive attitudes and beliefs towards alternative pain 
management methods have been associated with less painkiller use. For 
example, when complementary and alternative medicine (CAM) is regarded 
as natural and safe, it has been used instead of painkillers (Hyland et al., 
2003). In addition, Abe et al. (2008) found that neuromuscular patients with a 
belief that painkillers cause negative health side effects demonstrated lower 
painkiller use and preferred to use alternatives such as massage and change 
of posture instead of painkillers.   
1.4.2. Pain catastrophising 
Another psychological factor to consider is pain catastrophising, which has 
been defined as “an exaggerated negative mental set brought to bear during 
 11 
an actual or anticipated painful experience” (Sullivan et al., 2001, p. 53). 
Therefore, pain catastrophising is characterised by a fixed way of thinking 
about pain that is: out of proportion compared to the reality of the painful 
experience; negative in nature; and occurs when pain is experienced or when 
pain is expected to be experienced. This definition has been based on a factor 
analysis study conducted by Sullivan, Bishop and Pivik (1995), which showed 
there were three factors involved in pain catastrophising: (1) rumination, which 
refers to compulsively focusing attention on the pain and experiencing 
difficulty focusing attention away from the pain; (2) magnification, which refers 
to overestimating the consequences of the pain such as perceiving the pain to 
be life-threatening; and (3) helplessness, which refers to perceived inability to 
cope with the pain and perceived lack of control over symptoms (Sullivan et 
al., 1995). Later research supports these factors involved in pain 
catastrophising and the definition of Sullivan et al. (2001) (e.g. Martorella, 
Cote & Choiniere, 2008).  
There have been several studies investigating the role of pain catastrophising 
on outcomes related to pain (e.g. Sullivan et al., 2001; Quartana et al., 2009; 
Meeus et al., 2012). Among these studies, pain catastrophising has generally 
been found to have negative outcomes. One negative outcome has been 
higher pain intensity. For example, a review of the literature conducted by 
Sullivan et al. (2001) showed that pain catastrophising was a predictor of 
higher pain intensity in several studies. This has been reported among both 
clinical samples and non-clinical samples, including acute pain patients, 
chronic pain patients, people from the general population and people with 
pain from experimental procedures (Sullivan et al., 2001). A further negative 
outcome has been the development of chronic pain, since people with chronic 
pain have been found to demonstrate higher pain catastrophising than people 
without chronic pain (e.g. Linton, Buer, Vleayen & Hellsing, 2000; Osman et 
al., 2000). In addition to the development of chronic pain, other research has 
shown that pain catastrophising also predicts reduced physical functioning 
such as increased disability, and withdraw from daily activities and work (e.g. 
Keefe, Brown, Wallston & Caldwell, 1989).  
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Other negative outcomes reported from studies investigating the role of pain 
catastrophising have been negative emotions. For example, a review of the 
literature conducted by Keogh and Asmundson (2004) showed that pain 
catastrophising has been associated with negative outcomes such as 
depression, anxiety and fear in several studies. However, rather than 
outcomes of pain catastrophising, it has been argued that these negative 
emotions may be part of pain catastrophising (Hirsh, George, Riley & 
Robinson, 2007). Specifically, Hirsh et al. (2007) argued that measures of 
pain catastrophising overlap widely with measures of negative emotions, 
therefore negative emotions such as depression, anxiety and fear may be part 
of pain catastrophising rather than outcomes of pain catastrophising. 
Nevertheless, there have been some findings that pain catastrophising may 
be separate from negative emotions, since some pain patients with 
depression did not catastrophise about pain and some pain patients 
catastrophised about pain but did not have depression (e.g. Linton & Shaw, 
2011).  
More outcomes reported from studies investigating the role of pain 
catastrophising have been behaviours that people use to help cope with pain. 
In research investigating these behaviours, it has been found that pain 
catastrophising leads to a range of verbal and non-verbal behaviours among 
pain patients that help to cope with the pain such as facial expressions and 
communication (e.g. Thibault, Loisel, Durand, Catchlove & Sullivan, 2008). In 
addition to these behaviours, several studies have also reported that pain 
catastrophising leads to more healthcare use and more painkiller use among 
pain patients to help cope with pain (e.g. Jacobsen & Butler, 1995; Valdes et 
al., 2015). Conversely, there have been studies reporting pain catastrophising 
does not lead to more painkiller use but instead has no association to 
painkiller use among pain patients (e.g. Khan et al., 2011). Additionally, Van 
den Bussche et al. (2007) found pain catastrophising does not have an 
association with painkiller use among women during childbirth.  
In order to explain the role of pain catastrophising on outcomes related to 
pain, Vlaeyen and Linton (2000) proposed the fear-avoidance model (see 
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Figure 1). The model demonstrates that there are two ways people respond to 
pain: one way involves no fear, which leads to confrontation of the pain and 
recovery; and the other way involves pain catastrophising, leading to fear of 
pain, avoidance behaviours and negative outcomes, which are repeated as a 
cycle without recovery.   
 
 
Figure 1. The fear-avoidance model of Vlaeyen and Linton (2000).  
According to the fear-avoidance model, pain can be perceived as either 
adaptive or maladaptive. When pain is perceived as adaptive, the fear-
avoidance model suggests that pain catastrophising would be unlikely to 
occur. When pain is perceived as maladaptive, the fear-avoidance model 
suggests that pain catastrophising would be more likely to occur. The model 
highlights that there will be fear-avoidance behaviours as a result from pain 
catastrophising, which involve avoidance of specific tasks or movements due 
to fear of pain (Vlaeyen & Linton, 2000). As an example, chronic pain patients 
may avoid prescribed exercise programmes from fear that movement will 
cause pain. Another example is that chronic pain patients may use more 
Content removed for copyright reasons. 
Figure available from Vlaeyen, J.W., & Linton, S.J. (2000). Fear-avoidance 
and its consequences in chronic musculoskeletal pain: a state of the art. 
Pain, 85 (3), 317-332. 
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painkillers than prescribed to avoid experiencing pain. Therefore, the model 
explains the negative outcomes of pain catastrophising by fear-avoidance 
behaviours. Support for the model has been found by showing that fear of 
pain and avoidance behaviours can lead to problems such as fatigue, 
disability, emotional problems and dependence to painkillers (e.g. Borsbo, 
Gerdle & Peolsson, 2010).  
There have been criticisms of the fear-avoidance model that have led to the 
development of an alternative model; the fear-anxiety-avoidance model 
(Asmundson, Norton & Vlaeyen, 2004). To specify, the fear-avoidance model 
has been criticised for failing to differentiate between fear and anxiety. The 
difference between fear and anxiety has been clarified by Leeuw et al. (2007) 
by stating the following: 
“Fear is the emotional reaction to a specific, identifiable and immediate 
threat, such as a dangerous animal or an injury. Anxiety, in contrast to 
fear, is a future-oriented affective state and the source of threat is more 
elusive without a clear focus. Even though the components of anxiety 
are similar to those of fear, they are less intense. Furthermore, 
whereas fear motivates the individual to engage in defensive 
behaviours, anxiety is associated with preventative behaviours, 
including avoidance” (p. 77-78). 
The fear-anxiety-avoidance model has been proposed as an extension of the 
fear-avoidance model by separating anxiety and fear as two separate 




Figure 2. The fear-anxiety-avoidance model of Asmundson et al. (2004).  
As shown in Figure 2, the fear-anxiety-avoidance model is similar to the fear-
avoidance model but includes fear and anxiety as separate. Although this 
model accounts for the criticisms of the fear-avoidance model, both models 
have been developed for low back pain patients. Therefore, a problem with 
both of these models may be lack of relevance to further types of pain (e.g. 
Leeuw et al., 2007). However, there has recently been more support for the 
relevance of the models to other groups (e.g. Leeuw et al., 2007). 
1.4.3. Pain acceptance 
An additional psychological factor to consider is pain acceptance, which refers 
to a willingness to experience pain (e.g. McCracken & Eccleston, 2005; 
Christiaens et al., 2010; McCracken, 2010). For this reason, researchers also 
refer to pain acceptance as pain willingness (e.g. Hayes & Smith, 2005). 
Research has shown that pain acceptance involves the following three 
components: firstly, pain acceptance involves a choice because individuals 
choose to experience pain rather than choose to avoid or reduce the pain 
(e.g. Hayes et al., 2006); secondly, pain acceptance involves the ability to 
Content removed for copyright reasons. 
Figure available Leeuw, M., Houben, R.M., Severeijns, R., Picavet, H.S.J., 
Schouten, E.G., & Vlaeyen, J.W. (2007). Pain-related fear in low back pain: 
a prospective study in the general population. European Journal of Pain, 
11 (3), 256-266. 
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decrease the influence of pain on daily functioning by continuing with 
everyday activities while experiencing pain (e.g. Crombez et al., 2012; Cho, 
McCracken, Heiby, Moon & Lee, 2013); and thirdly, pain acceptance differs 
from pain tolerance because pain acceptance involves willingness to 
experience pain, but pain tolerance involves willingness to experience pain 
only to a limit (e.g. Dahl & Lundgren, 2006; Luoma, Hayes & Walser, 2007). 
There has been growing research investigating the role of pain acceptance on 
outcomes related to pain (e.g. McCracken & Vowles, 2008; Huggins et al., 
2012). Much of the research has involved using acceptance and commitment 
therapy (ACT) interventions to increase pain acceptance, followed by testing 
the role of increased pain acceptance on outcomes related to pain (e.g. 
Sephton et al., 2007; Vowles et al., 2007). In ACT interventions, pain 
acceptance is increased by increasing psychological flexibility and decreasing 
psychological inflexibility. According to McCracken and Gutiérrez-Martińez 
(2011), psychological flexibility is the “ability to act effectively in accordance 
with personal values and goals in the presence of potentially interfering 
thoughts and feelings” (p. 267). In relation to pain, psychological flexibility 
therefore involves the ability to act effectively in accordance with personal 
values and goals in the presence of pain (e.g. Hayes et al., 2006). In contrast, 
psychological inflexibility involves the inability to act effectively in accordance 
with such values and goals in the presence of pain (e.g. Kashdan & 
Rottenberg, 2010).  
Increases in pain acceptance following ACT interventions have been 
associated with improved outcomes related to pain. For example, studies of 
patients with whiplash-associated disorders have demonstrated significant 
improvements in physical functioning, psychological functioning and 
satisfaction with life following ACT interventions (e.g. Wicksell, Ahlqvist, Bring, 
Melin & Olsson, 2008; Wicksell et al., 2010). Studies involving patients with 
other types of pain conditions have reported similar results and have also 
reported improvement in pain intensity following ACT interventions (e.g. Dahl, 
Wilson & Nilsson, 2004; McCracken et al., 2005; Sephton et al., 2007; Vowles 
et al., 2007; Wicksell, Melin, Lekander & Olsson, 2009).  
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Besides studies using ACT interventions, there have also been cross-
sectional studies to assess the role of pain acceptance on outcomes related 
to pain (e.g. Huggins et al., 2012). Similarly to the ACT intervention studies, 
cross-sectional studies have reported that pain acceptance has been 
associated with better physical functioning, psychological functioning and less 
pain intensity (e.g. Huggins et al., 2012). In addition, longitudinal studies have 
shown that pain acceptance has been associated with improvements in these 
outcomes over time (e.g. McCracken & Eccleston, 2005; McCracken, 
Gauntlett-Gilbert & Vowles, 2007; McCracken & Vowles, 2008; Wicksell, 
Olsson & Melin, 2009).  
The definition of pain acceptance as a willingness to experience pain 
indicates pain acceptance may be associated with less painkiller use. Further, 
the improved outcomes that have been associated with pain acceptance also 
indicate that pain acceptance may be associated with less painkiller use. 
Indeed, a study conducted by McCracken and colleagues (2004) showed that 
pain acceptance was associated with less use of painkillers (McCracken, 
Carson, Eccleston & Keefe, 2004). Similarly, there have also been a small 
number of studies showing pain acceptance has been associated with 
significantly less medical treatments and healthcare visits (e.g. Dahl et al., 
2004; McCracken et al., 2004). In a review by Callister et al. (2003), cross-
cultural differences in pain acceptance were found, which was related to 
painkiller use among women with childbirth pain. To be more specific, pain 
acceptance was higher among women in cultures that are active in their 
religious faith, and these women relied more on a higher power rather than 
painkillers to give them strength. More recently, Christiaens et al. (2010) also 
found that acceptance of childbirth pain led to less painkiller use. In addition, 
the role of pain acceptance in problematic painkiller use was investigated in a 
recent study by Elander, Duarte, Maratos and Gilbert (2014). This study 
showed that lower pain acceptance predicted higher painkiller dependence in 




1.4.4. Pain self-efficacy 
Another psychological factor that should be considered is self-efficacy, which 
has been defined as the belief of a person that he or she is capable of 
performing a specific behavior or complete a specific task (e.g. Bandura, 
1977; Ashford & LeCroy, 2010). In order to provide a better understanding of 
self-efficacy, researchers have separated self-efficacy from a number of 
constructs, including ability, intention and other self-concepts (e.g. de Vries, 
Dijkstra & Kuhlman, 1988; Schunk & Usher, 2011). 
Firstly, self-efficacy differs from ability because self-efficacy refers to beliefs in 
ability to complete a behaviour rather than refers to the level of ability of a 
person to complete a behavior. For example, a person may have the ability to 
complete a behaviour but may not believe themself to have the ability, or a 
person may not have the ability to complete a behaviour but may believe 
themself to have the ability. Therefore, the level of ability of a person may not 
be consistent with a person’s belief in his or her own ability. Indeed, there 
have been several studies showing differences between the level of ability of 
a person and a person’s belief in his or her ability (e.g. Schwarzer, 2014).  
Secondly, self-efficacy differs from intention because self-efficacy refers to 
beliefs in ability to complete a behaviour whereas intention refers to aiming to 
complete a behaviour. In other words, self-efficacy can be described as 
whether a person believes he or she “can” complete a behaviour whereas 
intention refers to whether a person “will” complete a behaviour (e.g. Bandura, 
1977). For example, a person may have the intention to complete a behaviour 
but may not believe themself to have the ability, or a person may not have the 
intention to complete a behaviour but may believe themself to have the ability. 
Therefore, the intention of a person may not be consistent with a person’s 
belief in his or her own ability. Similar to the difference between self-efficacy 
and ability, the difference between self-efficacy and intention has been 
supported by several studies (e.g. de Vries et al., 1988). 
Thirdly, self-efficacy differs from other self-concepts such as self-esteem 
because self-efficacy is domain specific whereas the other self-concepts are 
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domain general. Therefore, self-efficacy can differ for different domains 
whereas other self-concepts remain consistent for different domains. A 
number of studies have supported the difference of self-efficacy to other self-
concepts (e.g. Schunk & Usher, 2011).  
Among the studies of pain self-efficacy, there have been many focusing on 
the role of pain self-efficacy on physical functioning in arthritis patients (e.g. 
Gaines et al., 2002; Maly et al., 2005). These studies have shown that higher 
pain self-efficacy in arthritis patients has been related to less disability and 
improved performance of physical activities such as walking and stair 
climbing. Similar results have also been reported in studies of back pain 
patients. For example, one study of back pain patients assessed physical 
functioning by requiring the patients to lift weights (Renemen, Geertzen, 
Groothoff & Brouwer, 2008). In this study, it was found that patients with 
higher pain self-efficacy lifted more weight than patients with lower pain self-
efficacy. Therefore, higher pain self-efficacy was positively related to physical 
functioning in back pain patients. As another example, higher pain self-
efficacy has been related to improved physical functioning by length of time 
patients could perform physical activities such as cycling, walking and running 
(e.g. Estlander et al., 1994; Cunha, Simmonds, Protas & Jones, 2002). Such 
results show that pain self-efficacy has been positively related to physical 
functioning in arthritis and back pain patients in these studies. 
Studies have also shown that pain self-efficacy has been related to better 
psychological functioning (e.g. Turk & Okifuji, 2002; Sharma et al., 2003) and 
lower pain intensity in several pain conditions such as arthritis, headache, 
cancer pain and back pain (e.g. Denison, Asenlöf & Lindberg, 2004; Yazdi-
Ravandi et al., 2013). Therefore, findings concerned with the role of pain self-
efficacy in physical functioning, psychological functioning and pain intensity 
have shown that pain self-efficacy has been linked to positive outcomes. In 
addition, other positive outcomes of pain self-efficacy have been reported 
including higher pain threshold, higher pain tolerance and lower pain duration 
(e.g. Keefe et al., 1997; Turk & Okifuji, 2002; Brox et al., 2005). Since positive 
outcomes have been found for pain self-efficacy, it is possible that pain self-
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efficacy could be related to less painkiller use. However, there have been few 
studies focusing on painkiller use, which showed that pain self-efficacy has 
been related to less painkiller use (e.g. Callister et al., 2003) and less 
painkiller dependence among the general population of the UK (Elander et al., 
2014). 
Although there have been few studies focusing on painkiller use, there have 
been several studies focusing on medication use for other chronic non-pain 
conditions (e.g. Ogedegebe, Mancuso, Allegrante & Charlson, 2003; Diorio et 
al., 2009; Gatti, Jacobson, Gazmararian, Schmotzer & Kripalani, 2009). The 
results of these studies have shown that higher self-efficacy for chronic non-
pain conditions has been related to medication adherence, which refers to 
using medication as prescribed.  
1.4.5. Alexithymia 
A further psychological factor to consider is alexithymia. The term 
“alexithymia” has been developed by Sifneos (1973) from words in the Greek 
language meaning a lack of words for emotions; a meaning lack, lexis 
meaning word and thymos meaning emotion. Indeed, alexithymia is 
characterised by a lack of words for emotions because alexithymic people 
show a difficulty describing emotions (e.g. Bagby, Parker & Taylor, 1994). 
However, a difficulty describing emotions is not the only feature of 
alexithymia. According to Sifneos (1973), there are a further four features. 
These include: (1) a difficulty identifying emotions; (2) a difficulty 
differentiating between emotions; (3) a lack of imagination; and (4) a 
preoccupation with physical symptoms. In later research, a further two 
features of alexithymia identified were a preoccupation with external events 
and a difficulty to differentiate between emotions and bodily sensations (e.g. 
Bagby & Taylor, 1997). All these features of alexithymia have received much 
research support, so have been accepted by researchers as accurate for 
describing alexithymia (e.g. Pogostin, Schoenbrun, Santorelli, Lundquist & 
Ready, 2013; Gilbert, McEwan, Catarino, Baião & Palmeira, 2014).  
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There have been several studies investigating the role of alexithymia in pain 
(e.g. Makino et al., 2013; Baudic et al., 2016). For example, studies have 
shown alexithymia has been associated with several chronic pain conditions 
including lower back pain, fibromyalgia, arthritis and headache (e.g. Lumley, 
Asselin & Norman, 1997; Huber, Suman, Biasi & Carli, 2009; Hosoi et al., 
2010; Makino et al., 2013). Also, studies have shown alexithymia as a risk 
factor for developing chronic pain (e.g. Baudic et al., 2016). However, there 
have been results showing alexithymia may have a greater role for some 
conditions than others (e.g. Sayar, Gulee & Topbas, 2004; Prasertsri, Holden, 
Keefe & Wilkie, 2011). For example, studies have shown that fibromyalgia 
patients had significantly higher alexithymia than arthritis patients (e.g. Sayar 
et al., 2004), and complex regional pain syndrome patients had significantly 
higher alexithymia than lower back pain patients (e.g. Margalit, Har, Brill & 
Vatine, 2014). In addition, some studies have showed no association between 
alexithymia and cancer pain specifically (e.g. Porcelli, Tulipani, Maiello, Cilenti 
& Todarello, 2007; Prasertsri et al., 2011).  
In a study comparing alexithymia in chronic pain patients, smoking patients 
and obesity patients, it was found that the chronic pain patients had 
significantly more alexithymia than the other patients (Lumley et al., 1997). 
Similar results were reported in a meta-analysis conducted by Kreitler and Niv 
(2001), which showed alexithymia was significantly higher in chronic pain 
patients than other patients. Therefore, the results demonstrate significantly 
higher alexithymia among patients with pain conditions generally than other 
conditions. Thus, the study of alexithymia in people with pain is important.  
Other studies have examined the role of alexithymia in pain tolerance and 
pain intensity, showing that alexithymia has an association with lower pain 
tolerance and higher pain intensity (e.g. Nyklicek & Vingerhoets, 2000; 
Lumley, Smith & Longo, 2002; Mehling & Krause, 2005; Tuzer et al., 2011; 
Castelli et al., 2013). Since generally alexithymia has a negative role in these 
pain outcomes, there could also be a negative role in painkiller use. Of 
relevance here, in a recent study conducted by Elander et al. (2014), the role 
of alexithymia in painkiller dependence was examined among the UK general 
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population. The results showed alexithymia had a negative role because 
people with high alexithymia reported more painkiller dependence than people 
with low alexithymia. To the best of my knowledge, there have been no other 
studies investigating the role of alexithymia in painkiller use apart from the 
study conducted by Elander et al. (2014). 
However, there have been studies showing that alexithymia has a negative 
role in substance dependence. For example, a number of studies have shown 
that alexithymia increases the risk for developing substance dependence (e.g. 
El Rasheed, 2003; Speranza et al., 2004). Studies have also shown a 
significant difference between patients with substance use disorder and 
people without substance use disorder in terms of alexithymia. Specifically, 
patients with substance use disorder had significantly higher alexithymia 
compared to people without substance use disorder (e.g. El Rasheed, 2003; 
Hamidi, Rostami, Farhoodi & Abdolmanafi, 2010). Recently, Petit et al. (2015) 
assessed alexithymia among patients in rehabilitation for alcohol dependence. 
The results showed that patients with less alexithymia were more likely to 
recover from alcohol dependence but patients with higher alexithymia were 
more likely to maintain alcohol dependence. These results of a negative role 
of alexithymia in substance dependence may support the idea that 
alexithymia has a negative role in painkiller use. 
1.5. Evaluation of previous research 
Researchers have used a range of methods to investigate accessibility of 
medications and psychological factors. Mainly, several types of 
questionnaires have been used, such as telephone (e.g. Breivik et al., 2006), 
postal (e.g. Torrance et al., 2006), face-to-face (e.g. Hyland et al., 2003) and 
online questionnaires (e.g. Elander et al., 2014). There has also been 
research using interviews, and these have been conducted either by 
telephone (e.g. Toblin et al., 2011) or face-to-face methods (e.g. Abe et al., 
2008). Only a few further methods have been used. Specifically, observations 
of dispensing procedures in pharmacies have been conducted for measuring 
accessibility (e.g. Sallam et al., 2009). In addition, researchers have used 
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physical measures, but these have been for other factors such as pressure 
pain threshold (e.g. Meeus et al., 2012) and urine analysis to measure 
substance abuse (e.g. El Rasheed, 2003). However, these methods have 
typically been combined with interviews or questionnaires, for example, urine 
analysis has been used to verify data from the self-reports (e.g. El Rasheed, 
2003). This shows that research regarding accessibility and psychological 
factors has largely relied on self-report methods.  
Using self-reports can be an advantage because it allows data to be collected 
from large samples in less time than other methods. For example, although 
observations in pharmacies have been used to measure accessibility of 
medications (e.g. Sallam et al., 2009), this method can be time consuming 
and requires much effort to obtain data from a large sample or multiple 
pharmacies. If self-reports were used, this would be more convenient for 
researchers, especially questionnaires administered online because of instant 
distribution and collection of the questionnaires, and minimal costs (e.g. Yun 
& Trumbo, 2000). These methods are discussed in more detail in the 
methodology chapter (see section 2.2). In addition, there may be less chance 
of bias with self-reports compared to observations. To clarify, people might 
behave differently than normally when they are being observed, so this 
method can lead to biased results (e.g. McCambridge, Witton & Elbourne, 
2014). For example, studies with observation components are vulnerable to 
the Hawthorne Effect, which refers to change in a person’s behaviour from 
awareness of being observed, and usually occurs to appear socially desirable 
to observers (e.g. Fernald, Coombs, DeAlleaume, West & Parnes, 2012; 
McCambridge, Witton, & Elbourne, 2014). If people are not aware of the 
observation, the bias may be reduced. However, this may not be ethical and it 
can be difficult to conduct observation without permission.  
The problem of bias can be reduced by self-reports that are not face-to-face 
because they allow more anonymity and privacy than observation (e.g. 
Wright, 2005; Van Selm & Jankowski, 2006). When self-reports have been 
used to measure accessibility, this involves asking about how difficult it would 
be to obtain prescription medication without prescription, the type of 
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medication used and the source where the medication was obtained (e.g. 
Ghandour et al., 2012). Due to the convenience for researchers and 
possibility for less bias, self-reports can be an advantage to measure 
accessibility. The disadvantage of using self-reports however concerns the 
fact that some factors can only be measured objectively such as biological or 
physiological factors, therefore self-reports are not useful for such factors.   
In terms of psychological factors, studies have mainly used self-reports to 
measure these factors (e.g. Christiaens et al., 2010; Baudic et al., 2016). 
Therefore, self-reports have been especially relied on by researchers of 
psychological factors, and appear to be a useful method for this purpose. 
However, there are limitations of self-reports that should be considered. 
These include acquiescence, extreme and central tendency responding and 
social desirability bias (e.g. Lanyon & Goodstein, 1997). To benefit from the 
advantages of self-report measures, researchers should try to reduce such 
limitations, by using methods including reverse scored items to reduce 
acquiescence, using fewer Likert scale items to reduce extreme and central 
tendency responding and social desirability scales to identify social desirability 
bias. These limitations and how to reduce them are discussed in the 
methodology chapter (see section 2.4).  
1.5.1. Gap analysis 
Further critique concerning existing research is that most studies about 
accessibility and psychological factors have focused on one country (e.g. El 
Rasheed, 2003), and there have been few cross-cultural designs or 
comparative studies between countries (e.g. Christiaens et al., 2010). Also, 
many of the studies have used cross-sectional designs (e.g. Lauwerier et al., 
2011), and there have been few longitudinal designs (e.g. McCracken et al., 
2007). These research designs are discussed further in the methodology 
chapter (see section 2.6 and 2.7). In brief, cross-cultural studies are useful to 
allow comparisons between countries (e.g. Matsumoto & Yoo, 2006). Due to 
high levels of painkiller prescriptions reported in several countries (e.g. 
Mumtaz et al., 2011; Stannard, 2012), more cross-cultural studies are needed 
to compare problematic painkiller use internationally. Meanwhile, longitudinal 
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studies are useful for investigating constructs over time, whereas cross-
sectional studies only allow investigating constructs at one point in time (e.g. 
Rajulton, 2001). Since painkiller prescriptions and problematic painkiller use 
have been increasing (e.g. Shapiro, 2015), more longitudinal research is 
needed to investigate what factors might have a role in how problematic 
painkiller use changes over time.  
Finally, most studies about accessibility and psychological factors have been 
concerned with outcomes other than problematic painkiller use, mainly pain 
outcomes and painkiller use frequency. Especially, there have been few 
studies of the general population, since the majority have been women with 
childbirth pain or clinical samples that are “extreme cases of the disorder 
being investigated that may not always be accessible in general population 
surveys” (Barnes, Murray, Patton, Bentler & Anderson, 2006, p. 266). This 
thesis therefore will focus to answer questions about the role of accessibility 
and psychological factors in problematic painkiller use cross-culturally and 
over time in the general population to address these gaps in the literature. 
These questions are detailed in sections 3.1.4, 5.1.2 and 6.1.7. 
1.6. Conclusion 
The literature demonstrates that accessibility of painkillers and psychological 
factors could have a role in problematic painkiller use, but more research is 
required. This is because most research has been about the role of these 
factors in pain outcomes and painkiller use frequency. The psychological 
factors examined have been attitudes and beliefs towards pain, attitudes and 
beliefs towards painkillers, attitudes and beliefs towards self-medication, 
attitudes and beliefs towards alternative methods of pain relief, pain 
acceptance, pain catastrophising, alexithymia and pain self-efficacy. The 
research focusing on accessibility and these psychological factors has 
generally been conducted with clinical samples or women with childbirth pain, 
therefore not much is known regarding the role of the factors in the general 
population.  
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Research within the general population is needed to help better understand 
the role of accessibility and psychological factors in problematic painkiller use, 
due to the harmful effects to wellbeing and the cost to society that this 
involves. Thus, the present thesis aims to build on the existing research by 
investigating the role of accessibility and psychological factors in the general 
population. In terms of problematic painkiller use, the present thesis focused 
on painkiller dependence in order to build on the few studies that have been 
conducted (e.g. Elander et al., 2014).   
1.7. Structure of the thesis 
The rest of this thesis consists of the following chapters: 
1.7.1. Chapter 2 - Methodology  
In the second chapter, methodological considerations are provided. This 
includes considerations about online surveys, ethical issues, self-report 
methods, shortened versions of scales, cross-sectional designs, longitudinal 
designs and cross-cultural research.  
1.7.2. Chapter 3 - The role of accessibility of painkillers and 
psychological factors in problematic painkiller use: A comparison 
between the general populations of the United Kingdom and Egypt 
In the third chapter, a report of the first study conducted for the thesis is 
provided, which compared the general populations of the UK and Egypt 
regarding the role of accessibility and psychological factors in problematic 
painkiller use. This chapter consists of four sections: introduction, method, 
results and discussion. The introduction provides a summary of the 
background, and the rationale, aims, research questions and hypotheses for 
the study. The method describes the participants, design, measures, 
materials, procedure and analytic strategy of the study. The results provide 
details about the outcomes obtained from the analyses. The discussion 
provides a summary of the results and discusses their implications, the 
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strengths and weaknesses of the study, suggestions for future research and 
conclusions. 
1.7.3. Chapter 4 - Developing a 14-item SOPA-B and 14-item PMAQ  
In the fourth chapter, a report of the second study conducted for the thesis is 
provided, which developed a 14-item version of the SOPA-B and PMAQ. The 
chapter will consist of the same four sections mentioned previously.  
1.7.4. Chapter 5 - The role of accessibility of painkillers and 
psychological factors in problematic painkiller use among the general 
population: A multi-national comparison 
In the fifth chapter, a report of the third study conducted for the thesis is 
provided. This was a multi-national comparison of the role of accessibility and 
psychological factors in problematic painkiller use among the general 
population. Again, the chapter will consist of the same four sections 
mentioned previously.  
1.7.5. Chapter 6 - A longitudinal investigation of the role of 
psychological factors in problematic painkiller use among the general 
population of the UK 
In the sixth chapter, a report of the fourth study conducted for the thesis is 
provided. This was a longitudinal investigation of the role of psychological 
factors in problematic painkiller use among the general population of the UK. 
The chapter will again consist of the same four sections mentioned previously.  
1.7.6. Chapter 7 - General discussion 
In the final chapter, a general discussion of the results from the thesis is 
provided. The general discussion will first discuss the results regarding the 
role of accessibility in problematic painkiller use among the general 
population, then the role of psychological factors. In addition, the general 
discussion will provide conclusions with respect to problematic painkiller use 























The following methodology chapter will present the methodological 
considerations of the present thesis. The methodology chapter will begin by 
discussing considerations of online surveys, followed by ethical 
considerations, and then discuss considerations of self-reports, shortened 
versions of scales, cross-sectional and longitudinal designs, and finally 
considerations of cross-cultural designs.   
2.2. Online surveys 
Surveys are defined as a way of gathering information from a sample of 
individuals (e.g. Scheuren, 2004). There are several different types of surveys 
that can be used but the present thesis uses online surveys. These surveys 
are described as a method in which “a computer plays a major role in both the 
delivery of a survey to potential respondents and the collection of survey data 
from actual respondents” (Jansen, Corley & Jansen, 2007, p. 2). There are 
three types of online surveys: point of contact surveys, email surveys and 
web-based surveys. In point of contact surveys, participants complete the 
survey on a computer provided by the researcher. This is usually conducted 
when the intention of the research is to control the environment the survey is 
completed in such as asking participants to complete the survey in a lab (e.g. 
Synodinos, Papacostas & Okimoto, 1994). Email surveys involve completing 
the survey in electronic mail or as an attached document (e.g. Kiesler & 
Sproull, 1986; Sproull, 1986), while web-based surveys “physically reside on a 
network server” and can be “accessed only through a web browser” (e.g. 
Green, 1995; Stanton, 1998).   
Each type of online survey has a number of unique advantages and 
disadvantages. For point of contact surveys, an advantage is that these are 
very useful for research requiring the survey to be completed in a controlled 
setting, but are not practical for research requiring large samples due to time 
costs (e.g. Jansen et al., 2007). For email surveys, an advantage is tracking 
participation, but a disadvantage is the data needs to be manually entered 
into a database for analysis (e.g. Paolo, Bonamino, Gibson, Partridge & 
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Kallail, 2000; Jansen et al., 2007). For web-based surveys, the advantages 
and disadvantages will be discussed in more detail below because this was 
the method used in this research (note: web-based surveys will be called 
online surveys from here on).  
There are several advantages of using online surveys compared to other 
methods. Firstly, online surveys provide an opportunity to collect data from a 
large number of participants from many parts of the world (e.g. Evans & 
Mathur, 2005; Wright, 2005). Although not everyone can be reached using 
online surveys, it is recognised that the majority of people in the world have 
internet access (e.g. Pfleeger & Pfleeger, 2002). Therefore, online surveys 
can be used to reach a large number of participants from around the world 
more easily than other methods (e.g. Wellman, 1997; Garton, 
Haythornthwaite & Wellman, 1999; Wright, 2005). In addition, since there are 
thousands of groups and organisations online, the internet allows researchers 
to survey a large number of participants who are linked to these groups and 
organisations (e.g. Wright, 2005). For example, there are many groups and 
organisations specifically for people with pain, so these online communities 
offer researchers opportunities to easily survey individuals from the general 
population who experience pain and use painkillers.  
Secondly, the cost of collecting data from a large number of participants in 
several countries around the world is less for online surveys compared to 
other methods. For example, paper surveys can involve printing and postage 
costs, and may involve travel costs to distribute and collect the survey (e.g. 
Llieva, Baron & Healey, 2002). Using online surveys does not involve these 
costs and does not require the researcher to travel to collect data. Although 
there are still costs associated with using online surveys, the cost for each 
response decreases with online surveys, whereas the cost for each response 
increases with paper surveys (e.g. Watt, 1999). So, online surveys are 
cheaper for collecting large data than paper surveys, especially from more 
than one country.  
Another advantage of using online surveys is to save time for the researcher. 
Since online surveys allow researchers to obtain a large sample of 
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participants internationally without the need to travel, online surveys save time 
for researchers compared to other methods that may require travel (e.g. 
Rhodes, Bowie, & Hergenrather, 2003). In addition, online distribution and 
collection is instant, whereas paper distribution and collection can take some 
time (e.g. Yun & Trumbo, 2000). Therefore, online surveys can allow 
researchers to collect data from a large sample of participants in less time 
than other methods (e.g. Yun & Trumbo, 2000). Moreover, online survey 
responses can be automatically transferred into a database, which saves time 
for the researcher compared to manually entering data (e.g. Andrews, 
Nonnecke & Preece, 2003). This also leads to more accurate responses 
because human error is limited compared to manually entering data (e.g. 
Andrews et al., 2003).    
A further advantage of using online surveys is the opportunity for anonymity 
and privacy because online surveys do not require researchers to be present 
while participants answer questions (e.g. Van Selm & Jankowski, 2006). This 
anonymity and privacy can reduce biased responding because participants do 
not need to worry about how the researcher will perceive them (e.g. 
Braithwaite, Waldron & Finn, 1999; Wright, 2005). For example, some people 
may not want to discuss their pain and painkiller use problems face-to-face to 
avoid stigma or negative perceptions. Since online surveys allow participants 
to be anonymous and share information privately, stigma or negative 
perceptions can be reduced (e.g. Riggle, Rostosky, & Reedy, 2005). 
At the same time, anonymity and privacy can be a disadvantage because 
participants and researchers cannot communicate the same way as face-to-
face methods (e.g. Stewart & Williams, 2005). For example, participants 
cannot ask researchers to clarify questions and researchers cannot ask 
participants to clarify their responses as easily as face-to-face methods. 
Rather, participants and researchers would communicate by e-mail or other 
indirect methods, which can lead to more risk for inaccurate responses by 
participants and inaccurate analysis by researchers (e.g. Mann & Stewart, 
2000). Here, piloting online surveys to make sure questions are clear and 
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understandable should reduce the problem (e.g. Mujis, 2012). Therefore, this 
was conducted in the present research.  
Finally, online surveys have several advantages compared to other methods 
because of technology improvements. For example, graphics and colour 
themes can help to minimise participant drop out from online surveys 
compared to other methods without graphics and colour themes (e.g. Dillman, 
2000). In addition, technology improvements can also improve the quality of 
data from online surveys compared to other methods. For example, when 
using online surveys, researchers can avoid missing data by making 
important questions required instead of optional, but this cannot be done for 
other methods (e.g. Stanton, 1998; Preece, Rogers & Sharp, 2002).  
While online surveys have many advantages over other methods, there are a 
number of issues that need to be considered for collecting data using online 
surveys. One issue is the sampling methods used for online surveys (e.g. Van 
Selm & Jankowski, 2006). According to Wright (2005), online survey research 
must use probability sampling, especially to generalise the results to the 
population. In probability sampling, participants are selected by a random 
number from a large list of participants such as email lists, then the selected 
participants are invited to participate (e.g. Cochran, 2007). However, to 
identify a list of participants would not always be possible due to data 
protection (e.g. Grinyer, 2009).  
An alternative sampling method is non-probability sampling, but this involves 
self-selection. In non-probability sampling, self-selection occurs when 
participants randomly come across invitations to participate in online surveys 
or when participants volunteer to be contacted about online surveys (e.g. 
Jansen et al., 2007). The problem with self-selection is the sample can be 
biased because some people may be more likely to participate than others 
(e.g. Yun & Trumbo, 2000; Zhang, 2000; Sohn, 2001). To reduce the self-
selection bias, it has been suggested that using incentives can help because 
more people can participate than without the incentives (e.g. Tuten, Bosnjak & 
Bandilla, 2000). Incentives were therefore used in this research. 
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Nevertheless, the bias should be reduced anyway because more people are 
using the internet from all backgrounds and ages. 
A further issue with online surveys is technical problems related to the internet 
and computers, including errors, network availability and network overload 
(e.g. Andrews et al., 2003). These technical problems may lead to problems 
with opening online surveys or completing online surveys, whereas offline 
surveys avoid these technical problems. If participants can save the online 
surveys, completion problems can reduce because participants can complete 
the survey at another time. Therefore, online surveys with options for saving 
are recommended (e.g. Lefever, Dal, & Matthiasdottir, 2007). 
Another problem of online surveys compared to offline surveys is that usually 
not all the content can be viewed before completing the surveys. For example, 
when online surveys consists of more than one page and when questions are 
compulsory to complete before moving to the next pages, not all the content 
can be viewed before completing the surveys. By not viewing all the content, 
drop out from online surveys can increase, whereas this is not an issue for 
offline surveys because the content can be easily viewed on the papers (e.g. 
Crawford, Couper & Lamias, 2001). Indeed, when participants can view all the 
content, it is more likely that the surveys will be completed, especially for 
surveys with questions about demographics, health and health behaviours 
(e.g. Andrews et al., 2003). This is because participants will consider these 
questions to interfere with their privacy less than when not all the content can 
be viewed (e.g. Andrews et al., 2003). If not all the content can be viewed 
before completing online surveys, it is important that the surveys are 
anonymous and confidential to reduce drop out (e.g. Reips, 2002). In addition, 
it is important to explain the content of the online surveys so participants can 
know what to expect, which can also reduce drop out (e.g. Reips, 2002). 
Another reason why viewing all the content can reduce drop out is that 
participants can see the length of the survey. In research comparing long and 
short surveys, it has been found that shorter surveys are associated with less 
drop out than longer surveys (e.g. Sheehan, 2001). When participants cannot 
view all the content, ways of reducing drop out include the use of a progress 
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indicator and providing estimations of the time to complete the survey (e.g. 
Andrews et al., 2003). These methods increase the trust of participants and 
motivation as participants can plan time as to when to complete the survey 
(e.g. Shaheen, 2001; Andrews et al., 2003). In addition, the location of 
demographic questions can especially influence drop out when participants 
cannot view all the content. More specifically, when demographic questions 
are asked at the beginning of surveys, drop out is significantly less than when 
demographic questions are not at the beginning. This is because participants 
feel less surprised and feel the researcher is more honest when demographic 
questions are at the beginning (e.g. Frick et al., 2001). So, the demographic 
questions should be asked at the beginning of surveys to reduce drop out.   
A major disadvantage of using online surveys is the difficulty making sure 
whether participants are from the required group for the inclusion criteria of 
the survey (e.g. Wright, 2005). To reduce the problem, online survey 
invitations should be advertised in locations specifically for the required group 
(e.g. Andrews et al., 2003). For example, when the inclusion criteria are 
people who have pain and use painkillers, online survey invitations can be 
sent to online forums for people in pain. This will help to obtain participants 
who have pain and use painkillers. Additionally, snowball sampling can be 
used by asking participants to forward the survey to people they know 
personally who have pain and use painkillers.  
2.3. Ethical considerations 
 
Several ethical guidelines have been developed for online research, including 
the Ethical decision-making and internet research guidelines of the 
Association of Internet Researchers (e.g. AoIR, 2012) and the Ethics 
guidelines for internet-mediated research of the British Psychological Society 
(e.g. BPS, 2013). The ethical guidelines for online and offline research are 
similar, but there are additional considerations needed for online research 
given unique feature of the internet environment. To demonstrate this, the 
BPS explains that the Ethics guidelines for internet-mediated research (BPS, 
2013) “provides guidelines on how the Code of Human Research Ethics 
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(BPS, 2014) may be interpreted in the context of internet-mediated research 
and what special considerations may apply” (BPS, 2013, p. 2). 
 
The ethical considerations shared between guidelines for online and offline 
research are: obtaining valid consent, protecting participants from risk, 
providing participants with the right to withdrawal, maintaining confidentiality 
and debriefing participants (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). 
However, the additional “special considerations” specific to online research 
concern etiquette for appropriate, polite and respectful behaviour online, 
which is called netiquette (e.g. Madge, 2007; AoIR, 2012; BPS, 2013). These 
ethical considerations will now be discussed.  
 
2.3.1. Valid consent 
 
Ethical guidelines recommend that researchers need to obtain consent from 
participants before data is collected from them (e.g. AoIR, 2012; BPS, 2013; 
BPS, 2014). The consent should be voluntary and based on information 
explaining the research and procedures. In addition, ethical guidelines 
recommend that participants should have the right to modify consent to allow 
withdrawal from research without need to explain the reason for withdrawal 
(e.g. AoIR, 2012; BPS, 2013; BPS, 2014). 
 
According to the BPS (2013), it is more difficult to ensure that participants 
have read and understood the information explaining the research in online 
surveys compared to face-to-face methods. Specifically, participants can 
more easily skim read the information or avoid reading the information for 
online surveys because the researcher cannot see the participants. When 
participants have not read and understood the information, the consent is not 
considered valid (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). Therefore, it is 
more difficult to obtain valid consent from participants in online survey 
research compared to face-to-face methods.   
 
In order to reduce the problem of invalid consent in online survey research, it 
is recommended to provide brief information explaining the research (e.g. 
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BPS, 2013). Keeping information brief will help to reduce the risk of skim 
reading the information or avoiding reading the information. Therefore, it will 
be more likely that participants read the information before providing consent, 
so valid consent is more likely (e.g. BPS, 2013). It is also recommended that 
simple language is used and technical terms are avoided to make the 
information easier to understand (e.g. Madge, 2007). If technical terms are 
used, it is recommended that they are explained fully (e.g. Madge, 2007). 
Further, after the information has been provided, it is recommended to provide 
brief statements that summarise the most important information for 
participants, so it will be more likely participants know this information (e.g. 
BPS, 2013). Additionally, it is recommended that researchers provide their 
contact details so participants can ask questions if more information is 
required before participating (e.g. Madge, 2007).  
 
In the present research, the recommendations for valid consent were 
followed. Specifically, participants were provided with information about the 
purpose, procedure and approximate duration of the online questionnaires. It 
was explained that taking part in the online questionnaires was voluntary so 
withdrawal was acceptable without needing to give a reason. Information 
about the research was followed with a number of short statements repeating 
the main information. Then, consent was obtained by asking participants to 
enter a unique identification code to confirm the participants had read and 
understood the information and would like to take part. To reduce 
understanding issues and to reduce issues of participants not reading the 
information, the information was simple and technical terms were avoided. In 
addition, participants were provided with the opportunity to ask the researcher 
or supervisors questions via email in case any information was unclear before 




Risk refers to “the potential physical or psychological harm, discomfort or 
stress to human participants that a research project may generate” (BPS, 
2014, p. 13). According to ethical guidelines, the risk to participants should be 
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“minimal” and not more than encountered in everyday life (e.g. AoIR, 2012; 
BPS, 2013; BPS, 2014). Any potential risks should be identified and managed 
as much as possible. If risks are unavoidable, it is recommended that the risks 
should not cause long-lasting harm and the long-term gains of the research 
should be more than the risks (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). 
 
There are two factors that increase risk in online survey research: the topic of 
the survey and the physical distance between the researcher and participants. 
For the topic of the survey, Holmes (2009) suggests that the risk is usually 
minimal when the topic is not sensitive. However, when the survey deals with 
a sensitive topic, the risk for harm, discomfort and stress is high. As a result 
from the physical distance between the researcher and participants, it is 
difficult for researchers to identify whether any harm, discomfort or stress has 
occurred (e.g. Kraut et al., 2004). Therefore, it is difficult for researchers to 
monitor the risk and to manage the risk when necessary (e.g. Kraut et al., 
2004). In addition to the physical distance, there is an emotional and 
psychological distance between researchers and participants in online survey 
research compared to face-to-face research, which also makes it more 
difficulty to monitor and manage risks (e.g. Hair & Clark, 2007). If research is 
high-risk, online surveys should be avoided (e.g. BPS, 2013). If research is 
low-risk, it is possible for researchers to manage the risk by providing 
participants with support and information via web links or contact details that 
can offer participants support if needed. 
 
The physical, psychological or emotional risks in the present research were 
not more than would be expected in everyday life because participants were 
not asked sensitive questions. In case participants were worried about their 
pain or painkiller use, the participants were given details of where to get help 
and more information in the debriefing information.  
2.3.3. Withdrawal 
 
In the ethical guidelines, it is recommended that participants should have the 
right to withdrawal from the research at any time during data collection until 
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analysis of the data is conducted (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). 
The participants should be made aware of the right to withdrawal, the 
procedure for withdrawal, the time limit for withdrawal and that the result of 
withdrawal is deletion of their data (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). 
In online survey research, withdrawal is not as easy as in face-to-face 
research for two reasons. Firstly, withdrawal of a participant in online survey 
research may not be as clear to the researcher as in face-to-face research 
(e.g. BPS, 2013). For example, if a participant withdraws from an online 
survey by closing the survey window, the withdrawal may be confused with a 
technical problem that made the survey window close or the survey window 
may have been closed unintentionally. Secondly, the data from online surveys 
is automatically stored in a database, even for participants that withdraw from 
the study (e.g. BPS, 2013). For example, if a participant withdraws by closing 
the survey window, the data is stored despite the survey not being fully 
completed.  
 
It is recommended to include a “withdraw” button in online surveys, which 
allows participants to withdraw (e.g. BPS, 2013). By using a “withdraw” 
button, it can become clear that participants have not completed the survey 
due to withdrawal rather than other reasons such as a technical problem. 
Also, the data for the participant can be deleted automatically with the 
“withdraw” button. However, this button feature is not available in all online 
survey software. Therefore, if there is confusion about why a participant has 
failed to complete a survey fully, it is preferred that the data should be deleted 
by researchers (e.g. BPS, 2013).  
 
In the present research, participants were free to withdraw at anytime during 
the study or up to four weeks after taking part in the research. Information 
about the withdrawal procedure was provided to participants prior to obtaining 
consent from them to take part. It was also provided again in the debrief to 
remind them about the procedure and time limit for withdrawal. A “withdraw” 
button was not available for the survey software used in the present research. 
Therefore, the participants were told that they could either withdraw by closing 
the survey window or by emailing the researcher or supervisors with their 
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unique identification code. This is a code that participants were asked to 
create before beginning the survey to allow their data to be identified 
anonymously if they want to withdraw. Then, the data was deleted for any 




Confidentiality is when the identity of participants is not disclosed to anyone 
except those involved in the research (e.g. Whelan, 2007). Ethical guidelines 
recommend that researchers need to keep confidential the identity of 
participants (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). A way to ensure 
confidentiality is anonymity, which involves not collecting any identity 
information from participants (e.g. Whelan, 2007). When data is not 
anonymous, confidentiality can be ensured by keeping the data secure and 
not sharing the data with others who are not involved in the research (e.g. 
Madge, 2007). 
 
The more confidential the data, the more likely participants will provide honest 
and truthful responses, especially research involving sensitive topics (e.g. 
Bruckman, 2002). However, the problem with maintaining confidentiality in 
online survey research is that researchers cannot guarantee that data will not 
be accessed by others (e.g. Mann & Stewart, 2000). As the BPS (2013) 
argues, “researchers need to be aware that it is impossible to maintain 
absolute confidentiality of participants’ personal information gathered online 
because the networks are not in the control of the researcher” (p. 10). For 
example, open access to data from online surveys is possible due to bugs or 
viruses in online survey software (e.g. Madge, 2007). Security agencies or 
governments can also access data from online surveys (e.g. Madge, 2007). 
Therefore, it may not be possible to maintain complete confidentiality of data 
collected from online surveys, however access is less likely if the data is not 
dealing with sensitive or illegal topics (e.g. Cho & LaRose, 1999). 
 
Another problem with maintaining confidentiality in online survey research is 
that it is difficult to avoid collecting identifying information from participants 
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(e.g. BPS, 2013). For example, IP addresses are usually recorded with 
participant responses, which can be used to identify participants (e.g. Nosek, 
Banaji, & Greenwald, 2002). Also, it can be possible to identify people from a 
combination of demographic variables such as age, financial status, 
educational status and employment status (e.g. Nosek et al., 2002). 
Additionally, email addresses can be used to identify participants if these are 
collected from participants for purposes such as prize draws (e.g. Garfinkel, 
2003).  
 
Given these problems, it is important to keep data confidential especially if 
information such as IP address, email address and demographic variables are 
collected. If this type of information is collected, the confidentiality of data can 
be improved by accessing data from a secure computer and network, and 
ensuring the use of antivirus software on such computers. Confidentiality 
should be sufficient if these steps are taken (e.g. Madge, 2007).  
 
The present research used all the ways identified above to aid maintaining 
confidentiality, including avoiding collecting identifying information from 
participants such as name and address, and accessing data from secure 
computers only. In addition, participants were asked to create a unique 
identification code to help anonymously identify data if withdrawal was 
requested, and to help match baseline to follow-up data anonymously and 
confidentially in the longitudinal research. Further, participants were made 
aware that confidentiality would be maintained by sharing the data between 




Debriefing involves providing participants with further information about the 
research after taking part (e.g. AoIR, 2012; BPS, 2013; BPS, 2014). In 
addition, debriefing involves providing participants with an opportunity to ask 
researchers questions about the research and an opportunity for researchers 
to acknowledge the help of participants in the research (e.g. AoIR, 2012; BPS, 
2013; BPS, 2014). According to ethical guidelines, debriefing is especially 
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important if research involves any deception or risks. If research involves any 
deception, the reason for the deception should be explained during the 
debrief. If any risks were involved, researchers need to manage the risk 
during the debrief and provide participants with guidance to help and support 
(e.g. AoIR, 2012; BPS, 2013; BPS, 2014).  
 
In online survey research, the problem is that participants might not read the 
debriefing information (e.g. BPS, 2013). For example, if participants withdraw 
by closing the survey window before completing the survey, they will not see 
the debrief. Also, participants may skim read or avoid reading the debrief. 
However, the problem is the same for other methods that are not face-to-face 
such as postal and paper surveys (e.g. Madge, 2007). To reduce the problem, 
it is recommended that researchers ensure the debrief is simple, brief and 
understandable (e.g. Madge, 2007). In addition, it is recommended that a 
“withdraw” button is added to surveys to direct participants to the debrief after 
withdrawal (e.g. BPS, 2013). Since a “withdraw” button feature is not available 
in all survey software, it is acceptable participants close the survey window 
and do not see the debrief, but only if the research is not high-risk (e.g. 
Barchard & Williams, 2008). 
 
After completing the online questionnaire, participants in the present research 
viewed a written debrief on the screen including further information about the 
study, information about withdrawal procedures and contact details in case of 
any questions. The debrief also acknowledged the help of participants and 
included links to websites where participants could get help and obtain 




Netiquette refers to etiquette on the internet, which involves appropriate, polite 
and respectful behaviour (e.g. Hall, Frederick & Johns, 2004). As a result of 
netiquette, ethical issues such as causing harm, discomfort and stress to 
participants can be reduced (e.g. Hall et al., 2004). There are also etiquette 
guidelines for offline research, but unique guidelines are needed for recruiting 
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participants online from forums and using online surveys (e.g. Hall et al., 
2004). 
 
There are several netiquette guidelines for recruiting participants online from 
forums. One of these guidelines is to ensure that invitations for participants to 
take part need to be posted on forums that are relevant to the research, 
otherwise the invitation may be perceived as spam or intrusive (e.g. Hewson, 
Yule, Laurent & Vogel, 2003). Another guideline is that permission should be 
requested from moderators before posting invitations to participate in forums, 
since permission can increase the trust of the forum members to the 
researchers (e.g. Cho & LaRose, 1999; Eysenbach & Till, 2001). An additional 
guideline is that researchers need to be familiar with the communication 
standards of the forums (e.g. Mann & Stewart, 2000).  
 
To become familiar with the communication standards of the forums, 
researchers should follow any guidelines specified by the forums, read 
frequently asked questions (FAQs) and read previous posts to understand 
communication standards such as abbreviations, jargon, acronyms and 
emoticons (e.g. Madge & O’Connor, 2002). Following the communication 
standards shows respect for the forum members and reduces negative 
perception of researchers (e.g. Madge & O’Connor, 2002). In longitudinal 
research, another guideline is to avoid sending too many reminder emails to 
participants to complete the online survey: up to two emails is sufficient, with a 
one week interval (e.g. Kleschinsky, Bosworth, Nelson, Walsh & Shaffer, 
2009).  
 
In terms of netiquette guidelines for using online surveys, it is recommended 
to avoid using technical terms so that participants can easily understand the 
information, instructions and questions included in online surveys (e.g. 
Madge, 2007). It is also recommended that all text and questions should be 
visible on the screen, so participants do not need to scroll up and down or left 
and right to see all the text (e.g. Mann & Stewart, 2000). Finally, information 
about the researchers should be included such as the name of the University 
and contact details. This again helps to increase trust to the researchers and 
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allows participants to contact the researchers to ask any questions if they 
wish (e.g. Madge & O’Connor, 2002). 
 
The present research followed netiquette guidelines by ensuring that 
invitations to participate were posted on forums relevant to pain and 
painkillers. Before invitations were posted, permission was obtained from 
forum moderators. Also, the online communication standards were followed 
after reading guidelines of the forums, FAQs and previous posts. Additionally, 
technical terms were avoided and it was ensured that all text could be viewed 
on the screen as was feasible. This was achieved by dividing longer scales 
into two separate pages to avoid scrolling where necessary. In addition, 
information about the researchers was provided, including the name of the 
researchers and their official contact details. In the longitudinal research, it 
was also ensured that no more than two reminder emails were sent to 
participants. 
2.4. Self-reports 
Self-report measures are methods of data collection that require participants 
to report information about themselves, including their own demographic 
information, attitudes, beliefs and behaviours (e.g. Barnea, Rahav, & 
Teichman, 1987). There are several types of self-report measures such as 
semi-structured interviews, structured interviews and paper questionnaires. 
However, online questionnaires are becoming a more commonly used self-
report method, especially for cross-cultural research with comparisons 
between countries (Evans & Mathur, 2005). 
All self-report methods have the assumption that asking participants about 
themselves can provide information that may be difficult or not possible to 
obtain using other methods. As Fransella (1981) said “If you don’t know what 
is wrong with a person, ask [the person]” (p. 166). Therefore, self-reports can 
allow researchers to obtain information by asking participants about 
themselves when other methods may not be possible or prove inadequate 
when trying to obtain such information. As a result, self-reports have been a 
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popular method for collecting data in the field of psychology, where many 
factors are difficult or cannot be directly measured or observed. For example, 
although pain experience can be measured with physiological measures, it 
would be time consuming for a large sample. In this way, self-reports can be a 
suitable method and preferable to other methods (e.g. Howard, 1994).  
Despite the advantages, there are also disadvantages when using self-
reports. Specifically, self-reports can lead to “response distortions”, which are 
issues with the responses provided by participants (e.g. Lanyon & Goodstein, 
1997). There are two types of response distortions: (1) response styles, which 
refers to responding in a particular direction regardless of the item, including 
acquiescence, extreme responding and central tendency responding; and (2) 
response biases, which refers to responding in a particular direction based on 
the item, including social desirability bias (e.g. Lanyon & Goodstein, 1997).  
2.4.1. Acquiescence 
Acquiescence is a response style that involves responding with a positive 
response to each question or agreeing with items. For example, acquiescence 
involves responding “yes” or “true” to items (e.g. Paulhaus, 1991). In 
acquiescence, participants may provide positive responses regardless of the 
item to try to complete the questionnaire with little effort or to complete the 
questionnaire more rapidly (e.g. Vehovar & Manfreda, 2008). Therefore, the 
issue with acquiescence is that the validity of the self-report questionnaire 
may be reduced since providing a positive response to each item means the 
measure may not be measuring what it is supposed to measure. In order to 
reduce acquiescence, questionnaires should include reverse scored items 
(e.g. Schriesheim & Hill, 1981). By using reverse scored items, it is possible to 
identify acquiescence by any inconsistent responses between the original 
items and the reverse scored items (e.g. Schriesheim & Hill, 1981). 
2.4.2. Extreme responding and central tendency responding  
Extreme responding and central tendency responding are response styles 
that involve selecting consistently either the most extreme response options 
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or the central response options. These response styles occur for Likert scale 
response formats that require participants to choose a response from options 
on a scale (e.g. Bachman & O’Malley, 1984). For example, on a scale from 
“strongly agree” to “strongly disagree”, participants with extreme response 
styles may choose these extreme responses consistently, whereas 
participants with central tendency response styles may choose the central 
option consistently, which could be “neither agree nor disagree”. Again similar 
to acquiescence, extreme responding and central tendency responding may 
also reduce the validity of the self-report, since the items may not be 
measuring what is supposed to be measured. However, these are more 
difficult to control other than changing the response format to not involve scale 
ratings. Therefore, researchers should accept these issues might influence 
the findings of the research when Likert scales have been used (e.g. 
Bachman & O’Mally, 1984). 
2.4.3. Social desirability bias 
Social desirability bias involves responding to items in a way that makes the 
participant appear more socially desirable. There are three factors that lead to 
social desirability bias: the method used for data collection; the topic of the 
research; and personality traits (e.g. Crowne & Marlowe, 1960; Parkes, 1980; 
Furnham & Henderson, 1982).  
In terms of the method used for data collection, it has been found that social 
desirability bias is more likely for face-to-face methods (e.g. Grimm, 2010). 
Since online surveys are not face-to-face, social desirability bias is argued to 
be reduced compared to face-to-face methods (e.g. Grimm, 2010). Also, 
social desirability bias can be reduced further when online surveys are 
confidential and anonymous because participants do not need to worry about 
being identified (e.g. Krumpal, 2013). However, the topic of the research can 
lead to social desirability bias for online surveys because people may not wish 
to respond honestly to some topics if they might be socially undesirable (e.g. 
Nederhof, 1985). For example, participants with painkiller dependence may 
not respond honestly about their painkiller use to make themselves appear 
more positive, gain social approval and avoid criticism. In terms of personality 
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traits, some people may demonstrate a tendency not to respond honestly, so 
the bias may be increased by personality traits (e.g. Crowne & Marlowe, 
1960).  
Since social desirability bias can lead participants to not respond honestly, 
social desirability can reduce the validity of self-reports (e.g. Furnham & 
Henderson, 1982). It might be possible to identify social desirability bias by 
including scales measuring social desirability such as the Marlowe-Crowne 
Social Desirability Scale (Crowne & Marlowe, 1960). However, such scales 
may not be necessary for online surveys, since these surveys are not face-to-
face, therefore social desirability bias should be minor (e.g. Wiersma, 2013).   
2.5. Shortened versions of scales  
Shortened versions of scales are scales that are developed from the original 
version by selecting items that have the highest association with each factor 
or subscale of the original version (e.g. Jensen et al., 2003). Therefore, 
shortened scales should have similar factors and subscales as the original 
version but fewer items. The disadvantages of long scales can be reduced by 
using shortened versions of scales, especially for scales consisting of 30-
items or more.  
One disadvantage of long scales is that these scales require more effort to 
complete than shorter scales (e.g. Debois, 2016), therefore participants may 
not wish to complete long scales. Other reasons to explain why participants 
may not wish to complete long scales are because long scales cause more 
fatigue and use much time to complete compared to shorter scales (e.g. 
Streiner, Norman, & Cairney, 2014). These problems are especially for 
longitudinal research with repeated measures over time because participants 
will need to complete the scales multiple times (e.g. McBride, 2013). In 
addition, such problems are increased if multiple scales are involved in the 
research (e.g. McBride, 2013). As a result, researchers use less scales in the 
same research. Therefore, longer scales may not just reduce the number of 
participants completing the scales but can also make it less feasible to 
measure multiple factors in one research project (e.g. Edwards et al., 2002).  
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Another disadvantage of long scales is that these scales can reduce the data 
quality (e.g. Drolet & Morrison, 2001; Richins, 2004; Galesic & Bosnjak, 
2009). Specifically, longer scales can lead to more errors than shorter scales 
due to fatigue (e.g. McBride, 2013). In addition, longer scales can lead to 
more errors than shorter scales due to participants saving time by using skim 
reading and response distortions such as acquiescence, extreme responding 
and central tendency responding to minimise responding effort (e.g. Drolet & 
Morrison 2001; Richins 2004; Galesic & Bosnjak 2009).  
Due to reduced effort and time of completing shortened scales, there should 
be fewer errors, fatigue, skim reading and response distortions (e.g. Rolstad, 
Adler, & Ryden, 2011). In addition, it should be possible to assess more 
factors if multiple short versions are used rather than multiple longer versions 
(e.g. Shrout & Yager, 1989; Burisch, 1997; Stanton, Sinar, Balzer, & Smith, 
2002). As a result of these advantages, it is recommended to use shorter 
versions of scales (e.g. Cheung et al., 2004). 
2.6. Cross-sectional and longitudinal designs 
A definition of cross-sectional and longitudinal designs has been provided by 
Rajulton (2001), who suggested that:  
“Cross-sectional information deals with status, while longitudinal 
information concerns progress and change in status. This implies that 
the term ‘longitudinal data’ denotes repeated measurements of the 
same individuals over a time span long enough to encompass a 
detectable change in their status” (p. 170 - 171).  
From Rajulton’s (2001) definition, cross-sectional designs involve measures of 
participants at one point in time, whereas longitudinal designs involve 
repeated measures of participants over time. Many researchers accept this 
definition of cross-sectional and longitudinal designs (e.g. Menard, 2002). 
Although longitudinal designs involve repeated measures over time, 
Rajulton’s (2001) definition does not specify the length of time involved or the 
number of time points for repeated measures over time. Other definitions of 
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longitudinal designs also do not specify these aspects. For example, Miller 
(1998) defined longitudinal designs as “repeated tests that span an 
appreciable length of time” (p. 27), which is fairly ambiguous. 
The reason definitions do not specify the length of time or the number of time 
points for repeated measures over time is because these should depend on 
the factors measured; some factors may change over short periods of time, 
whereas others may change over longer periods of time. Therefore, 
researchers should use the literature to decide the length of time or the 
number of time points for repeated measurement (e.g. Zapf, Dormann, & 
Frese, 1996). However, a problem with longitudinal studies is that researchers 
may decide on these aspects by other reasons such as the available funding 
to carry out repeated measurement over time and the time restrictions of the 
researchers (e.g. Ruspini, 2002).  
Often longitudinal designs use retrospective questions to help investigate 
change over time (e.g. Ruspini, 2000). In retrospective questions, participants 
are asked to report about themselves in the past, usually for a specific time 
frame (e.g. Ruspini, 2000). For example, a retrospective question about 
painkiller use would be to ask participants to report how often painkillers were 
used in the last month. Therefore, rather than repeating questions about 
painkillers every day for one month, it is possible to collect this information in 
one time by retrospective questioning. As a result, retrospective questions can 
save time and effort for both researchers and participants, so these questions 
were included in the longitudinal study in this thesis (e.g. Euser et al., 2009).  
Whilst there are advantages with retrospective questions for saving time and 
effort, there are also disadvantages, since these questions rely on the 
memory of the participant to recall information accurately (e.g. Caruan et al., 
2015). When the time frame is longer into the past and when the retrospective 
questions are about topics other than demographics, the problem for recall is 
increased (e.g. Ruspini, 2000). It is therefore recommended that researchers 
avoid using long time frames for retrospective questions and topics other than 
demographics (e.g. Ruspini, 2000). For this reason, the time frame of 
retrospective questions was not longer than one month in this research.  
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Although longitudinal designs have advantages, there are also disadvantages 
of longitudinal designs, especially compared to cross-sectional designs. 
Firstly, longitudinal designs can be more costly than cross-sectional designs 
since there are more costs involved in terms of money, time and effort 
compared to single time-point cross-sectional designs (e.g. Shadish, Cook & 
Campbell, 2002; Lynn, 2009). Specifically, the reason for greater costs is 
because repeated measures over time requires tasks such as contacting 
participants to participate at several time points, sending reminders to 
participate, matching baseline and follow-up data and combining data 
together for analyses.  
Secondly, longitudinal designs often involve attrition, which refers to “the 
continued loss of respondents from the sample due to nonresponse at each 
wave of a longitudinal survey” (Lynn, 2009, p. 10). Therefore, attrition refers to 
the loss of participants from each time point of the repeated measures. In a 
small number of cases, attrition might occur from reasons that the researcher 
cannot control such as when participants change their details or pass away 
(e.g. Adamson & Chojenta, 2007). However, in most cases, attrition occurs 
from reasons that the researcher may be able to reduce, such as participants 
ignoring contact to participate in follow-up research or not having time to 
participate (e.g. Adamson & Chojenta, 2007). Attrition from longitudinal 
research for these reasons may be reduced if researchers emphasise the 
benefits of the research, provide incentives, make the questionnaire a suitable 
length and send reminders to participate (e.g. Hanna, Scott, & Schmidt, 
2014). Therefore, to reduce attrition from the longitudinal study in this thesis, 
these methods were all used.  
2.7. Cross-cultural designs 
Cross-cultural designs involve comparison between two or more cultures (e.g. 
Matsumoto & Yoo, 2006). Due to cross-cultural designs comparing cultures, 
these designs are also sometimes referred to as comparative designs (e.g. 
Brislin, 1976). According to Matsumoto and Yoo (2006), “cross-cultural 
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research is not easy, and it brings with it a host of complex methodological 
issues that researchers must address” (p. 243).  
An issues associated with cross-cultural research is how to define culture. In 
existing cross-cultural research studies, the definition of culture has not been 
consistent. For example, some studies have defined culture as “country” 
whereas others have defined culture in other ways such as “race and 
ethnicity” (e.g. Rohner, 1984; Berry, 2002; Baumeister, 2005). However, the 
most common definition of culture has been as “country” (e.g. Matsumoto & 
Yoo, 2006). 
Another important issue associated with cross-cultural research besides the 
definition of culture is equivalence, which has been described as “by far the 
most important concept that researchers need to be aware of when 
conducting cross-cultural research” (Matsumoto & Yoo, 2006, p. 243). 
Equivalence generally refers to whether the results from different cultures can 
be compared meaningfully (e.g. Van de Vijver, 2001). More specifically, there 
are two main types of equivalence: measurement equivalence and linguistic 
equivalence.  
Measurement equivalence has been defined as “whether or not, under 
different conditions of observing and studying phenomena, measurement 
operations yield measures of the same attribute” (Horn & McArdle, 1992, p. 
117). Therefore, in terms of cross-cultural research, measurement 
equivalence refers to whether measures are valid in different cultures. If there 
is a lack of measurement equivalence, comparisons of results from different 
cultures will be meaningless (e.g. Cha, Kim & Erlen, 2007). Linguistic 
equivalence refers to whether measures in different languages have the same 
meaning, reading difficulty and “naturalness” of wording (e.g. Lonner, 1985; 
Van de Vijver & Leung, 1997). Similarly to measurement equivalence, 
comparisons of results from different cultures will be meaningless if there is a 
lack of linguistic equivalence, especially since words can have different 
meanings in different languages when translated (e.g. Gudykunst, 2003). 
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It is possible to increase measurement equivalence if linguistic equivalence is 
increased (e.g. Jones et al., 2001; John et al., 2006). To increase linguistic 
equivalence, Van de Vijver and Hambleton (1996) recommend that the 
translation of measures should be conducted by a bilingual person of the 
original language and the language required for the translation. However, it is 
preferred for two bilingual individuals to conduct the translation (e.g 
Gudykunst, 2003). When two people conduct the translation, Van de Vijver 
and Hambleton (1996) recommend that both do the translation independently 
followed by comparison of the translation together. If there are any 
differences, these should be resolved by agreement between the translators. 
In this way, the error of one person can be reduced and the translation is 
more reliable (e.g. Gudykunst, 2003).  
In addition to using one or two bilingual people to complete the translation, 
Van de Vijver and Hambleton (1996) also recommend that the translator or 
translators should have knowledge of the cultures and knowledge regarding 
the measures (e.g. Van de Vijver & Hambleton, 1996; Hambleton & de Jong, 
2003). It has been suggested that knowledge of these factors is important so 
that the translation can be sensitive to the cultures and use words meaningful 
for each culture rather than literal translations that may not be meaningful 
(e.g. Gudykunst, 2003).  
Finally, Van de Vijver and Hambleton (1996) recommend back translation is 
also conducted, which is the most accepted and most widely used translation 
procedure (e.g. Cha et al., 2007). The back translation procedure involves 
another one or two bilingual individuals translating the measure from the 
translated language back into the original language. When two people 
conduct the back translation, Van de Vijver and Hambleton (1996) 
recommended that it is conducted independently followed by comparison of 
the back translations together and comparison to the original. If there are any 
differences, these should be resolved by agreement between the two back 
translators. Researchers agree that back translation is required for linguistic 
equivalence and validation of a measure to use in a cross-cultural study (e.g. 
McDermott & Palchanes, 1992; Jones et al., 2001; John et al., 2006). 
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2.8. Conclusion 
To conclude, it is evident that a number of methodological factors are 
important to consider for the present research. Firstly, considerations for 
online surveys are needed. In summary, these considerations involved the 
following: piloting the surveys to ensure they are understandable; recruiting 
participants from relevant locations to ensure participants are from the 
required group; using incentives to reduce self-selection bias; using progress 
indicators to reduce drop out; ensuring anonymity and confidentiality to 
reduce drop out further; and making questions required instead of optional in 
order to reduce missing data.  
Secondly, ethical considerations are needed. To summarise, for valid 
consent, participants were provided with understandable information about 
the research, then required to confirm they would like to participate. This 
information included explaining about withdrawal, so participants were aware 
of their right to withdrawal before they provided consent. The risks of 
participating were not more than expected in daily life, but participants were 
provided with information for help about pain and painkiller use incase this 
was needed. To ensure confidentiality, participants were required to create a 
unique ID code, and their responses were only shared between the 
researcher and supervisors. After participants finished their surveys, there 
was a debrief to provide further information for participants and reminder 
about withdrawal. Netiquette guidelines were also followed, including 
obtaining permission to advertise research in forums, following 
communication standards of forums, avoid technical terms, and providing 
contact details of the researcher and supervisors. 
Thirdly, considerations for self-reports are needed, including acquiescence, 
extreme responding, central tendency responding and social desirability bias. 
Although acquiescence can be reduced by using reverse scored items, 
researchers should accept that the extreme responding and central tendency 
responding are more difficult to be reduced. To reduce social desirability bias, 
using online surveys should be sufficient. 
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In addition to these considerations, it is also important to consider scale length 
and use short scales if possible, since short scales can reduce errors, fatigue, 
skim reading and response distortions. Also, considerations of longitudinal 
designs are needed, which are mainly to reduce attrition by making 
participants aware of the benefits of the research, using incentives, ensuring 
the surveys are a suitable length and sending reminders to participants to 
complete follow-up measures. Finally, considerations of cross-cultural 
research are also needed, which involves using back translation to ensure 
cultural sensitivity and validity of the measures including linguistic equivalence 
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In the UK, the prevalence of painkiller use has been high and increasing over 
time (e.g. Donaldson, 2008; Chief Medical Officer, 2009; Euromonitor 
International, 2016). Similar results have been found for problematic painkiller 
use. For example, a recent study by Fingleton et al. (2016) showed the 
prevalence of problematic OTC painkiller use in the UK was higher than any 
other OTC medications. Several issues have been linked to problematic 
painkiller use such as health problems, social problems and death (e.g. 
Simoni-Wastila & Yang, 2006; Office for National Statistics, 2013; Shapiro et 
al., 2015). Therefore, problematic painkiller use is a serious issues in the UK 
that requires research to understand the factors that have a role, which will 
allow to prevent and reduce these serious problems. 
There have also been some suggestions that the prevalence of problematic 
painkiller use could be higher in developing countries like Egypt (e.g. Mumtaz 
et al., 2011; Ghandour et al., 2012). However, to the best of my knowledge, 
there are currently no findings to support these suggestions. It would therefore 
be useful to investigate problematic painkiller use in Egypt. It would also be 
useful to make a comparison with the UK to examine which factors can 
explain the difference between the UK and Egypt if problematic painkiller use 
is indeed higher in Egypt.  
In the literature, it has been shown that accessibility of painkillers and 
psychological factors could be important to explain problematic painkiller use, 
as outlined below.  
3.1.1. Accessibility of painkillers 
The literature has shown that greater accessibility of painkillers is associated 
with more frequent painkiller use (e.g. Sallam et al., 2009). As a result of more 
frequent painkiller use, it is possible that accessibility of painkillers can lead to 
more problematic painkiller use. 
 56 
There are differences between the UK and Egypt regarding accessibility of 
painkillers. More specifically, the UK has more control with accessibility of 
painkillers but Egypt has less control. As an example, there are some 
painkillers that are classified as prescription only medications (POM) in the 
UK but the same painkillers are OTC in Egypt (e.g. Benjamin et al., 1996; 
Sallam et al., 2009). A further difference between the two countries is law 
enforcement. For example, providing painkillers “under-the-counter” is 
common in Egypt. This involves providing painkillers without a prescription 
when a prescription should be required (e.g. Ghandour et al., 2012). In 
contrast, providing painkillers “under-the-counter” is not common in the UK. 
Another difference between the two countries is the medical records system 
(e.g. Sallam et al., 2009). Specifically, it is possible for painkiller prescriptions 
to be recorded on the medical records system and available for other doctors 
and medics in the UK, but this is not possible in Egypt because there is no 
medical records system. Therefore, it is possible to obtain prescriptions from 
multiple doctors in Egypt. 
To sum up, the easier accessibility of painkillers in Egypt compared to the UK 
indicates that problematic painkiller use is potentially more likely in Egypt than 
the UK. Therefore, it is important to investigate the role of accessibility in 
problematic painkiller use. 
3.1.2. Psychological factors 
In terms of psychological factors, there have been findings suggesting that 
attitudes and beliefs towards pain, painkillers, self-medication and alternative 
methods of pain relief could be important in explaining problematic painkiller 
use. 
3.1.2.1. Attitudes and beliefs towards pain  
Positive attitudes and beliefs towards pain have been associated with less 
painkiller use whereas negative attitudes and beliefs have been associated 
with more painkiller use. For example, less painkiller use has been found 
among women with childbirth pain when the pain was considered important 
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for the childbirth (Callister et al., 2003). Similar findings have been reported 
among students; less painkiller use has been found among students who 
considered pain should “run its course” (James & French, 2008). These 
results show that positive attitudes and beliefs towards pain could reduce 
problematic painkiller use.  
3.1.2.2. Attitudes and beliefs towards painkillers and self-medication 
Negative attitudes and beliefs towards painkillers and self-medication have 
been associated with less painkiller use, whereas positive attitudes and 
beliefs have been associated with more painkiller use. For example, more 
concern that painkillers can lead to addiction, tolerance and side effects have 
been associated with less painkiller use. These results have been found 
among chronic pain patients, women with childbirth pain and pre-surgery 
cardiac patients (e.g. McCracken et al., 2006; Cogan et al., 2014). Given 
these results, negative attitudes and beliefs towards painkillers and self-
medication could reduce problematic painkiller use. 
3.1.2.3. Attitudes and beliefs towards alternative methods of pain relief 
Positive attitudes and beliefs towards alternative methods of pain relief have 
been associated with less painkiller use whilst negative attitudes and beliefs 
have been associated with more painkiller use (Hyland et al., 2003). 
Therefore, problematic painkiller use may be more likely for people with 
negative attitudes and beliefs towards alternative methods of pain relief.  
3.1.3. Aim 
The above findings demonstrate that accessibility and psychological factors 
could have a role in problematic painkiller use. However, there has been a 
lack of research focusing on the role of these factors in problematic painkiller 
use. Also, there has been a lack of research focusing on the general 
population, especially the UK and Egypt. Hence, the aim of the present study 
was to examine the role of accessibility and psychological factors in 
problematic painkiller use among the general population of the UK and Egypt. 
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3.1.4. Research question 
What is the role of accessibility and psychological factors in problematic 
painkiller use among the general population of the UK and Egypt?  
3.1.5. Hypotheses 
There will be easier accessibility of painkillers in Egypt than the UK, which will 
have a role in more problematic painkiller use. 
More positive attitudes and beliefs to pain will have a role in less problematic 
painkiller use.  
More positive attitudes and beliefs to painkillers will have a role in more 
problematic painkiller use.  
More positive attitudes and beliefs to self-medication will have a role in more 
problematic painkiller use. 
More positive attitudes and beliefs to alternative methods of pain relief will 
have a role in less problematic painkiller use. 
For these predictions about attitudes and beliefs, it could not be predicted 
whether there will be differences between the UK and Egypt due to the lack of 
research about these countries. 
3.2. Method 
 
3.2.1. Participants  
A total of 745 members of the general population were participants in the 
study: 295 participants from the UK and 420 participants from Egypt. 
According to power analysis calculation with G*Power, the total sample 
provided sufficient power to detect meaningful differences between the UK 
and Egypt (Faul, Erdfelder, Lang & Buchner, 2007). Specifically, a-priori 
power analysis was conducted to calculate the sample size that was needed, 
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which showed that a total sample between 84 and 231 participants was 
required.  
A separate power analysis was conducted for each type of statistical test in 
the analysis (see section 3.2.6) using the following input parameters: an alpha 
significance level of 0.05, a power level of 0.80 and medium effect size 
between 0.15 to 0.5 depending on the statistical test. A summary of the type 
of statistical test, effect size and sample size is shown in Table 1. These input 
parameters were based on what is usually used and recommended from 
previous research (e.g. Hunt, 2015). 
Table 1. Type of statistical test, effect size and sample size required 
according to power calculations. 
 
Statistical test Effect size Sample size 
Chi-squared test Phi (Φ) = 0.3 88 
t-test Cohen’s d (d) = 0.5 102 
Correlation Correlation coefficient 
(r) = 0.3 
84 
Multiple regression Cohen’s f (f2) = 0.15 231 
 
Participants in both countries were recruited using online and offline 
convenience sampling. For the online convenience sampling, invitations to 
participate were posted on forums and social media websites relevant to pain 
and painkillers based in the UK and Egypt. Websites with volunteers to 
participate in online survey research were also used to recruit participants in 
both countries. In addition, invitations were sent by email to GP practices, 
pain clinics, universities, large organisations and large employers in the UK 
and Egypt. For the offline convenience sampling, in both countries, invitations 
were advertised offline in pharmacies, GP practices, pain clinics, universities, 
large organisations and large employers. To advertise offline, these locations 
were asked to print the invitation to participate and distribute to staff, students 
and patients. However, for the UK only, the researcher also conducted the 
offline recruitment by printing the invitations and distributing to these 
locations. In addition to online and offline convenience sampling, snowball 
sampling was also conducted by asking participants to recommend the study 
to others would be interested to participate. 
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Participants were included in the study based on the following inclusion 
criteria: the participants should be at least 18 years of age, experienced pain 
in the last month, used OTC or prescription painkillers in the last month and 
be resident in the UK or Egypt. If any participants did not meet any of the 
inclusion criteria, these participants were excluded from the study. 
Additionally, participants were excluded from the study based on the following 
exclusion criteria: if there was any missing data or if they participated more 
than once in the study.  
3.2.2. Design 
A cross-sectional online questionnaire design was used to assess the role of 
accessibility and psychological factors in problematic painkiller use among the 
general population of the UK and Egypt. 
3.2.3. Measures 
An online questionnaire was used for data collection for this study, which 
consisted of the following measures (see Appendix A & B): 
3.2.3.1. Demographics  
The questionnaire started with questions about the following demographics: 
gender, age, marital status, nationality, language spoken at home, length of 
residence in country, highest education level, employment status, whether or 
not pain influences employment, religion, religiousness, ethnic origin and 
financial status. 
3.2.3.2. Pain 
Following the demographics, the questionnaire asked about pain, specifically 
pain duration, pain frequency in the last month, pain intensity in the last 
month, type of pain experienced in the last month and pain diagnosis. Note, 
pain intensity in the last month was measured using the Brief Pain Inventory 
(BPI; Cleeland & Ryan, 1994). This involved asking participants to rate on a 
10-point scale the intensity of their pain “at its worst”, “at its least”, “on the 
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average: and “right now”. Responses ranged from “no pain” to “pain as bad as 
you can imagine”. The average of these four ratings indicated pain intensity in 
the last month.     
3.2.3.3. Painkillers 
After the questions about pain, the questionnaire asked about painkillers, 
specifically the type of painkillers taken in the last month, frequency of 
painkiller use in the last month, painkiller misuse in the last month, painkiller 
abuse in the last month and alternatives to painkillers used in the last month. 
It should be noted that painkiller misuse involved using more than the 
recommended dose of painkillers at least “sometimes” and using painkillers 
for longer than the recommended duration at least “sometimes” as shown in 
Table 3 (section 3.3.1). In addition, painkiller abuse involved using painkillers 
when not in pain at least “sometimes” also as shown in Table 3.  
3.2.3.4. Accessibility of painkillers 
Together with the questions about painkillers, the questionnaire asked about 
accessibility of painkillers, including source of OTC painkillers, perceived 
difficulty for obtaining strong painkillers without a prescription, using strong 
painkillers without a prescription and source of strong painkillers if used 
without a prescription. 
3.2.3.5. Scales  
The remainder of the questionnaire consisted of scales measuring painkiller 
dependence (Leeds Dependence Questionnaire (LDQ); Ferrari et al., 2006), 
attitudes and beliefs towards pain (Survey of Pain Attitudes-Brief (SOPA-B); 
Tait & Chibnall, 1997), attitudes and beliefs towards painkillers (Pain 
Medication Attitudes Questionnaire (PMAQ); McCracken et al., 2006), 
attitudes and beliefs towards self-medication (Self-Medicating Scale (SMS); 
James & French, 2008) and attitudes and beliefs towards alternative methods 
of pain relief (Holistic, Complementary and Alternative Medicine 
Questionnaire (HCAMQ); Hyland et al., 2003). 
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3.2.3.5.1. Leeds Dependence Questionnaire (LDQ) 
Painkiller dependence was assessed using a modified version of the LDQ 
(Ferrari et al., 2006). In the original version of the LDQ, there are 10 items 
measuring substance dependence (Raistrick et al., 1994), with each item 
referring to “drink” or “drugs”. For example, “Do you find yourself thinking 
about when you will next be able to have another drink or take drugs?” In the 
modified version of LDQ, the items specifically measured dependence to 
painkillers by referring to “painkillers” instead of “drink” or “drugs” (Ferrari et 
al., 2006). The LDQ has good internal consistency, test re-test reliability, 
content validity, concurrent validity, discriminant validity and convergent 
validity (Raistrick et al., 1994). 
Items are rated on a 4-point scale that consists of the following response 
options: “Never”, “Sometimes”, “Often” and “Always”. A total dependence 
score is calculated by summing the responses to the 10 items together. The 
minimum total dependence score is 0 and the maximum is 30. A score of 20 
or more is considered to represent severe dependence (Raistrick et al., 1994). 
However, this score is for guidance only as no cut off scores have been 
proposed.   
3.2.3.5.2. Survey of Pain Attitudes-Brief (SOPA-B) 
The SOPA-B (Tait & Chibnall, 1997) is a brief 30-item version of the original 
Survey of Pain Attitudes (SOPA), which consists of 57-items (Jensen et al., 
1987). There are seven subscales in the SOPA-B, which measure seven 
attitudes and beliefs towards pain: “Solicitude” from others, “Emotion” 
experienced with pain, “Medical Cure” for pain, pain “Control”, pain as an 
indicator for “Harm”, pain-related “Disability” and “Medication” as an 
appropriate treatment for pain. The “Emotion” and “Control” subscales are 
considered adaptive, but the other subscales are considered maladaptive 
(Tait & Chibnall, 1997). All of the SOPA-B subscales have acceptable internal 
consistency except for the Medication subscale which has low internal 
consistency (Tait & Chibnall, 1997). The SOPA and SOPA-B have high 
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correlations, therefore the scales have concurrent validity (Tait & Chibnall, 
1997).  
Items in the SOPA-B are rated on a 5-point scale from “Very Untrue” to “Very 
True”. A score for each subscale is calculated by summing the responses in 
the subscale and dividing the summed responses score by the number of 
items in the subscale. However, a total score for the SOPA-B is not possible. 
The authors do not propose cut off scores, but do propose that desirable 
scores before average are between 0-20 for each subscale except for the 
Emotion subscale, Disability subscale and Medication subscale. Specifically, 
desirable scores for the Emotion subscale are between 0-16, whilst desirable 
scores for the Disability and Medication subscale are between 0-12. The 
minimum score for each subscale before average is 0 and the maximum is 
25. This is except for the Emotion subscale where the maximum is 20, and 
the Disability and Medication subscale where the maximum is 15. The 
average score in each subscale can range from 0 to 4. Higher scores on the 
adaptive subscales indicate more positive attitudes and beliefs towards pain 
but higher scores on the maladaptive subscales indicate more negative 
attitudes and beliefs towards pain.  
3.2.3.5.3. Pain Medication Attitudes Questionnaire (PMAQ)   
Attitudes and beliefs towards painkillers were assessed using the PMAQ, 
which consists of 47-items (McCracken et al., 2006). The PMAQ measures 
seven attitudes and beliefs about painkillers: “Addiction” to painkillers, “Need” 
of painkillers, “Scrutiny” from others about using painkillers, “Side Effects” of 
painkillers, “Tolerance” of painkillers, “Mistrust of Doctors” prescribing 
painkillers and “Withdrawal” symptoms. These scales have “excellent internal 
consistency and predictable relations with measures of medication use, 
depression and disability supporting their validity” (McCracken et al., 2006, p. 
726).  
Items in the PMAQ are rated on a 6-point scale from “Never True” to “Always 
True”. The PMAQ is scored by summing responses within each subscale 
together to produce a score for each subscale. However, a total score for the 
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PMAQ is not possible. The minimum score for each subscale is 0 and the 
maximum score for each subscale is as follows: 25 for Addiction, 40 for Need, 
40 for Scrutiny, 35 for Side Effects, 30 for Tolerance, 35 for Mistrust of 
Doctors, and 30 for Withdrawal. Although there are no cut off scores, higher 
scores for each subscale indicate more negative attitudes and beliefs towards 
painkillers.  
3.2.3.5.4. Self-Medicating Scale (SMS) 
The SMS consists of 9 items measuring attitudes and beliefs towards self-
medication (James & French, 2008). There are three subscales in the SMS, 
which were named “Reluctance” to self-medicate, “Don’t Think Twice” about 
self-medication and allow the symptoms to “Run its Course”. The SMS has 
been described by James and French (2008) as having “good internal 
reliability, plus good content and construct validity indicating that it is a useful 
measure of self-medication beliefs” (p. 794). In addition, the SMS has good 
discriminant validity because it has been found to discriminate between high, 
low and non-users of painkillers (James & French, 2008).  
Items in the SMS are rated on a 5-point scale from “Strongly Agree” to 
“Strongly Disagree”. The SMS is scored by calculating total scores for each of 
the three subscales by summing the individual items in each subscale. Similar 
to the SOPA-B and PMAQ, a total score for the SMS is not possible. The 
minimum score for each subscale is 3 and the maximum is 15. Again, there 
are no cut off scores but higher scores for Reluctance and Run its Course 
indicate negative attitudes and beliefs towards self-medication but higher 
scores for Don’t Think Twice indicate positive attitudes and beliefs towards 
self-medication.   
3.2.3.5.5. Holistic, Complementary and Alternative Medicine Questionnaire 
(HCAMQ) 
The HCAMQ is an 11-item scale measuring attitudes and beliefs towards 
holistic, complementary and alternative medicine (Hyland et al., 2003). There 
are two subscales in the HCAMQ: the holistic health beliefs subscale (HH) 
 65 
and the complementary and alternative medicine subscale (CAM). In the HH 
subscale, there are five items originally part of the Holistic Health Beliefs 
Questionnaire (HHBQ; Hyland et al., 2003). In the CAM subscale, there are 
six items originally part of the Attitudes toward Alternative Medicine Scale 
(AAMS; Finnigan, 1991). The HCAMQ and the subscales have good test re-
test reliability, internal consistency, divergent validity and convergent validity 
(Hyland et al., 2003).  
Items in the HCAMQ are rated on a 6-point scale from “Strongly Agree” to 
“Strongly Disagree”. A total HCAMQ score is obtained by summing the 11 
items together. The minimum total score is 11 and the maximum is 66. In 
addition, a score for the HH and CAM subscales can be obtained by summing 
the items in each subscale together. The minimum score for the HH subscale 
is 5 and the maximum is 30, whilst the minimum for the CAM subscale is 6 
and the maximum is 36. A lower total HCAMQ score, HH score and CAM 
score indicates more positive attitudes and beliefs towards HH and CAM. 
3.2.4. Materials 
The online questionnaire was created on Google Drive Forms. A separate 
online questionnaire was created for each country: an English version was 
created for the UK and an Arabic version was created for Egypt.  
3.2.5. Procedure 
The study was approved by the Psychology Research Ethics Committee at 
the University of Derby. After ethical approval, the two versions of the online 
questionnaire were created. To translate the questionnaire to Arabic, a back 
translation procedure was used. In the back translation procedure, the 
questionnaire was first translated from English to Arabic by two independent 
bilingual Arabic-English translators. Both Arabic versions were compared by 
the translators. Any differences between the two Arabic versions were 
resolved by the two translators until the two Arabic versions were the same. 
Then, the questionnaire was back translated from Arabic to English by 
another two independent bilingual Arabic-English translators. Both back 
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translated versions were compared by the translators and were compared to 
the original questionnaire. Any differences were resolved by the two 
translators until the two back translated versions were the same and were the 
same as the original questionnaire. For the analysis, the data collected from 
Egypt was also translated into English. 
Each version of the online questionnaire was piloted online before they were 
live. Participants were given the opportunity to enter a prize draw to win an 
Amazon e-voucher worth £70. If participants wanted to enter the prize draw, 
they needed to provide their email address so that the e-voucher could be 
emailed to them if they won.  
3.2.6. Analytic strategy 
SPSS was used to analyse the data from the online questionnaires. To 
conduct the analysis, the data from the UK and Egypt were merged from two 
separate data files into one data file and a “country” variable was created to 
code the participants as from the UK or Egypt. After merging, data cleaning 
was conducted to remove the data from any participants who should be 
excluded based on the exclusion criteria. Then, the data was analysed using 
a number of methods, which were chi-squared tests, independent-samples t-
tests, Pearson correlations, stepwise multiple regression and Sobel tests of 
mediation effects.  
In the chi-squared tests and independent-samples t-tests, differences 
between the countries for the demographic measures, pain measures, 
painkiller use measures, accessibility measures and psychological factors 
were tested. In the Pearson correlations, the relationship of dependence to 
these measures were tested for each country. The stepwise multiple 
regression tested whether the measures were predictors of dependence for 
each country. The Sobel tests were used for mediation analysis to test 
whether any predictors of dependence were mediators for each other. Again, 
this was conducted separately for each country. 
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For any significant results, effect size is reported to show how large are those 
significant effects (e.g. Sullivan & Feinn, 2012). Each type of analysis required 
a different effect size, specifically: the effect size required for chi-squared test 
results was Phi (Φ); the effect size required for independent-samples t-test 
results was Cohen’s d (d); the effect size required for correlation results was 
correlation coefficient (r); and the effect size required for multiple regression 
results was Cohen’s f (f2). Each type of effect size can be interpreted as small, 
medium or large, and the values for this interpretation are summarised in the 
Table 2. These values are based on guidelines from the literature (e.g. 
Cohen, 1988; Murphy & Myors, 2004; Vacha-Haase & Thompson, 2004).   
Table 2. Summary of values for interpreting effect size 
 
Statistical test Effect size Small Medium Large 
Chi-squared test Phi (Φ) 0.10 0.30 0.50 
Independent-
samples t-test 
Cohen’s d (d) 0.20 0.50 0.80 
Correlation Correlation 
coefficient (r)  
0.10 0.30 0.50 
Multiple regression Cohen’s f (f2) 0.02 0.15 0.35 
3.3. Results 
The results will present firstly comparisons between the UK and Egypt testing 
whether there were differences between the countries for the measures of the 
study. Following the comparisons, the results will present correlations of the 
measures with dependence. Finally, the predictors of dependence and 
mediators will be presented. 
3.3.1. Comparisons between the UK and Egypt 
A number of chi-squared tests and independent-samples t-tests were 
conducted. For chi-squared tests, most variables with more than two 
categories were recoded into binary variables so that the results could be 
interpreted meaningfully. A summary of the original coding and the binary 
recoding of relevant variables into binary variables is shown in Table 3. 
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Table 3. Original coding and binary recoding for variables that were recoded into 
binary variables. 
Original coding  Binary coding 
Marital status Marital status 
Married/co-habiting In a relationship 
  




Nationality  Nationality  
British 
Egyptian 
British or Egyptian  
  











New Zealander  
Polish  
  
Language spoken at home Language spoken at home 
English 
Arabic 
English or Arabic 
  






Education level Education level 
No qualification No qualification 
  
Secondary (Egypt only) Qualification 
                                                        
2 To clarify, since nationality was not an exclusion criterion, any participants 
with a nationality other than British or Egyptian were not excluded from the 
study but were recoded as “not British or Egyptian”. This is different to country 
of residence, which was an exclusion criterion (see section 3.2.1). Nationality 
was not an exclusion criterion because this might be less likely to influence 
access to painkillers than country of residence. For example, people can 
obtain strong painkillers easily from medication outlets regardless of their 
nationality if the country has less strict legislation and less law enforcement 
regarding painkillers. Therefore, to measure access of painkillers in the 




GCSE/O level (UK only)  
A level (UK only)  
Undergraduate degree  
Postgraduate degree  
Other (please specify) Each response was recoded into no 
qualification or qualification. 
  
Employment status Employment status 





Employed full-time In employment 
Employed part-time  
Self-employed  
Other (please specify) Each response was recoded into not in 
employment or in employment. 
  
Religion Religion 







Other Each response was recoded into no religion 
or religion. 
  
Ethnic origin Ethnic origin  
White Ethnic majority 
Egyptian  
  
Mixed Ethnic minority 
Asian or Asian British  
Black or Black British  
Nubian  
Bedouin  
Any other ethnic group Each response was recoded into ethnic 
majority or ethnic minority. 
  
Pain duration Pain duration 
Less than 1 month 6 months or less 
1-3 months   
4-6 months  
  
7-9 months Longer than 6 months 
10-12 months  
Longer than 12 months  
  
Type of painkillers taken in the last month Type of painkillers taken in the last 
month 
Over-the-counter only  No prescription painkillers  
  
Prescription only Prescription painkillers 
Both prescription and over-the-counter  
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Alternatives to painkillers used in the last 
month 
Alternatives to painkillers used in the 
last month 
Nothing No alternatives 
  
Hot water Alternatives 









Spiritual healing  
Traditional Chinese medicine  
Aquatherapy  
Magnetic therapy  
Aromatherapy  
Reiki  
Ointments, creams or gels  
Laser therapy  
Other alternative (please specify) Each response was recoded into no 
alternatives or alternatives. 
  
Using more than the recommended dose of 
painkillers + using painkillers for longer 
than recommended duration in the last 
month 











Usually   
Always  
Table 4 shows a comparison between the UK sample and the Egypt sample 
for demographic variables. The results for marital status, nationality, language 
spoken at home, highest education level, employment status, religion and 





Table 4. A comparison of demographic variables for the UK sample and Egypt 
sample. 
 
 UK sample (n = 
295) 
Egypt sample (n = 
420) 
t or Χ2 Effect 
size 
Gender1   118.93** Φ = -
0.41 
Male  40 (13.6%) 225 (53.6%)   
Female 255 (86.4%) 195 (46.4%)   
Age2 41.14 (12.30, 19 - 
79) 
35.36 (12.72, 18 - 
66) 
6.06** d = 
0.46 
Marital status1    6.77* Φ = -
0.10 
Not in a relationship 98 (33.2%) 180 (42.9%)   
In a relationship 197 (66.8%) 240 (57.1%)   
Nationality1   30.80** Φ = 
0.21 
British or Egyptian 274 (92.9%) 420 (100.0%)   
Other  21 (7.1%) 0 (0.0%)   
Language spoken at home1   8.62*  Φ = 
0.11 
English or Arabic 289 (98.0%) 420 (100.0%)   
Other 6 (2.0%) 0 (0.0%)   
Length of residence in the 
UK or Egypt1 
  44.58**  Φ = -
0.25 
Since birth 265 (89.8%) 420 (100.0%)   
Other 30 (10.2%) 0 (0.0%)   
Highest education level1   12.98**  Φ = 
0.14 
No qualification 9 (3.1%) 0 (0.0%)   
Qualification 286 (96.9%) 420 (100.0%)   
Employment status1   0.91  
Not in employment 141 (47.8%) 216 (51.4%)   
In employment 154 (52.2%) 204 (48.6%)   
Whether or not pain 
influences employment1 
  7.21* Φ = -
0.10 
Yes 145 (49.2%) 164 (39.0%)   
No 150 (50.8%) 256 (61.0%)   
Religion1   239.11** Φ = 
0.58 
No religion 136 (46.1%) 0 (0.0%)   
Religion 159 (53.9%) 420 (100.0%)   
Religiousness2 2.09 (1.20, 1 – 5) 3.44 (1.08, 1 – 5)  -15.53** d = -
1.18 
Ethnic origin1   7.01* Φ = 
0.10 
Ethnic minority  14 (4.7%) 6 (1.4%)   
Ethnic majority  281 (95.3%) 414 (98.6%)   
Financial status1   2.70  
A little or a lot poorer than 
most 
91 (30.8%) 128 (30.5%)   
About the same as most 172 (58.3%) 229 (54.5%)   
A little or a lot richer than 
most 
32 (10.8%) 63 (15.0%)   
 
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001, Φ = Phi, d = Cohen’s d 
 
 72 
As shown in Table 4, all comparisons were significant except for employment 
status and financial status. Specifically, there was a significant difference 
between the two countries in marital status, language spoken at home, 
whether or not pain influences employment and ethnic origin. There was a 
highly significant difference between the two countries in gender, age, 
nationality, length of residence in the UK or Egypt, highest education level, 
religion and religiousness. Most of these comparisons had either a medium or 
large effect size as demonstrated in Table 4, except for the following, which 
had small effect size: marital status, whether or not pain influences 
employment and ethnic origin. 
The results in Table 4 show most of the participants in the UK sample were 
females. However, in the Egypt sample gender reported was more balanced 
than the UK sample. On average, participants in the UK sample were older 
than the Egypt sample by 5.78 years. The majority of participants in each 
sample were in a relationship; approximately two-thirds were in a relationship 
in the UK sample and over half were in a relationship in the Egypt sample. 
These participants reported their marital status as married/cohabiting but for 
participants not in a relationship, the most common reported marital status 
was single and few participants were widowed or divorced/separated (see 
Table 50, Appendix G).  
Almost the entire UK sample was British nationality, spoke English at home 
and the majority lived in the UK since birth (see Table 4). Only a few of the UK 
sample reported that they have lived in the UK since another date; the dates 
specified by these participants were from 1958 to 2007. Very few of the UK 
sample were other nationalities; the most common other nationalities were 
Irish, American, Dutch, German and Polish (see Table 50, Appendix G). Also, 
very few of the UK sample spoke other languages, mostly Welsh (see Table 
50, Appendix G). All of the Egypt sample was Egyptian nationality and spoke 
Arabic at home (see Table 4). In addition, all of the Egypt sample lived in 
Egypt since birth (see Table 4).  
Table 4 shows that a small proportion of participants had no qualification in 
the UK sample but there were no participants with no qualification in the Egypt 
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sample. For participants with a qualification, the most common qualifications 
in the UK sample were undergraduate degree and postgraduate degree, each 
approximately one-quarter (see Table 50, Appendix G). Among the Egypt 
sample, the most common qualification was secondary qualification, which 
was over two-thirds of participants, followed by undergraduate degree, which 
was over one-quarter of participants (see Table 50, Appendix G). 
Although there were no significant differences in employment status, there 
were more people whose pain influenced their employment in the UK than 
Egypt; almost half of the UK sample reported that pain influenced their current 
employment status compared to just over one-third in the Egypt sample (see 
Table 4).  
Under half of the UK sample reported no religion but none of the Egypt 
sample reported no religion (see Table 4). The most common religion in the 
UK sample was Christianity, which was a similar proportion to no religion (see 
Table 50, Appendix G). In the Egypt sample, two-thirds of participants 
reported their religion was Islam and one-third reported their religion was 
Christianity (see Table 50, Appendix G). For religiousness, participants were 
generally more religious in Egypt than the UK because there were higher 
religiousness scores for the Egypt participants than the UK participants (see 
Table 4). For ethnic origin, almost all of the UK sample and Egypt sample 
were the ethnic majority, which was White for the UK sample and Egyptian for 
the Egypt sample (see Table 50, Appendix G). 
Table 5 compares the UK sample and Egypt sample for pain variables. The 













Table 5. A comparison of pain variables for the UK sample and Egypt 
sample. 
 
 UK sample Egypt sample t or Χ2 Effect 
size 
Pain duration1   310.73** Φ = -
0.66 
6 months or less 24 (8.1%) 315 (75.0%)   
Longer than 6 months 271 (91.9%) 105 (25.0%)   
Pain frequency in the last 
month (days)2 
24.22 (9.88, 2 – 
31) 
3.89 (3.22, 1 – 31) 34.10** d = 2.77 
Pain intensity in the last 
month2 
17.62 (5.66, 4.00 – 
31.75) 
15.61 (6.16, 0.00 – 
32.50) 
4.52** d = 0.34 
Type of pain experienced 
in the last month1 
    
Headache 185 (62.7%) 109 (26.0%) 96.71** Φ = -
0.37 
Migraine 89 (30.2%) 113 (26.9%) 0.91  
Period pain 97 (38.0%) 40 (20.5%) 61.04** Φ = -
0.29 
Toothache 43 (14.6%) 74 (17.6%) 1.17  
Abdominal pain 139 (47.1%) 92 (21.9%) 50.37** Φ = -
0.27 
Chest pain 68 (23.1%) 76 (18.1%) 2.65  
Foot pain 119 (40.3%) 62 (14.8%) 59.96** Φ = -
0.29 
Sore throat 49 (16.6%) 33 (7.9%) 13.08** Φ = -
0.14 
Back pain 206 (69.8%) 59 (14.0%) 231.16** Φ = -
0.57 
Joint pain 190 (64.4%) 58 (13.8%) 195.82** Φ = -
0.52 
Earache 28 (9.5%) 10 (2.4%) 17.41** Φ = -
0.16 
Muscle pain 190 (64.4%) 47 (11.2%) 221.46** Φ = -
0.56 
Other 61 (20.7%) 24 (5.7%) 37.04** Φ = -
0.23 
Pain diagnosis1   41.35** Φ = -
0.24 
Yes 254 (86.1%) 271 (64.5%)   
No 41 (13.9%) 149 (35.5%)   
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001, Φ = Phi, d = Cohen’s d 
Table 5 shows that most pain variables were highly significantly different 
between each country and only three variables were non-significantly 
different. The non-significantly different variables were migraine, toothache 
and chest pain. There was a highly significant difference between the two 
countries for all of the other pain variables. These comparisons had either 
medium or large effect size, and there were no comparisons with small effect 
size. 
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Almost all of the UK sample had chronic pain for longer than 6 months but 
there was more variation in the Egypt sample; three-quarters of the Egypt 
sample had acute pain for 6 months or less and one-quarter had chronic pain 
for longer than 6 months (see Table 5). Most of the UK sample with chronic 
pain for longer than 6 months actually had pain for longer than 12 months 
(see Table 51, Appendix G). Most of the Egypt sample with acute pain for 6 
months or less actually had pain for less than 1 month, followed by 1-3 
months and 4-6 months but most of the Egypt sample with chronic pain for 
longer than 6 months had pain for 7-9 months (see Table 51, Appendix G). 
When asked about how many days pain had been experienced in the last 
month, participants in the UK reported pain for more days than participants in 
Egypt and pain intensity was higher in the UK than Egypt (see Table 5). For 
type of pain experienced in the last month, Table 5 shows the most common 
types of pain for participants in the UK were back pain, joint pain, muscle pain 
and headache, each approximately two-third of participants or higher. In the 
Egypt sample, the most common types of pain were headache and abdominal 
pain, each less than one-third of participants. In addition, a greater proportion 
of UK participants reported a diagnosis for their pain compared to Egypt 
participants (see Table 5).  
Table 6 compares the UK sample and Egypt sample for painkiller use 
variables. The results for type of painkillers taken in the last month, 
alternatives to painkillers taken in the last month, painkiller misuse in the last 
month and painkiller abuse in the last month before binary recoding is shown 







Table 6. A comparison of painkiller use variables for the UK sample and 
Egypt sample. 
 
 UK sample Egypt sample t or Χ2 Effect 
size 
Type of painkillers taken in 
the last month1 
  23.65** Φ = -
0.18 
No prescription painkillers 
(OTC only) 
56 (19.0%) 150 (35.7%)   
Prescription painkillers 239 (81.0%) 270 (64.3%)   
Frequency of painkiller use 
in the last month (days)2 
21.79 (11.44, 1 – 
31) 
3.37 (3.71, 1 – 
31) 
30.78** d = 
2.17 






Yes 129 (43.7%) 378 (90.0%)   
No 166 (56.3%) 42 (10.0%)   






Yes 27 (9.2%) 338 (80.5%)   
No 268 (90.8%) 82 (19.5%)   
Alternatives to painkillers 





No alternatives 20 (6.8%) 197 (46.9%)   
Alternatives 275 (93.2%) 223 (53.1%)   
 
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001, Φ = Phi, d = Cohen’s d 
 
The results in Table 6 shows all painkiller use variables were highly 
significantly different between each country, with either medium or large effect 
size. It shows most participants used prescription painkillers in both samples 
but this was higher in the UK sample than the Egypt sample and participants 
who used OTC painkillers only were higher in the Egypt sample than the UK 
sample. Among the participants who used prescription painkillers, most 
participants in the UK used both prescription and OTC painkillers in the last 
month and a similar but smaller proportion used prescription painkillers only 
(see Table 52, Appendix G). In Egypt, most participants used prescription 
painkillers only and a similar but smaller proportion used both prescription and 
OTC painkillers (see Table 52, Appendix G). 
In the UK sample, painkillers were used most days in the month but painkillers 
were used for fewer days in the month in the Egypt sample (see Table 6). 
However, painkiller misuse was more prevalent in Egypt than the UK; almost 
all of participants in the Egypt sample misused painkillers compared with less 
than one-half of participants in the UK sample (see Table 6). Most of the UK 
sample never used more than the recommended dose of painkillers and never 
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used painkillers for longer than the recommended duration. In contrast, most 
participants in the Egypt sample sometimes used more than the 
recommended dose of painkillers and sometimes used painkillers for longer 
than the recommended duration (see Table 52, Appendix G). Also, painkiller 
abuse was more prevalent in Egypt than the UK; over three-quarter of 
participants in the Egypt sample abused painkillers but few participants in the 
UK sample abused painkillers (see Table 6).  
Using alternatives to painkillers was more common in the UK than Egypt 
because almost all of the UK sample reported using alternatives compared to 
approximately half of the Egypt sample (see Table 6). Participants who used 
alternatives in the Egypt sample used mostly massage and physiotherapy 
(see Table 52, Appendix G). In the UK sample, several alternative methods 
were used, in order of prevalence: hot water bottle, exercise, massage, 
ointments creams or gels, physiotherapy ice and a drink of water (see Table 
52, Appendix G). 
Table 7 compares accessibility variables between the UK sample and Egypt 
sample. The table shows most of the comparisons between the UK and Egypt 
for accessibility were significant. The only non-significant comparisons were 
obtaining strong painkillers from a family member who is not a medical 
professional, obtaining OTC painkillers from a friend who is not a medical 
professional, the internet and “other”. For family member who is a medical 








Table 7. A comparison of accessibility variables for the UK sample and Egypt 
sample. 
 
 UK sample Egypt sample t or Χ2 Effect 
size 
Source of over-the-counter 
painkillers1 
    
Pharmacy 138 (46.8%) 349 (83.1%) 105.22** Φ = 
0.38 
Supermarket shelf 119 (40.3%) 9 (2.1%) 172.02** Φ = -
0.49 
Family member who IS a medical 
professional 
0 (0.0%) 0 (0.0%) -  
Family member who is NOT a 
medical professional 
6 (2.0%) 49 (11.7%) 22.65** Φ = 
0.18 
Friend who IS a medical professional 1 (0.3%) 26 (6.2%) 16.33** Φ = 
0.15 
Friend who is NOT a medical 
professional 
4 (1.4%) 11 (2.6%) 1.35  
Internet 4 (1.4%) 10 (2.4%) 0.95  
Other 4 (1.4%) 3 (0.7%) 0.74  
Perceived difficulty for obtaining 
strong painkillers without a 
prescription2 
2.11 (1.22, 1 – 
5) 






Using strong painkillers without a 
prescription1 
  136.81** Φ = 
0.44 
Yes 59 (20.0%) 270 (64.3%)   
No 236 (80.0%) 150 (35.7%)   
Source of strong painkillers (if 
strong painkillers were used 
without a prescription) 1 
    
Pharmacy 22 (7.5%) 309 (73.6%) 304.65** Φ = 
0.65 
Family member who IS a medical 
professional 
0 (0.0%) 44 (10.5%) 32.93** Φ = 
0.22 
Family member who is NOT a 
medical professional 
21 (7.1%) 21 (5.0%) 1.41  
Friend who IS a medical professional 4 (1.4%) 46 (11.0%) 24.54** Φ = 
0.19 
Friend who is NOT a medical 
professional 
17 (5.8%) 5 (1.2%) 12.15** Φ = -
0.13 




1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001, Φ = Phi, d = Cohen’s d 
 
The significant comparisons were obtaining strong painkillers from “other”. 
The highly significant comparisons were obtaining OTC painkillers from a 
pharmacy, supermarket shelf, family member who is not a medical 
professional, friend who is a medical professional, perceived difficulty for 
obtaining strong painkillers without a prescription, using strong painkillers 
without a prescription, obtaining strong painkillers from the pharmacy, family 
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member who is a medical professional, friend who is a medical professional 
and friend who is not a medical professional. Only one comparison had small 
effect size, which was obtaining strong painkillers from “other”. The remaining 
comparisons had either medium or large effect size.  
Table 7 shows that among the participants that used OTC painkillers, the 
most common source for obtaining these painkillers in the UK and Egypt was 
the pharmacy. The second most common source for obtaining OTC painkillers 
in the UK was the supermarket shelf. In Egypt, the second most common 
source for obtaining OTC painkillers was a family member who is not a 
medical professional. The remaining sources were low proportions. 
Table 7 also shows participants in Egypt perceived obtaining strong painkillers 
without a prescription as easier than participants in the UK. Almost two-thirds 
of the participants in Egypt obtained strong painkillers without a prescription 
compared to less than one-quarter of participants in the UK. The most 
common source for obtaining strong painkillers without a prescription in both 
countries was the pharmacy but the proportion in the UK sample was low 
compared to the Egypt sample.  
Table 8 compares scores for the LDQ, SOPA-B, PMAQ, SMS and HCAMQ 









Table 8. A comparison of scores for the LDQ, SOPA-B, PMAQ, SMS and 
HCAMQ between the UK sample and Egypt sample. 
 






LDQ total 10.18 (5.75) 16.53 (6.10) –14.04**  d = -1.07 
SOPA-B Solicitude  1.66 (0.98) 2.39 (0.84) -10.35** d = -0.80 
SOPA-B Emotion  2.39 (1.08) 2.37 (0.88) 0.25  
SOPA-B Medical Cure  1.56 (0.89) 1.80 (0.58) -4.12** d = 0.89 
SOPA-B Control  1.67 (0.82) 2.41 (0.79) -12.11** d = -0.92 
SOPA-B Harm  2.07 (0.90) 1.97 (0.56) 1.70  
SOPA-B Disability  2.63 (1.11) 1.92 (0.52) 10.09** d = 0.82 
SOPA-B Medication  2.67 (0.87) 2.39 (0.94) 4.02** d = 0.31 
PMAQ Addiction  7.11 (6.60) 14.84 (5.00) -17.00** d = -1.32 
PMAQ Need  19.47 (9.85) 22.65 (6.00) -4.94** d = -0.39 
PMAQ Scrutiny  11.72 (7.96) 20.83 (3.69) -18.33** d = -1.47 
PMAQ Side Effects  13.34 (8.40) 20.67 (6.59) -12.53** d = -1.00 
PMAQ Tolerance  12.75 (7.99) 17.69 (5.66) -9.13** d = -0.71 
PMAQ Mistrust of Doctors  13.62 (8.28) 15.95 (3.74) -4.52** d = -0.36 
PMAQ Withdrawal  10.17 (8.04) 17.65 (5.79) -13.67** d = -1.07 
SMS Reluctance  11.35 (3.48) 9.87 (3.31) 5.75** d = 0.44 
SMS Don’t Think Twice  9.81 (3.32) 10.23 (3.03) -1.74  
SMS Run its Course  7.65 (2.97) 10.20 (3.01) -11.24** d = -0.85 
HCAMQ  32.58 (7.22) 37.02 (3.92) -9.63** d = -0.76 
HCAMQ HH  10.78 (3.90) 14.86 (5.64) –11.42** d = -0.84 
HCAMQ CAM  21. 80 (5.81) 22.17 (2.95) –1.01  
 
Note: *p ≤ 0.05, **p ≤ 0.001, d = Cohen’s d 
The table shows dependence scores in the Egypt sample were higher than 
the UK sample. For the SOPA-B, the table shows that the Egypt sample had 
significantly higher scores than the UK sample for Solicitude, Medical Cure 
and Control. The UK sample had significantly higher scores than the Egypt 
sample for Disability and Medication. However, there were no significant 
differences between the two samples on the Emotion subscale and the Harm 
subscale. For the PMAQ, participants in the Egypt sample had significantly 
higher scores for all subscales. For the SMS, the UK sample had higher 
scores than the Egypt sample for the Reluctance subscale and had lower 
scores than the Egypt sample on the Run its Course subscale, but there were 
no significant differences for the Don’t Think Twice subscale. The Egypt 
sample had higher total scores for the HCAMQ than the UK sample and 
higher scores than the UK sample for the HH subscale, but there were no 
differences for the CAM subscale. All of the significant comparisons had either 
medium or large effect size. 
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To extend the analysis regarding LDQ score, Table 9 shows the frequency 
and proportion of participants with severe dependence in the UK and Egypt.  
Table 9. Frequency and proportion of participants with severe 
dependence in the UK sample and Egypt sample. 
Country Severe dependence  
N (%) 
UK 21 (7.12) 
Egypt 136 (32.38) 
As mentioned previously (see section 3.2.3.5.1), severe dependence involves 
obtaining a score of 20 or more on the LDQ (Raistrick et al., 1994). The 
results show that there were more participants with severe dependence in 
Egypt than the UK, since almost one-third had severe dependence in Egypt 
compared to only small proportions in the UK. 
3.3.2. Correlations of dependence with demographic variables, pain 
variables, painkiller use variables and scale scores  
The correlations of dependence with demographic variables, pain variables, 
painkiller use variables and scale scores were analysed using Pearsons 
correlation. A separate correlations analysis was conducted for each country. 
The results of these correlations are presented in two separate correlations 
matrices below. Table 10 shows the correlations relevant to the UK sample 




Table 10. Correlations of dependence (LDQ scores) with demographic variables, pain variables, painkiller use variables and scale scores in the UK. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Age 1                   
2. Pain frequency  .30** 1                  
3. Pain intensity .22** .56** 1                 
4. Painkiller use 
frequency 
.26** .75** .51** 1                
5. Reluctance  -.21** -.32** -.17** -.43** 1               
6. Don’t Think Twice  .19** .17** .16** .36** -.40** 1              
7. Run its Course  -.17** -.16** -.12** -.276** .43** -.47** 1             
8. Addiction  .00 .27** .17** .33** -.19** .26** -.17** 1            
9. Need  .15** .38** .41** .53** -.32** .39** -.38** .51** 1           
10. Scrutiny  -.09 .13* .11 .11 -.04 .07 .01 .47** .10 1          
11. Side Effects  .03 .29** .33** .30** -.06 .05 -.05 .56** .44** .37** 1         
12. Tolerance  .10 .42** .41** .47** -.16** .17** -.14* .65** .68** .40** .70** 1        
13. Mistrust of Doctors  -.04 .01 -.01 -.07 .05 -.08 .14* .03 -.01 .25** .11 .15* 1       
14. Withdrawal  .14* .38** .36** .48** -.34** .42** -.31** .69** .68** .29** .49** .63** .03 1      
15. Solicitude  -.09 .03 .02 -.07 -.05 .14* -.17** .13* .20** .15** .11 .17** .06 .23** 1     
16. Emotion  .11 .19** .11 .11 -.14* .16** -.11 .16** .15** .20** .18** .23** .15* .23** .40** 1    
17. Medical Cure  -.24** -.31** -.23** -.26** .19** -.12* .18** -.12* -.31** -.09 -.19** -.34** -.14* -.27** -.15** -.25** 1   
18. Control  .23** .02 -.12** -.04 -.08 -.03 .14* -.07 -.23** -.05 -.09 -.16** -.05 -.12* -.00 .33** .06 1  
19. Harm  -.01 .18** .34** .21** -.13* .15* -.16** .15* .34** -.04 .13* .27** -.05 .26** .12* .00 -.09 -.31** 1 
20. Disability  .14* .51** .46** .46** -.16* .15* -.20** .25** .54** .04 .36** .49** -.00 .39** .12* .12* -.26** -.26** .50** 
21. Medication  .11 .19** .23** .37** -.22** .34** -.35** .17** .55** -.08 .15** .33** -.17** .39** .15* .11 -.27** -.18** .22** 
22. HH  -.00 .03 .05 .06 -.06 -.02 -.14* .11 0.2 .06 .02 .04 -.01 .03 -.05 -.24** .08 -.21** .07 
23. CAM  -.03 -.17** -.09 -.11* .04 .04 -.01 -.07 -.03 -.05 -.06 -.06 .07 -.02 .08 -.08 .04 -.24** .04 
24. HCAMQ  -.03 -.13* -.05 -.06 .00 .02 -.08 .01 -.12 .07 -.04 -.03 .05 .01 .04 -.19** .08 -.31** .07 
25. LDQ  .12* .39** .36** .53** -.30** .32** -.25** .47** .72** .09 .47** .58** -.05 .56** .13* .18** -.17** -.04 .22** 
 
 20 21 22 23 24 25 
20. Disability  1      
21. Medication  .32** 1     
22. HH  .02 .04 1    
23. CAM  -.09 .00 .07 1   
24. HCAMQ  -.06 .02 .60** .84** 1  
25. LDQ  .42** .39** .04 -.07 -.04 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001 
 
5 – 7 SMS subscales 
8 – 14 PMAQ subscales 
15 – 21 SOPA-B subscales 
22 – 24 HCAMQ subscales 
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Table 11. Correlations of dependence (LDQ scores) with demographic variables, pain variables, painkiller use variables and scale scores in Egypt. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Age 1                   
2. Pain frequency  .11* 1                  
3. Pain intensity .12* .16** 1                 
4. Painkiller use frequency .14** .67** .18** 1                
5. Reluctance  .12* .06 .34** .12* 1               
6. Don’t Think Twice  .04 .03 .35** .08 .75** 1              
7. Run its Course  .04 .04 .30** .06 .56** .72** 1             
8. Addiction  .08 .10* .19** .16** .12* .14** .17** 1            
9. Need  .09 .04 .26** .14** .18** .19** .18** .79** 1           
10. Scrutiny  -.01 .07 .04 .06 .02 .03 .11* .68** .46** 1          
11. Side Effects  .09 .07 .25** .13** .17** .20** .19** .87** .89** .55** 1         
12. Tolerance  .09 .08 .22** .14** .15** .17** .17** .89** .86** .59** .94** 1        
13. Mistrust of Doctors  -.08 -.08 -.25** -.14** -.16** -.22** -.09 -.52** -.55** -.09 -.62** -.61** 1       
14. Withdrawal  .10* .02 .23** .10* .18** -21** .19** .88** .85** .55** .92** .92** -.63** 1      
15. Solicitude  .04 .01 .19** .09 .12* .16** .22** .60** .58** .38** .61** .61** -.36** .60** 1     
16. Emotion  .08 .10 .22** .17** .24** .23** .19** .60** .61** .31** .63** .63** -.46** .60** .83** 1    
17. Medical Cure  -.02 -.04 -.24** -.09 -.15** -.15** -.18** -.55** -.54** -.34** -.57** -.56** .35** -.57** -.75** -.71** 1   
18. Control  .09 .02 .15** .10* .09 .13** .20** .60** .54** .36** .61** .61** -.41** .58** .79** .72** -.61** 1  
19. Harm  -.07 .08 -.17** .00 -.26** -.17** -.06 -.16** -.25** .09 -.24** -.20** .27** -.23** -.24** -.45** .40** -.11* 1 
20. Disability  -.03 .12* .11* .07 -.08 -.03 -.04 -.28** -.27** -.11* -.28** -.30** .24** -.30** -.31** -.37** .26** -.48** .11* 
21. Medication  .05 .01 .22** .09 .18** .20** .24** .57** .55** .32** .57** .57** -.38** .56** .85** .80** -.72** -.72** -.30** 
22. HH  -.06 -.11* -.40** -.15** -.56** -.57** -.57** -.20** -.26** -.04 -.26** -.24** .25** -.25** -.25** -.33** -.72** .72** -.30** 
23. CAM  .03 .03 .32** .08 .50** .48** .44** .16** .18** -.01 .19 .17** -.19** .20** .17** .25** -.16** .16** -.25** 
24. HCAMQ  -.06 -.13** -.33** -.16** -.44** -.46** -.49** -.18** -.24** -.07 -.24** -.22** .22** -.21** -.23** -.29** .17** -.20** .13** 
25. LDQ  .11* .01 .04 .06 -.01 .01 .03 .25** .23** .17** .23** .23** -.13** .25** .33** .29** -.25** .29** -.07 
 
 20 21 22 23 24 25 
20. Disability  1      
21. Medication  -.28** 1     
22. HH  .06 -.27** 1    
23. CAM  -.07 .19** -.76** 1   
24. HCAMQ  .04 -.26** .87** -.34** 1  
25. LDQ  -.14** .30** -.08 .03 -.10* 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001 
 
5 – 7 SMS subscales 
8 – 14 PMAQ subscales 
15 – 21 SOPA-B subscales 
22 – 24 HCAMQ subscales 
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3.3.2.1. Age  
There was a small but significant positive correlation between age and 
dependence in both countries. 
3.3.2.2. Pain frequency  
Pain frequency had a small but highly significant positive correlation with 
dependence in the UK sample, but there was no significant correlation 
between pain frequency and dependence in the Egypt sample. 
3.3.2.3. Pain intensity 
In the UK sample, there was a small but highly significant positive correlation 
between pain intensity and dependence but there was no significant 
correlation in the Egypt sample.  
3.3.2.4. Painkiller use frequency  
There was a moderate positive correlation between painkiller use frequency 
and dependence in the UK sample and the correlation was highly significant. 
However, no significant correlation was found between painkiller use 
frequency and dependence in the Egypt sample.  
3.3.2.5. Self-Medicating Scale (SMS) 
In the UK sample, the Reluctance subscale and the Run its Course subscale 
had a small negative correlation to dependence and were both highly 
significant. The Don’t Think Twice subscale had a small positive correlation to 
dependence, which was also highly significant. In contrast, there were no 





3.3.2.6. Pain Medication Attitudes Questionnaire (PMAQ)   
Almost all of the PMAQ subscales had highly significant and positive 
correlations with dependence in the UK sample. These subscales were 
Addiction, Need, Side Effects, Tolerance and Withdrawal. All of these 
subscales had a moderate correlation with dependence except the Need 
subscale, which demonstrated a large correlation with dependence. The 
subscales with no significant correlation to dependence in the UK sample 
were the Scrutiny subscale and the Mistrust of Doctors subscale.  
The correlations between the PMAQ subscales and dependence in the Egypt 
sample were similar to the UK because most were positive and highly 
significant. These subscales were Addiction, Need, Scrutiny, Side Effects, 
Tolerance and Withdrawal. However, these were small correlations instead of 
moderate or large correlations in the UK sample. Unlike the UK sample, there 
was one negative correlation, which was between the Mistrust of Doctors 
subscale and dependence. Also, unlike the UK sample, there were no non-
significant correlations.  
3.3.2.7. Survey of Pain Attitudes-Brief (SOPA-B) 
Most of the SOPA-B subscales were highly significantly correlated with 
dependence in the UK sample. There was only one non-significant 
correlation, which was between the Control subscale and dependence. The 
subscales with a highly significant correlation with dependence were the 
Emotion, Harm and Medication subscale. These were all small positive 
correlations. The Solicitude subscale also had a small positive correlation to 
dependence but this was significant instead of highly significant. The Disability 
subscale had a highly significant positive correlation to dependence, which 
was moderate. There was one negative correlation between the Medical Cure 
subscale and dependence, which was small but highly significant.  
The correlations in the Egypt sample had some similarities to the UK. One 
similarity was the Medical Cure subscale had a negative correlation to 
dependence, which was small and highly significant. Another similarity was 
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the Emotion and Medication subscale had a highly significant small and 
positive correlation to dependence. However, there were also some 
differences between the correlations of the Egypt sample and the UK sample. 
One difference was the Control subscale had a small positive and highly 
significant correlation to dependence, whereas in the UK sample there was no 
significant correlation. Another difference was the Solicitude subscale had a 
highly significant small and positive correlation with dependence, rather than a 
significant small positive correlation in the UK sample. Another difference was 
the Harm subscale was not significantly correlated to dependence, rather than 
a highly significant small positive correlation in the UK sample. A final 
difference was the Disability subscale had a highly significant small and 
negative correlation to dependence, whereas in the UK sample there was a 
highly significant positive moderate correlation.   
3.3.2.8. Holistic, Complementary and Alternative Medicine Questionnaire 
(HCAMQ 
There were no significant correlations between any HCAMQ measures and 
dependence in the UK sample. In the Egypt sample, there was a small but 
significant negative correlation between HCAMQ total and dependence. The 
other HCAMQ measures were non-significant in the Egypt sample.  
3.3.3. Predictors of dependence 
A stepwise multiple regression analysis was conducted to assess predictors 
of dependence for each sample. In the stepwise multiple regression, 
dependence was entered as the dependent variable and five blocks of 
predictor variables were entered into the analysis. The first block consisted of 
the demographic variables. The second block consisted of the pain variables. 
The third block consisted of the painkiller use variables. The fourth block 
consisted of the accessibility variables. The fifth block consisted of the 
psychological factors. This structure of the multiple regression analyses was 
the same as previous analysis of painkiller dependence (e.g. Elander et al., 
2014). A summary of the multiple regression results for the UK sample is 
provided in Table 12 and for the Egypt sample in Table 13. 
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Table 12. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and 
adjusted R2 (AR2) for each block in the multiple regression analysis for the UK sample 
with painkiller dependence as the dependent variable. 
 Entry Beta Final Beta ΔR2 R2 AR2 
Block 1: demographics 
measures 
  0.07* 0.07 0.07 
Employment status -0.25** 0.01    
Religiousness 0.12* 0.02    
Block 2: pain measures   0.18* 0.25 0.24 
Pain frequency  0.34** -0.03    
Pain diagnosis 0.20** -0.02    
Toothache 0.17** 0.07    
Pain duration 0.14* 0.03    
Block 3: painkiller use 
measures 
  0.09** 0.34 0.33 
Painkiller use frequency 0.47** 0.21**    
Block 4: accessibility 
measures 
  0.01* 0.35 0.33 
OTC from internet -0.08* -0.08*    
Block 5: psychological 
factors measures 
  0.26* 0.61 0.59 
PMAQ Need 0.59** 0.59**    
PMAQ Side Effects 0.18** 0.18**    
SOPA-B Control 0.12* 0.13**    
SOPA-B Medical Cure 0.09* 0.09*    
 
Note: *p ≤ 0.05, **p ≤ 0.001 
As shown in Table 12, all of the predictors in the entry model were significant 
or highly significant and all were positive except employment status (entry 
Beta = -0.25, p < 0.001) and OTC from internet (entry Beta = -0.08, p < 0.05). 
In the final model, there were six predictor variables that were significant or 
highly significant: painkiller use frequency (final Beta = 0.21, p < 0.001); OTC 
from internet (final Beta = -0.08, p < 0.05); PMAQ Need (final Beta = 0.59, p < 
0.001); PMAQ Side Effects (final Beta = 0.18, p < 0.001); SOPA-B Control 
(final Beta = 0.13, p < 0.001); and SOPA-B Medical Cure (final Beta = 0.09, p 
< 0.05). All of these predictors were positive except for OTC from internet and 
the strongest predictor was PMAQ Need. The model was highly significant [F 
(12, 282) = 36.71, p < 0.001] and explained almost two-thirds of the variance 
in dependence (R2 = 0.61; 61%), with large effect size (f2 = 1.56). 
Mediation tests were conducted for the variables that were significant at entry 
but not the final model. These tests showed that employment status was 
mediated by pain duration (Sobel = -0.56; p < 0.05; 95% CI -1.01 to -0.11), 
religiousness was mediated by PMAQ Need (Sobel = 0.44; p < 0.05; 95% CI 
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0.05 to 0.84), pain frequency was mediated by painkiller use frequency (Sobel 
= 0.24; p < 0.05; 95% CI 0.17 to 0.31), pain diagnosis was mediated by 
PMAQ Need (Sobel = 4.49; p < 0.001; 95% CI 3.15 to 5.84), toothache was 
mediated by PMAQ Need (Sobel = 1.81; p < 0.05; 95% CI 0.46 to 3.13), and 
pain duration was mediated by PMAQ Need (Sobel = 5.87; p < 0.001; 95% CI 
4.16 to 7.58). 
Table 13. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and 
adjusted R2 (AR2) for each block in the multiple regression analysis for the Egypt 
sample with painkiller dependence as the dependent variable. 
 Entry Beta Final Beta ΔR2 R2 AR2 
Block 1: demographics 
measures 
  0.03* 0.03 0.02 
Religiousness 0.11* 0.01    
Age 0.10* 0.08    
Employment status 0.10* 0.07    
Alternatives -0.15* -0.07    
Block 2: pain measures   0.06* 0.09 0.07 
Other type of pain 0.17** 0.10*    
Pain duration -0.14* -0.10*    
Foot pain -0.11* -0.06    
Block 3: painkiller use 
measures 
  – – – 
– – –    
Block 4: accessibility 
measures 
  – – – 
– – –    
Block 5: psychological factors 
measures 
  0.04* 0.13 0.12 
SOPA-B Solicitude 0.25** 0.25**    
 
Note: *p ≤ 0.05, **p ≤ 0.001 
Similar to the UK sample, all of the predictors in the entry model were 
significant or highly significant for the Egypt sample (see Table 13). However, 
there were fewer predictors in the final model for the Egypt sample compared 
to the UK sample. Specifically, there were only three predictors that were 
significant or highly significant: pain duration (final Beta = -0.10, p < 0.05); 
other type of pain (final Beta = 0.10, p < 0.05); and SOPA-B Solicitude (final 
Beta = 0.25, p < 0.001). These predictors were positive except pain duration 
and the strongest predictor was SOPA-B Solicitude. The model was highly 
significant [F (8, 411) = 9.16, p < 0.001] but explained a small proportion of 
the variance (R2 = 0.13; 13%), with medium effect size (f2 = 0.15).  
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Mediation tests showed that religiousness was mediated by pain duration 
(Sobel = 0.20; p < 0.05; 95% CI 0.23 to 2.10), age was mediated by both 
employment status (Sobel = 0.03; p < 0.001; 95% CI 0.01 to 0.06) and pain 
duration (Sobel = 0.03; p < 0.001; 95% CI 0.01 to 0.05), and employment 
status was mediated by pain duration (Sobel = -0.056; p < 0.05; 95% CI -1.01 
to -0.11). For alternatives and foot pain, there was no significant mediation (p 
> 0.05). 
3.4. Discussion  
The present study aimed to examine the role of accessibility of painkillers and 
psychological factors in problematic painkiller use among the general 
populations of the UK and Egypt. In the below discussion, the results obtained 
from the present study will be summarised first. Then, the implications of the 
results for the literature and society will be discussed, followed by the 
strengths and weakness of the study. Finally, suggestions for future research 
will be outlined, followed by the conclusions of the study. 
3.4.1. Summary of results 
The results of the present study showed that the UK and Egypt general 
populations were significantly different for most variables that were measured. 
In terms of demographic variables, the two countries were significantly 
different for all variables except education level and financial status. 
Compared to the Egypt sample, the UK sample had more females; older 
participants; more participants in a relationship; more participants in 
employment; fewer participants that pain influenced their employment; fewer 
participants with a religious belief; and less religiousness.  
In terms of pain variables, the two countries were significantly different for all 
variables except three types of pain, which were migraine, toothache and 
chest pain. Compared to the Egypt sample, the UK sample had longer pain 
duration; higher pain frequency; higher pain intensity; and more participants 
with pain diagnosis.   
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Regarding painkiller use variables, the two countries were significantly 
different for all variables. Compared to the Egypt sample, the UK sample had 
more participants using prescription painkillers; higher painkiller use 
frequency; less misuse of painkillers; less abuse of painkillers; and more 
participants using alternative methods of pain relief. 
For accessibility variables, the two countries were significantly different for 
most variables. Compared to the Egypt sample, the UK sample had fewer 
participants who obtained OTC painkillers from the pharmacy, family member 
who is not a medical professional and friend who is not a medical 
professional; more participants who obtained OTC painkillers from the 
supermarket shelf; perceived obtaining strong painkillers without a 
prescription more difficult; fewer participants use strong painkillers without a 
prescription; fewer participants who obtained strong painkillers from each 
source except family member who is not a medical professional, friend who is 
not a medical professional and “other”.  
In terms of painkiller dependence, a comparison between the two samples 
showed the UK sample had less painkiller dependence than the Egypt 
sample.  
The results of the SOPA-B showed there were differences between the two 
samples for most attitudes and beliefs towards pain. More specifically, the 
results showed the UK sample had lower scores than the Egypt sample for 
the Control subscale, Solicitude subscale and Medical Cure subscale but 
higher scores than the Egypt sample for the Disability subscale and 
Medication subscale. The only subscale where there were no differences 
between the two samples was the Emotion subscale.  
The results of the PMAQ showed there were differences between the two 
samples for all attitudes and beliefs towards painkillers. Specifically, the 
results showed the UK sample had lower scores than the Egypt sample for 
each PMAQ subscales: Addiction, Need, Scrutiny, Side Effects, Tolerance, 
Mistrust of Doctors and Withdrawal.  
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In terms of SMS, the results showed there were differences between the two 
samples for most attitudes and beliefs towards self-medication. To clarify, the 
results showed the UK sample had higher scores than the Egypt sample on 
the Reluctance subscale, but lower scores than the Egypt sample on the Run 
its Course subscale. The only subscale there was not differences between the 
two samples was the Don’t Think Twice subscale. 
For the HCAMQ, the results showed there were differences between the two 
samples for most attitudes and beliefs towards holistic, complementary and 
alternative medicine. One of these differences was that the UK sample had 
lower total HCAMQ scores than the Egypt sample. Another of these 
differences was that the UK sample had lower scores for the HH subscale 
than the Egypt sample. However, there were no differences between the two 
samples for the CAM subscale.   
The correlations revealed that the two samples were similar only in that age 
had a small but significant positive correlation with dependence. In terms of 
differences between the two samples, it was found that pain frequency, pain 
intensity and painkiller use frequency had significant correlations with 
dependence in the UK sample. Specifically, small but significant positive 
correlations were found for pain frequency and pain intensity and a moderate 
significant positive correlation was found for painkiller use frequency in the UK 
sample. However, there were no significant correlations for the Egypt sample. 
For attitudes and beliefs towards pain (SOPA-B), it was found that Emotion, 
Medication and Solicitude had small positive correlations with dependence for 
both samples. Another similar correlation for both samples was that Medical 
Cure had a small negative correlation with dependence. The differences 
between the two samples were: Harm had a small positive correlation with 
dependence in the UK sample but no significant correlation in the Egypt 
sample; Disability had a moderate positive correlation with dependence in the 
UK sample, but a small negative correlation in the Egypt sample; and Control 
had no significant correlation with dependence in UK sample, but a small 
positive correlation in the Egypt sample. 
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For attitudes and beliefs towards painkillers (PMAQ), both samples had 
positive correlations with dependence for the following subscales: Addiction, 
Side Effects, Tolerance, Withdrawal and Need. Although both samples had 
positive correlations, these correlations were small in the Egypt sample, but 
moderate in the UK sample, apart from Need that was large for the UK 
sample. The other differences were that Scrutiny had no significant correlation 
with dependence in the UK sample, but a small positive correlation in the 
Egypt sample. Also, Mistrust of Doctors had no significant correlation with 
dependence in the UK sample, but a small negative correlation in the Egypt 
sample.  
For attitudes and beliefs towards self-medication (SMS), the samples had 
different correlations with dependence for all subscales. In the UK sample, 
there was a small but significant positive correlation for Don’t Think Twice and 
a small but significant negative correlation for Reluctance and Run its Course 
but none were significant for the Egypt sample.  
For attitudes and beliefs towards holistic, complementary and alternative 
medicine (HCAMQ), the HH and CAM subscales had non-significant 
correlations with dependence in both samples. In addition, the total HCAMQ 
had a non-significant correlation with dependence in the UK sample, but a 
small significant negative correlation in the Egypt sample. 
The results of the multiple regression showed there were differences between 
the UK sample and Egypt sample because there were different predictors in 
each sample. Overall, there were more predictors in the UK sample. 
Specifically, the predictors in the UK sample were: painkiller use frequency; 
two PMAQ subscales, which were Need and Side Effects; two SOPA-B 
subscales, which were Control and Medical Cure; and OTC painkillers from 
the internet. In contrast, there were few predictors in the Egypt sample. 
Specifically, the predictors in the Egypt sample were: other type of pain; pain 
duration; and SOPA-B Solicitude subscale. Therefore, the only similar 
predictors between the samples were attitudes and beliefs towards pain 
predicted dependence. However, the attitudes and beliefs were Control and 
Medical Cure in the UK sample but Solicitude in the Egypt sample.  
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3.4.2. Implications 
The results of the study have implications for the literature by providing 
understanding about the role of accessibility of painkillers and psychological 
factors in problematic painkiller use among the general population of the UK 
and Egypt. For accessibility, the results generally suggest that there was 
easier accessibility of painkillers in Egypt, which supports the literature (e.g. 
Benjamin et al., 1996; Sallam et al., 2009). However, accessibility of 
painkillers mostly did not have a role in painkiller dependence, since most 
variables did not predict painkiller dependence. This result is unexpected 
because previous studies showed that easier accessibility has been 
associated with more frequent painkiller use (e.g. Sallam et al., 2009).   
In the UK, obtaining OTC painkillers from the internet predicted less painkiller 
dependence, which could be explained by the stoic culture of the UK (e.g. 
Wolf, 1985; Ondeck, 2003). Obtaining OTC painkillers from the internet 
usually takes more time than obtaining the painkillers from offline locations 
due to the dispatch and delivery time. Therefore, this could be related to the 
fact that stoic cultures can endure pain more than expressive cultures. Due to 
predicting less painkiller dependence, it might be better to encourage 
obtaining OTC painkillers from the internet in the UK.  
However, a problem with this conclusion concerns that only four participants 
in the UK obtained OTC painkillers online. Moreover, there might be other 
factors associated with obtaining painkillers online that explain the decreased 
dependence, therefore encouraging online access might not be useful. For 
example, previous research has shown that younger age is associated with 
internet use (e.g. File & Ryan, 2014), and younger age is also associated with 
less pain (e.g. Molton & Terrill, 2014). Considering these findings, younger 
age might explain why online access was associated with less dependence in 
the present research.  
Besides younger age, socioeconomic status might be another factor that 
explains the results. This is because previous research has shown that higher 
socioeconomic status is associated with more internet use (e.g. Silver, 2014). 
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In addition, higher socioeconomic status has also been associated with 
employment and higher education, and all of these factors have been 
associated with less pain (e.g. Blyth et al., 2001; Smith et al., 2001; Poleshuck 
& Green, 2008). Therefore, these appear to be other factors that might explain 
why online access was associated with less dependence in the present 
research. 
As a result of these findings, it might not be appropriate to encourage online 
access to painkillers. Nonetheless, there can be more potential advantages of 
obtaining OTC painkillers from the internet such as convenience for disabled 
or housebound individuals to receive painkillers to their home (e.g. Maxwell & 
Webb, 2008). In addition, obtaining OTC painkillers from the internet can be 
useful for individuals with conditions that might be a source of embarrassment 
or ignored by medical professionals or pharmacists (e.g. Flower, 2004).  
Apart from obtaining OTC painkillers from the internet, the remaining 
accessibility variables were not significant predictors in the UK sample and 
none were significant predictors in the Egypt sample. Considering these 
results, for the UK sample, it might be useful to compare people who obtained 
OTC painkillers from the internet with people who did not. This might help to 
understand the reason for less dependence among people who obtained 
painkillers from the internet if there are differences between the two groups, 
since these differences might be contributing factors.  
To make such comparisons, additional chi-squared tests and independent-
samples t-tests were conducted here for the UK sample. These tests 
compared all the variables in the study between people who obtained 
painkillers online and people who did not. For people who did not obtain 
painkillers online, this included those who obtained them from the pharmacy, 
supermarket shelf, friends and family.  
The results showed that only abdominal pain was significantly different 
between people who obtained painkillers from the internet and people who did 
not [Χ2 (1) = 4.55, p < 0.05, Φ = 0.12]. This result means that abdominal pain 
might be another factor to explain the results with factors influencing internet 
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use. However, the reason for this difference in abdominal pain is unclear, and 
since only four participants are concerned, further research should be 
conducted. 
For psychological factors, the results suggest that several attitudes and 
beliefs towards pain and painkillers had a role in painkiller dependence, but 
there were not any attitudes and beliefs towards self-medication and 
alternative methods of pain relief that had a role. These results do not fully 
support the literature because the non-significant roles are unexpected. 
Possibly, this could be explained by the present study focusing on problematic 
painkiller use in the general population, whereas the literature focused on 
frequency of painkiller use in non-general population samples such as women 
with childbirth pain (e.g. Callister et al., 2003; Christiaens et al., 2010).  
In terms of attitudes and beliefs towards pain, SOPA-B Medical Cure and 
Control predicted more painkiller dependence in the UK. These results could 
be explained by the stoic and independent culture of the UK. Specifically, 
stoic cultures have a “stiff upper lip” and prefer to endure pain, therefore this 
may explain why they have more negative attitudes and beliefs towards 
medical cures (e.g. Callister et al., 2003). Also, independent cultures would 
feel more control of pain than other cultures that share pain with others (e.g. 
Wolf, 1985; Ondeck, 2003). In Egypt, Solicitude predicted more painkiller 
dependence. Since Solicitude involves seeking sympathy from others, this 
might be explained by Egypt having a more expressive culture that prefers to 
vocalise their pain and seek social support from others (e.g. Wolf, 1985; 
Ondeck, 2003).  
In terms of attitudes and beliefs towards painkillers, PMAQ Need was the 
strongest predictor of more painkiller dependence in the UK, followed by Side 
Effects. However, there were no predictors in Egypt. Since Need and Side 
Effects involve physiological aspects of painkiller dependence, perhaps this 
suggests people in the UK are more sensitive to physical symptoms and they 
affect dependence more than in Egypt.  
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The study also has implications for understanding differences in painkiller 
dependence. The Egypt sample had higher dependence when their use of 
painkillers was less than the UK. Also, the level of painkiller misuse and 
abuse was high compared to the UK. These results suggest that 
“dependence” could mean something different in Egypt, and western concepts 
of “misuse” and “abuse” may not be appropriate for Egypt. However, it has 
been argued that the criteria for dependence have cultural sensitivity because 
they can be applied to most races or ethnic groups (DSM-IV; American 
Psychiatric Association, 2000). As the people in the Egypt sample have less 
chronic pain, more research is needed on people’s ways and reasons for 
using painkillers in Egypt.  
Finally, the study provides new findings for the validity of the PMAQ because 
Addiction, Need, Tolerance and Withdrawal correlated with painkiller 
dependence. To the best of my knowledge, the correlation between PMAQ 
subscales with painkiller dependence has not been tested before, so the 
present study shows further the validity of the PMAQ.  
Besides implications for the literature, the study has implications for society 
because understanding the role of accessibility and psychological factors can 
allows developing interventions based on these factors to prevent or reduce 
problematic painkiller use among the general population. Since there were 
differences between the samples, the results suggest that different 
interventions may be needed for the general population of the UK and Egypt. 
For example, interventions to change attitudes and beliefs towards pain and 
painkillers could be developed, because these factors were predictors of 
painkiller dependence. For the UK, interventions could be created to change 
attitudes and beliefs about medical cures for pain, control of pain, need of 
painkillers and side effects of painkillers. For Egypt, interventions could be 
created to change attitudes and beliefs about solicitude from others. In 
addition, interventions could be created for both countries to educate people 
about the dangers of illegal accessibility of painkillers. This would be 
especially useful for Egypt due to the easier accessibility of painkillers.  
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Another implication for society could be to use the factors that predicted more 
painkiller dependence as warning signs about risk of dependence. Therefore, 
attitudes and beliefs towards medical cures for pain, control of pain, need of 
painkillers and side effects of painkillers can be used as a warning in the UK, 
since these predicted more painkiller dependence in the UK. Meanwhile, 
attitudes and beliefs towards solicitude from others can be used as a warning 
in Egypt, since this predicted more painkiller dependence in Egypt. 
3.4.3. Strengths and weaknesses 
There are number of strengths and weaknesses of the present study that 
should be mentioned. A strength has been the large sample sizes obtained 
from each country, which provides confidence about the results because 
small effects are more likely to be detected, therefore reducing type 2 errors 
compared to smaller samples (e.g. Banerjee et al., 2009). To clarify, this 
refers to reducing errors of rejecting results as non-significant incorrectly or by 
chance, which therefore allows the analysis to be more sensitive (e.g. 
Banerjee et al., 2009; Ellis, 2010). In fact, the samples were larger than the 
size requirements by the power analysis; the sample size obtained was 745 
whereas the sample size required was between 84 and 231. However, there 
are risks with having larger samples than required because the study might 
become over-powered. Nonetheless, using larger samples than required has 
advantages because this allows subgroups to be analysed, since type 2 
errors would be reduced for the subgroups. This was conducted for example 
by analysing the UK sample and Egypt sample as subgroups. 
An additional strength has been the procedure used to translate the 
questionnaire into Arabic for the data collection in Egypt. As several 
researchers have suggested, using back translation should help ensure 
linguistic equivalence and validation of translated questionnaires (e.g. 
McDermott & Palchanes, 1992; Jones et al., 2001; John et al., 2006). Further, 
the study followed the recommendations about the translators such as 
knowledge of the cultures in the study. This should aid cultural sensitivity and 
linguistic equivalence by ensuring the words used were sensitive for each 
culture.  
 98 
Although there were strengths of the study, a weakness was that the majority 
of the UK sample were females, so the sample was not fully representative of 
the general population. In Egypt, the sample was more equal despite that the 
same recruitment methods were used such as posting the link for the 
questionnaire on forums and social media about pain. The difference in 
gender between the two samples was significant. In addition to gender, the 
two samples were also significantly different for most of the remaining 
demographic factors, including age, marital status, education level and 
religious beliefs. Since the two samples were different for most demographics, 
it is possible that this might have influenced the results regarding 
dependence. This is especially likely because previous research has shown 
that demographics are associated with pain and substance use problems (e.g. 
Van Hecke, Torrance & Smith, 2013; Jones, Logan, Gladden & Bohm, 2015; 
Avci et al., 2017). Therefore, different demographics might also be associated 
with dependence. However, in this case there were not any demographics 
that were found as significant predictors of dependence. Thus, it is unlikely 
that the difference in demographics between the two samples influenced the 
results regarding dependence.   
A further problem with the study was that the majority of the UK sample were 
participants with chronic pain whereas the majority of the Egypt sample were 
participants with acute pain. Also, participants in the UK sample used 
painkillers for most days whereas participants in the Egypt sample used 
painkillers for few days. These were significant predictors of problematic 
painkiller use: painkiller use frequency was a significant predictor of 
problematic painkiller use in the UK sample and pain duration was a 
significant predictor of problematic painkiller use in the Egypt sample. Since 
painkiller use frequency was most days in the UK sample and pain duration 
was acute pain in the Egypt sample, it is difficult to know if these would be 
predictors if more matched samples had been recruited.  
An additional weakness of the study was using multiple comparisons, for 
several chi-squared and t-tests were used to compare the two samples on 
multiple measures. This is a problem because multiple comparisons increase 
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the chance of a type 1 error, which involves accepting results as significant 
incorrectly or by chance (e.g. Banerjee, Chitnis, Jadhav, Bhawalker & 
Chaudhury, 2009). To reduce this problem, the alpha level of significance of p 
0.05 in this study could have been divided by the number of comparisons in 
the analysis. After this, any results equal to or less than the new alpha value 
are significant. Although type 1 errors can be reduced with this method, there 
are still problems because further errors or missed findings might be possible, 
therefore this method is not recommended (e.g. Rothman, 1990). Indeed, it 
can lead to type 2 errors, which involves accepting results as non-significant 
incorrectly or by chance (e.g. Banerjee et al., 2009). Therefore, rather than 
adjust the alpha level, effect size can be calculated to demonstrate how large 
the significant differences between the samples are, which will avoid the 
problems of adjusting the alpha method (e.g. Sullivan & Feinn, 2012). In this 
study, effect size was calculated for all significant comparisons. The majority 
of effects were either medium or large size, therefore the results can be 
considered as meaningful (e.g. Fan, 2001).  
A further method to avoid problems of multiple comparisons is to conduct a 
multivariate analysis. In this type of analysis, multiple variables are entered in 
one analysis, and involves at least two outcome variables usually from 
repeated measures or clustered data (e.g. Hidalgo & Goodman, 2013). 
However, multivariate analysis was not used in this study because there was 
only one outcome variable focused in the analysis, which was dependence. 
This allowed the analysis to investigate the role of accessibility and 
psychological factors in this outcome, which was the aim of the study. Since 
multivariate analysis can avoid problems of multiple comparisons, future 
research can benefit from this analysis as well as calculating effect sizes.   
3.4.4. Future research 
Since the results showed differences between the two countries, it would be 
useful to extend the study to further countries given the results clearly 
indicated differences between the UK and Egypt regarding the role of 
accessibility of painkillers and psychological factors in problematic painkiller 
use. However, some of the scales in the questionnaire consisted of many 
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items. These scales were the PMAQ (47 items) and the SOPA-B (30 items). 
Although there was no negative feedback about the length of the 
questionnaire, it would be an advantage to shorten these scales to reduce any 
burden on participants especially because the questionnaire included several 
scales (e.g. Stanton et al., 2002). In the next chapter of the thesis, the PMAQ 
and SOPA-B were shortened to 14 items. In the following chapter, the present 
study was extended to more countries using these shortened scales in the 
questionnaire.   
3.4.5. Conclusion 
In conclusion, the study has demonstrated that accessibility and psychological 
factors have a role in problematic painkiller use among the general 
population, but differences exist depending on the specific culture 
investigated. For example, there were differences in the role of accessibility in 
the two countries, since obtaining OTC painkillers from the internet predicted 
less painkiller dependence in the UK only. In addition, there were differences 
in the role of attitudes and beliefs towards pain and painkillers since SOPA-B 
Medical Cure, SOPA-B Control, PMAQ Need and PMAQ Side Effects 
predicted more painkiller dependence in the UK, but only SOPA-B Solicitude 
predicted more painkiller dependence in Egypt. To extend the study, the 
following research will focus on more countries than the UK and Egypt to 
compare further the role of accessibility and psychological factors in 
problematic painkiller use, but before focusing on more countries, the PMAQ 
and SOPA-B scales in the questionnaire will be shortened in the next chapter 


































In the comparative study between the UK and Egypt (Chapter 3), attitudes 
and beliefs towards pain and painkillers had a role in problematic painkiller 
use among the general populations of these countries. To measure attitudes 
and beliefs towards pain and painkillers, the Survey of Pain Attitudes-Brief 
(SOPA-B) and the Pain Medication Attitudes Questionnaire (PMAQ) were 
used in the comparative study. Since there are 30 items in the SOPA-B and 
47 items in the PMAQ, these measures will be shortened in the present study 
before using the measures for the further research. This is especially because 
there are the advantages of using shorter measures, including saving time 
and reducing the burden for participants (e.g. Stanton et al., 2002). 
4.1.1. Survey of Pain Attitudes-Brief (SOPA-B) 
The SOPA-B was developed by Tait and Chibnall (1997) as a 30-item 
questionnaire to measure attitudes and beliefs towards pain. There are seven 
subscales in the SOPA-B to measure the following seven attitudes and beliefs 
to pain: “Solicitude” from others, “Emotion” experienced with pain, “Medical 
Cure” for pain, pain “Control”, pain as an indicator for “Harm”, pain-related 
“Disability” and “Medication” as an appropriate treatment for pain. 
Tait and Chibnall (1997) reported the SOPA-B has good internal reliability for 
most subscales, but one subscale with low internal reliability was the 
Medication subscale. Tait and Chibnall (1997) also reported the SOPA-B has 
good validity because most subscales had significant correlations with 
measures of pain, coping, disability, pain behaviours and depression but one 
subscale with no correlations was Medical Cure.  
The SOPA-B was developed from the 57-item Survey of Pain Attitudes 
(SOPA-57; Jensen et al., 1994), which has the same subscales as the SOPA-
B to measure attitudes and beliefs towards pain. There have been other 
versions of the SOPA-57 developed including a 35-item version (SOPA-35; 
Jensen & Karoly, 1989; Strong et al., 1992), 14-item version (SOPA-14; 
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Jensen et al., 2003) and 7-item version (SOPA-7; Jensen et al., 2003), but the 
57-item version has been used most in research.  
Although the SOPA-B was developed from the SOPA-57, Jensen et al. (2000) 
claimed the items in the SOPA-B subscales might have different meanings to 
items in the SOPA-57 subscales. The reason for the different meaning was 
because the method used to develop the SOPA-B was different from the 
method used to develop the SOPA-57; for the SOPA-57, it was accepted for 
the items to load onto more than one factor, but items were allowed to load 
onto only one factor for the SOPA-B.  
Since items in the SOPA-57 were allowed to load onto more than one factor, 
the SOPA-57 measures attitudes related to each other instead of independent 
to each other, whereas the SOPA-B measures attitudes that are independent 
to each other and have more focused meanings than the SOPA-57 (Jensen et 
al., 2000). For example, the Harm subscale in the SOPA-57 includes items 
about believing pain indicates damage and another items about believing 
exercise and other activity could be harmful, but the Harm subscale in the 
SOPA-B includes items only about believing exercise and other activity could 
be harmful. 
The SOPA-35 was developed from the SOPA-57 with a similar method to the 
SOPA-57 because it was accepted for items to be associated with more than 
one subscale rather than only one subscale. Therefore, the SOPA-35 
subscales have similar meanings as the SOPA-57 but not focused meanings 
like the SOPA-B. However, some items were reworded and shortened to 
make the items simpler in the SOPA-35 (Jensen et al., 2000).  
To develop the SOPA-35, correlation analysis was used to examine the 
correlations of items to subscales. The items with the highest correlations 
were selected and reviewed to evaluate if the item had the same meaning of 
the subscale it was selected. The SOPA-35 had several items the same as 
the SOPA-B and the Solicitude subscale had all the same items. The two 
versions are therefore similar but the main difference according to Jensen et 
al. (2000) was the SOPA-B subscales are more focused.  
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The SOPA-57, SOPA-35 and SOPA-B all have good internal reliability, test-
retest reliability and validity (Jensen et al., 2000). Therefore, the conclusion 
from Jensen et al. (2000) was that because all versions were valid and 
reliable, the results do not support using a specific version but the advantage 
of using the SOPA-B is for measuring focused attitudes and beliefs.  
The SOPA-7 and SOPA-14 were developed the most recently, which have the 
same subscales as the SOPA-B to measure attitudes and beliefs towards 
pain; the SOPA-7 consisted of one item in each subscale and the SOPA-14 
consisted of two items in each subscale (Jensen et al., 2003). Again, these 
versions were developed from the SOPA-57 by the same method as the 
SOPA-35, so the subscales also do not measure focused attitudes as the 
SOPA-B. There is therefore no brief version than the SOPA-B to measure 
focused attitudes and beliefs. Since the SOPA-B has 30 items, a shorter 
version is needed because it is time consuming for completing similar to the 
PMAQ and has burden especially if multiple measures are used together with 
the SOPA-B.  
4.1.2. Pain Medication Attitudes Questionnaire (PMAQ) 
The PMAQ was developed by McCracken et al. (2006) as a 47-item 
questionnaire, which has seven subscales to measure the following seven 
attitudes and beliefs towards painkillers: “Addiction” to painkillers, “Need” of 
painkillers, “Scrutiny” from others about using painkillers, “Side Effects” of 
painkillers, “Tolerance” of painkillers, “Mistrust of Doctors” prescribing 
painkillers and “Withdrawal” symptoms. 
McCracken et al. (2006) showed the PMAQ has good internal reliability. In 
addition, McCracken et al. (2006) showed the PMAQ has good validity 
because the subscales had significant correlations with painkiller use, 
depression and disability: higher scores for Side Effects and lower scores for 
Withdrawal and Need were correlated with underuse of painkillers; higher 
scores for Scrutiny and Need were correlated with overuse of painkillers; 
higher scores for Tolerance and Need were correlated with depression; and 
higher scores for Tolerance and Side Effects were correlated with disability.   
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In a study by Rosser et al. (2011), there were similar findings to McCracken et 
al. (2006). In addition, both studies found attitudes and beliefs towards 
painkillers predicted painkiller underuse or overuse more than pain intensity 
(McCracken et al., 2006; Rosser et al., 2011). However, there was also a new 
finding that Mistrust of Doctors was associated with underuse of painkillers 
(Rosser et al., 2011).  
Other factors were investigated as correlates of PMAQ scores by Lauwerier, 
Paemeleire, Van Damme, Goubert and Crombez (2011) including a problem-
solving attitude to pain, accepting pain cannot be solved, believing life is 
meaningful despite pain, believing pain can be solved, and medication 
overuse headache. A problem-solving attitude to pain was correlated with 
higher scores for Need, Tolerance and Withdrawal. Accepting pain cannot be 
solved was correlated with lower scores for Scrutiny, Tolerance and 
Withdrawal. Believing life is meaningful despite pain was correlated with lower 
scores for Addiction, Need, Tolerance, Mistrust of Doctors and Withdrawal. 
Believing pain can be solved was correlated with lower scores for Scrutiny, 
Tolerance and Mistrust of Doctors. Finally, medication overuse headache was 
correlated with higher scores for Need and Scrutiny.  
As shown by McCracken et al. (2006), Rosser et al. (2011) and Lauwerier et 
al. (2011), the PMAQ is useful to investigate the role of attitudes and beliefs 
towards painkillers because significant correlations were found with painkiller 
use and other measures. In particular, the PMAQ is useful because there are 
no alternative measures of attitudes and beliefs towards painkillers. Although 
the PMAQ is useful, it is time consuming for completing because there are 47 
items and has burden especially if multiple measures are used together with 
the PMAQ. Therefore, a shorter version of the PMAQ is needed.  
4.1.3. Aims 
One aim of the present study was to produce a shorter version of the SOPA-B 
with 2 items in each subscale and a total 14 items instead of 30 items. 
Another aim was to produce a shorter version of the PMAQ with 2 items in 
each subscale and a total 14 items instead of 47 items. This number of items 
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was chosen based on the method used by Jensen et al. (2003) for shortening 
scales. 
4.2. Methods 
To develop a 14-item SOPA-B and PMAQ, the data from the UK sample of 
the comparative study between the UK and Egypt (Chapter 3) was used, 
since those participants completed the full SOPA-B and PMAQ. Because the 
same data was used, more detail about the participants, design, measures 
and materials can be found in Chapter 3 but will be summarised below.  
4.2.1. Participants 
The participants were 295 members of the general population in the UK 
recruited by online convenience sampling, offline convenience sampling and 
snowball sampling. To be included in the study, it was required that the 
participants were: at least 18 years of age, experienced pain in the last month, 
used OTC or prescription painkillers in the last month and were resident in the 
UK. If any of these criteria were not achieved, participants were excluded. In 
addition, participants were excluded if there was any missing data or from 
participating more than once in the study. The demographics, pain and 
painkiller use characteristics of the sample are shown in Table 14.  
Table 14. Demographic, pain and painkiller use characteristics of the sample. 
 
N 295 
Age1 41.14 (12.30, 19-79) 
Gender2  
Male 40 (13.6%) 
Female 255 (86.4%) 
Marital status1  
Not in a relationship  98 (33.2%) 
In a relationship 197 (66.8%) 
Diagnosed medical conditions1  
Arthritis  54 (18%) 
Endometriosis 55 (19%) 
Fibromyalgia  121 (41%) 
Migraine 22 (8%) 
Neuralgia/neuropathy/nerve pain 13 (4%) 
Spinal/disc/back pain 25 (9%) 
Pain for longer than one year1 259 (87.8%) 
Prescribed pain medication1 239 (81.0%) 
 
Note: 1 M (SD, range), 2 N (%) 
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4.2.2. Design  
 
A cross-sectional online questionnaire design was used to collect data. 
 
4.2.3. Measures  
The online questionnaire consisted of questions about demographics, pain, 
painkillers and accessibility of painkillers. In addition, the online questionnaire 
consisted of scales measuring painkiller dependence (LDQ; Ferrari et al., 
2006), attitudes and beliefs towards pain (SOPA-B; Tait & Chibnall, 1997), 
attitudes and beliefs towards painkillers (PMAQ; McCracken et al., 2006), 
attitudes and beliefs towards self-medication (SMS; James & French, 2008) 
and attitudes and beliefs towards alternative methods of pain relief (HCAMQ; 
Hyland et al., 2003). More information about these measures is provided in 
Chapter 3.  
4.2.4. Materials 
Google Drive Forms was used to create the online questionnaire, and the 
data analysis was conducted using SPSS. 
4.2.5. Procedure and analytic strategy 
Ethical approval to collect data was provided by the University of Derby 
Psychology Research Ethics Committee.  
There were two stages involved in the present study; the first stage involved 
shortening the SOPA-B and PMAQ to 14 items with 2 items in each subscale 
using the method of Jensen et al. (2003); and the second stage involved 
testing the validity of the short versions.  
In the first stage, the SOPA-B and PMAQ was shortened by using correlation 
analysis followed by multiple regression analysis. The correlation analysis 
involved correlations between individual items and their full parent subscale 
scores, which were the scores from the full length SOPA-B and PMAQ. The 
item with the highest correlation was selected as the first item for each 
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subscale of the short version. The second item was selected by multiple 
regression analysis, with individual items as the predictor variables and their 
full parent subscale scores as the dependent variables. The predictor 
variables were entered in two blocks; the item selected from the correlation 
was entered in the first block and the other items in the second block. The 
item with the highest Beta value from the second block was selected as the 
second item for each subscale for the short version. 
In the second stage, validity was assessed by computing scores for the 2-item 
subscales and testing the correlation of the scores with the full parent scores. 
Validity was also assessed by comparing the 2-item subscale scores’ and the 
full parent scores’ correlations with other measures to see if the correlations 
with other measures were different. If either the full parent subscale scores or 
the 2-item subscales scores but not both were significantly correlated with 
other measures, the correlations were compared directly using Steiger’s Z test 
in the FZT computator recommended by Wuensch (2014).  
4.3. Results 
The results of the correlation and multiple regression analysis for item 
selection are presented first. Then, the results of the validity analysis for the 
shortened SOPA-B subscales and the shorted PMAQ subscales are 
presented.    
4.3.1. Item selection 
Table 15 shows the results of correlations between items with their subscales. 
The item with the highest correlation was selected as the first item for the 2-
item subscales. The results of the multiple regression to select the second 
item for the 2-item subscales is also shown in Table 15. The item with the 
highest Beta value from the second block was selected as the second item for 
the 2-item subscales.
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Table 15. Correlations of PMAQ and SOPA-B items with their subscales, and Beta values from multiple regression. 
SOPA-B subscales 
Solicitude Emotion Medical Cure Control Harm Disability Medication 
3: .822; .265b 6: .854; .314a 4: .667; .297 1: .645; .310b 11: .751; .276 23: .839; .434a 2: .699; .467b 
7: .807; .242 10: .847; .286 8: .734; .330a 12: .699; .311a 16: .732; .282 26: .818; .389 5: .779; .436a 
9: .706; .231 15: .800; .313b 21: .586; .262 17: .680; .291 19: .570; .315b 30: .812; .392b 13: .773; .432 
14: .809; .248 25: .813; .296 24: .721; .265 20: .674; .295 27: .663; .278   
18: .841; .265a  29: .717; .300b 22: .658; .283 28: .809; .275a   
 
PMAQ subscales 
Addiction Need Scrutiny Side Effects Tolerance Mistrust of Doctors Withdrawal 
1: .841; .259 2: .845; .177 3: .708; .206 4: .790; .199 5: .807; .212 6: .435; .205 7: .844; .232 
8: .854; .270b 9: .734; .183 10: .613; .186 11: .757; .212 12: .832; .219a 13: .793; .210 14: .783; .233b 
15: .878; .212a 16: .668; .185b 17: .456; .205 18: .501; .171 19: .806; .226b 20: .777; .193 21: .845; .203a 
22: .829; .212 23: .638; .155 24: .653; .178 25: .801; .174a 26: .737; .197 27: .801; .203 28: .741; .207 
29: .865; .219 30: .674; .161 31: .707; .209b 32: .781; .201 33: .698; .211 34: .476; .169 35: .759; .203 
 36: .591; .149 37: .780; .184a 38: .675; .220b 39: .796; .215 40: .814; .213b 41: .758; .187 
 42: .863; .196a 43: .607; .203 44: .799; .190  45: .880; .202a  
 46: .744; .171 47: .585; .198     
 
Note: 
All correlations are significant at p ≤ 0.001 
a First item selected (highest correlation) 
b Second item selected (highest Beta value in multiple regression)
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For the SOPA-B, the table shows the item with the highest correlation in 
Solicitude was item 18, Emotion was item 6, Medical Cure was item 8, Control 
was item 12, Harm was item 28, Disability was item 23 and Medication was 
item 5. The item with the highest Beta value for Solicitude was item 3, 
Emotion was item 15, Medical Cure was item 29, Control was item 1, Harm 
was item 19, Disability was item 30 and Medication was item 2. 
For the PMAQ, the table shows the item with the highest correlation in 
Addiction was item 15, Need was item 42, Scrutiny was item 37, Side Effects 
was item 25, Tolerance was item 12, Mistrust of Doctors was item 45 and 
Withdrawal was item 21. The item with the highest Beta value in Addiction 
was item 8, Need was item 16, Scrutiny was item 31, Side Effects was item 
38, Tolerance was item 19, Mistrust of Doctors was item 40 and Withdrawal 
was item 14.  
The 14-item versions of the SOPA-B (SOPA-B-14) and PMAQ (PMAQ-14) 





Neither true nor untrue (or does not apply) 
Somewhat true 
Very true  
 
1. There are many times when I can influence the amount of pain I feel 
2. I will probably always have to take pain medication 
3. When I hurt, I want my family to treat me better 
4. I have had the most relief from the pain with the use of medications 
5. Anxiety increases the pain I feel 
6. I have given up my search for the complete elimination of my pain through 
the work of the medical profession 
7. Just by concentrating or relaxing, I can 'take the edge' off my pain 
8. Depression increases the pain I feel 
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9. Often I need more tender loving care than I am now getting when I am in 
pain 
10. Something is wrong with my body which prevents much movement or 
exercise 
11. My pain does not stop me from leading a physically active life 
12. Exercise can decrease the amount of pain I experience 
13. I'm convinced that there is no medical procedure that will help my pain 




Almost never true 
Seldom true 
Often true 
Almost always true 
Always true 
 
1. I am concerned that taking medication for a long time will lead to addiction 
2. I worry that my pain medication/s will stop working 
3. I am afraid that stopping my pain medication/s will cause me to feel ill 
4. I fear that I am becoming an addict 
5. I would be unwilling to reduce my pain medication/s 
6. I feel that I will eventually run out of pain medication/s that will help with 
the pain 
7. I worry that withdrawal from my pain medication/s will cause me some 
harm 
8. I find it hard to put up with the side effects from my pain medication/s 
9. Needing to take medication for my pain embarrasses me 
10.  I worry what others think about my use of pain medication/s 
11.  I worry about damage to internal organs from my pain medication/s 
12.  I feel confident about my doctor’s management of my pain medication/s 
13.  I depend on my pain medication/s 
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14.  I feel satisfied with information my doctor gives me about medications 
4.3.2. Validity of 2-item SOPA-B subscales 
To assess the validity of the 2-item SOPA-B subscales, scores for 2-item 
subscales were computed and correlated with full parent SOPA-B subscales. 
Subscale scores were computed in the same way as the full parent subscale 
scores. For the SOPA-B, this involved summing the items in each subscale 
and dividing the summed score by the number of items in the subscale. The 
computed scores and the results of the correlations are shown in Table 16. 
Table 16. Descriptive statistics for full parent and 2-item SOPA-B subscales and 
correlations between them. 
 
 Full parent  
M (SD, min-max) 
2-item  
M (SD, min-max) 
Correlation 
Solicitude 1.66 (0.98, 0-4) 1.81 (1.18, 0-4) .918*** 
Emotion 2.39 (1.08, 0-4) 2.38 (1.19, 0-4) .941*** 
Medical Cure 1.56 (0.89, 0-4) 1.88 (1.18, 0-4) .864*** 
Control 1.67 (0.82, 0-3.8) 1.58 (1.03, 0-4) .831*** 
Harm 2.07 (0.90, 0-4) 2.23 (1.04, 0-4) .866*** 
Disability 2.62 (1.11, 0-4) 2.46 (1.21, 0-4) .950*** 
Medication 2.67 (0.87, 0-4) 2.81 (0.93, 0-4) .925*** 
 
Note: ***p ≤ 0.001 
The table shows the correlations between the 2-item and full parent subscales 
were high and highly significant; the correlations ranged between .831 to .950. 
The highest correlation was for Disability, followed by Emotion and the lowest 
was for Control, followed by Harm. 
The validity of 2-item SOPA-B subscales was assessed by comparing the 2-
item subscale scores and the full parent subscale scores correlations with 
other measures. The correlations of the 2-item and full parent subscales with 
pain duration, pain frequency, pain intensity, painkiller use frequency, exceed 










Table 17. Comparison of the 2-item and the full parent SOPA-B subscales correlations to pain, 















Solicitude FP .005 .026 .022 -.072 .086 .132* 
Solicitude SF .045 .053 .091 -.056 .104 .155** 
Emotion FP .126* .187** .110 .105 .049 .184** 
Emotion SF .096 .165** .107 .086 .027 .174*** 
Medical Cure FP -.388*** -.309*** -.228*** -.256*** -.076 -.173** 
Medical Cure SF -.299*** -.238*** -.188** -.167** -.060 -.107 
Control FP -.092 .017 -.166** -.035 -.051 -.042 
Control SF -.160** -.013 -.177** -.092 -.122* -.071 
Harm FP  .158** .182** .338*** .209*** .090 .222*** 
Harm SF .224*** .285*** .372*** .287*** .106 .305*** 
Disability FP  .359*** .507*** .460*** .462*** .090 .419*** 
Disability SF .354*** .446*** .433*** .408*** .107 .420*** 
Medication FP  .295*** .189** .226*** .374*** .200** .393*** 
Medication SF .370*** .261*** .290*** .392*** .184** .400*** 
 
Note: FP = Full parent, SF = Short form (2-item), * p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001 
The table shows the 2-item and full parent subscales of Medical Cure, Harm, 
Disability and Medication were correlated with pain duration, pain frequency, 
pain intensity and dependence. The highest correlation was for Disability. The 
2-item and full parent subscales of Control had correlations with pain intensity 
only and Medication was the only subscale correlated with exceeding dose. 
The majority of 2-item subscales had the same correlation as the full parent 
subscales to the pain, painkiller use and dependence measures. There were 
only three discrepant correlations where the 2-item and full parent correlations 
were significantly different; Control and pain duration (Z = 2.01586, p < 0.05); 
Control and exceeding dose (Z = 2.09507, p < 0.05); and Medical Cure and 
dependence (Z = 2.18521, p < 0.05).   
In addition to the above measures, the validity of the 2-item SOPA-B 
subscales was also assessed by comparing 2-item subscales and full parent 
subscales’ correlations with the following measures: attitudes and beliefs 
towards self-medication (SMS); and attitudes and beliefs towards alternative 
methods of pain relief (HCAMQ). The results of these correlations are shown 
in Table 18. 
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Table 18. Comparison of the 2-item and the full parent SOPA-B subscales correlations to the 
SMS and HCAMQ.   
 
 SMS HCAMQ 




HH CAM HCAMQ 
total 
Solicitude FP -.054 .142* -.167** -.045 .077 .038 
Solicitude SF -.061 .135* -.133* -.053 .050 .012 
Emotion FP -.142* .162** -.110 -.240*** -.076 -.191** 
Emotion SF -.126* .149* -.110 -.234*** -.051 -.168** 
Medical Cure FP .193** -.119* .184** .080 .039 .075 
Medical Cure SF .150* -.070 .169** .087 .036 .076 
Control FP -.082 -.031 .135* -.213*** -.243*** -.310*** 
Control SF -.063 -.076 .156** -.207*** -.158** -.239*** 
Harm FP  -.131* .147* -.155** .065 .042 .068 
Harm SF -.160** .182** -.145* .011 .026 .027 
Disability FP  -.117* .145* -.201** .023 -.091 -.061 
Disability SF -.079 .152**3 -.193** .050 -.078 -.035 
Medication FP  -.222*** .339*** -.351*** .037 .004 .023 
Medication SF -.219*** .288*** -.286*** .012 -.031 -.018 
 
Note: FP = Full parent, SF = Short form (2-item), * p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001 
The table indicates the 2-item and full parent subscales had the following 
correlations with SMS attitudes: Harm was correlated to all SMS subscales; 
Solicitude and Disability was correlated to Don’t Think Twice and Run its 
Course; Emotion was correlated to Reluctance and Don’t Think Twice; 
Medical Cure was correlated with Reluctance and Run its Course; an Control 
was correlated with Run its Course. For the HCAMQ attitudes, only Emotion 
and Control showed correlations because Emotion was correlated to HH and 
Control was correlated to HH and CAM. 
All the 2-item subscales had the same correlations as the full parent 
subscales to the SMS and HCAMQ measures except for one correlation 
which was significantly different: Disability and Reluctance (Z = 2.06348, p < 
0.05). 
4.3.3. Validity of 2-item PMAQ subscales 
The validity of the 2-item PMAQ subscales was assessed in the same way as 
the 2-item SOPA-B subscales, first by computing the 2-item subscale scores 
and then correlation analysis between the 2-item and full parent subscales. 
Again, subscale scores were computed in the same way as the full parent 
subscale scores. For the PMAQ, this involved summing the items in each of 
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the subscales. The computed scores and the results of the correlation are 
shown in Table 19. 
Table 19. Descriptive statistics for full parent and 2-item PMAQ subscales and 
correlations between them. 
 
 Full parent  
M (SD, min-max) 
2-item  
M (SD, min-max) 
Correlation 
Addiction 7.11 (6.60, 0-25) 3.06 (2.88, 0-10)  .954*** 
Need 19.47 (9.85, 0-40) 4.64 (3.28, 0-10) .879*** 
Scrutiny 11.72 (7.96, 0-40) 2.28 (2.88, 0-10)  .804*** 
Side Effects 13.34 (8.40, 0-35) 4.11 (2.72, 0-10) .889*** 
Tolerance 12.75 (7.80, 0-30) 4.50 (3.23, 0-10) .903*** 
Mistrust of Doctors 13.62 (8.28, 0-33) 4.52 (3.19, 0-10) .910*** 
Withdrawal 10.17 (8.04, 0-30) 3.81 (3.17, 0-10) .900*** 
 
Note: ***p ≤ 0.001 
As shown in Table 19, the correlations between 2-item and full parent 
subscales were high and highly significant; the correlations ranged between 
.804 to .945. The highest correlations were for Addiction, followed by Mistrust 
of Doctors and Withdrawal, and the lowest correlations were for Scrutiny, 
followed by Need. 
The validity of the 2-item PMAQ subscales was also assessed by comparing 
2-item subscales and full parent subscales’ correlations with other measures, 
including: pain duration; pain frequency; pain intensity; painkiller use 
frequency; exceed dose; and painkiller dependence. The results of these 
correlations are shown in Table 20.
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Pain intensity Painkiller use 
frequency 
Exceed dose Painkiller dependence 
(LDQ score) 
          
Addiction FP .287*** .274*** .127**  .326*** .147*  .473***  
Addiction SF .263*** .257*** .164**  .291*** .144*  .414***  
Need FP .410*** .382*** .413***  .531*** .202***  .724***  
Need SF .312*** .266*** .296***  .408*** .120*  .614***  
Scrutiny FP .102 .126* .109  .107 .130*  .087  
Scrutiny SF .155** .145* .194**  .170** .162**  .215***  
Side Effects FP .348*** .294*** .328***  .300*** .052  .471***  
Side Effects SF .300*** .271*** .291***  .281*** .077  .414**  
Tolerance FP .412*** .422*** .410***  .467*** .154**  .578***  
Tolerance SF .370*** .376*** .353***  .458*** .145*  .569***  
Mistrust of Doctors FP .020 .012 -.014  -.070 .000  -.047  
Mistrust of Doctors SF -.024 -.047 -.042  -.132* -.027  -.133*  
Withdrawal FP .332*** .380*** .364***  .477*** .117*  .564***  
Withdrawal SF .334*** .335*** .320***  .466*** .157**  .556***  
 
Note: FP = Full parent, SF = Short form (2-item), * p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001
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The 2-item and full parent subscales of Addiction, Need, Side Effects, 
Tolerance and Withdrawal were correlated with pain duration, pain frequency, 
pain intensity, painkiller use frequency and dependence but there was no 
significant correlation for Scrutiny and Mistrust of Doctors.  
The majority of 2-item subscales had the same correlation as the full parent 
subscales to the pain, painkiller use and dependence measures. There were 
only three discrepant correlations in which the 2-item and full parent 
correlations to these measures were significantly different: Scrutiny and pain 
intensity (Z = 2.349, p < 0.05); Scrutiny and dependence (Z = 3.537, p < 
0.01); and Mistrust of Doctors and dependence (Z = 3.478, p < 0.01). 
The correlations of 2-item and full parent subscale with SMS attitudes and 
HCAMQ attitudes are shown in Table 21. 
Table 21. Comparison of the 2-item and the full parent PMAQ subscales correlations to the 
SMS and HCAMQ.  
 
 SMS HCAMQ 




HH CAM HCAMQ 
total 
Addiction FP -.191** .264*** -.169** .110 -.065 .007 
Addiction SF -.165* .212** -.141* .101 -.075 -.005 
Need FP -.322*** .393*** -.379*** .016 -.031 -.016 
Need SF -.363*** .422*** -.404*** .023 -.006 .007 
Scrutiny FP -.036 .072 .005 .055 .047 .067 
Scrutiny SF -.032 .029 -.002 .027 .015 .027 
Side Effects FP -.059 .05 -.045 .022 -.059 -.035 
Side Effects SF -.085 .06 -.057 -.022 -.075 -.072 
Tolerance FP -0.157** .169** -.144* .036 -.057 -.027 
Tolerance SF -.160** .235*** -.172** .048 -.024 .007 
Mistrust of Doctors FP .054 -.075 .144* -.009 .069 .05 
Mistrust of Doctors SF .092 .127* .183** -.056 .103 .053 
Withdrawal FP -.341*** .415*** -.306*** .033 -.015 .006 
Withdrawal SF -.283*** .357*** -.291*** .044 -.013 .013 
 
Notes: FP = Full parent, SF = Short form (2-item), * p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001 
The 2-item and full parent subscales of Addiction, Need, Tolerance and 
Withdrawal had correlations with all SMS subscales. The highest correlations 
were with the Don’t Think Twice subscale. However, Scrutiny, Side Effects 
and Mistrust of Doctors had no significant correlation to any SMS subscales. 
Also, none of the 2-item or full parent subscales had a significant correlation 
with any HCAMQ subscales.  
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The majority of 2-item subscales had the same correlation as the full parent 
subscales to the SMS and HCAMQ measures. There was only one pair of 
discrepant correlations which the 2-item and full parent correlations to these 
measures was significantly different: Mistrust of Doctors and Don’t Think 
Twice (Z = 8.127, p < 0.01). 
4.4. Discussion 
The present study developed 14-item versions of the SOPA-B and PMAQ with 
2-item subscales and tested the validity of these short versions. The validity 
analysis of correlations between 2-item subscales and full parent subscales 
showed all 2-item subscales had high correlations to the full parent subscales, 
which shows the 2-item and full parent subscales were related to each other. 
When the correlations of 2-item subscales with other measures were 
compared to the correlations of full parent subscales to other measures, there 
were only a few discrepant correlations that were significantly different. Since 
there were high correlations between the 2-item and full parent subscales, 
and similarity in correlations to other measures, the short form can be used 
instead of the longer version. 
In addition to similar correlations of the 2-item and full parent subscales to 
other measures, the validity analysis also showed that findings about the 
validity of the PMAQ from previous research were repeated for the short 
version. For example, McCracken et al. (2006) found overuse of painkillers 
was associated with Addiction, Need, Scrutiny, Tolerance and Withdrawal but 
not Side Effects or Mistrust of Doctors. These findings were replicated in the 
present study because the same pattern of significant and non-significant 
correlations was found between the 2-item subscales and exceeding doses of 
painkillers. Another example is that McCracken et al. (2006) found pain 
intensity and number of prescription painkillers was correlated with Need, 
Tolerance and Withdrawal. These findings were replicated because the 2-item 
subscales had the highest correlation to pain intensity and painkiller use 
frequency.  
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The study also provides further findings for the validity of the PMAQ because 
both 2-item and full parent subscales of Addiction, Need, Tolerance and 
Withdrawal correlated with painkiller dependence. To the best of my 
knowledge, the correlation between PMAQ subscales with painkiller 
dependence has not been tested before except the previous study in this 
thesis (Chapter 3), so the present study shows further the validity of the 
PMAQ. 
Other new findings were the 2-item and full parent subscales of Addiction, 
Need, Tolerance and Withdrawal were correlated to all SMS subscales but 
Mistrust of Doctors correlated with only Run its Course subscale of the SMS. 
Therefore, PMAQ subscales are related to attitudes and beliefs to self-
medication in predictable ways. Another new finding was 2-item and full 
parent PMAQ subscales were not correlated to HCAMQ. Because the PMAQ 
and SMS both measures attitudes and beliefs to medication but the HCAMQ 
measures attitudes and beliefs to alternative methods, the relationship 
between PMAQ and SMS subscales but not HCAMQ shows attitudes and 
beliefs to medications may be specific and do not extend to other methods 
than painkillers. 
The PMAQ-14 is a significant improvement for measuring attitudes and beliefs 
to painkillers because it allows these attitudes and beliefs to be measured 
more easily than the previous 47-item PMAQ, which was the only measure of 
attitudes and beliefs to painkillers available. The easier measuring of attitudes 
and beliefs to painkillers is useful because it can reduce the problems of the 
47-item version such as the time needed to complete the scale and the 
difficulty using the scale with other measures.  
In addition, the easier measuring of attitudes and beliefs to painkillers is useful 
because these attitudes and beliefs have been related to important results 
such as adherence for painkillers (e.g. McCracken et al., 2006; Rosser et al., 
2011) and problematic painkiller use is increasing internationally (e.g. 
McCabe, West, Morales, Cranford & Boyd, 2007; Boyd, Teter, West, Morales 
& McCabe, 2009; Casati, Sedefov & Pfeiffer-Gerschel, 2012) so attitudes and 
beliefs should be measured for interventions to treat problematic painkiller 
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use. For example, the PMAQ-14 can now be used in large national surveys to 
test if pain medication attitudes and beliefs are predictors and risk factors of 
problematic painkiller use.  
The SOPA-B-14 is also a useful measure because attitudes and beliefs to 
pain can be measured easier than the 30-item SOPA-B. However, there has 
been a 14-item measure of attitudes to pain available (SOPA-14), so the 
present study has developed an alternative 14-item measure of attitudes to 
pain.  
The SOPA-B-14 of the present study is different from the SOPA-14 because it 
was developed from the 30-item SOPA-B instead of the 57-item SOPA. Also, 
the methods used to develop both were different; items in the SOPA-14 were 
allowed to be associated with more than one subscale but items in the SOPA-
B-14 were allowed to be associated with only one subscale. Therefore, the 
SOPA-B-14 provides a focused measure of attitudes and beliefs to pain than 
the SOPA-14. However, the differences between the SOPA-14 and the 
SOPA-B-14 are quite subtle and small, so both could also be used as 
alternative measures such as in studies measuring attitudes and beliefs to 
pain several times, to avoid familiarity or recall effects with repeating the same 
scale. 
4.4.1. Conclusion 
Many research studies are developing shorter versions to be used for 
screening to minimise the time to complete the measures (e.g. Tan, Nguyen, 
Cardin & Jensen, 2006). This study provides an alternative short measure of 
attitudes and beliefs to pain and a new short measure of attitudes and beliefs 
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5.1. Introduction  
In the comparative study between the UK and Egypt (Chapter 3), the findings 
showed accessibility of painkillers and psychological factors had a role in 
problematic painkiller use but the role was different in each country. 
Specifically, accessibility of painkillers included the following: source of OTC 
painkillers; perceived difficulty for obtaining strong painkillers without a 
prescription; using strong painkillers without a prescription; and source of 
strong painkillers if used without a prescription. The results showed that 
obtaining OTC painkillers from the internet predicted less painkiller 
dependence in the UK but there were no accessibility variables that predicted 
painkiller dependence in Egypt. Therefore, there were differences for the role 
of accessibility between the UK and Egypt but most accessibility variables had 
no role in problematic painkiller use. 
In terms of psychological factors, the role of attitudes and beliefs was 
examined, including attitudes and beliefs towards pain, painkillers, self-
medication and alternative methods of pain relief. The results showed that 
attitudes and beliefs predicted painkiller dependence in the UK and Egypt but 
there were differences between the countries about the particular attitudes 
and beliefs that predicted painkiller dependence.  
Using the SOPA-B (Tait & Chibnall, 1997) to measure attitudes and beliefs 
towards pain, the results showed that the Control and Medical Cure subscales 
predicted more painkiller dependence in the UK. However, only the Solicitude 
subscale predicted more painkiller dependence in Egypt. Attitudes and beliefs 
towards pain therefore had different roles in problematic painkiller use 
depending on the country. Using the PMAQ (McCracken et al., 2006) to 
measure attitudes and beliefs towards painkillers, it was found that the Need 
subscale and the Side Effects subscale predicted more painkiller dependence 
in the UK but no subscales predicted painkiller dependence in Egypt. Similar 
to attitudes and beliefs towards pain, attitudes and beliefs towards painkillers 
had different roles depending on the country. In contrast, attitudes and beliefs 
to self-medication (SMS; James & French, 2008) and alternative methods of 
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pain relief (HCAMQ; Hyland et al., 2003) did not predict problematic painkiller 
use in the UK and Egypt.  
Because accessibility and psychological factors had different roles in 
problematic painkiller use in the general population of the UK and Egypt, 
research comparing more countries than the UK and Egypt should be 
conducted to provide more understanding. This could include other western 
and English-speaking countries, but also other non-western and non-English-
speaking countries. Therefore, the following aim, research question and 
hypotheses were used for the present study. 
5.1.1. Aim 
To conduct a multi-national comparison of the role of accessibility and 
psychological factors in problematic painkiller use among the general 
population. Other than the UK and Egypt, the countries that were involved in 
the multi-national comparison were Germany, USA, Australia and China. 
These countries were chosen to compare other western and non-western 
countries to the UK and Egypt.  
5.1.2. Research question 
What is the role of accessibility and psychological factors in problematic 
painkiller use among the general populations of the UK, Egypt, Germany, 
USA, Australia and China?  
5.1.3. Hypotheses 
There will be differences in accessibility of painkillers between countries, and 
differences in the role in problematic painkiller use. 
There will be differences in attitudes and beliefs to pain between countries, 
and differences in their role in problematic painkiller use. 
There will be differences in attitudes and beliefs to painkillers between 
countries, and differences in their role in problematic painkiller use. 
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There will be differences in attitudes and beliefs to self-medication between 
countries, and differences in their role in problematic painkiller use. 
There will be differences in attitudes and beliefs to alternative methods of pain 
relief between countries, and differences in their role in problematic painkiller 
use. 
Since not much is known about the role of accessibility and psychological 
factors in these countries, the hypotheses were not specific. However, 
differences were predicted based on the results of the comparative study 
between the UK and Egypt. 
5.2. Method 
5.2.1. Participants 
The participants were a total of 1277 members of the general population from 
six countries: UK (N = 295); Egypt (N = 420); Germany (N = 217); USA (N = 
146); Australia (N = 93); and China (N = 76). Power analysis was conducted 
with G*Power, which showed that the sample size of the study provided 
sufficient power to detect meaningful differences between countries (Faul et 
al., 2007). The power analysis was conducted in a similar way to how it was 
described in Chapter 3. To specify, a separate a-priori power analysis was 
conducted for each type of statistical test in the analysis (see section 5.2.6). 
This involved using the following input parameters, which are based on 
recommendations from previous research (e.g. Hunt, 2015): an alpha 
significance level of 0.05, a power level of 0.80 and medium effect size 
between 0.13 to 0.3 depending on the statistical test. In Table 22, the type of 
statistical test, effect size and sample size is summarised. The results showed 




Table 22. Type of statistical test, effect size and sample size required 
according to power calculations. 
Statistical test Effect size Sample size 
One-way ANOVA Partial eta-squared (ηp²) = 0.06 768 
Chi-squared test Phi (Φ) and Cramer’s V (φc) = 0.3 143 
Correlation Correlation coefficient (r) = 0.3 84 
Multiple regression Cohen’s f (f2) = 0.15 231 
It should be noted that the “USA” also included participants in Canada, while 
“China” also included participants in Macau and Hong Kong. However, these 
were combined into “USA” or “China” because the majority of the participants 
in these locations were from the USA or China. A number of methods were 
used to recruit the participants. These methods were the same as the online 
convenience sampling, offline convenience sampling and snowball sampling 
described in Chapter 3, section 3.2.1. Therefore, the same recruitment 
strategy as the comparative study between the UK and Egypt was used for 
each of the additional countries involved in the present study.  
In the online convenience sampling, participants were recruited by posting 
invitations to participate on forums and social media websites. These were 
relevant to pain and painkillers, and based in each country. For example, 
participants in the USA were recruited by posting invitations on online forums 
such as chronicpainsite.com, which is for people with chronic pain living in the 
USA. Meanwhile, participants in Australia were recruited by posting invitations 
on online forums such as chronicpainaustralia.org.au, which is also for people 
with chronic pain but living in Australia. To ensure residence in these 
countries, participants were asked to specify their country of residence and 
were excluded if resident in other countries as described in the following 
exclusion criteria. Additionally, the online convenience sampling involved 
posting invitations on websites whose subscribers are volunteers that are 
willing to participate in online surveys, as well as sending email invitations to 
GP practices, pain clinics, universities, large organisations and large 
employers in each country. In the offline convenience sampling, invitations to 
participate were advertised in these locations, and in pharmacies. This was 
progressed by asking these locations to print the invitations and distribute to 
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staff, students and patients. Finally, the snowball sampling involved asking 
participants to recommend the study to anyone who might wish to participate.  
To take part in the study, the participants were required to meet the following 
inclusion criteria: the participants should be at least 18 years of age, 
experienced pain in the last month, used OTC or prescription painkillers in the 
last month and be resident in Germany, USA (including Canada), Australia or 
China (including Macau and Hong Kong). Participants were excluded from the 
study if any of the inclusion criteria were not achieved. There were also 
another two exclusion criteria: the participants were excluded if there was any 
missing data or if they had participated more than once in the study. Because 
the present study extended the comparative study between the UK and Egypt 
(Chapter 3), the previous data from the UK and Egypt was used for the 
present study. However, data from the other countries were new. 
5.2.2. Design 
The study used a cross-sectional online questionnaire design to assess the 
role of accessibility and psychological factors in problematic painkiller use 
among the general populations of the UK, Egypt, Germany, USA, Australia 
and China.  
5.2.3. Measures 
The online questionnaire used in the present study was similar to the online 
questionnaire used in the comparative study between the UK and Egypt 
(Chapter 3, section 3.2.3). However, there were adjustments to make the 
questionnaire suitable for the countries in the present study. The 
questionnaire for the present study is in Appendix C to E, but a summary of 
the questionnaire and the specific adjustments to the questionnaire for the 
present study will be described below.  
5.2.3.1. Demographics 
At the beginning of the questionnaire were questions about the following 
demographics: gender, age, marital status, nationality, language spoken at 
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home, length of residence in country, highest education level, employment 
status, whether or not pain influences employment, religion, religiousness, 
ethnic origin and financial status. However, there were a number of 
adjustments to the demographic questions. 
One of the adjustments was for the question about ethnic origin. Specifically, 
the online questionnaire for USA, Australia and China included the same 
question as the comparative study between the UK and Egypt. However, the 
response options were adjusted to be more suitable for the USA, Australia 
and China, which were “White”, “Mixed”, “Asian”, “Black”, “Any other ethnic 
group” and “If you selected any other ethnic group, please specify below”. 
Following the advice of a German native (see section 5.2.5), the online 
questionnaire for Germany did not include the question about ethnic origin 
because ethic origin is a sensitive topic in Germany. Therefore, the question 
was not included to avoid offence and increase cultural sensitivity.  
Another adjustment was for the question about highest education level. To 
specify, the online questionnaire for each country used the same question and 
response options as the online questionnaire for Egypt but not the UK. This is 
because “GCSE / O level” and “A level” were not suitable for the countries, 
but these were replaced with “Secondary school” in the online questionnaire 
for Egypt, which is more suitable for the other countries. All other questions 
and responses about demographics were the same as Chapter 3. 
5.2.3.2. Pain 
After the demographic questions, the questionnaire asked questions about 
pain, including pain duration, pain frequency in the last month, pain intensity 
in the last month, type of pain experienced in the last month and pain 
diagnosis. There were no adjustments necessary for the questions about 




5.2.3.3. Painkillers  
Following the questions about pain, the questionnaire asked about painkillers, 
specifically type of painkillers taken in the last month, frequency of painkiller 
use in the last month, painkiller misuse in the last month, painkiller abuse in 
the last month and alternatives to painkillers used in the last month. Similar to 
the questions about pain, there were no adjustments necessary for the 
questions about painkillers, so all the questions and responses about 
painkillers were the same as Chapter 3. 
5.2.3.4. Accessibility of painkillers  
Along with the questions about painkillers, the questionnaire asked about 
accessibility of painkillers, specifically source of OTC painkillers, perceived 
difficulty for obtaining strong painkillers without a prescription, using strong 
painkillers without a prescription and source of strong painkillers if used 
without a prescription. Again, there were no adjustments necessary for the 
questions about accessibility of painkillers, so all the questions and responses 
about accessibility of painkillers were the same as Chapter 3. 
5.2.3.5. Scales  
The rest of the questionnaire consisted of scales measuring painkiller 
dependence (LDQ; Ferrari et al., 2006), attitudes and beliefs towards pain 
(SOPA-B-14; see Chapter 4), attitudes and beliefs towards painkillers (PMAQ-
14; see Chapter 4 & Elander et al., 2017 in Appendix J), attitudes and beliefs 
towards self-medication (SMS; James & French, 2008) and attitudes and 
beliefs towards alternative methods of pain relief (HCAMQ; Hyland et al., 
2003).  
5.2.3.5.1. Leeds Dependence Questionnaire (LDQ) 
Painkiller dependence was measured using the same modified version of the 
LDQ (Ferrari et al., 2006) as the comparative study between the UK and 
Egypt (Chapter 3). 
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5.2.3.5.2. Survey of Pain Attitudes-Brief-14 (SOPA-B-14) 
Attitudes and beliefs towards pain were measured using the SOPA-B (Tait & 
Chibnall, 1997) in the comparative study between the UK and Egypt (Chapter 
3). However, the shortened version of the SOPA-B (SOPA-B-14) developed in 
the previous chapter (Chapter 4) was used for the present study because of 
the advantages of shorter scales such as saving time for participants and less 
burden (e.g. Stanton et al., 2002). Therefore, the online questionnaire for the 
present study used the SOPA-B-14 rather than the SOPA-B to measure 
attitudes and beliefs towards pain.  
5.2.3.5.3. Pain Medication Attitudes Questionnaire-14 (PMAQ-14)   
Attitudes and beliefs towards painkillers were measured using the PMAQ 
(McCracken et al., 2006) in the comparative study between the UK and Egypt 
(Chapter 3). However, the shortened version of the PMAQ (PMAQ-14; 
Elander et al., 2017) developed in the previous chapter (Chapter 4) was used 
for the present study because of the advantages of shorter scales again. 
Hence, the online questionnaire for the present study used the PMAQ-14 
rather than the PMAQ to measure attitudes and beliefs towards painkillers.  
5.2.3.5.4. Self-Medicating Scale (SMS) 
Attitudes and beliefs towards self-medication were measured using the SMS 
(James & French, 2008); the same scale as the comparative study between 
the UK and Egypt (Chapter 3). 
5.2.3.5.5. Holistic, Complementary and Alternative Medicine Questionnaire 
(HCAMQ) 
To measure attitudes and beliefs towards holistic, complementary and 
alternative medicine, the HCAMQ was used (Hyland et al., 2003); the same 




Google Drive Forms was used to create the online questionnaire. A separate 
online questionnaire was created for each country: an English version was 
created for the USA and Australia; a German version was created for 
Germany; and a Mandarin Chinese version was created for China. 
Additionally, SPSS was used for the data analysis. 
5.2.5. Procedure 
Before the present study was conducted, ethical approval was provided by the 
University of Derby Research Ethics Committee. Then, the three versions of 
the online questionnaire were created.  
The translation of the questionnaire to German and Mandarin Chinese was 
conducted by following the back translation procedure recommended by Van 
de Vijver and Hambleton (1996). First, the questionnaire was translated from 
English to German and Chinese by two independent translators for each 
language, who were bilingual German-English or Chinese-English. Then, both 
versions for each language were compared by the translators. If there were 
any differences between the two versions for each language, the differences 
were resolved by the translators until the versions were the same. After any 
differences were resolved, the questionnaire was back translated from 
German and Chinese back to English by another two independent translators 
for each language, who were bilingual German-English and Chinese-English. 
Next, both back translated versions for each language were compared by the 
translators and were compared to the original questionnaire. If there were any 
differences between the two back translated versions for each language, the 
differences were resolved by the translators until the back translations were 
the same and were the same as the original questionnaire.  
The researcher conducted recruitment of participants from USA and Australia. 
However, to recruit participants from Germany and China, research assistants 
fluent in German and Chinese were employed using funding from the 
University of Derby. These research assistants also provided advice on 
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adjustments to the questionnaire needed for cultural sensitivity because they 
were Germany and China natives. In addition, the research assistants 
conducted translation of the data obtained from these countries. The German 
and Mandarin Chinese versions of the materials are given in Appendix D and 
E.  
An Amazon e-voucher worth £50 was available for participants to win if they 
entered the prize draw of the study. To enter the prize draw, participants 
needed to provide their email address so that the e-voucher could be emailed 
to them if they won.  
5.2.6. Analytic strategy 
To prepare the data for analysis, the data from each country was combined 
into one data file in SPSS and a variable called “country” was added to code 
participants by country of the residence. Then, data cleaning was conducted 
to remove the data from any participants who should be excluded based on 
the exclusion criteria. The data analysis involved a number of methods, which 
were chi-squared test, independent-samples one-way ANOVA, Pearson 
correlation, stepwise multiple regression and Sobel tests of mediation effects.  
Firstly, the chi-squared test and independent-samples one-way ANOVA were 
used to test whether there were differences between the countries for the 
demographic measures, pain measures, painkiller use measures, accessibility 
measures and psychological factors. Secondly, Pearson correlations were 
used to test the relationship of dependence to these measures. These 
correlations were conducted separately for each country. Thirdly, stepwise 
multiple regression was used to test whether the correlated measures were 
predictors of dependence. After stepwise multiple regression, the Sobel test 
was used for mediation analysis to test whether any predictors of dependence 
were mediators for each other. These stepwise multiple regression and Sobel 
tests were conducted separately for each country. 
Similarly to the previous comparative study in this thesis (Chapter 3), when 
any significant results were obtained, effect size is reported to show how large 
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are those effects (e.g. Sullivan & Feinn, 2012). As stated in Chapter 3, the 
effect size required for chi-squared test results was Phi (Φ). However, 
Cramer’s V (φc) was also required in this study for chi-squared test results for 
variables with more than two categories. This was not required in Chapter 3 
because there were no significant variables with more than two categories 
unlike this study. Meanwhile, the effect size required for one-way ANOVA was 
partial eta-squared (ηp²), for correlation was correlation coefficient (r), and for 
multiple regression was Cohen’s f (f2). As before, each type of effect size can 
be interpreted as small, medium or large, based on guidelines values from the 
literature (e.g. Cohen, 1988; Murphy & Myors, 2004; Vacha-Haase & 
Thompson, 2004). These values are summarised in the Table 23.  
Table 23. Summary of values for interpreting effect size. 
 
Statistical test Effect size Small Medium Large 
One-way ANOVA Partial eta-
squared (ηp²) 
0.01 0.06 0.14 
Chi-squared test Phi (Φ) and 
Cramer’s V (φc) 
0.10 0.30 0.50 
Correlation Correlation 
coefficient (r)  
0.10 0.30 0.50 
Multiple regression Cohen’s f (f2) 0.02 0.15 0.35 
5.3. Results 
The results of the study are presented in the following order: first, the 
comparisons between the countries for the measures of the study for testing 
whether there were differences between the countries; then, the correlations 
of the measures with dependence; and finally, the predictors of dependence 
and mediators. 
5.3.1. Comparisons between the UK, Egypt, Germany, USA, Australia 
and China  
To do the chi-squared tests, most variables with more than two categories 
were recoded into binary variables as described previously in Chapter 3.  
The results for the comparisons between the countries are summarised in 
Tables 24, 25, 26, 27 and 28. The results before binary recoding are 
summarised in Table 53, 54 and 55 as given in Appendix H. The results for 
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demographic measures will be described first, followed by pain measures, 
painkiller use measures, accessibility measures and finally psychological 
factors measures.  
Table 24 compares the results of demographic variables for each country. A 
comparison of marital status, nationality, language spoken at home, highest 
education level, religion and ethnic origin before the binary recoding is shown 
for each country in Table 53 (Appendix H).
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Table 24. A comparison of demographic variables between the countries. 
 
 
 UK Egypt Germany USA Australia China F or Χ2 Effect 
size 
Gender1       180.43** Φ = 0.38 
Male  40 (13.6%) 225 (53.6%) 40 (18.4%) 24 (16.4%) 19 (20.4%) 26 (34.2%)   
Female 255 (86.4%) 195 (46.4%) 177 (81.6%) 122 (83.6%) 74 (79.6%) 50 (65.8%)   
Age2 41.14 
(12.30, 19 - 
79) 
35.36 (12.72, 
18 - 66) 
30.51 (10.60, 
18 - 62) 
47.14 
(11.47, 23 - 
73) 
46.53 (14.11, 
19 - 80) 
31.14 (10.83, 
18 -57) 
59.43** ηp² = 
0.18 
Marital status1        52.25** Φ = 0.21 
Not in a relationship 98 (33.2%) 180 (42.9%) 97 (44.7%) 27 (18.5%) 37 (39.8%) 47 (61.8%)   
In a relationship 197 (66.8%) 240 (57.1%) 120 (55.3%) 119 (81.5%) 56 (60.2%) 29 (38.2%)   
Nationality1       92.33** Φ = 0.27 
National 274 (92.9%) 420 (100.0%) 173 (79.7%) 132 (90.4%) 83 (89.2%) 74 (97.4%)   
Other  21 (7.1%) 0 (0.0%) 44 (20.3%) 14 (9.6%) 10 (10.8%) 2 (2.6%)   
Language spoken at home1       20.11**  Φ = 0.13 
Main language 289 (98.0%) 420 (100.0%) 209 (96.3%) 146 (100%) 91 (97.8%) 76 (100%)   
Other 6 (2.0%) 0 (0.0%) 8 (3.7%) 0 (0.0%) 2 (2.2%) 0 (0.0%)   
Length of residence1       78.67**  Φ = 0.25 
Since birth 265 (89.8%) 420 (100.0%) 191 (88%) 143 (97.9%) 74 (79.6%) 67 (88.2%)   
Other 30 (10.2%) 0 (0.0%) 26 (12%) 3 (2.1%) 19 (20.4%) 9 (11.8%)   
Highest education level1       21.16**  Φ = 0.13 
No qualification 9 (3.1%) 0 (0.0%) 9 (4.1%) 0 (0.0%) 2 (2.2%) 1 (1.3%)   
Qualification 286 (96.9%) 420 (100.0%) 208 (95.9%) 146 (100%) 91 (97.8%) 75 (98.7%)   
Employment status1       60.80** Φ = 0.24 
Not in employment 141 (47.8%) 216 (51.4%) 170 (78.3%) 84 (57.5%) 51 (54.8%) 26 (34.2%)   
In employment 154 (52.2%) 204 (48.6%) 47 (21.7%) 62 (42.5%) 42 (45.2%) 50 (65.8%)   
Whether or not pain influences 
employment1 
      69.15** Φ = 0.24 
Yes 145 (49.2%) 164 (39.0%) 51 (23.5%) 81 (55.5%) 59 (63.4%) 25 (32.9%)   
No 150 (50.8%) 256 (61.0%) 166 (76.5%) 65 (44.5%) 34 (36.6%) 51 (67.1%)   
Religion1       344.21** Φ = 0.53 
No religion 136 (46.1%) 0 (0.0%) 91 (41.9%) 29 (19.9%) 49 (52.7%) 58 (76.3%)   
Religion 159 (53.9%) 420 (100.0%) 126 (58.1%) 117 (80.1%) 44 (47.3%) 18 (23.7%)   
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Religiousness2 2.09 (1.20,  
1 – 5) 
3.44 (1.08,  
1 – 5)  
2.25 (1.77,  
1 – 5) 
2.82 (1.29,  
1 – 5) 
1.96 (1.16,  
1 – 5) 
2.45 (1.38,  
1 – 5) 
69.33** ηp² = 
0.21 
Ethnic origin1       17.11* Φ = 0.13 
Ethnic minority  14 (4.7%) 6 (1.4%) – 11 (7.5%) 4 (4.3%) 0 (0.0%)   
Ethnic majority  281 (95.3%) 414 (98.6%) – 135 (92.5%) 89 (95.7%) 76 (100%)   
Financial status1       32.45** φc = 0.12 
A little or a lot poorer than most 91 (30.8%) 128 (30.5%) 79 (36.4%) 37 (25.3%) 34 (36.6%) 7 (13.2%)   
About the same as most 172 (58.3%) 229 (54.5%) 124 (57.1%) 90 (61.6%) 49 (52.7%) 45 (84.9%)   
A little or a lot richer than most 32 (10.8%) 63 (15.0%) 14 (6.5%) 19 (13.0%) 10 (10.8%) 1 (1.9%)   
 


















The results in Table 24 show that there was a significant difference between 
the countries for ethnic origin and a highly significant difference between the 
countries for the remaining demographic variables. These were gender, age, 
marital status, nationality, language spoken at home, length of residence, 
highest education level, employment status, whether or not pain influences 
employment, religion, religiousness and financial status. All of these results 
had either medium or large effect size. 
As shown in Table 24, there were more females in each country than males 
except for Egypt, which was more balanced. The difference between the 
proportions of females compared to males was higher in some countries than 
others; the UK, Germany, USA, and Australia had the most difference 
whereas China had less difference. 
The average age of participants in all countries ranged between 30.51 years 
to 47.14 years. The countries with younger average age with in that range 
were Germany, China and Egypt while the older in this range were the UK, 
Australia and USA.  
All countries had more participants in a relationship than not in a relationship 
except for China, where the proportion not in a relationship was higher than in 
a relationship. In the other countries, the difference between the proportion of 
participants in a relationship compared to not in a relationship was highest for 
USA, then UK, Australia and least for Egypt and Germany.  
Almost all participants in each country were nationals of the country they were 
resident but for Egypt it was all participants. For language spoken at home, 
almost all of participants spoke the language of their country of residence at 
home but for Egypt, USA and China it was all participants.  
The majority of participants had lived in their country of residence since birth 
but for Egypt it was all participants. There were few participants who had lived 
in their country of residence since “other” time, but Australia had the highest 
percentage, approximately double that of other countries.  
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Nearly all the participants in each country had a qualification but for Egypt and 
USA it was all participants. The other countries had a small proportion with no 
qualifications.  
The proportion of participants in employment and not in employment was 
balanced for most countries except Germany and China; there were over 
three-quarters not in employment in Germany and over one-third not in 
employment in China. There was variation in whether or not pain influenced 
employment. There was a higher proportion of participants who reported pain 
influenced employment in Australia and USA but a higher proportion who 
reported pain did not influence employment in China, Germany, Egypt and 
UK. From the countries with higher proportion of people whose pain 
influenced employment, there was more in Australia than USA. From the 
countries with higher proportion for pain not influenced employment, the most 
was Germany, then China, Egypt and UK. 
For religion, there was a higher proportion who reported no religion in China 
and Australia but the proportions were more balanced for Australia compared 
to China. In the other countries, there was a higher proportion who reported a 
religion than no religion but this was more balanced for the UK and Germany 
than USA and Egypt. The religiousness scores ranged between 1.96 and 
3.44, and were highest for Egypt and USA while China, Germany and UK had 
lower scores and the lowest score was for Australia. In all countries, most 
participants perceived their financial status as the same as most, fewer 
perceived their financial status as a little or a lot poorer than most and least 
perceived their financial status as a little or a lot richer than most. 
The results for the comparison of pain variables between the countries is 
summarised in Table 25 and the original results for pain duration before 






Table 25. A comparison of pain variables between the countries.  
 UK Egypt  Germany USA Australia China F or Χ2 Effect 
size 
Pain duration1       480.17** Φ = 0.62 
6 months or less 24 (8.1%) 315 (75.0%) 87 (40.1%) 7 (4.8%) 5 (5.4%) 47 (61.6%)   
Longer than 6 months 271 (91.9%) 105 (25.0%) 130 (59.9%) 139 (95.2%) 88 (94.6%) 29 (38.2%)   
Pain frequency in the 
last month (days)2 
24.22 (9.88,  
2 – 31) 
3.89 (3.22,  
1 – 31) 
12.58 (10.58,  
1 – 31) 
26.76 (7.56,  
1 – 31) 
27.92 (6.74,  
1 – 31) 
7.16 (7.36,  
1 – 31) 
637.92** ηp² = 
0.62 
Pain intensity in the last 
month2 
17.62 (5.66,  
4.00 – 31.75) 
15.61 (6.16,  
0.00 – 32.50) 
12.65 (4.70,  
4.25 – 27.00) 
16.75 (4.70,  
5.75 – 29.50) 
17.04 (5.27,  
4.25 – 29.00) 
10.03 (4.95,  
0.00 – 24.25) 
45.76** ηp² = 
0.13 
Type of pain 
experienced in the last 
month1 
        
Headache 185 (62.7%) 109 (26.0%) 147 (67.7%) 69 (47.3%) 47 (50.5%) 34 (44.7%) 141.83** Φ = 0.34 
Migraine 89 (30.2%) 113 (26.9%) 50 (23.0%) 48 (32.9%) 21 (22.6%) 13 (17.1%) 10.51  
Period pain 97 (32.9%) 40 (9.5%) 84 (38.7%) 22 (15.1%) 10 (10.8%) 25 (32.9%) 108.86** Φ = 0.30 
Toothache 43 (14.6%) 74 (17.6%) 28 (12.9%) 15 (10.3%) 10 (10.8%) 12 (15.8%) 6.96  
Abdominal pain 139 (47.1%) 92 (21.9%) 64 (29.5%) 55 (37.7%) 28 (30.1%) 9 (11.8%) 68.38** Φ = 0.23 
Chest pain 68 (23.1%) 76 (18.1%) 25 (11.5%) 22 (15.1%) 12 (12.9%) 1 (1.3%) 27.85** Φ = 0.15 
Foot pain 119 (40.3%) 62 (14.8%) 48 (22.1%) 46 (31.5%) 39 (41.9%) 8 (10.5%) 85.19** Φ = 0.26 
Sore throat 49 (16.6%) 33 (7.9%) 30 (13.8%) 19 (13.0%) 8 (8.6%) 16 (21.1%) 19.68** Φ = 0.13 
Back pain 206 (69.8%) 59 (14.0%) 125 (57.6%) 101 (69.2%) 71 (76.3%) 21 (27.6%) 327.20** Φ = 0.51 
Joint pain 190 (64.4%) 58 (13.8%) 64 (29.5%) 84 (57.5%) 66 (71.0%) 12 (15.8%) 280.73** Φ = 0.47 
Earache 28 (9.5%) 10 (2.4%) 20 (2.4%) 15 (10.3%) 6 (6.5%) 1 (1.3%) 25.79** Φ = 0.14 
Muscle pain 190 (64.4%) 47 (11.2%) 79 (36.4%) 82 (56.2%) 55 (59.1%) 25 (32.9%) 253.70** Φ = 0.45 
Other 61 (20.7%) 24 (5.7%) 19 (8.8%) 60 (41.1%) 33 (35.5%) 10 (13.2%) 137.02** Φ = 0.33 
Pain diagnosis1       187.31** Φ = 0.39 
Yes 254 (86.1%) 271 (64.5%) 110 (50.7%) 139 (95.2%) 83 (89.2%) 27 (35.5%)   
No 41 (13.9%) 149 (35.5%) 107 (49.3%) 7 (4.8%) 10 (10.8%) 49 (64.5%)   
 






Most of the comparisons in Table 25 were highly significant and only two were 
non-significant, which were migraine and toothache. The highly significant 
comparisons were for pain duration, pain frequency, pain intensity, headache, 
period pain, abdominal pain, chest pain, foot pain, sore throat, back pain, joint 
pain, earache, muscle pain, “other” pain and pain diagnosis. These 
comparisons had either medium or large effect size. 
Table 54 shows almost all of the participants in the USA, Australia and UK 
had chronic pain for longer than 6 months but the majority of participants in 
Egypt and China had pain for 6 months or less (Appendix H). For Germany, 
the proportion was more balanced but a slightly higher proportion had pain for 
longer than 6 months compared to 6 months or less.  
Pain frequency in the last month ranged from 3.89 to 27.92 days. The highest 
pain frequency was Australia, USA and UK because participants in these 
countries had pain for most days. Participants in Germany had pain for almost 
half days. The lowest pain frequency was for Egypt and China because 
participants in these countries had pain for fewest days. Pain intensity scores 
ranged from 10.03 to 17.62. The highest pain intensity were found for 
participants in UK, Australia and USA and Egypt. Participants in Germany had 
lower scores and participants in China had the lowest score.  
In each country, headache was the most common or one of the most common 
types of pain. Back pain was also very common in every country except Egypt 
and China. In addition, joint pain and muscle pain were also common in every 
country except Egypt, Germany and China. Almost all of participants in the 
USA had a diagnosis for their pain and most participants in Australia and UK 
also had a diagnosis. Half of the participants in Germany and almost two-
thirds of participants in Egypt had a diagnosis but almost two-thirds of 
participants in China did not have a diagnosis. 
The comparisons for painkiller use variables are shown in Table 26. The 
original results before binary recoding for type of painkillers taken in the last 
month, alternatives to painkillers taken in the last month, painkiller misuse in 
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the last month and painkiller abuse in the last month are presented in Table 





























Table 26. A comparison of painkiller use variables between the countries.  
 UK  Egypt  Germany USA Australia China F or Χ2 Effect 
size 
Type of painkillers taken in the last month1       178.09** Φ = 0.38 
No prescription painkillers (OTC only) 56 (19.0%) 150 (35.7%) 125 (57.6%) 14 (9.6%) 12 (12.9%) 50 (65.8%)   
Prescription painkillers 239 (81.0%) 270 (64.3%) 92 (42.4%) 132 (90.4%) 81 (87.1%) 26 (34.2%)   
Frequency of painkiller use in the last month 
(days)2 
21.79 (11.44, 
1 – 31) 
3.37 (3.71,  
1 – 31) 
8.40 (9.83,  
1 – 31) 
23.68 (10.21, 
1 – 31) 
26.11 (9.02, 
2 – 31) 
3.08 (3.87, 
1 – 30) 
342.25** ηp² = 
0.55 
Painkiller misuse in the last month1       370.13** Φ = 0.55 
Yes 129 (43.7%) 378 (90.0%) 53 (24.4%) 45 (30.8%) 50 (53.8%) 17 (22.4%)   
No 166 (56.3%) 42 (10.0%) 164 (75.6%) 101 (69.2%) 43 (46.2%) 59 (77.6%)   
Painkiller abuse in the last month1       642.21** Φ = 0.72 
Yes 27 (9.2%) 338 (80.5%) 12 (5.5%) 7 (4.8%) 17 (18.3%) 15 (19.7%)   
No 268 (90.8%) 82 (19.5%) 205 (94.5%) 139 (95.2%) 76 (81.7%) 61 (80.3%)   
Alternatives to painkillers used in the last month1       294.26** Φ = 0.49 
No alternatives 20 (6.8%) 197 (46.9%) 11 (5.1%) 7 (4.8%) 4 (4.3%) 8 (10.5%)   
Alternatives 275 (93.2%) 223 (53.1%) 206 (94.9%) 139 (95.2%) 89 (95.7%) 68 (89.5%)   
 











There was a highly significant difference between the countries for all 
painkiller use variables: type of painkillers taken in the last month, frequency 
of painkiller use in the last month, misuse of painkillers, abuse of painkillers 
and using alternative methods of pain relief. The effect sizes of these 
comparisons were all either medium or large. 
Prescription painkillers were used by nearly all participants in the USA, 
Australia and UK. A smaller proportion used prescription painkillers in Egypt 
but the countries where more participants did not use prescription painkillers 
were China and Germany, although the proportion in Germany was more 
balanced than China. Painkiller use frequency in the last month ranged 
between 3.08 to 26.11 days. The highest pain frequency was Australia, which 
was most days, followed by USA and UK, which were also most days but few 
than Australia. Painkillers were used for less than one-third of the days in 
Germany and few days in Egypt and China. 
The country with the highest proportion of misuse was Egypt because almost 
all participants misused painkillers. Over half of the participants in Australia 
reported painkiller misuse but over half of participants in the UK reported no 
painkiller misuse. Most of participants in the other countries did not misuse 
painkillers. The majority of participants in Egypt abused painkillers but the 
majority of participants in the other countries did not abuse painkillers. 
The proportion of participants who used alternative methods of pain relief was 
higher in each country compared to not using alternative methods but there 
was some variation between the countries; alternatives were used by a high 
proportion or almost all of participants in each country but the proportion was 
more balanced for Egypt. 




Table 27. A comparison of accessibility variables between the countries.   
 UK  Egypt  Germany USA Australia China F or Χ2 Effect 
size 
Source of over-the-counter 
painkillers1 
        
Pharmacy 138 (46.8%) 349 (83.1%) 164 (75.6%) 87 (59.6%) 69 (74.2%) 48 (63.2%) 118.90** Φ = 0.31 
Supermarket shelf 119 (40.3%) 9 (2.1%) 2 (0.9%) 51 (34.9%) 15 (16.1%) 16 (21.1%) 253.54** Φ = 0.45 
Family member who IS a medical 
professional 
0 (0.0%) 0 (0.0%) 25 (11.5%) 0 (0.0%) 1 (1.1%) 4 (5.3%) 101.36** Φ = 0.29 
Family member who is NOT a medical 
professional 
6 (2.0%) 49 (11.7%) 10 (4.6%) 1 (0.7%) 1 (1.1%) 3 (3.9%) 47.30** Φ = 0.20 
Friend who IS a medical professional 1 (0.3%) 26 (6.2%) 1 (0.5%) 2 (1.4%) 1 (1.1%) 3 (3.9%) 31.94** Φ = 0.16 
Friend who is NOT a medical 
professional 
4 (1.4%) 11 (2.6%) 7 (3.2%) 0 (0.0%) 1 (1.1%) 2 (2.6%) 6.63  
Internet 4 (1.4%) 10 (2.4%) 0 (0.0%) 1 (0.7%) 2 (2.2%) 0 (0.0%) 8.21  
Other 4 (1.4%) 3 (0.7%) 6 (2.8%) 4 (2.7%) 2 (2.2%) 2 (2.6%) 5.63  
Perceived difficulty for obtaining 
strong painkillers without a 
prescription2 
2.11 (1.22,  
1 – 5) 
3.55 (1.09,  
1 – 5) 
2.65 (1.27,  
1 – 5) 
1.93 (1.14,  
1 – 5) 
1.78 (1.15,  
1 – 5) 
2.36 (1.45,  





Using strong painkillers without a 
prescription1 
      239.81** Φ = 0.44 
Yes 59 (20.0%) 270 (64.3%) 53 (24.4%) 25 (17.1%) 20 (21.5%) 11 (14.5%)   
No 236 (80.0%) 150 (35.7%) 164 (75.6%) 121 (82.9%) 73 (78.5%) 65 (85.5%)   
Source of strong painkillers (if strong 
painkillers were used without a 
prescription) 1 
        
Pharmacy 22 (7.5%) 309 (73.6%) 12 (5.5%) 12 (8.2%) 10 (10.8%) 19 (25.0%) 554.65** Φ = 0.67 
Family member who IS a medical 
professional 
0 (0.0%) 44 (10.5%) 9 (4.1%) 1 (0.7%) 2 (2.2%) 1 (1.3%) 55.95** Φ = 0.21 
Family member who is NOT a medical 
professional 





Friend who IS a medical professional 4 (1.4%) 46 (11.0%) 8 (3.7%) 4 (2.7%) 2 (2.2%) 2 (2.6%) 41.88** Φ = 0.18 
Friend who is NOT a medical 
professional 
17 (5.8%) 5 (1.2%) 18 (8.3%) 14 (9.6%) 4 (4.3%) 0 (0.0%) 30.42** Φ = 0.16 
Other 4 (1.4%) 0 (0.0%) 9 (4.1%) 4 (2.7%) 0 (0.0%) 0 (0.0%) 22.70** Φ = 0.14 
 
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001, Φ = Phi, ηp² = Partial eta-squared 
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The results in Table 27 shows there was a highly significant difference for 
most comparisons for the source of OTC painkillers. These were obtaining 
OTC painkillers from the pharmacy, supermarket shelf, family member who is 
a medical professional, family member who is not a medical professional and 
friend who is a medical professional. All of these comparisons had medium 
effect size. Meanwhile, the source of OTC painkillers where differences were 
non-significant were obtaining OTC painkillers from a friend who is not a 
medical professional, the internet and “other”.  
There was a highly significant difference for most of the remaining 
accessibility variables. These were perceived difficulty for obtaining strong 
painkillers without prescription, using strong painkillers without a prescription 
and obtaining strong painkillers (if strong painkillers were used without a 
prescription) from the pharmacy, family member who is a medical 
professional, friend who is a medical professional, friend who is not a medical 
professional and “other”. The effect size of these comparisons was either 
medium or large. Only one of the sources of strong painkillers used without a 
prescription was non-significant, which was from a family member who is not 
a medical professional.  
The most common source for obtaining OTC painkillers for participants who 
used OTC painkillers in each country was the pharmacy. All other sources 
were not common in each country except for supermarket shelf in the UK and 
USA because in the UK almost the same proportion of participants obtained 
painkillers from the supermarket shelf as the pharmacy, and over one-third of 
participants obtained OTC painkillers from the supermarket shelf in the USA. 
The range of scores for perceived difficulty for obtaining strong painkillers 
without a prescription was between 1.78 and 3.55. Participants in Egypt had 
the highest scores, so these participants perceived obtaining strong painkillers 
without a prescription as easy. The next highest score was Germany, followed 
by China and UK and the lowest scores was USA and Australia, so 
participants in the USA and Australia perceived obtaining strong painkillers 
without a prescription as more difficult.  
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The only country where most participants used strong painkillers without a 
prescription was Egypt, which was almost two-thirds of participants. In the 
other countries, only one-quarter or less participants used strong painkillers 
without a prescription. 
The pharmacy was the most common source of strong painkillers without a 
prescription in each country except Germany, USA and Australia, where 
family member or friend who was not a medical professional was the most 
common source instead.  
Table 28 shows the comparisons for dependence and psychological factors 
between each country. As demonstrated, all of the comparisons were either 










Table 28. A comparison of painkiller dependence and other psychological factors between the countries.  












F Effect size 
LDQ total 10.18 (5.75) 16.53 (6.10) 5.03 (4.18) 7.66 (5.20) 10.34 (5.94) 5.50 (4.45) 176.84**  ηp² = 0.40 
SOPA-B Solicitude  1.81 (1.18) 2.43 (0.91) 1.58 (1.09) 2.02 (1.15) 1.97 (1.08) 2.98 (0.80) 41.33** ηp² = 0.12 
SOPA-B Emotion  2.38 (1.19) 2.40 (1.02) 1.88 (1.28) 2.55 (1.15) 2.51 (1.19) 2.63 (0.87) 8.80** ηp² = 0.04 
SOPA-B Medical Cure  2.12 (1.18) 2.37 (0.92) 2.21 (1.19) 2.00 (1.26) 1.72 (1.15) 2.70 (1.01) 10.27** ηp² = 0.04 
SOPA-B Control  1.58 (1.03) 2.39 (0.92) 1.71 (1.08) 1.60 (1.08) 1.78 (1.19) 2.13 (0.85) 33.55** ηp² = 0.11 
SOPA-B Harm  2.01 (0.83) 2.35 (0.95) 1.54 (1.12) 2.48 (0.92) 2.42 (1.03) 2.57 (0.70) 28.27** ηp² = 0.11 
SOPA-B Disability  2.07 (0.68) 2.42 (1.00) 1.25 (1.12) 2.64 (1.05) 2.52 (1.02) 1.80 (0.84) 45.87** ηp² = 0.19 
SOPA-B Medication  2.81 (0.93) 2.40 (1.05) 1.95 (1.15) 2.97 (1.02) 2.50 (1.02) 1.74 (0.86) 35.03** ηp² = 0.12 
PMAQ Addiction  3.06 (2.23) 5.90 (1.92) 2.88 (2.91) 2.90 (2.31) 3.24 (2.89) 4.80 (2.44) 99.33** ηp² = 0.25 
PMAQ Need  4.64 (3.28) 5.81 (2.25) 2.44 (2.85) 5.14 (2.92) 4.62 (2.30) 2.42 (2.38) 62.07** ηp² = 0.18 
PMAQ Scrutiny  2.27 (2.88) 5.83 (2.32) 1.20 (2.01) 3.29 (3.16) 3.18 (3.07) 1.72 (1.95) 162.89** ηp² = 0.34 
PMAQ Side Effects  4.11 (2.72) 5.93 (2.22) 2.90 (2.87) 3.95 (2.37) 4.39 (2.35) 4.91 (2.41) 48.65** ηp² = 0.16 
PMAQ Tolerance  4.49 (3.23) 5.88 (2.37) 1.97 (2.69) 4.12 (2.42) 4.43 (3.07) 3.87 (2.14) 68.26** ηp² = 0.20 
PMAQ Mistrust of Doctors  5.48 (3.19) 5.97 (2.36) 4.14 (2.98) 3.51 (2.83) 3.60 (2.97) 4.63 (2.30) 31.17** ηp² = 0.11 
PMAQ Withdrawal  3.81 (3.17) 5.89 (2.44) 1.27 (2.43) 3.49 (2.97) 2.94 (3.05) 2.75 (2.54) 111.47** ηp² = 0.27 
SMS Reluctance  11.35 (3.48) 9.87 (3.31) 12.23 (3.29) 11.05 (3.36) 10.92 (3.27) 11.89 (2.34) 18.52** ηp² = 0.07 
SMS Don’t Think Twice  9.81 (3.32) 10.23 (3.03) 7.07 (2.92) 8.87 (2.99) 9.31 (3.36) 9.42 (2.79) 35.02** ηp² = 0.12 
SMS Run its Course  7.65 (2.97) 10.20 (3.01) 8.55 (2.96) 7.55 (2.86) 7.81 (2.68) 9.39 (2.03) 36.63** ηp² = 0.13 
HCAMQ  32.58 (7.22) 37.02 (3.92) 31.51 (6.38) 31.46 (6.35) 32.81 (7.19) 33.74 (3.91) 54.01** ηp² = 0.14 
HCAMQ HH  10.78 (3.90) 14.86 (5.64) 10.13 (3.17) 10.34 (3.16) 10.41 (3.24) 9.36 (3.44) 47.66** ηp² = 0.20 
HCAMQ CAM  21. 80 (5.81) 22.17 (2.95) 21.37 (5.36) 21.12 (5.00) 22.40 (5.97) 24.38 (3.57) 8.27** ηp² = 0.02 
 




There was a highly significant difference between the countries for 
dependence and all the psychological factors.  
5.3.1.1. Leeds Dependence Questionnaire (LDQ) 
Mean dependence scores ranged between 5.03 and 16.53. Participants in 
Egypt had the highest dependence scores, followed by Australia and the UK 
which both had similar dependence scores, and the USA had a lower 
dependence score. The countries with lowest dependence scores were China 
and Germany. To analyse further the LDQ scores, the results in Table 29 
shows the frequency and proportion of participants with severe dependence in 
each country, defined as a score of 20 or more on the LDQ (Raistrick et al., 
1994) (see section 3.2.3.5.1). 
Table 29. Frequency and proportion of 
participants with severe dependence in each 
country. 
Country Severe dependence  
N (%) 
UK 21 (7.12) 
Egypt 136 (32.38) 
Germany 2 (0.92) 
USA 3 (2.05) 
Australia  6 (6.45) 
China 0 (0) 
As shown, the only country with a high proportion of participants with severe 
dependence was Egypt. In contrast, the remaining countries had a low 
proportion of severe dependence and there were no participants with severe 
dependence in China. 
5.3.1.2. Survey of Pain Attitudes-Brief-14 (SOPA-B-14) 
Mean scores on the SOBA-B-14 ranged from 1.25 to 2.98. In the UK, the 
highest score was for Medication, followed by Emotion. Scores for the other 
subscales were lower compared to these subscales. In Egypt, most of the 
scores were similar but the highest scores were for Solicitude. In Germany, 
the highest score was for Medical Cure. In the USA, the highest score was 
Medication, followed by Disability, Emotion and Harm. The lower scores were 
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for Solicitude and Medical Cure and the lowest score was for Control. In 
Australia, the higher scores were for Disability, Emotion, Medication and 
Harm. The lower scores were for Solicitude, Control and Medical Cure. In 
China, the higher scores were for Solicitude, Medical Cure, Emotion, Harm 
and Control. The lower scores were for Disability and Medication. 
For the adaptive subscales, Egypt had the highest score for Control, followed 
by China. The other countries had lower scores for Control and the lowest 
score was for the USA. For Emotion, China had the highest score, followed by 
USA, Australia, Egypt and UK. The lowest score for Emotion was Germany. 
For maladaptive subscales, the comparisons between the countries show that 
China, Egypt and USA had the highest scores for Solicitude but Australia, UK 
and Germany had the lowest scores. Medical Cure scores were highest for 
China and lower for the other countries but lowest for Australia. The highest 
scores for Harm were China, USA, Australia and Egypt while the lowest 
scores for Harm were the UK and Germany. For Disability, the highest scores 
were for USA, Australia and Egypt but the lowest Disability scores were for 
the UK, Germany and China. For medication, the highest scores were for 
USA, UK, Australia and Egypt while the lowest was for Germany and China. 
5.3.1.3. Pain Medication Attitudes Questionnaire-14 (PMAQ-14) 
Scores for all countries on the PMAQ-14 were from 1.20 to 5.97. In the UK, 
scores were highest for Mistrust of Doctors, Need, Tolerance and Side 
Effects. Lower scores were for Withdrawal, Addiction and Scrutiny. In Egypt, 
all subscale scores were high and similar but the highest was Mistrust of 
Doctors and the Lowest was Need. In Germany, the highest score was for 
Mistrust of Doctors. All other subscale scores in Germany were low compared 
to Mistrust of Doctors but the lowest was Scrutiny. In the USA, the scores 
were highest for Need and Tolerance. The lower scores were Side Effects, 
Mistrust of Doctors, Withdrawal, Scrutiny and Addiction. In Australia, the 
higher scores were for Need, Tolerance and Side Effects. The lower scores 
were for Mistrust of Doctors, Addiction, Scrutiny and Withdrawal. In China, the 
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higher scores were for Side Effects, Addiction and Mistrust of Doctors while 
the lower scores were for Tolerance, Withdrawal, Need and Scrutiny. 
The comparisons between the countries in shows that Egypt had the highest 
score for Addiction, followed by China. The other countries had lower scores 
and the lowest score was for Germany. The highest score for the Need 
subscale was for Egypt, followed by USA, UK and Australia while the lower 
scores were for Germany and China. Scrutiny scores were highest for Egypt. 
All other countries had a low scrutiny scores compared to Egypt and the 
lowest was for Germany. Side Effects scores were highest for Egypt, followed 
by China, Australia and UK while USA and Germany had lower scores. The 
highest scores for Tolerance were for Egypt, followed by UK, Australia and 
USA while the lower scores were for China and Germany. Mistrust of Doctors 
scores were highest for Egypt, UK, China and Germany but lower for Australia 
and USA. For Withdrawal, Egypt has the highest score while the scores in the 
other countries were low compared to Egypt and the lowest score for 
Withdrawal was for Germany. 
5.3.1.4. Self-Medicating Scale (SMS) 
Scores for SMS subscales ranged from 7.07 to 12.23. In the UK, the highest 
score was for Reluctance, followed by Don’t Think Twice and Run its Course. 
In Egypt, the scores for each subscale were similar but the highest score was 
for Don’t Think Twice, followed by Run its Course and Reluctance. For 
Germany, the highest score was for Reluctance, then Run its Course and 
Don’t Think Twice. For the USA, the highest score was for Reluctance, 
followed by Don’t Think Twice and Run its Course. The highest score for 
Australia and China was also Reluctance, followed by Don’t Think Twice and 
Run its Course but in China Don’t Think Twice and Run its Course were 
almost same. 
The highest score for Reluctance was found in Germany. The Reluctance 
scores for China, UK and USA were lower but similar to Germany and similar 
to each other. The lowest Reluctance scores were for Australia then Egypt. 
Don’t Think Twice scores were highest for Egypt. The scores of UK, China 
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and Australia were lower but similar to Egypt and similar to each other. The 
lowest scores were for USA and Germany. Run its Course scores were 
highest for Egypt and China, followed by Germany, Australia, UK and USA. 
5.3.1.5. Holistic, Complementary and Alternative Medicine Questionnaire 
(HCAMQ) 
Scores for the HCAMQ ranged from 9.36 to 37.02. The highest score for 
HCAMQ total was for Egypt. The other countries had low scores in 
comparison to Egypt and were similar to each other. The lowest score was for 
the USA. The highest score for HCAMQ HH was also Egypt. The other 
countries had lower scores compared to Egypt that were similar to each other. 
The lowest score was for China. For HCAMQ CAM, China had the highest 
score, followed by Australia, Egypt, UK, Germany and USA.  
5.3.2. Correlations of dependence with demographic variables, pain 
variables, painkiller use variables, accessibility, and psychological 
factors 
The relationship between dependence and demographic variables, pain 
variables, painkiller use variables, accessibility, and psychological factors was 
analysed using Pearsons correlations. The relationship between these 
variables was analysed separately for each country and the results are 
summarised in the correlation matrices in Table 30 to Table 33. These tables 
summarise the results of the correlation analysis for Germany, USA, Australia 
and China. The correlations for the UK and Egypt are shown in Chapter 3, 
section 3.3.2.
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Table 30. Correlations of painkiller dependence (LDQ scores) with demographic variables, pain variables, painkiller use variables, accessibility, and 
psychological factors in Germany.  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Age 1                   
2. Religiousness .10 1                  
3. Pain frequency .49** .10 1                 
4. Pain intensity .45** .08 .58** 1                
5. Painkiller use 
frequency 
.62** .08 .73** .60** 1               
6. Perceived difficulty -.20** .01 -.30** -.24** -.32** 1              
7. Reluctance  -.25** .08 -.10 -.01 -.34** .07 1             
8. Don’t Think Twice  .47** -.03 .24** .38** .52** -.19** -.42** 1            
9. Run its Course  -.38** .06 -.23** -.34** -.45** .14* .49** -.58** 1           
10. Addiction  .40** .06 .28** .34** .34** -.03 -.12 .20** -.12 1          
11. Need  .50** -.06 .43** .52** .67** -.24** -.43** .62** -.52** .30** 1         
12. Scrutiny  .27** .05 .28** .23** .30** -.02 -.09 .17* -.01 .41** .29** 1        
13. Side Effects  .46** .02 .51** .47** .54** -.17* -.20** .30** -.19** .51** .45** .47** 1       
14. Tolerance  .53** .12 .49** .54** .62** -.23** -.32** .49** -.34** .56** .60** .42** .59** 1      
15. Mistrust of Doctors  .06 .06 .07 .08 .00 -.04 .15* -.14* .09 .05 -.01 .09 .14* .16* 1     
16. Withdrawal  .56** .01 .50** .53** .71** -.25** -.38** .53** -.38** .50** .68** .31** .56** .68** -.07 1    
17. Solicitude  -.02 .08 .07 .15* .06 .04 -.16* .10 -.12 .13 .11 .05 .17* .14* -.06 .12 1   
18. Emotion  .22** .07 .21** .17* .17* -.08 -.15* .11 -.02 .29** .17* .08 .34** .25** -.01 .31** .40** 1  
19. Medical Cure  -.37** .03 0.35** -.36** -.31** .19** .11 -.19** .14* -.24** -.36** -.19** -.33** -.36** -.18** -.28** -.08 -.16* 1 
20. Harm  .29** .07 .42** .35** .44** -.21** -.11 .29** -.19** .15* .35** .17* .26** .32** .01 .32** .11 .12 -.11 
21. Disability  .31** .03 .41** .41** .47** -.31** -.17* .33** -.23** .28** .38** .18** .32** .42** .03 .50** .10 .09 -.17 
22. Control  -.07 -.02 -.01 -.17* -.16* -.01 .08 -.27** .29** .07 -.17* -.01 -.02 -.13 -.03 -.03 .02 .27** .07 
23. Medication  .44** .03 .33** .49** .55** -.20** -.37** .54** -.56** .21** .72** .19** .34** .43** -.03 .49** .10 .09 -.36** 
24. HH  .07 -.03 .07 .12 .16* -.11 -.03 .12 -.11 -.03 .14* .08 -.03 .04 .04 -.01 -.07 -.18** -.06 
25. CAM  -.18** -.16* -.10 -.16* -.01 -.03 -.08 .09 -.05 -.13 .07 .08 .01 -.07 -.03 -.04 -.05 -.13 .02 
26. HCAMQ  -.12 -.15* -.05 -.07 .07 -.08 -.09 .14* -.09 -.12 .13 .11 -.01 -.04 -.01 -.04 -.08 -.20** -.01 
27. LDQ  .53** -.03 .49** .48** .69** -.20** -.38** .47** -.45** .34** .70** .28** .51** .59** -.02 .68** .11 .17* -.32** 
 
 20 21 22 23 24 25 26 27 
20. Harm  1        
21. Disability  .47** 1       
22. Control  -.20** -.12 1      
23. Medication  .32** .31** -.25** 1     
24. HH  .13 .06 -.15* .06 1    
25. CAM  .08 .05 -.11 .13 .06 1   
26. HCAMQ  .13 .06 -.17* .14* .55** .87** 1  
27. LDQ  .32** .37** -.04 .59** .06 -.02 .01 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001 
 
7 – 9 SMS subscales 
10 – 16 PMAQ-14 subscales 
17 – 23 SOPA-B-14 subscales 
24 – 26 HCAMQ subscales 
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Table 31. Correlations of painkiller dependence (LDQ scores) with demographic variables, pain variables, painkiller use variables, accessibility, and 
psychological factors in the USA. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Age 1                   
2. Religiousness ..20* 1                  
3. Pain frequency .15 -.04 1                 
4. Pain intensity .11 .02 .39** 1                
5. Painkiller use 
frequency 
.05 -.02 .64** .23** 1               
6. Perceived difficulty -.28** -.17* -.03 .10 .09 1              
7. Reluctance  -.04 .09 -.03 .02 -.30** -.11 1             
8. Don’t Think Twice  .05 .07 .12 .03 .35** -.07 -.41** 1            
9. Run its Course  -.04 .01 -.22** .05 -.29** .14 .40** -.48** 1           
10. Addiction  .03 .08 -.00 .00 -.02 -.13 -.13 .13 -.05 1          
11. Need  .01 .05 .26** .23** .46** .05 -.30** .31** -.21** .02 1         
12. Scrutiny  -.22** -.04 .00 .08 .06 .05 .00 -.10 .25** .24** .16 1        
13. Side Effects  -.02 -.14 .01 .13 -.02 .02 -.07 -.00 .10 .20* -.06 .43** 1       
14. Tolerance  -.07 .01 .06 .18* .19* .03 -.23** .25** -.17* .35** .32** .26** .23** 1      
15. Mistrust of Doctors  .04 -.05 -.08 .21* -.07 .13 -.03 .10 .11 .08 -.06 .10 .28** .21* 1     
16. Withdrawal  .07 .10 .27** .26** .40** .16 -.40** .40** -.20* .33** .39** .20* .07 .47** -.01 1    
17. Solicitude  -.23** -.18* .02 .05 .04 .02 .02 .08 -.04 .14 .12 .13 .23** .24** .11 .06 1   
18. Emotion  .04 -.14 -.03 .04 -.06 .03 .02 .04 -.07 .14 .14 -.03 .10 .20* .16 .23** .41** 1  
19. Medical Cure  -.06 .06 -.05 -.22** -.03 -.06 .04 -.08 -.07 -.09 -.14 -.03 -.02 -.23** -.16 -.06 -.15 -.21* 1 
20. Harm  .01 .02 .15 .28** .16 .02 -.06 .17* -.05 .01 .25** .11 .10 .12 .13 .14 -.02 .01 -.14 
21. Disability  .04 -.01 .27** .33** .12 -.06 .13 .09 -.01 .01 .19* .14 .21* .16* .01 .12 .15 .14 -.19* 
22. Control  .06 -.16 -.12 -.09 -.23** .09 .14 -.29** .12 -.09 -.25** -.02 -.06 -.18* -.07 -.20* .06 .14 .24** 
23. Medication  -.05 .00 .29** .16 .43** .06 -.33** .35** -.29** -.06 .50** .05 .02 .17* -.15 .36** .18* .17* -.23** 
24. HH  .06 -.07 .02 .11 .03 .06 -.17* .06 -.06 .03 .04 -.00 -.07 -.03 -.02 .05 -.06 -.12 -.18* 
25. CAM  -.02 -.00 .02 -.05 .10 .11 -.10 .16 -.07 .06 .15 -.04 -.09 .07 -.27** .14 .00 -.01 -.12 
26. HCAMQ  .01 -.04 .02 .02 .10 .11 -.16* .15 -.06 .07 .14 -.04 -.10 .04 -.22** .14 -.03 -.07 -.18* 
27. LDQ  .06 .00 .31** .25** .46** .04 -.35** .41** -.37** .22** .49** .04 .00 .38** -.02 .53** .16 .10 -.09 
 
 20 21 22 23 24 25 26 27 
20. Harm  1        
21. Disability  .40** 1       
22. Control  -.28** -.22** 1      
23. Medication  .22** .07 -.25** 1     
24. HH  .21** .12 -.10 .10 1    
25. CAM  .02 .08 -.20* .16 .17* 1   
26. HCAMQ  .12 .12 -.21* .18* .63** .87** 1  
27. LDQ  .21* .21* -.16 .40** .06 .02 .04 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001 
 
7 – 9 SMS subscales 
10 – 16 PMAQ-14 subscales 
17 – 23 SOPA-B-14 subscales 
24 – 26 HCAMQ subscales 
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Table 32. Correlations of painkiller dependence (LDQ scores) with demographic variables, pain variables, painkiller use variables, accessibility, and 
psychological factors in Australia. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Age 1                   
2. Religiousness .19 1                  
3. Pain frequency .23* .10 1                 
4. Pain intensity .19 .19 .42** 1                
5. Painkiller use 
frequency 
.19 .14 .67** .31** 1               
6. Perceived difficulty -.16 -.06 -.23* -.20 -.09 1              
7. Reluctance  -.06 -.09 -.03 .11 -.21* .11 1             
8. Don’t Think Twice  .19 .08 .20 .15 .36** -.12 -.38** 1            
9. Run its Course  -.15 -.09 -.21* -.18 -.21* .18 .32** -.57** 1           
10. Addiction  -.03 .09 .05 .04 .12 -.01 -.27** .21* -.10 1          
11. Need  .24* .02 .36** .34** .50** -18 -.30** .51** -.36** .39** 1         
12. Scrutiny  -.27* .07 .07 .05 .15 -.09 -.11 .11 -.18 .32** .23* 1        
13. Side Effects  .11 .24* .11 .33** .09 -.20 -.17 .10 -.28** .49** .33** .27** 1       
14. Tolerance  -.05 .03 .26* .26* .13 -.09 -.11 .28** -.14 .58** .52** .30** .53** 1      
15. Mistrust of Doctors  .00 .15 -.03 .02 .02 .15 .15 -.10 .09 -.03 -.23* .05 .05 -.12 1     
16. Withdrawal  .10 .00 .22* .26* .33** -.15 -.25* .39** -.25* .55** .61** .23* .48** .57** -.03 1    
17. Solicitude  -.17 -.08 .04 -.08 .01 .00 -.09 -.07 .14 .05 -.01 .04 .04 .11 .07 -.06 1   
18. Emotion  -.13 .05 .11 .04 .06 .10 -.06 -.03 .12 .12 .00 .24* .13 .17 -.11 -.08 .37** 1  
19. Medical Cure  -.13 .03 -.13 -.17 -.13 -.02 .17 .01 -.01 .04 -.25* -.27** -.21* -.16 -.15 -.10 -.21* -.19 1 
20. Harm  .00 .03 .16 .18 .17 -.01 .20 .13 -.03 .11 .24* -.04 -.03 .14 .06 .10 -.07 -.14 .13 
21. Disability  -.02 .05 .31** .32** .18 .01 .13 .11 -.07 .14 .25* .15 .19 .30** .09 .11 .07 .11 .01 
22. Control  -.08 .04 -.01 -.13 -.05 -.04 -.11 -.32** .45** -.06 -.22* .04 -.07 -.14 -.06 -.19 .21* .46** -.14 
23. Medication  .15 -.10 .19 .24* .37** -.11 -.08 .39** -.30** .10 .51** .08 .06 .20 -.24* .15 -.20 .10 -.06 
24. HH  -.11 .06 .03 .04 .14 .03 -.10 .15 -.03 .07 .16 .03 -.10 .11 .09 .14 -.12 -.31** .10 
25. CAM  .09 -.12 .11 .03 .11 -.01 -.06 .07 -.04 -.11 .24* -.11 -.19 -.10 -.06 .01 -.04 -.09 -.02 
26. HCAMQ  .02 -.08 .10 .04 .15 .00 -.09 .13 -.04 -.06 .27** -.08 -.20 -.03 -.01 .07 -.08 -.22* .03 
27. LDQ  .07 -.04 .25* .20 .42** -.08 -.19 .46** -.23* .41** .63** .16 .34** .49** -.16 .46** -.00 .16 -.09 
 
 20 21 22 23 24 25 26 27 
20. Harm  1        
21. Disability  .50** 1       
22. Control  -.31** -.09 1      
23. Medication  .24* .11 -.30** 1     
24. HH  .30** .04 -.22* .08 1    
25. CAM  .12 .00 .04 .16 .15 1   
26. HCAMQ  .24* .02 -.07 .17 .57** .90** 1  
27. LDQ  .28** .19 -.11 .43** .05 .14 .14 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001 
 
7 – 9 SMS subscales 
10 – 16 PMAQ-14 subscales 
17 – 23 SOPA-B-14 subscales 




Table 33. Correlations of painkiller dependence (LDQ scores) with demographic variables, pain variables, painkiller use variables, accessibility, and 
psychological factors in China. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Age 1                   
2. Religiousness -.24* 1                  
3. Pain frequency .24* -.11 1                 
4. Pain intensity -.13 .31** .20 1                
5. Painkiller use 
frequency 
.40** .02 .53** .29* 1               
6. Perceived difficulty -.20 -.09 .03 -.11 -.14 1              
7. Reluctance  .04 .16 .03 .22 -.21 .02 1             
8. Don’t Think Twice  .10 -.04 -.16 -.15 .04 -.11 -.24* 1            
9. Run its Course  -.20 .10 .01 .02 -.15 -.05 .30** -.20 1           
10. Addiction  .07 .05 -.10 .32** .06 -.02 .01 -.07 -.29* 1          
11. Need  .30** .14 .10 .32** .39** -.10 -.16 .37** -.34** .35** 1         
12. Scrutiny  .02 -.05 .01 .04 .13 .11 -.28* .26* -.22 .20 .47** 1        
13. Side Effects  .14 .08 .19 .39** .22 -.21 .20 -.24* -.04 .55** .15 .12 1       
14. Tolerance  -.02 .08 .11 .38** .23* .10 -.08 .05 -.34** .58** .54** .45** .26* 1      
15. Mistrust of Doctors  -.38** .02 -.02 -.23* -.19 .12 -.06 -.02 .13 -.39** -.23 .11 -.35** -.09 1     
16. Withdrawal  .08 .09 .04 .35** .29* .15 -.20 .30** -.24* .44** .75** .51** .08 .68** -.07 1    
17. Solicitude  .09 .08 -.04 .20 .01 -.16 .05 -.07 -.28* .44** .11 -.09 .36** .16 -.41** .01 1   
18. Emotion  .02 .13 .09 .41** .11 -.05 .21 .01 -.18 .14 .28* .11 .14 .32** -.20 .25* .48** 1  
19. Medical Cure  -.08 .06 -.08 -.23* -.22 .15 .10 -.11 .12 -.20 -.41** -.32** -.01 -.39** .03 -.39** -.15 -.26* 1 
20. Harm  -.14 .01 -.26* .16 -.11 -.26* .11 -.03 -.15 .29* .00 .06 .35** .13 -.16 -.01 .36** .29* -.14 
21. Disability  .10 -.34** .16 -.21 .13 .13 -.16 .17 -.03 -.18 .13 .46** -.13 .19 .22 .18 -.27* .08 -.15 
22. Control  .00 -.11 .29* .06 .03 .10 .12 -.40** .00 .03 -.20 -.18 .17 -.12 -.18 -.20 .24* .23* .13 
23. Medication  .31** -.07 .12 .19 .28* -.02 -.11 .41** -.31** .35** .58** .26* .13 .42** -.33** .53** .16 .28* -.26* 
24. HH  -.08 -.13 -.07 -.12 .04 .08 -.41** .09 -.33** -.00 .15 .44** -.08 .30** .16 .16 -.11 -.13 -.22 
25. CAM  .26* .12 -.09 .16 .12 -.15 .10 .19 -.27* .37** .23* -.24* .14 .10 -.29* .20 .24* .05 .02 
26. HCAMQ  .17 -.01 -.15 .04 .15 -.07 -.27* .25* -.54** .33** .34** .17 .06 .35** -.13 .32** .12 -.06 -.17 
27. LDQ  .39** .05 .24* .41** .47** .01 .01 .32** -.23* .25* .70** .32** .14 .38** -.28* .59** .10 .29* -.24* 
 
 20 21 22 23 24 25 26 27 
20. Harm  1        
21. Disability  -.05 1       
22. Control  .00 -.16 1      
23. Medication  -.04 .11 -.06 1     
24. HH  -.05 .20 -.25* .07 1    
25. CAM  .24* -.29* .01 .30** -.38** 1   
26. HCAMQ  .17 -.08 -.22 .34** .53** .58** 1  
27. LDQ  -.08 .18 -.07 .57** .01 .18 .17 1 
 
Note: *p ≤ 0.05; **p ≤ 0.001 
 
7 – 9 SMS subscales 
10 – 16 PMAQ-14 subscales 
17 – 23 SOPA-B-14 subscales 
24 – 26 HCAMQ subscales
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5.3.2.1. Age 
There was a large and highly significant positive correlation between age and 
dependence in Germany and a moderate but highly significant correlation for 
dependence in China. However, there was no significant correlation found in 
the USA or Australia. 
5.3.2.2. Religiousness 
None of the countries had a significant relationship between religiousness and 
dependence.  
5.3.2.3. Pain frequency  
There were moderate and highly significant positive correlations between pain 
frequency and dependence in Germany and USA. In Australia and China, the 
correlations between pain frequency and dependence were small but 
significant positive correlations.  
5.3.2.4. Pain intensity 
Pain intensity had a moderate and highly significant positive correlation to 
dependence in Germany and China. In the USA, there was a small but highly 
significant positive correlation for dependence but no significant correlation in 
Australia. 
5.3.2.5. Painkiller use frequency 
A large and highly significant positive correlation was found between painkiller 
use frequency and dependence in Germany and there were moderate but 
highly significant positive correlations with dependence in China, USA and 
Australia.  
5.3.2.6. Perceived difficulty for obtaining strong painkillers without a 
prescription 
There was a small but highly significant negative correlation between 
perceived difficulty for obtaining strong painkillers without a prescription and 
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dependence in Germany but the correlation to dependence was non-
significant in USA, Australia, China.  
5.3.2.7. Self-Medicating Scale (SMS) 
A moderate and highly significant negative correlation was found between 
Reluctance and dependence in Germany and USA but there was no 
significant correlation in Australia and China. 
A moderate and highly significant positive correlation was found between 
Don’t Think Twice and dependence in Germany, Australia and USA while the 
correlation to dependence in China was a lower but moderate positive 
correlation and highly significant. 
There was a moderate and highly significant negative correlation between 
Run its Course and dependence in Germany and a lower but moderate and 
highly significant negative correlation in USA. The correlation in Australia and 
China between Run its Course and dependence were identical. Both of these 
correlations were small but significant negative correlations. 
5.3.2.8. Pain Medication Attitudes Questionnaire-14 (PMAQ-14)   
Addiction had a moderate and highly significant positive correlation with 
dependence in Australia and a lower moderate but highly significant 
correlation to dependence in Germany. There was a small but highly 
significant positive correlation to dependence in USA and a small but 
significant positive correlation to dependence in China. 
Need had a large and highly significant positive correlation for dependence in 
Germany, China and Australia but a moderate and highly significant positive 
correlation for dependence in USA. 
There was a small but highly significant positive correlation between Scrutiny 
and dependence in Germany. In China, there was a moderate and highly 
significant correlation to dependence but the correlation to dependence in 
USA and Australia was non-significant. 
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A large and highly significant positive correlation between Side Effects and 
dependence was found in Germany and a moderate and highly significant 
positive correlation was found in Australia but the correlation to dependence 
was non-significant in USA and China. 
Tolerance had a large and highly significant positive correlation to 
dependence in Germany. In Australia, there was a moderate and highly 
significant positive correlation to dependence and lower moderate but highly 
significant positive correlations in USA and China, which were both equal. 
There was a small but significant negative correlation between Mistrust of 
Doctors and dependence in China but no significant correlations to 
dependence were found in Germany, USA and Australia.  
A large and highly significant positive correlation between Withdrawal and 
dependence was found in Germany and lower but large positive correlations 
were found to dependence in China and USA. The correlation to dependence 
in Australia was a moderate and highly significant positive correlation. 
5.3.2.9. Survey of Pain Attitudes-Brief-14 (SOPA-B-14) 
There were no significant correlations found between Solicitude and 
dependence in any countries.  
Emotion had a small but significant positive correlation to dependence in 
China and a lower but significant positive correlation to dependence in 
Germany. However, the correlation to dependence in USA and Australia was 
non-significant. 
A moderate and highly significant negative correlation between Medical Cure 
and dependence was found in Germany and a small but significant negative 
correlation to dependence was found in China. In USA and Australia, the 
correlation between Medical cure and dependence was non-significant. 
Harm had a moderate and highly significant positive correlation to 
dependence in Germany and a small but significant positive correlation to 
dependence in Australia. The correlation to dependence in USA was also 
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small and a significant positive correlation but lower than Australia. The 
correlation to dependence in China was non-significant. 
There was a moderate and highly significant positive correlation between 
Disability and dependence in Germany and a small but significant positive 
correlation to dependence in USA. In Australia and China, the correlation to 
dependence was non-significant.  
There were no significant correlations found between Control and 
dependence in any country.  
Medication had a large and highly significant positive correlation to 
dependence in Germany and China but a moderate and highly significant 
positive correlation to dependence in Australia and USA. 
5.3.2.10. Holistic, Complementary and Alternative Medicine Questionnaire 
(HCAMQ) 
For the HCAMQ total, HH and CAM subscale, the correlations to dependence 
were non-significant in each country. 
5.3.3. Predictors of dependence 
Predictors of dependence were assessed using stepwise multiple regression 
analysis. The analysis was conducted by entering predictor variables in five 
blocks. In the first block, demographic variables. In the second block, pain 
variables. In the third block, painkiller use variables. In the fourth block, 
accessibility variables. In the fifth block, psychological factors variables. The 
dependent variable for the analysis was dependence (LDQ score). 
A separate stepwise multiple regression was conducted for each country. The 
result of each multiple regression analysis are provided in Table 34 to Table 
37. These tables summarise the results of the regression analysis for 
Germany, USA, Australia and China but the regression analysis result for the 
UK and Egypt are in Chapter 3. After the multiple regression, Sobel tests were 
conducted if any variables were significant at entry but not the final model, to 
test for mediation. 
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Table 34 summarises the results of the multiple regression for Germany. The 
predictors in the model were all highly significant or significant at entry and 
seven predictors remained highly significant or significant in the final model. 
The strongest of these predictors was the psychological factors PMAQ Need 
(final Beta = 0.24, p < 0.001) and PMAQ Withdrawal (final Beta = 0.21, p < 
0.001). The weakest predictor was misuse of painkillers (final Beta = 0.12, p < 
0.05). All of the highly significant or significant predictors in the final model 
were positive except education (final Beta = -0.14, p < 0.001). The model was 
highly significant [F (13, 203) = 31.86, p < 0.001] and explained over two-
thirds of the variance in dependence (R2 = 0.67; 67%). The effect size of the 
model was large (f2 = 2.03). 
Mediation tests were conducted for age, nationality, pain frequency in the last 
month, pain duration, pain intensity and strong painkillers from pharmacy 
because these variables were significant in the entry but not the final model. 
The mediation tests showed age was mediated by pain frequency in the last 
month (Sobel = 0.06; p < 0.001; 95% CI 0.03 to 0.09). Pain frequency in the 
last month was mediated by painkiller use frequency in the last month (Sobel 
= 0.21; p < 0.001; 95% CI 0.16 to 0.26). In addition, pain duration was 
mediated by painkiller use frequency in the last month (Sobel = 1.98; p < 
0.001; 95% CI 1.22 to 2.73) and pain intensity was also mediated by painkiller 
use frequency in the last month (Sobel = 0.34; p < 0.001; 95% CI 0.25 to 
0.43). However, there were no significant mediation of nationality (p > 0.05) or 








Table 34. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and adjusted 
R2 (AR2) for each block in the multiple regression analysis for Germany with painkiller 





ΔR2 R2 AR2 
Block 1: demographics measures    0.36* 0.36 0.35 
Age 0.53** 0.05    
Education -0.26** -0.14**    
Nationality 0.14* 0.04    
Block 2: pain measures    0.09* 0.45 0.43 
Pain frequency last month 0.26** 0.02    
Pain duration 0.16* 0.02    
Pain intensity 0.14* -0.09    
Block 3: painkiller use measures    0.11* 0.56 0.54 
Painkiller use frequency last month 0.54** 0.19*    
Misuse of painkillers 0.13* 0.12*    
Using alternatives 0.10* 0.13*    
Block 4: accessibility measures    0.01* 0.57 0.55 
Strong painkillers from pharmacy 0.10* 0.08    
Block 5: psychological factors measures    0.10* 0.67 0.65 
PMAQ Need  0.39** 0.24**    
PMAQ Withdrawal  0.20* 0.21**    
SOPA-B Medication  0.16* 0.16*    
 
Note: *p ≤ 0.05, **p ≤ 0.001 
Table 35 shows the results of the multiple regression for the USA. All of the 
predictors in the model were highly significant or significant in the entry but 
only five predictors were highly significant or significant in the final model: 
painkiller use frequency last month (final Beta = 0.18, p < 0.05); strong 
painkillers from other (final Beta = 0.18, p < 0.05); PMAQ Withdrawal total 
(final Beta = 0.31, p < 0.001); SMS Run its Course (final Beta = -0.19, p < 
0.05); and PMAQ Need total (final Beta = 0.20, p < 0.05). All of these 
predictors were positive except SMS Run its Course and the strongest 
predictor was PMAQ Withdrawal. The other predictors were lower and similar 
in strength to each other. The model was highly significant [F (9, 135) = 14.82, 
p < 0.001] and explained half of the variance in dependence (R2 = 0.50; 50%), 
with large effect size (f2 = 1.00). 
Mediation tests were conducted for pain influences employment, pain 
frequency in the last month, chest pain and obtaining OTC painkillers from a 
family member who is not a medical professional. Pain influences 
employment was mediated by pain frequency in the last month (Sobel = 0.78; 
p < 0.05; 95% CI 0.12 to 1.43). Pain frequency in the last month was 
mediated by painkiller use frequency in the last month (Sobel = 0.21; p < 
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0.001; 95% CI 0.11 to 0.31). There were no significant mediators of chest pain 
(p > 0.05) or obtaining OTC painkillers from a family member who is not a 
medical professional (p > 0.05). 
Table 35. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and adjusted 
R2 (AR2) for each block in the multiple regression analysis for the USA with painkiller 





ΔR2 R2 AR2 
Block 1: demographics measures   0.04* 0.04 0.03 
Pain influences employment 0.19* 0.10    
Block 2: pain measures   0.10** 0.14 0.12 
Pain frequency last month 0.26* 0.01    
Chest pain -0.19* -0.12    
Block 3: painkiller use measures   0.12** 0.26 0.24 
Painkiller use frequency last month 0.45** 0.18*    
Block 4: accessibility measures   0.06** 0.32 0.29 
Strong painkillers from other 0.20* 0.18*    
OTC painkillers from family member who is not a 
medical professional 
0.16* 0.10    
Block 5: psychological factors measures   0.18** 0.50 0.46 
PMAQ Withdrawal  0.37** 0.31**    
SMS Run its Course  -0.20* -0.19*    
PMAQ Need  0.20* 0.20*    
 
Note: *p ≤ 0.05, **p ≤ 0.001 
The results of the multiple regression for Australia are shown in Table 36. All 
of the predictors were highly significant or significant in the entry and almost 
all were significant in the final model except for gender (final Beta = -0.13, p > 
0.05) and painkiller use frequency last month (final Beta = 0.04, p > 0.05). The 
strongest predictor of dependence was PMAQ Need (final Beta = 0.35, p < 
0.05), followed by pain influences employment (final Beta = 0.23, p < 0.05), 
PMAQ Tolerance (final Beta = 0.23, p < 0.05), SOPA-B Medication (final Beta 
= 0.19, p < 0.05), length of residence (final Beta = -0.19, p < 0.05) and the 
lowest was HCAMQ HH (final Beta = -0.16, p < 0.05). All were positive except 
for length of residence and HCAMQ HH. The model was highly significant [F 
(8, 83) = 13.78, p < 0.001], explained over half of the variance in dependence 
(R2 = 0.57; 57%), and had large effect size (f2 = 1.33). 
Mediation tests for gender and painkiller use frequency in the last month 
showed that there were no significant mediators of gender (p > 0.05) but 
painkiller use frequency was mediated by PMAQ Need (Sobel = 0.18; p < 
0.001; 95% CI 0.10 to 0.28). 
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Table 36. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and adjusted 
R2 (AR2) for each block in the multiple regression analysis for Australia with painkiller 





ΔR2 R2 AR2 
Block 1: demographics measures   0.20** 0.20 0.18 
Pain influences employment 0.31* 0.23*    
Length of residence -0.25* -0.19*    
Gender -0.22* -0.13    
Block 2: pain measures   – – – 
– – –    
Block 3: painkiller use measures   0.08** 0.28 0.25 
Painkiller use frequency last month 0.32* 0.04    
Block 4: accessibility measures   – – – 
– – –    
Block 5: psychological factors measures   0.29** 0.57 0.53 
PMAQ Need  0.54** 0.35*    
PMAQ Tolerance  0.22* 0.23*    
SOPA-B Medication  0.18* 0.19*    
HCAMQ HH  -0.16* -0.16*    
 
Note: *p ≤ 0.05, **p ≤ 0.001 
The results of the multiple regression for China are shown in Table 37. All of 
the predictors were highly significant or significant in the entry and most were 
highly significant or significant in the final model except for toothache (final 
Beta = 0.16, p > 0.05) and OTC painkillers from a family member who is not a 
medical professional (final Beta = 0.16, p > 0.05). The strongest predictor of 
dependence was PMAQ Need (final Beta = 0.46, p < 0.001), followed by age 
(final Beta = 0.37, p < 0.001), misuse of painkillers in the last month (final 
Beta = 0.28, p < 0.001), sore throat (final Beta = 0.23, p < 0.001) and the last 
was pain intensity (final Beta = 0.18, p < 0.05). All of these predictors were 
positive. The model was highly significant [F (7, 45) = 19.28, p < 0.001] and 
explained three-quarters of the variance in dependence (R2 = 0.75; 75%), with 
large effect size (f2 = 3.00). 
Mediation tests for toothache and obtaining OTC painkillers from a family 
member who is not a medical professional showed that there were no 
significant mediators of toothache (p > 0.05) or for obtaining OTC painkillers 




Table 37. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and adjusted 
R2 (AR2) for each block in the multiple regression analysis for China with painkiller 





ΔR2 R2 AR2 
Block 1: demographics measures   0.23** 0.23 0.21 
Age  0.48** 0.37**    
Block 2: pain measures   0.28** 0.51 0.46 
Pain intensity 0.42** 0.18*    
Toothache 0.23* 0.16    
Sore throat  0.25* 0.23**    
Block 3: painkiller use measures   0.05** 0.56 0.51 
Misuse of painkillers in the last month 0.25* 0.28**    
Block 4: accessibility measures   0.05** 0.60 0.55 
OTC painkillers from a family member who is not a 
medical professional 
0.24* 0.16    
Block 5: psychological factors measures   0.15** 0.75 0.71 
PMAQ Need  0.46** 0.46**    
 
Note: *p ≤ 0.05, **p ≤ 0.001 
5.4. Discussion 
Similar to the comparative study between the UK and Egypt (Chapter 3), the 
aim of the present study was to examine the role of accessibility of painkillers 
and psychological factors in problematic painkiller use among the general 
population. However, the present study extended the comparative study by 
doing a multi-national comparison. This discussion will start with a summary 
of the results obtained for the present study. Following the summary of 
results, the implications of the results for the literature and society will be 
discussed. After the implications, the strengths and weaknesses of the study 
will be discussed, followed by suggestions for future research and the 
conclusions of the study. 
5.4.1. Summary of results 
A comparison of the countries showed that they were significantly different for 
most variables except the following: experiencing migraine and toothache; 
obtaining OTC painkillers from a friend who is not a medical professional, the 
internet and “other” source; and obtaining strong painkillers from a family 
member who is not a medical professional. There was also a significant 
difference in painkiller dependence between the countries, where Egypt had 
the highest dependence, but China and Germany had the lowest 
dependence. 
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There were also several differences between the countries for correlations of 
dependence with the measures of the study. In addition, the multiple 
regression analyses showed differences between the countries for predictors 
of dependence. Regarding accessibility, obtaining strong painkillers from 
“other” source was a significant predictor for more problematic painkiller use 
in the USA. There were no other predictors except for obtaining OTC 
painkillers from the internet, which was a significant predictor for less 
problematic painkiller use in the UK, as shown in the previous comparative 
study (Chapter 3). Regarding psychological factors, together with the results 
of the previous comparative study, the following were predictors of more 
problematic painkiller use: SOPA-B Medical Cure and Control in the UK; 
SOPA-B Solicitude in Egypt; SOPA-B Medication in Germany and Australia; 
PMAQ Need in all the countries except Egypt; PMAQ Side Effects in the UK; 
PMAQ Withdrawal in USA and Germany; and PMAQ Tolerance in Australia. 
However, SMS Run its Course in the USA and HCAMQ HH in Australia 
predicted less problematic painkiller use. Therefore, attitudes and beliefs 
towards pain, painkillers, self-medication and alternative methods of pain 
relief predicted problematic painkiller use, but there were differences between 
the countries.  
5.4.2. Implications 
There are several implications of the present study that are similar to the 
previous comparative study described in Chapter 3. One implication was 
providing understanding for the literature about the role of accessibility and 
psychological factors in problematic painkiller use among the general 
population. This understanding was extended to the countries included in the 
study, therefore further understanding has been provided from the previous 
comparative study in Chapter 3.   
In Chapter 3, obtaining OTC painkillers from the internet was a predictor for 
less dependence in the UK. For this reason, it might be worth encouraging 
people to buy OTC painkillers online. However, as discussed earlier in section 
3.4.2, this might be a problem because there are factors influencing internet 
use and pain that might explain the less dependence such as age and 
socioeconomic status (e.g. File & Ryan, 2014; Silver, 2014). In this present 
 166 
study, an additional accessibility predictor of dependence was obtaining 
strong painkillers from “other” sources, which predicted more dependence in 
the USA.  
To help understand the reason for predicting more dependence in the USA, 
an additional analysis comparing people who obtained strong painkillers from 
“other” sources with people who did not was conducted here for the USA. 
Specifically, chi-squared tests and independent-samples t-tests were used. In 
these tests, all the variables in the study were compared between people who 
obtained strong painkillers from “other” sources and those who did not. 
Regarding “other” sources, this involved obtaining strong painkillers from 
leftover prescriptions or from people other than friends or family such as a 
“dealer”. For people who did not use “other” sources, this includes a 
pharmacy, friends and family. 
The results showed that there was a significant difference between people 
who obtained strong painkillers from “other” sources and people who did not 
in two variables: pain frequency [t (89.67) = -5.96, p < 0.001, d = -1.26] and 
whether strong painkillers were used without a prescription [Χ2 (1) = 9.71, p < 
0.05, Φ = 0.26]. Therefore, pain frequency and using strong painkillers without 
prescription might help explain the reason why “other” sources predicted more 
dependence in the USA. However, there were only four participants in the 
USA who obtained strong painkillers without a prescription from “other” 
sources, so further research is required.  
Other than implications for the literature, there are also implications for society 
similar to the implications of the comparative study between the UK and Egypt 
(Chapter 3). More specifically, the study has implications for preventing or 
reducing problematic painkiller use among the general population, since the 
results about the role of accessibility and psychological factors can be used to 
develop interventions based on these factors to prevent or reduce problematic 
painkiller use. Like the comparative study, the results suggest that different 
interventions should be developed for the different countries because there 
were differences for the role of accessibility and psychological factors in each 
country. For example, to reduce or prevent problematic painkiller use in the 
USA, interventions could focus on increasing Run its Course attitudes and 
 167 
beliefs towards self-medication, since these predicated less problematic 
painkiller use in the USA.  
Additional implications for the society are improved healthcare because the 
results can be used to educate healthcare professionals about problematic 
painkiller use, which can help healthcare professionals to provide better 
healthcare for patients. For example, the results could be used to help 
healthcare professionals identify whether patients can have risk for 
problematic painkiller use. Also, the results could be used to help healthcare 
professionals understand the problematic painkiller use of patients and 
therefore provide better healthcare for patients.  
5.4.3. Strengths and weaknesses 
There are many strengths of the present study but also there are weaknesses 
that should be considered. A strength of the study has been using back 
translation for the German and Chinese versions of the questionnaire, which 
is the same method used for the Arabic version of the questionnaire for the 
comparative study between the UK and Egypt (Chapter 3). As mentioned for 
the Arabic version, using back translation can help the linguistic equivalence 
and validation of the questionnaire (e.g. McDermott & Palchanes, 1992; Jones 
et al., 2001; John et al., 2006). Additionally to back translation, again the 
study followed recommendations about the translators, such as the translators 
having knowledge about the countries involved in the study, which helped the 
linguistic equivalence and also the cultural sensitivity.  
Although the study has strengths, there are also weakness of the study. To 
specify, a weakness of the study has been using online methods; the same 
weakness as the comparative study between the UK and Egypt (Chapter 3). 
However, online methods are also a strength compared to other methods, as 
demonstrated by several research (e.g. Ritter et al., 2004; Ramsey et al., 
2016). 
Using online methods can be a problem because of difficulty ensuring 
participants did not complete the questionnaire more than once. To reduce 
the problem, the participants were required to provide a unique ID code. If any 
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unique ID codes were provided more than once, the participants were 
excluded. Also, the participants that entered the prize draw were required to 
provide an email address. If any email address was provided more than once, 
the participants were excluded. Further, the responses of the participants to 
the demographic questions were used to check if participants completed the 
questionnaire more than once. If all the same demographics were provided 
more than once, the participants were excluded.  
Another weakness of the study was that the countries targeted differed 
significantly in terms of demographic factors. As mentioned in Chapter 3, 
differences between countries may have influenced results regarding 
dependence because demographic factors have been associated with pain 
and substance use problems in previous research (e.g. Van Hecke et al., 
2013; Jones et al., 2015; Avici et al., 2017). Therefore, demographic factors 
might also be associated with dependence. Despite this, the multiple 
regression analysis showed that demographics were mostly not significant 
predictors of dependence. Therefore, the influence of demographics on 
dependence appears small.  
5.4.4. Future research 
Because there were differences between the countries for the role of 
accessibility and psychological factors in problematic painkiller use among the 
general population, it would be useful for future research to extend the results 
by comparing the role of these factors in more countries. 
To compare more countries would require more funding, especially for non-
English speaking countries since translators would be needed to translate the 
questionnaire to another languages. Also, research assistants would be 
needed to recruit participants from the non-English speaking countries. Due to 
limited funding, comparison of more countries would not be possible for the 
present thesis but should be considered for future research. 
Another useful future research study would be to conduct a longitudinal study 
to examine whether there changes in problematic painkiller use over time and 
the factors that might have a role for changes in problematic painkiller use 
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over time. Since accessibility usually is more stable over time but 
psychological factors usually are more changeable over time, research should 
focus on the role of psychological factors to examine whether psychological 
factors have a role over time for problematic painkiller use. The next study in 
the thesis (Chapter 6) will therefore be a longitudinal study, which will 
examine problematic painkiller use over time and the role of psychological 
factors. 
5.4.5. Conclusion 
To conclude, psychological factors had a role in every country, but 
accessibility had a role in the UK and USA only. Although accessibility had a 
role in most countries and psychological factors had a role in all the countries, 
there were differences between the countries about the particular accessibility 
variables and psychological factors. In addition, the study showed there were 
differences between the countries about painkiller dependence because 
painkiller dependence was higher in Egypt, UK and Australia but lower in 
China and Germany. Therefore, the findings from the present study have 
been similar to the comparative study between the UK and Egypt (Chapter 3) 
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There has been a growing literature showing that psychological factors have a 
role in pain. Among the psychological factors that have a role in pain, the 
factors that have been most researched are pain catastrophising, pain 
acceptance, pain self-efficacy and alexithymia (e.g. Quartana et al., 2009; 
Higgins et al., 2012). Since these factors have a role in pain, it is possible they 
could also have a role in problematic painkiller use. However, there has been 
a lack of research focusing on the role of these psychological factors. 
There has also been a lack of research focusing on the general population 
and the role of these psychological factors over time, since most studies have 
focused on clinical samples or childbirth pain and most studies have been 
cross-sectional. Some general population longitudinal studies have been 
conducted (e.g. McCabe et al., 2007; Boyd et al., 2009), but these are about 
non-medical use of analgesics and other medication over time, which showed 
that non-medical use was associated with developing substance and opioid 
use disorder. 
In addition to the psychological factors mentioned above, the literature shows 
attitudes and beliefs towards pain and painkillers are other psychological 
factors that should be considered (e.g. Callister et al., 2003; McCracken et al., 
2006). In the previous two studies of the thesis, the results showed that 
attitudes and beliefs towards painkillers predicted problematic painkiller use 
among the general population of almost each country but attitudes and beliefs 
towards pain only predicted problematic painkiller use among the general 
population of some countries. 
Because attitudes and beliefs towards painkillers had a role for problematic 
painkiller use more consistently than the attitudes and beliefs towards pain, 
more research should be conducted to investigate the role of attitudes and 
beliefs towards painkillers. Especially, research should be conducted to 




The relevant results from the literature about each of the psychological factors 
will be summarised below; the results for attitudes and beliefs towards 
painkillers will be summarised first, followed by pain catastrophising, pain 
acceptance, pain self-efficacy and alexithymia.  
6.1.1. Attitudes and beliefs towards painkillers 
In the literature, it has been found that negative attitudes and beliefs towards 
painkillers have been associated with less painkiller use but positive attitudes 
and beliefs towards painkillers have been associated with more painkiller use 
(e.g. McCracken et al., 2006; Cogan et al., 2014). These results have been 
found among chronic pain patients, women with childbirth pain and pre-
surgery cardiac patients. There has also been similar findings for problematic 
painkiller use among the general population by the previous two studies of the 
thesis, which showed negative attitudes and beliefs about painkillers were 
predictors of more painkiller dependence.  
6.1.2. Pain catastrophising 
There has been much research about the role of pain catastrophising on 
many pain outcomes but there has been less research about the role of pain 
catastrophising on painkiller use.  
The research about the role of pain catastrophising on pain outcomes has 
shown that pain catastrophising has a negative relationship with pain 
outcomes. More specifically, research has shown pain catastrophising links 
to: higher pain intensity (e.g. Sullivan et al., 2001; Quartana et al., 2009); 
psychological functioning problems from the pain such as depression, anxiety 
and fear (e.g. Keogh & Asmundson, 2004); negative pain coping behaviours 
such as negative facial expressions, complaining and more healthcare use 
from the pain (e.g. Thibault et al., 2008); the development of chronic pain (e.g. 
Osman et al., 2000); and less physical functioning from the pain (e.g. Keefe et 
al., 1989).  
In terms of painkiller dependence, a recent study conducted by Elander et al. 
(2014) showed that pain catastrophising was related to more painkiller 
dependence among the general population of the UK. Other than the study 
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conducted by Elander et al. (2014), there has not been any research focusing 
on the role of pain catastrophising in problematic painkiller use among the 
general population. 
6.1.3. Pain acceptance 
Similarly to pain catastrophising, there has been much research about the role 
of pain acceptance on several pain outcomes but there has been less 
research about the role of pain acceptance on painkiller use. 
About the role of pain acceptance in pain outcomes, the research has shown 
that improvement in pain acceptance after ACT has a relationship to positive 
pain outcomes such as improvement of physical functioning, psychological 
functioning and life satisfaction despite pain (e.g. Wicksell et al., 2010). 
Similar results have been found in cross-sectional studies without ACT; 
participants with higher pain acceptance showed these positive outcomes 
compared to participants with lower pain acceptance (e.g. Higgins et al., 
2012). There have also been similar results reported in longitudinal studies 
without ACT intervention, which showed that higher pain acceptance 
predicted improvement for pain outcomes over time (e.g. McCracken et al., 
2007; Mason et al., 2008). 
In terms of painkiller use, the improved pain outcomes found by some studies 
above suggests that pain acceptance could reduce painkiller use. There have 
been a few studies focusing on the role of pain acceptance in painkiller use, 
which showed that pain acceptance has a negative relationship with painkiller 
use (e.g. Callister et al., 2003; McCracken et al., 2004; Christiaens et al., 
2010). Similarly, a study conducted by Elander et al. (2014) showed that pain 
acceptance had negative correlation with painkiller dependence and lower 
pain acceptance predicted painkiller dependence in the general population of 
the UK. Other than the study conducted by Elander et al. (2014), there has 





6.1.4. Pain self-efficacy 
For pain self-efficacy, there has again been much research about the role of 
pain self-efficacy on several pain outcomes but there has been less research 
about the role of pain self-efficacy on painkiller use. 
The studies focusing on the role of pain self-efficacy for pain outcomes have 
showed that pain self-efficacy has a positive role for pain outcomes. To 
specify, several studies have showed pain self-efficacy has been related to 
physical functioning among arthritis and back pain patients despite pain (e.g. 
Sharma et al., 2003; Renemen et al., 2008). Other research has shown that 
pain self-efficacy also has positive pain outcomes such as less pain intensity, 
higher pain threshold, higher pain tolerance and less pain duration across 
several conditions (e.g. Brox et al., 2005; Yazdi-Ravandi et al., 2013).  
In the little research that has been conducted about painkiller use, it has been 
found that pain self-efficacy has been related to less painkiller use (e.g. 
Callister et al., 2003) and there has been a study showing that pain self-
efficacy related to less painkiller dependence among the general population of 
the UK (Elander et al., 2014). Other than painkillers, there has also been 
some research which showed that pain self-efficacy has a role for medication 
adherence among patients with non-pain conditions using medications other 
than painkillers (e.g. Gatti et al., 2009), therefore supports that pain self-
efficacy could be related to less problematic painkiller use. 
6.1.5. Alexithymia 
Similar to most of the other factors mentioned, research focusing on the role 
of alexithymia has been conducted for pain outcomes but there has been a 
lack of research about the role of alexithymia in painkiller use.  
The research about the role of alexithymia for pain outcomes showed 
alexithymia has a negative role for pain outcomes. For example, the research 
has showed alexithymia is a risk factor for developing chronic pain (e.g. 
Makino et al., 2013; Baudic et al., 2016). Other than developing chronic pain, 
alexithymia has also a negative role for other pain outcomes, which are lower 
pain tolerance and higher pain intensity (e.g. Castelli et al., 2013).  
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In contrast to the pain outcomes above, there has been a lack of research 
about the role of alexithymia for painkiller use; only one study has been 
conducted, which showed that alexithymia was related and predicted more 
painkiller dependence among the general population of the UK (Elander et al., 
2014). There have been similar results to painkiller dependence for substance 
dependence, supporting that alexithymia could have a role for problematic 
painkiller use (e.g. Hamidi et al., 2010).  
The following aim, research question and hypotheses were used for the 
present study based on the results in this review. 
6.1.6. Aim 
To investigate the role of psychological factors in problematic painkiller use 
over time among the general population of the UK.  
6.1.7. Research question 
What is the role of psychological factors in problematic painkiller use over 
time among the general population of the UK? 
6.1.8. Hypotheses 
More positive attitudes and beliefs towards painkillers will increase 
problematic painkiller use over time. 
Higher pain catastrophising will increase problematic painkiller use over time. 
Lower pain acceptance will increase problematic painkiller use over time. 
Lower pain self-efficacy will increase problematic painkiller use over time. 







A sample of 780 participants was recruited from the general population. 
However, there was attrition of 251 participants from the study. Thus, the final 
sample consisted of 529 participants, which provided sufficient power 
according to power analysis calculation (Faul et al., 2007). 
The participants were recruited using online convenience sampling, offline 
convenience sampling and snowball sampling. These methods were 
conducted in similar ways as described in Chapter 3, section 3.2.1. 
The inclusion criteria to take part in the study were: participants should be at 
least 18 years of age, experienced pain in the last month, used OTC or 
prescription painkillers in the last month and be resident in the UK. When any 
of the inclusion criteria were not achieved by the participants, these 
participants were excluded from the study. Further exclusion criteria were: 
attrition from the study, if there was any missing data and participating more 
than once for each time point in the longitudinal design.   
6.2.2. Design 
A longitudinal online survey design was used in the present study, which 
involved collection of data at two time points: baseline and follow-up. There 
was an interval of three months between the baseline and follow-up.  
6.2.3. Measures 
An online questionnaire was used for the data collection at baseline and 
follow-up (see Appendix D), which contained the same questions at both time 
points. In the online questionnaire, there were the same questions as the 
questionnaire used for the UK in the comparative study between the UK and 
Egypt (Chapter 3) up to the LDQ; the same questions about demographics, 
pain, painkillers and scale measuring painkiller dependence.  
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6.2.3.1. Demographics  
The beginning of the questionnaire consisted of questions about the following 
demographics: gender, age, marital status, nationality, language spoken at 
home, length of residence in the UK, highest education level, employment 
status, whether or not pain influences employment, religion, religiousness, 
ethic origin, financial status, mental health condition diagnosis and alcohol/ 
drug dependence diagnosis.  
6.2.3.2. Pain 
After the demographics, the questionnaire asked about pain, specifically 
about pain duration, pain frequency in the last month, pain intensity in the last 
month, type of pain experienced in the last month and pain diagnosis. 
6.2.3.3. Painkillers  
Following the questions about pain, the questionnaire asked about painkillers, 
specifically the type of painkillers taken in the last month, frequency of 
painkiller use in the last month, painkiller misuse in the last month, painkiller 
abuse in the last month and alternatives to painkillers used in the last month.  
6.2.3.4. Scales 
6.2.3.4.1. Leeds Dependence Questionnaire (LDQ) 
The same modified version of the LDQ (Ferrari et al., 2006) was used to 
measure painkiller dependence as the comparative study between the UK 
and Egypt (Chapter 3).  
After the LDQ, the questionnaire contained different measures from the 
questionnaire used for the UK in the comparative study between the UK and 
Egypt (Chapter 3). Specifically, the remaining of the questionnaire consisted 
the following scales: the PMAQ-14 developed in Chapter 4 for measuring 
attitudes and beliefs towards painkillers (Elander et al., 2017); the Pain 
Catastrophising Scale-4 (PCS-4) to measure pain catastrophising (Bot et al., 
2014); the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8) to measure 
pain acceptance (Fish et al., 2010); the Pain Self-Efficacy Questionnaire-2 
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(PSEQ-2) to measure pain self-efficacy (Nicholas et al., 2015); and the 
Toronto Alexithymia Scale-20 (TAS-20) to measure alexithymia (Bagby et al., 
1994). These measures are described below:  
6.2.3.4.2. Pain Medication Attitudes Questionnaire-14 (PMAQ-14) 
The PMAQ-14 was developed by Elander et al., (2017) to measure attitudes 
and beliefs towards painkillers. The scale is a shortened version of the original 
47-item PMAQ developed by McCracken et al., (2006). There are seven 
subscales in the PMAQ-14 with 2-items in each subscale. The seven 
subscales are: Addiction, Need, Scrutiny, Side Effects, Tolerance, Mistrust of 
Doctors and Withdrawal. A score for each subscale can be calculated by 
summing the scores of the two items. 
6.2.3.4.3. Pain Catastrophising Scale-4 (PCS-4) 
The PCS-4 (Bot et al., 2014) is a 4-item version of the original 13-item version 
of the scale developed by Sullivan et al. (1995) to measure pain 
catastrophising. The 4-items are statements describing catastrophic thoughts 
and feelings. Each item is rated on a 5-point Likert scale that shows frequency 
that the catastrophic thoughts and feelings occur when experiencing pain. The 
5-point scale ranges from “Not at all” (0) to “All the time” (4). A total pain 
catastrophising score can be calculated by summing the score of the 4-items. 
The total score can range from a minimum of 0 to a maximum of 16. A higher 
total score indicates higher pain catastrophising levels. 
The PCS-4 has good internal consistency and high correlation with the 
original 13-item version (Bot et al., 2014). Both versions have similar 
correlations with measures of disability, depression and pain (Bot et al., 
2014).  
6.2.3.4.4. Chronic Pain Acceptance Questionnaire-8 (CPAQ-8) 
The CPAQ-8 (Fish et al., 2010) is an 8-item version of the 20-item CPAQ 
developed by McCracken et al., (2004) to measure pain acceptance. The 
CPAQ-8 consists of two subscales: Pain Willingness (PW) and Activity 
Engagement (AE). The PW subscale measures “willingness to experience 
 179 
pain, which is the inverse of engaging in behaviours to limit contact with pain” 
(Fish et al., 2010, p. 1). The AE subscale measures “the degree to which one 
engages in life activities regardless of pain” (Fish et al., 2010, p. 1). There are 
4-items in each subscale. The items are each rated on a 7-point Likert scale 
from “Never True” (0) to “Always True” (6).  
A score for each subscale can be calculated by summing the score of each 
item in the subscale together. The items in the PW subscale are reversed but 
there are no reversed items in the AE subscale. The subscale scores range 
from a minimum score of 0 to a maximum score of 24. Higher PW scores 
indicate greater pain willingness and higher AE scores indicate greater activity 
engagement. Additionally, a total score for the CPAQ-8 can be calculated by 
summing the subscale scores together. The total score can range from a 
minimum score of 0 to a maximum score of 48. Higher scores indicate greater 
pain acceptance.  
The CPAQ-8 has good internal reliability and high correlation with the CPAQ 
(Fish et al., 2010). The CPAQ and CPAQ-8 have similar correlations to other 
measures. Specifically, higher PW, AE and total pain acceptance scores have 
been correlated with fewer medical visits for pain, less depression, lower 
anxiety, lower pain interference and lower pain severity (Fish et al., 2010).  
6.2.3.4.5. Pain Self-Efficacy Questionnaire-2 (PSEQ-2) 
The PSEQ-2 (Nicholas et al., 2015) is a shortened version of the 10-item 
PSEQ, developed by Nicholas (2006) to measure pain self-efficacy. The 2-
items in the PSEQ-2 are rated on a 7-point Likert scale from “Not at all 
confident” (0) to “Completely confident” (6). A total pain-self efficacy score is 
calculated by summing the items in the PSEQ-2. The total score can range 
from a minimum of 0 to a maximum of 12. Higher scores represent stronger 
pain self-efficacy.  
The PSEQ-2 has good internal consistency and high correlation with the 10-
item version (Nicholas et al., 2015). In addition, correlation with measures of 
disability, depression and pain were similar between the 2-item and 10-item 
version (Nicholas et al., 2015). Therefore, the PSEQ-2 has good convergent 
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validity. There were small correlations between the PSEQ-2 and education, so 
the scale has good divergent validity (Briet et al., 2014; Nicholas et al., 2015). 
6.2.3.4.6. Toronto Alexithymia Scale-20 (TAS-20) 
The TAS-20 (Bagby et al., 1994) is a revised version of the 26-item TAS 
(Taylor, Ryan & Bagby, 1985). Both measure alexithymia but the TAS-20 
accounts for problems with the factor structure and psychometric properties of 
the 26-item version. Unlike the 26-item version, the 20-item version has “a 
stable and replicable three factor structure that was theoretically congruent 
with the alexithymia construct” (Bagby et al., 1994). 
There are three subscales in the TAS-20, which are the difficulty identifying 
feelings subscale (DIF), the difficulty describing feelings subscale (DDF) and 
the externally oriented thinking subscale (EOT). The DIF subscale consists of 
seven items measuring ability to identify feelings and to distinguish feelings 
from somatic sensations that accompany emotional arousal. The DDF 
subscale consists of five items measuring ability to describe feelings to others. 
The EOT subscale consists of eight items measuring the tendency to focus 
attention externally.  
The TAS-20 requires that items are rated on a 5-point Likert scale, which 
ranges from “Strongly disagree” (1) to ”Strongly agree” (5). Five items are 
reversed scored. It is possible to calculate a total alexithymia score by 
summing the score of the 20-items together but scores for each subscale 
cannot be calculated. A total score between 20 to 51 indicates no alexithymia, 
52 to 61 indicates borderline alexithymia and 62 to 100 indicates alexithymia. 
Bagby et al., (1994) reported that the TAS-20 has good internal reliability, 
test-retest reliability, convergent validity, discriminant validity, concurrent 
validity and consensual validity. Convergent validity was reported by positive 
correlations between the TAS-20 and personality traits linked to alexithymia 
such as neuroticism. Discriminant validity was reported by negative 
correlations between the TAS-20 and personality traits not linked to 
alexithymia such as psychological mindedness, need-for-cognition, openness 
to experience and the positive emotions aspect of extraversion. Concurrent 
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and consensual validity was reported by correlations between the TAS-20 and 
observer-ratings of alexithymia.   
6.2.4. Materials 
The online questionnaire was set up using Qualtrics for the baseline and 
follow-up questionnaire. A separate link was created for each questionnaire. 
In addition, a £20 Amazon e-voucher was the prize for the first prize draw and 
a £50 Amazon e-voucher was the prize for the second prize draw. The follow-
up prize was more than the baseline to try to reduce attrition from the study at 
the follow-up. Also, SPSS was employed for the analysis of the data.  
6.2.5. Procedure 
6.2.5.1. Baseline 
Ethical approval to conduct the study was provided by the University of Derby 
Research Ethics Committee. After approval, the participants were recruited 
using online and offline convenience sampling and snowball sampling. The 
recruitment of participants using online convenience sampling involved 
posting an invitation on forums and social media and involved sending the 
invitation via email to participants who provided their approval and email 
address from the previous study. The recruitment of participants using offline 
convenience sampling involved advertising the invitation in pharmacies. The 
snowball sampling involved asking the participants to forward the invitation to 
others.  
The invitation explained to participants the purpose of the questionnaire and 
the approximate time for completion. The invitation also explained to 
participants the opportunity to enter the prize draw and provided the 
questionnaire link. If participants were interested in participating, they were 
asked to click on the questionnaire link to provide them with more information.  
When the participants clicked on the questionnaire link, the information page 
of the questionnaire was displayed, which provided further information about 
the study and questionnaire. Specifically, the information page provided 
information about inclusion criteria, anonymity of participants, withdrawal 
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procedure, prizes, ethical approval and the follow-up questionnaire. The 
contact details of the researcher and supervisors were also provided to allow 
participants the opportunity to ask any questions via email before they 
participated.  
After reading the information page, the participants were asked to provide 
their consent to participate by reading the declaration on the next page of the 
questionnaire. The declaration summarised the information they needed to 
understand before participating and then enter their unique identification code 
which consist of the first three letters of their mothers maiden name followed 
by the last two digits of the telephone number. On this page, the participants 
were also asked if they would like to enter the prize draw. If yes, the 
participants were asked to enter an email address they would like the Amazon 
e-voucher sent to if they won the prize daw. Also on this page, the participants 
were asked to enter the email address they would like the invitation to 
participate in the follow-up questionnaire after three months to be sent. 
When participants completed the questionnaire, the debrief was displayed on 
the final page of the questionnaire. The debrief thanked participants for 
completing the questionnaire and reminded them about the withdrawal 
procedure, the follow-up and the contact details of the researcher and 
supervisors. The debrief also provided participants with links to information 
and organisations if interested to read more about pain and painkiller use and 
were advised to talk with their doctor if they worried about their painkiller use. 
The first prize draw was conducted in the month after the baseline data was 
collected. To conduct the prize draw, a random number generator was used. 
6.2.5.2. Follow-up 
The participants were sent invitations via email to participate in the follow-up 
three months after their baseline response. The invitations were sent to the 
email address provided by the participants at baseline. The invitation 
explained to participants that the questionnaire was the same as the baseline 
and reminded participants about the purpose of the questionnaire and the 
approximate duration of the questionnaire. The invitation also included a 
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reminder of the unique identification code provided in the baseline for each 
participant.  
If participants did not complete the questionnaire after the invitation was sent, 
a reminder email was sent after one week. A second reminder email was sent 
the following week if the questionnaire was not completed after the first 
reminder. The second prize draw was conducted in the month after the follow-
up data was collected.  
6.2.6. Analytic strategy 
Before analysis, data cleaning was conducted which involved removing 
duplicate responses and incomplete responses. After data cleaning, the 
baseline and follow-up data was merged in SPSS using the unique 
identification code the participants had provided. To allow the data to be 
merged, the unique identification codes were changed to the same case 
because of the case sensitivity of SPSS for merging. 
First, comparison between dropouts and non-dropouts was conducted using 
chi-squared tests and independent-samples t-tests were used. These groups 
were compared for all the measures of the study. Then, changes in the 
measures from baseline to follow-up were analysed with McNemar’s chi-
squared tests and repeated measures t-tests. After this, correlation analysis 
was used to analyse the relationship between dependence and the measures. 
Finally, multiple regression analysis was used to assess if baseline measures 
were predictors of dependence at follow-up, followed by Sobel tests to 
analyse whether any predictors of dependence were mediators for each other. 
6.3. Results 
The results begins with comparisons between the non-dropout and dropout 
group, followed by comparisons between the baseline and follow-up 
measures. Then, correlations between the measures and dependence will be 
presented. Finally, predictors of dependence will be presented. 
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6.3.1. Comparisons between the non-dropout group and the dropout 
group 
To compare whether the non-dropout group and the dropout group were 
significantly different at baseline, chi-squared tests and independent-samples 
t-tests were used. In order to conduct these tests, a binary variable was 
created, which coded participants as non-dropout or dropout: the participants 
were coded as non-dropout if they completed the baseline questionnaire and 
follow-up questionnaire but were coded as dropout if they completed only the 
baseline questionnaire.  
For chi-squared tests, most variables with more than two categories were 
recoded into binary variables. Table 3 shows the original coding and the 
binary recoding for the variables recoded into binary variables (Chapter 3, 
section 3.3.1).  
Table 38 compares the non-dropout sample and the dropout sample for 
demographic variables. The results for marital status, education level and 











Table 38. Baseline demographic variables for the non-dropout sample and the dropout 
sample.  
 Non-dropout sample Dropout sample t or X2 
Gender1   0.01 
Male 52 (10.2%) 25 (10.5%)  
Female 458 (89.8%) 214 (89.5%)  
Age2 46.98 (12.22, 18 – 81) 43.15 (11.41, 19 – 73) 4.09** 
Marital status1   0.03 
Not in a relationship 157 (30.8%) 72 (30.1%)  
In a relationship 353 (69.2%) 167 (69.9%)  
Nationality1   0.09 
British 495 (97.1%) 231 (96.7%)  
Other 15 (2.9%) 8 (3.3%)  
Country of residence1   N/A 
UK 510 (100.0%) 239 (100.0%)  
Highest education level1   5.70* 
No qualification 18 (3.5%) 18 (7.5%)  
Qualification 492 (96.5%) 221 (92.5%)  
Employment status1   0.27 
Not in employment 233 (45.7%) 114 (47.7%)  
In employment 277 (54.3%) 125 (52.3%)  
Whether or not pain 
influences employment1 
  1.08 
Yes 246 (48.2%) 125 (52.3%)  
No 264 (51.8%) 114 (47.7%)  
Financial status1   6.16* 
A little or a lot poorer than 
most 
148 (29.0%) 89 (37.2%)  
About the same as most 300 (58.8%) 130 (54.4%)  
A little or a lot richer than 
most 
62 (12.2%) 20 (8.4%)  
Mental health condition 
diagnosis1 
  1.39 
Yes  271 (53.1%) 138 (57.7%)  
No  239 (46.9%) 101 (42.3%)  
Alcohol or drug 
dependence diagnosis1 
  0.79 
Yes  8 (1.6%) 6 (2.5%)  
No  502 (98.4%) 233 (97.5%)  
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001 
The chi-squared tests and independent-samples t-tests for demographic 
variables showed there was a highly significant difference in age, and a 
significant difference in education level and financial status. All the rest of 
demographic variables did not differ significantly: gender, marital status, 
nationality, employment status, whether or not pain influences employment, 
mental health condition diagnosis and alcohol or drug dependence diagnosis. 
The results in Table 38 shows that the proportion or mean of most 
demographic variables in each sample were similar and some almost 
identical. The two samples were identical in country of residence, since all the 
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participants in the non-dropout sample and the dropout sample were living in 
the UK. The two samples were almost identical in proportion of gender, 
marital status and nationality. For gender, the majority of the samples were 
female and the minority were male. For marital status, over two-thirds of 
participants in each sample were in a relationship and less than one-third 
were not in a relationship. The most common marital status for participants 
not in a relationship was single, then divorced/separated and the last was 
widowed. For nationality, almost all the participants in each sample were 
British nationality. The other nationalities were Australian, American, 
Canadian, Danish, Dutch German, Irish, Japanese, New Zealander, Nigerian, 
Seychellois, Spanish, Swedish, and Portuguese (Table 56, Appendix I). 
For the rest of demographic variables, the mean age of the non-dropout 
sample was a few years older than the dropout sample. Almost all of the 
participants in each sample had a qualification but those in the non-dropout 
group were more likely to have a qualification. Few participants in each 
sample had no qualifications. The most common qualifications among both 
groups were GCSE/ O Level, undergraduate degree and postgraduate degree 
(Table 56, Appendix I). Over half of the participants in both samples were in 
employment (Table 38). The most common employment category among both 
groups was employed full-time and the most common not in employment 
category was retired. In each sample, there were also similar proportions of 
participants whose pain influenced their employment. 
For financial status, over half of participants in each sample were about the 
same as most, but the non-dropout sample was more likely to rate themselves 
as better off and the dropout sample was more likely to rate themselves as 
less well off than most. Over half of participants had a mental health condition 
diagnosis and a similar proportion had no mental heath condition diagnosis 
but were fewer. Almost all participants had no alcohol or drug dependence 
diagnosis in the non-dropout sample and dropout sample. Few participants 
had an alcohol or drug dependence diagnosis. 
Table 39 compares the non-dropout sample and the dropout sample for pain 
variables. Like the demographic variables, there were similarities between the 
proportions and means of most variables in each sample and some variables 
 187 
were almost identical. The results for pain duration before binary recoding are 
shown in Table 57 (Appendix I). 
Table 39. Baseline pain variables for the non-dropout sample and the dropout sample. 
 Non-dropout sample Dropout sample t or X2 
Pain duration1   1.25 
Less than 6 months 17 (3.3%) 12 (5.0%)  
Longer than 6 months 493 (96.7%) 227 (95.0%)  
Pain frequency in the 
last month (days)2 
24.39 (9.52, 1 – 31) 24.14 (9.52, 2 – 31) 0.34 
Pain intensity in the last 
month2 
17.10 (4.92, 3.00 – 
32.25) 
17.91 (5.17, 6.25 – 32.50) −2.08* 
Type of pain 
experienced in the last 
month1 
   
Headache 289 (56.7%) 141 (59.0%) 0.36 
Migraine 170 (33.3%) 87 (36.4%) 0.68 
Period pain 121 (23.7%) 65 (27.2%) 1.05 
Toothache 50 (9.8%) 28 (11.7%) 0.64 
Abdominal pain 183 (35.9%) 110 (46.0%) 7.03* 
Chest pain 85 (16.7%) 54 (22.6%) 3.78 
Foot pain 216 (42.4%) 90 (37.7%) 1.49 
Sore throat 91 (17.8%) 43 (18.0%) 0.00  
Back pain 325 (63.7%) 168 (70.3%) 3.12 
Joint pain 356 (69.8%) 162 (67.8%) 0.31 
Earache 51 (10.0%) 22 (9.2%) 0.12 
Muscle pain 279 (54.7%) 138 (57.7%) 0.61 
Other 110 (21.6%) 40 (16.7%) 2.37 
Pain diagnosis1   3.91* 
Yes 481 (94.3%) 216 (90.4%)  
No 29 (5.7%) 23 (9.6%)  
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001 
The chi-squared tests and independent-samples t-tests showed there was a 
significant difference in pain intensity, abdominal pain and pain diagnosis. All 
other pain variables were not significantly different. 
Most participants in each sample had chronic pain longer than 6 months. The 
mean number of days pain was experienced was almost the same for both 
samples, which was most of the month. Pain intensity was slightly but 
significantly higher among those who dropped out. 
For the type of pain experienced in the last month, there was a similarity in the 
proportion of each type of pain in each sample. A pain diagnosis was slightly 
but significantly more likely among the non-dropouts. 
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A comparison of painkiller use variables between each sample is shown in 
Table 40. The results for type of painkillers taken in the last month, 
alternatives to painkillers used in the last month, painkiller misuse in the last 
month and painkiller abuse in the last month before binary recoding is shown 
in Table 58 (Appendix I). 
Table 40. Baseline painkiller use variables for the non-dropout sample and the dropout 
sample.  
 Non-dropout sample Dropout sample t or X2 
Type of painkillers taken 
in the last month1 
  0.51 
No prescription painkillers 
(OTC only) 
69 (13.5%) 37 (15.5%)  
Prescription painkillers 441 (86.5%) 202 (84.5%)  
Frequency of painkiller 
use in the last month 
(days)2 
21.71 (11.04, 1 – 31) 21.81 (11.09, 1 – 
31) 
−0.11 
Painkiller misuse in the 
last month1 
  10.23** 
Yes 193 (37.8%) 120 (50.2%)  
No 317 (62.2%) 119 (49.8%)  
Painkiller abuse in the 
last month1 
  2.91 
Yes 77 (15.1%) 48 (20.1%)  
No 433 (84.9%) 191 (79.9%)  
Alternatives to 
painkillers used in the 
last month1 
  4.98* 
No alternatives 35 (6.9%) 28 (11.7%)  
Alternatives 475 (93.1%) 211 (88.3%)  
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001 
The chi-squared tests and independent-samples t-tests showed that there 
was a significant difference between groups for using alternative methods of 
pain relief. There was also a highly significant difference for misuse of 
painkillers but all other variables were not significantly different. 
The two groups were similar in the type of painkillers used because most 
participants used prescription painkillers. A small proportion used over-the-
counter painkillers only. Another similarity was the mean number of days 
painkillers were used because participants used painkillers for most days in 
the last month. For painkiller misuse, the samples were not similar because 
half of the dropout sample misused painkillers and over one-third of the non-
dropout sample misused painkillers. Most participants in both groups did not 
abuse painkillers. 
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Nearly all participants used alternative methods of pain relief, but the 
proportion who did not was higher among the dropouts. The most common 
alternatives used by participants in both groups were hot water bottle and 
exercise (Table 58, Appendix I). 
Table 41 compares each sample for dependence and psychological factors. It 
shows the LDQ scores of the dropout sample were higher than the non-
dropout sample and the difference was highly significant.  
Table 41. Baseline scores for painkiller dependence and psychological factors 








LDQ  9.69 (5.66) 20.02 (5.99) −22.83** 
PMAQ Addiction  4.51 (2.50) 6.58 (2.67) −10.34** 
PMAQ Need  4.77 (2.34) 6.52 (2.63) −8.79** 
PMAQ Scrutiny  3.73 (2.49) 6.21 (2.83) −11.57** 
PMAQ Side Effects  3.99 (2.17) 5.97 (2.50) −10.57** 
PMAQ Tolerance  3.02 (2.81) 5.60 (3.28) −10.48** 
PMAQ Mistrust of Doctors  6.18 (2.70) 5.81 (2.94) 1.70 
PMAQ Withdrawal  2.25 (2.17) 4.54 (2.41) −12.48** 
PCS  9.09 (4.17) 13.88 (4.25) −14.58** 
CPAQ Pain Willingness  17.00 (5.17) 11.04 (6.62) 12.27** 
CPAQ Activity Engagement  14.46 (5.76) 16.81 (6.11) −5.11** 
CPAQ total 31.46 (7.65) 27.85 (8.33) 5.67** 
PSEQ  6.26 (3.45) 7.55 (3.54) −4.73** 
TAS  57.68 (10.52) 55.16 (13.19) 2.59* 
     
Note: *p ≤ 0.05, **p ≤ 0.001 
The dropout sample had significantly higher scores for each PMAQ subscale 
except Mistrust of Doctors. For the PCS, the dropout sample also had 
significantly higher scores than the non-dropout sample. For the CPAQ, the 
dropout sample had significantly higher scores on the Activity Engagement 
subscale but the dropout sample had significantly lower scores on the Pain 
Willingness subscale. The CPAQ total scores were also significantly lower for 
the dropout sample. For the PSEQ, the dropout sample had significantly 
higher scores than the non-dropout sample. However, for the TAS, the non-




6.3.2. Comparisons between baseline and follow-up measures 
To compare the non-dropout group at baseline and follow-up, McNemar’s chi-
squared tests and paired-samples t-tests were used. The assumptions of 
these tests were checked with the data. 
Table 42 compares pain variables at baseline and follow-up, showing that 
many of the variables were stable across time points and a few decreased 




Table 42. Pain variables at baseline and follow-up for the non-dropout sample.  
 Baseline Follow-up t or X2 
Pain duration1   1.07 
Less than 6 months  17 (3.3%) 12 (2.4%)  
Longer than 6 months  493 (96.7%) 498 (97.6%)  
Pain frequency in the 
last month (days)2 
24.39 (9.52, 1– 31) 23.77 (9.79, 1 – 31) –1.85 
Pain intensity in the last 
month2 
17.10 (4.92, 3.00 – 
32.25) 
16.63 (5.32, 2.00 – 
30.25) 
–2.85* 
Type of pain 
experienced in the last 
month1 
   
Headache 289 (56.7%) 291 (57.1%) 0.01 
Migraine 170 (33.3%) 171 (33.5%) 0.00 
Period pain 121 (23.7%) 125 (24.5%) 0.14 
Toothache 50 (9.8%) 56 (11.0%) 0.40 
Abdominal pain 183 (35.9%) 181 (35.5%) 0.01 
Chest pain 85 (16.7%) 98 (19.2%) 2.03 
Foot pain 216 (42.4%) 213 (41.8%) 0.04 
Sore throat 91 (17.8%) 105 (20.6%) 1.48 
Back pain 325 (63.7%) 342 (67.1%) 2.44 
Joint pain 356 (69.8%) 368 (72.2%) 1.68 
Earache 51 (10.0%) 55 (10.8%) 0.13 
Muscle pain 279 (54.7%) 308 (60.4%) 7.61* 
Other 110 (21.6%) 85 (16.7%) 5.94* 
Pain diagnosis1   9.38** 
Yes 481 (94.3%) 497 (97.5%)  
No 29 (5.7%) 13 (2.5%)  
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001 
The McNemar’s tests and paired-samples t-tests showed that baseline and 
follow-up were different significantly for pain intensity, muscle pain, “other” 
pain, and pain diagnosis which was highly significant. 
There was a small but significant decrease from baseline to follow-up in pain 
intensity. The most common type of pain at baseline was joint pain, which was 
over two-thirds of participants and the proportion increased at the follow-up 
but was not significant. The next common type of pain at baseline was back 
pain and also increased at follow-up but was not significant. Other most 
common types of pain at baseline were headache and muscle pain and these 
also increased at follow-up, which muscle pain was significant. Almost all the 
participants had a pain diagnosis. There was also a small but significant 
increase from baseline to follow-up in pain diagnosis. 
Table 43 compares baseline and follow-up results for painkiller use variables. 
Table 60 shows the results for type of painkillers taken in the last month, 
alternatives to painkillers used in the last month, painkiller misuse in the last 
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month and painkiller abuse in the last month before binary recoding (Appendix 
I). 
Table 43. Painkiller use variables at baseline and follow-up for the non-dropout sample. 
 Baseline Follow-up t or X2 
Type of painkillers taken 
in the last month1 
  2.75 
No prescription painkillers 
(OTC only) 
69 (13.5%) 81 (15.9%)  
Prescription painkillers 441 (86.5%) 429 (84.1%)  
Frequency of painkiller 
use in the last month 
(days)2  
21.71 (11.04, 1 – 31) 21.75 (11.01, 1– 
31) 
0.14 
Painkiller misuse in the 
last month1 
  1.06 
Yes 193 (37.8%) 181 (35.5%)  
No 317 (62.2%) 329 (64.5%)  
Painkiller abuse in the 
last month1 
  0.02 
Yes 77 (15.1%) 79 (15.5%)  
No 433 (84.9%) 431 (84.5%)  
Whether or not 
alternatives were used in 
the last month1 
  0.00 
Yes 475 (93.1%) 474 (92.9%)  
No 35 (6.9%) 36 (7.1%)  
 
Note: 1 N (%), 2 M (SD, range), *p ≤ 0.05, **p ≤ 0.001 
The McNemar’s tests and paired-samples t-tests showed there were no 
significant differences in painkiller use variables between baseline and follow-
up: type of painkillers, frequency of painkiller use in the last month, misuse of 
painkillers, abuse of painkillers and alternative methods of pain relief. 
The results in Table 43 shows the majority of participants had taken 
prescription painkillers in the last month at baseline and there was a small but 
non-significant decrease to follow-up. The proportion of participants who had 
not taken any prescription painkillers was small but increased from baseline to 
follow-up, although not significantly. Most participants used both prescription 
and over-the-counter painkillers (Table 60, Appendix I). 
The mean number of days painkillers were taken in the last month were 
almost identical at baseline and follow-up, which was most days in the last 
month. Approximately one-third of participants misused painkillers in the last 
month at baseline and there was a small but non-significant decrease to 
follow-up.  
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There was a small proportion of participants who had abused painkillers and 
the proportion was almost identical between baseline and follow-up. The 
majority of participants used alternative methods of pain relief in the last 
month at baseline and follow-up. The most common alternative methods were 
hot water bottle and exercise (Table 60, Appendix I). 
Table 44 compares baseline and follow-up for dependence and psychological 
factors. The table shows that all of the comparisons between baseline and 
follow-up were highly significant. Specifically, LDQ total scores decreased 
from baseline to follow-up. Only one of the PMAQ subscales scores 
decreased overtime, which was the Side Effects. Most of the other PMAQ 
subscales scores increased over time. These were Addiction, Scrutiny, 
Tolerance and Mistrust of Doctors. However, two PMAQ subscales scores 
remained the same over time but were significant. These were the Need 
subscale and the Withdrawal subscale. 
Table 44. Baseline, follow-up and change scores for painkiller dependence and 
psychological factors measures for the non-dropout sample. 








LDQ  9.69 (5.66) 9.35 (5.48) −0.35 (4.13) -1.90 0.73** 
PMAQ Addiction  4.51 (2.50) 4.52 (2.52) 0.01 (2.24) 0.06 0.60** 
PMAQ Need  4.77 (2.34) 4.77 (2.15) 0.01 (2.19) 0.06 0.53** 
PMAQ Scrutiny  3.73 (2.49) 3.75 (2.61) 0.02 (2.29) 0.19 0.60** 
PMAQ Side Effects  3.99 (2.17) 3.96 (2.11) -0.03 (2.02) -0.29 0.56** 
PMAQ Tolerance  3.02 (2.81) 3.13 (2.82) 0.11 (2.23) 1.11 0.69** 
PMAQ Mistrust of Doctors  6.18 (2.70) 6.42 (2.68) 0.24 (3.07) 1.77 0.35** 
PMAQ Withdrawal  2.25 (2.17) 2.25 (2.17) 0.01 (1.83) 0.07 0.64** 
PCS  9.09 (4.17) 8.83 (4.29) −0.26 (3.39) −1.74 0.68** 
CPAQ Pain Willingness  17.00 (5.17) 17.25 (5.08) 0.24 (5.42) 1.01 0.44** 
CPAQ Activity Engagement  14.46 (5.76) 14.23 (5.97) −0.22 (3.97) −1.24 0.77** 
CPAQ total 31.46 (7.65) 31.48 (7.64) 0.03 (6.47) 0.09 0.64** 
PSEQ  6.26 (3.45) 6.31 (3.54) 0.05 (2.32) 0.52 0.78** 
TAS  57.68 (10.52) 57.18 (10.27) −0.50 (7.88) −1.43 0.71** 
 
Note: *p ≤ 0.05, **p ≤ 0.001 
PCS scores decreased from baseline to follow-up. Only the Activity 
Engagement subscale scores of the CPAQ decreased over time. The Pain 
Willingness subscale scores of the CPAQ and the CPAQ total scores 
increased from baseline to follow-up increased from baseline to follow-up. 
PSEQ scores increased from baseline to follow-up. TAS scores increased 
from baseline to follow-up.  
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Table 44 also shows the values for Pearsons correlations, testing the 
correlation between scores at baseline and follow-up. These were all positive 
and highly significant, showing that measures at baseline were positively 
related to measures at follow-up. The correlations were highest for the PSEQ, 
CPAQ Activity Engagement, LDQ, and TAS, and lowest for CPAQ Pain 
Willingness, PMAQ Mistrust of Doctors, PMAQ Need and PMAQ Side Effects. 
6.3.3. Correlations of dependence with demographic variables, pain 
variables, painkiller use variables and psychological factors 
Pearsons correlations were used to analyse the associations between 
dependence, demographic variables, pain variables, painkiller use variables 
and psychological factors. These are shown in Table 45. Note, the 
correlations included change scores, which were computed by subtracting the 















       Table 45. Correlations between demographic, pain, painkiller use variables and painkiller dependence.  
 



















 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Age 1              
2. Age FU 1.00** 1             
3. Pain frequency .21** .21** 1            
4. Pain frequency FU .23** .23** .69** 1           
5. Pain frequency 
change 
.04 .04 −.36** .42** 1          
6. Pain intensity .08 .08 .41** .34** −.08 1         
7. Pain intensity FU .13** .14** .43** .51** .11* .74** 1        
8. Pain intensity 
change 
.09* .09* .08 .28** .26** −.27** .45** 1       
9. Painkiller use 
frequency 
.20** .20** .68** .60** −.09* .40** .46** .13** 1      
10. Painkiller use 
frequency FU 
.23** .23** .63** .60** −.01 .36** .45** .18** .85** 1     
11. Painkiller use 
frequency change 
.07 .06 −.11* .01 .14** −.09* .02 .09* −.28** .27** 1    
12. LDQ  -.00 -.00 .30** .27** −.02 .32** .32** .04 .46** .42** −.07 1   
13. LDQ FU .00 .00 .26** .33** .10* .25** .34** .16** .44** .43** .02 .73** 1  
14. LDQ change .00 .00 −.06 .06 .16** −.11* .01 .16** −.05 -.01 .07 −.41** .33** 1 
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6.3.3.1. Age 
The table shows there was no correlation between age and dependence. 
6.3.3.2. Pain frequency  
There were highly significant positive correlations between pain frequency at 
baseline and follow-up with dependence at baseline and follow-up but these 
were small correlations. Pain frequency at baseline or follow-up were not 
correlated with change in dependence. There was a significant positive 
correlation between pain frequency change and dependence at follow-up, and 
a highly significant positive correlation with dependence change but these 
were small correlations. However, pain frequency change was not correlated 
with dependence at baseline.  
6.3.3.3. Pain intensity 
Most of the correlations between pain intensity and dependence were 
significant. Baseline pain intensity was positively correlated with baseline and 
follow-up dependence, although these were small correlations but highly 
significant. Baseline pain intensity was negatively correlated with change in 
dependence. This was also a small correlation but significant.  
There were small but highly significant positive correlations between follow-up 
pain intensity with baseline and follow-up dependence but there was no 
significant relationship between follow-up pain intensity and change in 
dependence. For pain intensity change, there was no significant correlation to 
baseline dependence but there were highly significant correlations to follow-
up dependence and change in dependence. These were positive but small 
correlations. 
6.3.3.4. Painkiller use frequency  
There was a highly significant moderate positive correlation between painkiller 
use frequency and dependence at baseline and follow-up but there was no 
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significant correlation between baseline painkiller use frequency and change 
in dependence. There was also a highly significant moderate positive 
correlation between follow-up painkiller use frequency and dependence at 
baseline and follow-up but there was no correlation with change in 
dependence. For painkiller use frequency change, there was no significant 
correlation with baseline, follow-up or change in dependence.  
6.3.3.5. Leeds Dependence Questionnaire (LDQ) 
There was a highly significant relationship between baseline and follow-up 
dependence. This was a large and positive correlation. 
There was also a highly significant relationship between baseline dependence 
and dependence change. This was negative and moderate correlation. 
Follow-up dependence had a small but highly significant positive correlation 
with change in dependence.  












Table 46. Correlations between PMAQ subscale results and painkiller dependence. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Addiction  1              
2. Addiction FU .60** 1             
3. Addiction change −.44** .45** 1            
4. Need  .43** .36** -.07 1           
5. Need FU .37** .45** .10* .53** 1          
6. Need change −.10* .06 .17** -.55** .42** 1         
7. Scrutiny .21** .21** .00 .15** .17** .01 1        
8. Scrutiny FU .18** .28** .12** .13** .17** .03 .60** 1       
9. Scrutiny change −.03 .09* .13** -.01 .02 .02 -.41** .49** 1      
10. Side Effects  .07 .08 .01 .41** .30** -.15** .44** .30** -.14** 1     
11. Side Effects FU .11* .15** .05 .29** .41** .10* .32** .47** .19** .56** 1    
12. Side Effects change .03 .07 .04 -.14** .12** .27** -.14** .17** .35** -.50** .45** 1   
13. Tolerance  .58** .45** -.14** .42** .35** -.11* .27** .27** .01 .17** .17** -.00 1  
14. Tolerance FU .50** .58** .09* .32** .43** .09* .31** .38** .10* .18** .22** .04 .69** 1 
15. Tolerance change −.10* .16** .29** -.13** .11* .25** .04 .14** .11* .01 .07 .06 -.39** .40** 
16. Mistrust of Doctors  -.01 -.06 -.06 -.04 .03 -.02 -.07 .01 .09 -.01 .01 .03 .03 -.00 
17. Mistrust of Doctors FU -.01 .01 .02 .02 .07 .05 -.15** -.19** .03 -.06 -.06 -.00 -.00 .04 
18. Mistrust of Doctors change -.00 .06 .07 -.02 .04 .06 -.07 -.11* -.05 -.04 -.06 -.03 -.03 .04 
19. Withdrawal  .34** .27** -.07* .21** .23** -.01 .45** .34** -.11* .22** .17** -.06 .50** .44** 
20. Withdrawal FU .30** .36** .07 .18** .26** .06 .35** .47** .16** .20** .28** .08 .40** .49** 
21. Withdrawal change −.04 .10* .16** -.04 .04 .07 -.12** .17** .32** -.03 .14** .17** -.12** .06 
22. LDQ .54** .45** -.10* .40** .35** -.09* .31** .31** .02 .15** .16** -.00 .60** .50** 
23. LDQ FU .47** .52** .06 .32** .42** .07 .25** .31** .08 .45** .44** -.01 .13** .16** 
24. LDQ change −.12** .07 .21** -.12** .08 .21** -.09* -.01 .09 -.05 .05 .11* -.04 -.00 
 
 15 16 17 18 19 20 21 22 23 24 
15. Tolerance change 1          
16. Mistrust of Doctors  -.04 1         
17. Mistrust of Doctors FU .05 .35** 1        
18. Mistrust of Doctors change .08 -.58** .57** 1       
19. Withdrawal  -.08 -.07 -.03 .04 1      
20. Withdrawal FU .11* -.09* -.03 .06 .64** 1     
21. Withdrawal change .23** -.03 .01 .03 -.42** .42** 1    
22. LDQ -.12* .01 .02 .01 .47** .39** -.09* 1   
23. LDQ FU .03 .51** .57** .07 .00 .02 .01 .73** 1  
24. LDQ change .04 -.14** .06 .26** -.01 -.01 -.00 −.41** .33** 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001
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6.3.3.6. Pain Medication Attitudes Questionnaire-14 (PMAQ-14)   
Baseline Addiction had a highly significant correlation with dependence at 
baseline and follow-up. These were moderate and positive correlations but 
there was a small and negative significant correlation between baseline 
Addiction and dependence change. Follow-up Addiction had a highly 
significant positive relationship with baseline and follow-up dependence but 
was not related to change in dependence.  
Change in Addiction was related significantly to dependence at baseline but 
was a small negative correlation. There was no significant correlation between 
change in Addiction and dependence at follow-up but there was a highly 
significant relationship between change in Addiction and change in 
dependence. This was a small and positive correlation.  
Need at baseline showed a moderate highly significant positive correlation 
with dependence at baseline. For baseline Need with follow-up dependence, 
there was a small highly significant positive correlation. For baseline Need 
with change in dependence, there was a small negative highly significant 
correlation.  
Need at follow-up showed a moderate highly significant positive correlation 
with dependence at follow-up and a small highly significant positive correlation 
with baseline dependence but no correlation with change in dependence.  
Change in Need showed a small highly significant positive correlation with 
dependence change but was not related to dependence at either baseline or 
follow-up. 
Scrutiny at baseline was highly significantly related to baseline dependence 
but this was a small and positive relationship. Scrutiny also showed a small 
but highly significant positive relationship to follow-up dependence and a 
small but significant negative correlation with dependence change. 
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Scrutiny at follow-up showed identical correlation to baseline and follow-up 
dependence. These were small and positive correlations that were highly 
significant but there was no relationship between follow-up Scrutiny and 
change in dependence. Change in Scrutiny was not related to baseline, 
follow-up or change in dependence.  
Side Effects at baseline had a small but highly significant positive correlation 
with both baseline and follow-up dependence but there was no relationship 
with change in dependence. Side Effects at follow-up also had small but 
highly significant positive correlations with both baseline and follow-up 
dependence but there was no relationship to change in dependence. There 
were no relationships between Side Effects change and any dependence 
variables. 
There was a highly significant moderate positive correlation between 
Tolerance at baseline and dependence at both baseline and follow-up but a 
small highly significant positive correlation with dependence change. 
Tolerance at follow-up was moderately correlated with both baseline and 
follow-up dependence. These were highly significant and positive correlations. 
For change in Tolerance, the correlation with baseline dependence was a 
significant small and negative correlation. There was also a small and 
negative correlation with dependence change but this was highly significant. 
However, there was no relationship to follow-up dependence.  
Mistrust of Doctors at baseline, follow-up and change in Mistrust of Doctors 
showed no correlations with dependence at baseline, follow-up or change in 
dependence. 
Withdrawal at baseline showed a moderate correlation with dependence at 
baseline and follow-up but no correlation with dependence change. The 
correlations were both highly significant and positive but there was no 
correlation with dependence change. 
Withdrawal at follow-up had a small relationship with dependence at baseline 
but a moderate relationship with dependence at follow-up. Both correlations 
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were positive and highly significant but there was no correlation with 
dependence change. 
Withdrawal change showed small correlations with dependence. There was a 
significant negative relationship to baseline dependence and a significant 
positive relationship to dependence change which was positive but no 
relationship to dependence at follow-up.  

















Table 47. Correlations between PCS, CPAQ, PSEQ, TAS and painkiller dependence. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
1. PCS 1            
2. PCS FU .68** 1           
3. PCS change  -.37** 43** 1          
4. P W  -.20** .03 .10* 1         
5. P W FU -.07 -.03 .05 .44** 1        
6. P W change  -.02 -.06 -.05 -.54** .52** 1       
7. A E  -.31** -.40** .03 .02 .05 .02 1      
8. A E FU -.43** -.44** -.03 -.02 .05 .07 .77** 1     
 9. A E change  -.02 -.09* -.08 -.07 .01 .08 -.29** .38** 1    
10. CPAQ -.39** -.28** .09* .68** .33** -.34** .75** .55** -.26** 1   
11. CPAQ FU -.38** -.36** .01 .26** .67** .38** .60** .78** .29** .62** 1  
12. CPAQ change -.03 -.10* -.09* -.46** .41** .82** -.15** .27** .63** -.41** .46** 1 
13. PSEQ  -.32** -.39** .05 .01 .02 .01 .79** .73** -.04 .59** .55** -.02 
14. PSEQ FU -.42** -.46** -.07 -.04 .01 .04 .69** .85** .27** .48** .63** .19** 
15. PSEQ change  .01 -.13** -.17** -.07 -.01 .06 -.12** .21** .48** -.13** .15** .32** 
16. TAS  .27** .31** -.03 .02 -.02 -.03 -.32** -.31** .00 -.23** -.24** -.03 
17. TAS FU .32** .38** .08 -.03 -.02 .01 -.32** -.34** -.05 -.24** -.26** -.02 
18. TAS change  -.04 .08 .15** -.07 .00 .07 .03 -.02 -.07 -.03 -.02 .01 
19. LDQ .60** .41** -.05 .01 .04 .03 -.33** -.38** -.09* -.24** -.26** -.03 
20. LDQ FU .40** .47** .11* -.07 -.01 .06 -.33** -.38** -.10* -.29** -.29** -.01 
21. LDQ change -.11* .06 .21** -.11* -.07 .04 .02 .02 -.01 -.05 -.03 .02 
 
 13 14 15 16 17 18 19 20 21 
13. PSEQ  1         
14. PSEQ FU -.04 1        
15. PSEQ change  .05 .35** 1       
16. TAS  .08 -.58** .57** 1      
17. TAS FU -.08 -.07 -.03 .04 1     
18. TAS change  .11* -.09* -.03 .06 .64** 1    
19. LDQ  .23** -.03 .01 .03 -.42** .42** 1   
20. LDQ FU -.12* .01 .02 .01 .47** .39** -.09* 1  
21. LDQ change .03 .51** .57** .07 .00 .02 .01 .73** 1 
 
Note: *p ≤ 0.05, **p ≤ 0.001, P W = Pain Willingness, A E = Activity Engagement  
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6.3.3.7. Pain Catastrophising Scale-4 (PCS-4) 
There were moderate relationships between baseline pain catastrophising 
and dependence at baseline and follow-up. Both were highly significant and 
positive correlations. There was a small correlation with dependence change, 
which was significant and negative.  
Follow-up pain catastrophising had a highly significant moderate positive 
correlation with dependence at baseline and follow-up but there was no 
correlation with dependence change. 
There were small correlations between pain catastrophising change and 
dependence. However, the highest of these correlations was with change in 
dependence, which was positive and highly significant. The next highest was 
with dependence at follow-up, which was a positive and significant correlation. 
Then there was no correlation with dependence at baseline. 
6.3.3.8. Chronic Pain Acceptance Questionnaire-8 (CPAQ-8) 
Most of the correlations between Pain Willingness and dependence at 
baseline, follow-up and change were very small and non-significant. There 
was only one significant correlation, which was between baseline Pain 
Willingness and change in dependence, which was a small and negative 
significant correlation.  
All of the correlations between Activity Engagement and dependence were 
significant except for correlations to change in dependence. For baseline 
Activity Engagement, there was a highly significant correlation with 
dependence at baseline and follow-up but these were small and negative 
correlations. There was no correlation with dependence change. 
For follow-up Activity Engagement, there were also small and negative but 
highly significant correlations with baseline and follow-up dependence, but no 
correlation with dependence change.  
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Change in Activity Engagement had small negative but significant correlations 
with dependence at baseline and follow-up and no correlation with 
dependence change. 
For CPAQ total, the correlations between baseline chronic pain acceptance 
and dependence that were significant were with dependence at baseline and 
follow-up but not change in dependence. These were small and negative 
correlations but were highly significant.  
Follow-up chronic pain acceptance had highly significant small negative 
correlations with dependence at baseline and follow-up but was not correlated 
with change in dependence. Change in chronic pain acceptance was not 
related to any dependence variables. 
6.3.3.9. Pain Self-Efficacy Questionnaire-2 (PSEQ-2) 
Pain self-efficacy at baseline had a small negative correlation with 
dependence at baseline and follow-up, which were highly significant. 
However, there was no significant correlation with change in dependence. 
Pain self-efficacy at follow-up also had highly significant small negative 
correlations with dependence at baseline and follow-up and no significant 
correlation with dependence change. There were no significant correlations 
between change in pain self-efficacy and any dependence variables. 
6.3.3.10. Toronto Alexithymia Scale-20 (TAS-20) 
Alexithymia at baseline had small positive and highly significant correlations 
with dependence at baseline and follow-up but no significant correlation with 
dependence change. Alexithymia at follow-up also had small positive and 
highly significant correlations with dependence at baseline and follow-up but 
no significant correlation with dependence change. There were no 




6.3.4. Predictors of dependence 
The patterns of correlations with dependence at follow-up showed that there 
were several significant correlations with baseline measures. A multiple 
regression analysis was therefore conducted using the stepwise method to 
assess the influence of baseline measures on dependence at follow-up to see 
if the baseline measures are predictors of dependence at follow-up. The 
dependent variable in the multiple regression analysis was dependence at 
follow-up. The predictor variables were entered in four blocks: demographics 
variables were entered in block 1; pain variables were entered in block 2; 
painkiller use variables were entered in block 3; and psychological factors 
variables were entered in block 4. The results are shown in Table 48. 
Table 48. Entry Beta values, final Beta values, change in R2 (ΔR2), total R2 (R2) and adjusted 
R2 (AR2) for each block in the multiple regression analysis with painkiller dependence 





ΔR2 R2 AR2 
Block 1: demographics measures   0.09* 0.09 0.08 
Whether or not pain influences employment 0.20** 0.04    
Financial status −0.15** −0.07*    
Mental health condition diagnosis 0.11* 0.04    
Gender −0.12* −0.04    
Block 2: pain measures   0.05* 0.14 0.13 
Pain frequency in the last month 0.18** −0.10*    
Pain duration 0.13* 0.08*    
Pain intensity  0.12* −0.05    
Block 3: painkiller use measures   0.15* 0.29 0.27 
Frequency of painkiller use in the last month 0.46** 0.17**    
Misuse of painkillers in the last month 0.17** 0.05    
Abuse of painkillers in the last month 0.10* 0.02    
Block 4: psychological factors measures   0.28** 0.57 0.56 
Baseline LDQ  0.63** 0.58**    
PMAQ Withdrawal  0.12** 0.12**    
Note: *p ≤ 0.05, **p ≤ 0.001 
The multiple regression showed that the final model was highly significant [F 
(12, 497) = 56.59, p < 0.001]. Table 48 shows that the final model explained 
over half of the variance (R2 = 0.57; 57%). The table also shows all of the 
predictors were significant at entry. The strongest predictor was baseline LDQ 
(entry Beta = 0.63). The next strongest was frequency of painkiller use in the 
last month (entry Beta = 0.46). These were both highly significant predictors 
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(p < 0.001). There were two negative predictors, which were financial status 
(entry Beta = –0.15, p < 0.001) and gender (entry Beta = –0.12, p < 0.05). All 
of the entry Beta values were reduced in the final model except LDQ and 
PMAQ Withdrawal. Therefore, the only psychological factor that predicted 
dependence at follow-up was PMAQ Withdrawal. 
Mediation analysis was conducted for the variables that were significant at 
entry but not in the final model. Each of these variables was mediated by 
baseline LDQ: whether or not pain influences employment (Sobel = −1.30; p < 
0.001; 95% CI −1.98 to −0.62); mental health condition diagnosis (Sobel = 
1.17; p < 0.001; 95% CI 0.48 to 1.85); gender (Sobel = −1.61; p < 0.05; 95% 
CI −2.75 to −0.48); pain intensity (Sobel = 0.26; p < 0.001; 95% CI 0.19 to 
0.33); abuse of painkillers in the last month (Sobel = 2.08; p <0.001; 95% CI 
1.39 to 2.78); and abuse of painkillers in the last month (Sobel = 2.15; p < 
0.001; 95% CI 1.20 to 3.09).  
6.4. Discussion 
In the previous studies of the thesis and some literature, attitudes and beliefs 
towards painkillers were psychological factors that had a role in problematic 
painkiller use. Also, in the literature, other psychological factors that had a role 
in problematic painkiller use were pain catastrophising, pain acceptance, pain 
self-efficacy and alexithymia. The present longitudinal study aimed to examine 
the role of psychological factors in problematic painkiller use over time among 
the general population of the UK.  
The discussion will begin by providing a summary for the results of the study. 
Next, the implications of the results for the literature and society will be 
discussed. Then, the strengths and weaknesses of the study will be outlined, 





6.4.1. Summary of results  
When the dropout and non-dropout sample were compared, it was found that 
the two samples were significantly different for only a small number of 
demographic variables, pain variables and painkiller use variables but most of 
the psychological factors and dependence.  
For the demographic variables, the two samples were only significantly 
different for age, highest education level and financial status: the dropout 
sample was younger than the non-dropout sample; there were fewer 
participants with a qualification in the dropout sample than the non-dropout 
sample; and there were fewer participants that were “about the same as most” 
or “a little or a lot richer than most” in the dropout sample than the non-
dropout sample but there were more participants that were “a little or a lot 
poorer than most” in the dropout sample than the non-dropout sample.  
For the pain variables, the two samples were only significantly different for 
pain intensity, abdominal pain and pain diagnosis. To specify these significant 
differences, the dropout sample had: higher pain intensity than the non-
dropout sample; more participants with abdominal pain than the non-dropout 
sample; and fewer participants with a pain diagnosis than the non-dropout 
sample.   
For the painkiller use variables, the two samples were only significantly 
different for misuse of painkillers, which was more prevalent in the dropout 
sample than the non-dropout sample, and using alternative methods of pain 
relief, which was less prevalent in the dropout sample. 
For dependence, the two samples were significantly different; the dropout 
sample had higher dependence scores than the non-dropout sample, 
therefore the dropout sample had more painkiller dependence than the non-
dropout sample.  
For the psychological factors, two samples were significantly different for most 
of the factors. In terms of attitudes and beliefs towards painkillers, it was 
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found that the dropout sample had higher scores for Addiction, Need, 
Scrutiny, Side Effects, Tolerance and Withdrawal than the non-dropout 
sample but there was no significant difference between the two samples for 
Mistrust of Doctors.  
In terms of pain catastrophising, the dropout sample had significantly higher 
scores than the non-dropout sample. In terms of pain acceptance, the dropout 
sample had significantly higher scores than the non-dropout sample for 
Activity Engagement but had significantly lower scores than the non-dropout 
sample for Pain Willingness and the total CPAQ. In terms of pain self-efficacy, 
the dropout sample had significantly higher scores than the non-dropout 
sample. In terms of alexithymia, the dropout sample had significantly lower 
scores than the non-dropout sample. These results showed that those who 
dropped out of the study were generally more severely affected by pain and 
had more problematic painkiller use and more negative attitudes and beliefs.  
A comparison of the baseline and follow-up data showed that there were no 
significant differences between baseline and follow-up for most of the pain 
variables and painkiller use variables but there were significant differences for 
the psychological factors and dependence. The demographics were all the 
same from baseline to follow-up so it was not necessarily to test significant 
differences. For the pain variables, it was found that the only significant 
differences from baseline to follow-up were that pain intensity decreased, 
participants with muscle pain increased, participants with “other” pain 
decreased and participants with pain diagnosis increased.  
All of the painkiller use variables were not significantly different from baseline 
to follow-up. In contrast, all of the psychological factors and dependence were 
significantly different from baseline and follow-up. For attitudes and beliefs 
towards painkillers, there was an increase for each of these attitudes and 
beliefs from baseline to follow-up except for Side Effects which decreased. 
For pain catastrophising, there was a decrease from baseline to follow-up. For 
pain acceptance, it was found that Pain Willingness and total CPAQ increased 
from baseline to follow-up but Activity Engagement decreased. For pain self-
efficacy, there was an increase from baseline to follow-up but alexithymia and 
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dependence decreased. This showed that many psychological factors and 
dependence generally improved over time except attitudes and beliefs 
towards painkillers, which most became more negative over time. 
The predictors of dependence were investigated by multiple regression of 
dependence at follow-up with baseline predictors. From the analysis, it was 
found that only one psychological factor predicted follow-up dependence, 
which was PMAQ Withdrawal. 
6.4.2. Implications 
The present study has a number of implications for the literature and for 
society. One implication is the study has provided an understanding about the 
role of psychological factors in problematic painkiller use over time. 
Specifically, the study has shown that attitudes and beliefs towards withdrawal 
from painkillers predicted increased painkiller dependence over time. This 
does not support previous findings about attitudes and beliefs towards 
painkillers (e.g. McCracken et al., 2006; Cogan et al., 2014), since more 
negative attitudes and beliefs were associated with less painkiller use in these 
studies. It might be possible that the difference from previous studies is due to 
differences in the participants; the previous studies involved chronic pain 
patients and women with childbirth pain, but not the general population. In 
addition, previous studies were about painkiller use frequency, but not 
problematic painkiller use. Therefore, the present study demonstrates that the 
role of attitudes and beliefs towards painkillers might be different for 
problematic painkiller use, especially dependence, in the general population.  
Based on previous findings, it was expected that the remaining psychological 
factors should have had a role in problematic painkiller use. This is especially 
because these factors were associated with painkiller dependence in the 
general population (Elander et al., 2014). However, the present study showed 
these factors were not predictors, which might be because painkiller 
dependence was investigated over time. Thus, although the remaining 
psychological factors had a role in problematic painkiller use in previous work, 
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the present study clarified that the role does not act over time, that is, did not 
predict changes. 
The present study findings can be used for preventing or reducing problematic 
painkiller use among the general population. Specifically, the results of the 
study can be used for developing interventions based on decreasing negative 
attitudes and beliefs towards withdrawal from painkillers, for example by 
providing education to make people more aware of the significance of 
symptoms of withdrawal from painkillers.  
6.4.3. Strengths and weaknesses 
The present study has a number of strengths and weaknesses that should be 
outlined. First of all, the longitudinal design was a strength to allow 
investigation of problematic painkiller use over time. An additional strength 
has been the large sample size, which met the power analysis requirements. 
Despite the large sample size, there was a large attrition, which is a weakness 
of the study because comparisons of the dropout sample and non-dropout 
sample showed there were several significant differences between these 
samples. Due to these differences, in some ways the dropout sample were 
potentially of greater interest, as they seemed more disadvantaged.  
There were also other weakness of the study, which were similar to the 
weaknesses of the previous studies of the thesis. One of these weaknesses 
was the sample composition. For example, the majority of the participants 
were females. This means we can be less confident about interpreting the 
findings in relation to male painkiller users. Another weakness of the study 
similar to the previous studies of the thesis was the difficulty to ensure 
participants did not complete each baseline and follow-up questionnaire more 
than once to enter the prize draws more often. In order to reduce the problem, 
participants were required to provide an email address to enter the prize draw 
and if any were repeated, the participants were excluded. Also, participants 
were required to provide a unique ID code and demographic information. If 
any were repeated, the participants were excluded. 
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An additional weakness of the longitudinal study was that data were not 
collected about access to painkillers. These data were collected for the 
studies in the UK and Egypt, and the international study, but not the 
longitudinal study. This was because the longitudinal study focused on factors 
that could change over time, and access to painkillers is less likely to change 
over time than psychological factors. Also, because the longitudinal study took 
place in just one country – the UK – where the issues of access had been 
examined already in the thesis. For the longitudinal study it was also 
important to keep the surveys short in order to maximize participation and 
reduce participant attrition. However, for future research it might be 
worthwhile to study how different modes of access to painkillers influence 
patterns of change in painkiller dependence. 
6.4.4. Future research 
To follow the present study, it would be useful for future research to develop 
an intervention based on attitudes and beliefs towards withdrawal from 
painkillers, since this had a role in problematic painkiller use over time. After 
developing the intervention, it could be tested whether the intervention 
effective for reducing problematic painkiller use among the general population 
of the UK. For example, this might take the form of an educational intervention 
to increase people’s understanding of withdrawal and increase awareness 
that attitudes and beliefs towards withdrawal was predictive of painkiller 
dependence over time. 
Another useful future research project would be to replicate the present study 
among the general population of other countries to compare the role of 
psychological factors over time. Again, following these studies, it would be 
useful to develop interventions based on the psychological factors that had a 
role in problematic painkiller use over time to test whether the interventions 





In conclusion, the results showed that psychological factors mostly did not 
predict problematic painkiller use over time except for attitude and beliefs 
towards withdrawal from painkillers. To follow-up these results, it would be 
useful to test whether reducing negative attitudes and beliefs towards 






































































The aim of the thesis was to investigate the role of accessibility of painkillers 
and psychological factors in problematic painkiller use in the general 
population. To do this, three studies were conducted: one study compared the 
general population of the UK and Egypt about the role of accessibility and 
psychological factors in problematic painkiller use; another study was a multi-
national comparison that compared the role of accessibility and psychological 
factors in problematic painkiller use among the general population of 
Germany, USA, Australia and China to extend the comparison between the 
UK and Egypt; and another study focused on the role of psychological factors 
in problematic painkiller use over time among the general population of the 
UK. 
The present discussion will have five sections. In the first section, the results 
from the thesis about the role of accessibility will be discussed. In the second 
section, the results from the thesis about the role of psychological factors will 
be discussed. In the third section, the implications of the results will be 
provided. In the fourth section, the future directions for this research will be 
provided. In the fifth section, the conclusion of the thesis will be provided. 
7.1.1. The role of accessibility in problematic painkiller use 
There were two studies that involved measuring accessibility. One study was 
a comparison between the UK and Egypt and the other study was a multi-
national comparison of Germany, USA, Australia and China to extend the 
comparison between the UK and Egypt. In these studies, accessibility of 
painkillers measured by the following: source of OTC painkillers; perceived 
difficulty for obtaining strong painkillers without a prescription; using strong 
painkillers without a prescription; and source of strong painkillers if strong 
painkillers were used without a prescription.  
In the study comparing the UK and Egypt, it was predicted that there would be 
easier accessibility of painkillers in Egypt than the UK, which would have a 
role in more problematic painkiller use. The easier accessibility of painkillers 
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in Egypt was supported by results about obtaining strong painkillers without a 
prescription. More specifically, the results showed that people in the UK 
perceived obtaining strong painkillers without a prescription as more difficult 
than people in Egypt and fewer people used strong painkillers without a 
prescription than in Egypt. Therefore, these results shows that accessibility of 
strong painkillers illegally to be easier in Egypt than the UK, which supports 
the previous literature about less control and less law enforcement in Egypt 
than the UK (e.g. Sallam et al., 2009). It is possible that there might be more 
people obtaining strong painkillers without a prescription but who did not want 
to admit this because it is illegal. However, this should have been reduced 
because the participants were assured the online questionnaire was 
anonymous and confidential (e.g. Wright, 2005). 
Further support for easier accessibility of painkillers in Egypt than the UK was 
provided by results about the source of strong painkillers without a 
prescription. To specify, most participants obtained strong painkillers illegally 
from the pharmacy in Egypt compared to a small percentage in the UK. Again, 
these results support the previous literature about less control and less law 
enforcement in Egypt than the UK (e.g. Sallam et al., 2009) because it would 
not be possible to get strong painkillers from a pharmacy if there was more 
control and law enforcement. After the pharmacy, the sources of strong 
painkillers illegally in Egypt were family and friends who are medical 
professionals but the sources in the UK were family and friends who are not 
medical professionals. These results also support the previous literature about 
less control and less law enforcement in Egypt than the UK because family 
and friends in the medical profession especially should not distribute 
painkillers illegally. Despite there being more illegal accessibility in Egypt, 
there was still illegal accessibility in the UK. Therefore, there should be more 
control about accessibility of strong painkillers without a prescription in both 
countries but especially Egypt. These findings can be compared with research 
by Benjamin et al. (1996), Zafar et al. (2008), Sallam et al. (2009), Mumtaz et 
al. (2011) and Ghandour et al. (2012), who all conducted studies of painkiller 
use in middle eastern countries, highlighting the fact that high rates of 
painkiller use were often attributed to easier access to strong painkillers. 
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Although easier accessibility of painkillers in Egypt than the UK was 
supported, the role of easier accessibility in problematic painkiller use was not 
supported. Specifically, it was predicted that easier accessibility of painkillers 
will have a role in more problematic painkiller use. However, the results 
showed that accessibility variables mostly were not significant predictors for 
problematic painkiller use: only obtaining OTC painkillers from the internet 
was a significant predictor for less problematic painkiller use in the UK and 
there were no significant predictors in Egypt.  
Because accessibility mostly were not significant predictors of problematic 
painkiller use, the results indicate that accessibility of painkillers may not be 
enough alone to explain problematic painkiller use. Instead, there could be 
other factors needed for accessibility to have a role in problematic painkiller 
use. It is possible that the other factors could be psychological factors 
because some of these factors had a significant role in problematic painkiller 
use in the present research. Therefore, easy accessibility of painkillers may 
not have a role in problematic painkiller use unless there are the 
psychological factors. So, even if painkillers are easy to access, the painkillers 
would not be used in a problematic way unless there are the psychological 
factors.  
When accessibility was investigated in the multi-national comparison, it was 
predicted that there would be differences in accessibility of painkillers 
between the countries, and differences in their role in problematic painkiller 
use. The differences in accessibility of painkillers between the countries were 
supported by the results about obtaining strong painkillers without a 
prescription. Specifically, the results showed that Australia and the USA 
perceived obtaining strong painkillers without a prescription as most difficult 
whereas Egypt perceived obtaining strong painkillers without a prescription as 
most easy. In addition, the people using strong painkillers without a 
prescription were least in China and the USA but most in Egypt. Therefore, 
accessibility of strong painkillers illegally was most easy in Egypt but most 
difficult in Australia, USA and China. These results suggest that there could 
be the most control and most law enforcement in Australia, USA and China to 
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explain the difficulty about obtaining strong painkillers illegally, but least 
control and least law enforcement in Egypt because obtaining strong 
painkillers illegally was most easy in Egypt. Again, these results supports the 
previous literature about less control and less law enforcement in Egypt (e.g. 
Sallam et al., 2009) but provides understanding about the other countries by 
showing Australia, USA and China as having more control and more law 
enforcement.  
The source of strong painkillers also supported differences in accessibility 
between the countries. Specifically, most participants obtained strong 
painkillers illegally from the pharmacy except for Germany, USA and 
Australia, which most participants obtained strong painkillers from friends and 
family. Since obtaining strong painkillers is more difficult illegally from the 
pharmacy than friends and family when there is more control and more law 
enforcement, the results shows that obtaining strong painkillers illegally 
appears most difficult in Germany, USA and Australia than the other 
countries, which could be from more control and more law enforcement in 
Germany, USA and Australia. Therefore, the results have provided 
understanding about differences in accessibility of painkillers between the 
countries. Additionally, the results have shown there should be more effort to 
reduce obtaining strong painkillers illegally because obtaining painkillers 
illegally occurred in the countries. 
About the role of accessibility in problematic painkiller use, the results 
supported that there will be differences in the role of accessibility between the 
countries for the multi-national study. Specifically, the results showed that 
there were differences between the countries because accessibility variables 
were only significant predictors for problematic painkiller use in the UK and 
USA. In the UK, obtaining OTC painkillers from the internet was a significant 
predictor for less problematic painkiller use. In the USA, obtaining strong 
painkillers from other source was a significant predictor for more problematic 
painkiller use. In the other countries, there were no accessibility variables 
significant predictors for problematic painkiller use. Therefore, although 
accessibility had a role in the UK and USA, there was mostly no role of 
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accessibility, which supports that accessibility of painkillers may not be 
enough alone to explain problematic painkiller use unless there are the 
psychological factors.  
7.1.2. The role of psychological factors in problematic painkiller use 
There were three studies that involved measuring psychological factors. One 
study was a comparison between the UK and Egypt. Another study was a 
multi-national comparison extended to more countries than the UK and Egypt, 
which were Germany, USA, Australia and China. Another study was a 
longitudinal study of the UK. In the study of comparison between the UK and 
Egypt and the multi-national study, the psychological factors were attitudes 
and beliefs towards pain, painkillers, self-medication and alternative methods. 
However, the longitudinal study focused on attitudes and beliefs towards 
painkillers with other psychological factors, which were pain catastrophising, 
pain acceptance, pain self-efficacy and alexithymia.  
In the study comparing the UK and Egypt, there were the following predictions 
about psychological factors: more positive attitudes and beliefs to pain will 
have a role in less problematic painkiller use; more positive attitudes and 
beliefs to painkillers will have a role in more problematic painkiller use; more 
positive attitudes and beliefs to self-medication will have a role in more 
problematic painkiller use; and more positive attitudes and beliefs to 
alternative methods of pain relief will have a role in less problematic painkiller 
use. 
For attitudes and beliefs towards pain, there was some support that more 
positive attitudes and beliefs towards pain will have a role in less problematic 
painkiller use. More specifically, SOPA-B Medical Cure was a predictor for 
more dependence but only for the UK. In addition, SOPA-B Solicitude was a 
predictor for more dependence but only for Egypt. Since Medical Cure and 
Solicitude are maladaptive, the results support the prediction. However, the 
remaining results do not support the prediction because most attitudes and 
beliefs towards pain had no role in problematic painkiller use. For the attitudes 
and beliefs towards pain with a role, it was opposite to the prediction; SOPA-B 
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Control was a predictor for more dependence in the UK. Since Control is 
adaptive, there should have been a role for less dependence rather than more 
dependence, therefore does not support the prediction. 
The results demonstrate that only Medical Cure in the UK and Solicitude in 
Egypt were consistent with the prediction. Therefore, positive attitudes and 
beliefs towards pain do not always have a role for less problematic painkiller 
use. In addition, the results demonstrate that attitudes and beliefs towards 
pain have different roles in the countries because there were not the same 
roles in the UK and Egypt. These different roles of attitudes and beliefs 
towards pain in the different countries supports Jensen and Karoly (2008) 
about what may be adaptive for some people might not be adaptive for 
another people and vice versa. Thus, the different roles in the countries can 
be explained in this way because what may be adaptive for the UK might not 
be adaptive for Egypt or no role in Egypt and vice versa, which was found by 
these results. In this way, the findings also add to what existing studies have 
shown about attitudes and beliefs towards pain (e.g. Tait & Chibnall, 1997). 
In the multi-national study, it was predicted that there will be differences in 
attitudes and beliefs towards pain between the countries, and differences in 
the role for problematic painkiller use. It found support for the prediction 
because the results showed differences in attitudes and beliefs towards pain 
between the countries and some differences in the role for problematic 
painkiller use.  
For the differences in attitudes and beliefs towards pain between the 
countries, China and USA had more negative attitudes and beliefs than the 
other countries because there were the highest scores for many maladaptive 
subscales of the SOPA-B. However, Germany had more positive attitudes 
and beliefs than the other countries because there were the lowest scores on 
many maladaptive subscales. Therefore, there were differences in attitudes 
and beliefs towards pain between the countries. 
For the differences in the role for problematic painkiller use, SOPA-B 
Medication was a predictor for more dependence in Germany and Australia 
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only but the other attitudes and beliefs towards pain had no role in 
problematic painkiller use. Although these results demonstrate differences in 
the role for problematic painkiller use, these results also demonstrate 
similarity between Germany and Australia for Medication. In addition, these 
results demonstrate similarity by mostly no role of the other attitudes and 
beliefs for all the countries. Therefore, the results provide understanding that 
attitudes and beliefs towards pain have some similarities and some 
differences between countries, but are mostly not predictors for problematic 
painkiller use. 
For attitudes and beliefs towards painkillers, the comparative study between 
the UK and Egypt showed no support for the prediction about more positive 
attitudes and beliefs to painkillers will have a role in more problematic 
painkiller use. Instead, the results showed more negative attitudes and beliefs 
to painkillers had a role in more problematic painkiller use rather than more 
positive attitudes and beliefs to painkillers. However, these results were only 
for PMAQ Need and Side Effects in the UK; the other attitudes and beliefs 
about painkillers had no role in the UK and all attitudes and beliefs to 
painkillers and no role in Egypt. These results indicate that attitudes and 
beliefs to painkillers do not have the same role as had been predicted.  
In the multi-national study, it was predicted that there would be differences in 
attitudes and beliefs to painkillers between the countries, and differences in 
the role for problematic painkiller use. Support for the prediction was found 
because there were differences in attitudes and beliefs to painkillers between 
the countries, and differences in the role for problematic painkiller use. 
About differences in attitudes and beliefs to painkillers between the countries, 
the results showed support because there were differences; Egypt had the 
most negative attitudes and beliefs and Germany had the most positive 
attitudes and beliefs. It might be possible to explain that Egypt had the most 
negative attitudes and beliefs to painkillers because there was the most illegal 
accessibility in Egypt, which could make people see painkillers in a more 
negative way and not safe. In contrast, Germany has control and law 
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enforcement about painkillers (e.g. Hanoch et al., 2007), which could make 
people see painkillers in a more positive way and safe. 
About differences in the role for problematic painkiller use, the results showed 
support because there were different attitudes and beliefs to painkillers that 
had a role in problematic painkiller use in the countries. Specifically, there 
were the following differences: PMAQ Need was a predictor for more 
problematic painkiller use in all the countries except for Egypt because there 
was no role; PMAQ Side Effects was a predictor for more problematic 
painkiller use in the UK only but there was no role in the other countries; 
PMAQ Withdrawal was a predictor for more problematic painkiller use in the 
USA and Germany but there was no role in the other countries; and PMAQ 
Tolerance was a predictor for more problematic painkiller use in Australia but 
there was no role in the other countries. 
Similar to the comparative study between the UK and Egypt, although there 
were differences in the role for problematic painkiller use, these results also 
demonstrate similarity: Need had a role for more problematic painkiller use in 
the UK, USA, Germany, China and Australia; Withdrawal had a role for more 
problematic painkiller use in USA and Germany; and there was similarity by 
no role of the other attitudes and beliefs for all the countries. Therefore, the 
results provide again understanding that attitudes and beliefs towards pain 
have some similarities and some differences between countries, but are 
mostly not predictors for problematic painkiller use. 
For attitudes and beliefs towards self-medication, the comparative study 
between the UK and Egypt showed that there were no predictors of 
problematic painkiller use, so the prediction about more positive attitudes and 
beliefs to self-medication will have a role in more problematic painkiller use 
was not supported. However, the multi-national study predicted there will be 
differences in attitudes and beliefs to self-medication between the countries, 
and differences in the role for problematic painkiller use, which was supported 
by the results from the multi-national study. 
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The differences in attitudes and beliefs to self-medication between the 
countries was supported because there were significant differences between 
the countries. Generally, Germany showed more positive attitudes and beliefs 
to self-medication but Egypt showed more negative attitudes and beliefs to 
self-medication. Similar to the attitudes and beliefs towards painkillers, these 
results might be explained by the differences in accessibility between the 
countries. Specifically, people might see self-medication of painkillers in a 
more positive way and safe, since Germany has control and law enforcement 
about painkillers (e.g. Hanoch et al., 2007). However, Egypt has less control 
and law enforcement about painkillers (e.g. Sallam et al., 2009), which could 
make people see self-medication of painkillers in a more negative way and 
not safe.  
The differences in the role for problematic painkiller use was supported 
because SMS Run its Course was a predictor for less problematic painkiller 
use in the USA only but not for the other countries. However, the other 
attitudes and beliefs to self-medication had no role in all the countries, 
therefore the no role was a similarity between the countries. These results 
provide understanding that attitudes and beliefs towards self-medication have 
mostly no role for problematic painkiller use, although the results also provide 
understanding that there are still differences between countries for Run its 
Course. 
For attitudes and beliefs towards alternative methods of pain relief, the results 
from the comparative study between the UK and Egypt showed that there 
were no predictors of problematic painkiller use, so the prediction about more 
positive attitudes and beliefs to alternative methods of pain relief will have a 
role in less problematic painkiller use was not supported. However, in the 
multi-national study, it was predicted that there will be differences in attitudes 
and beliefs to alternative methods of pain relief between the countries, and 
differences in the role for problematic painkiller use, which was supported by 
the results from the multi-national study. 
Regarding differences between the countries, the results showed generally 
the USA and Germany had more positive attitudes and beliefs to alternative 
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methods of pain relief but Egypt had more negative attitudes and beliefs. 
Since these results are a similar pattern to attitudes and beliefs towards 
painkillers, the results demonstrate there could be a link between attitudes 
and beliefs towards painkillers and alternative methods of pain relief. 
About differences in the role for problematic painkiller use, the results showed 
that HCAMQ HH was a predictor for less problematic painkiller use in 
Australia only but the other attitudes and beliefs towards pain had no role in 
problematic painkiller use. Similar to attitudes and beliefs towards pain, 
painkillers and self-medication, these results demonstrate that attitudes and 
beliefs towards alternative methods of pain relief have mostly no role for 
problematic painkiller use although there were differences.   
In the longitudinal study, there were the following predictions about 
psychological factors: more positive attitudes and beliefs towards painkillers 
will have a role in more problematic painkiller use over time; higher pain 
catastrophising will have a role in more problematic painkiller use over time; 
lower pain acceptance will have a role in more problematic painkiller use over 
time; lower pain self-efficacy will have a role in more problematic painkiller 
use over time; and higher alexithymia will have a role in more problematic 
painkiller use over time.  
The results from the longitudinal study showed no support for the predictions 
because there were no psychological factors predictors for problematic 
painkiller use over time except for PMAQ Withdrawal. However, the results 
about PMAQ Withdrawal also showed no support for the prediction because 
more negative PMAQ Withdrawal was a predictor for more problematic 
painkiller use over time rather than more positive PMAQ Withdrawal. 
Therefore, more negative attitudes and beliefs towards painkillers was a 
predictor for more problematic painkiller use over time but this was only for 
Withdrawal.  
These results have provided understanding about the role of psychological 
factors over time, showing that only Withdrawal had a role for problematic 
painkiller use over time from the factors that were investigated. To help 
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reduce problematic painkiller use over time, therefore there should be focus 
on attitudes and beliefs towards withdrawal from painkillers.  
7.2. Implications 
There are a number of implications concerning this research in respect to both 
current literature and to benefit painkiller users in the general population. 
Regarding the literature, the thesis has helped to clarify the role of 
accessibility of painkillers and psychological factors in problematic painkiller 
use. This understanding has been provided for the general population of 
several countries, which were the UK, Egypt, Germany, USA, Australia and 
China. To expand, in terms of accessibility, the thesis demonstrated that 
Egypt had the easiest accessibility, whereas the most difficult was in 
Australia, USA and China. However, the only countries where accessibility 
had a role in dependence were the UK and USA because this factor predicted 
lower dependence in the UK and higher dependence in the USA. Since 
accessibility of painkillers was easiest in Egypt, the results support the limited 
literature about accessibility in this country (e.g. Sallam et al., 2009), but 
additionally provide new understanding about the countries compared to each 
other because such direct comparisons were previously not available.  
The easier access of painkillers in Egypt suggests that there might be less 
control and law enforcement about painkiller access in this country as 
compared to further countries. The easier access included illegal access to 
strong painkillers, which was greatest in Egypt. Therefore, this means that 
more effort is needed, for example by authorities and people who dispense 
painkillers, to reduce obtaining painkillers illegally especially in Egypt. 
Meanwhile, more difficult access to painkillers in Australia, USA and China 
suggests these countries might have the most control and law enforcement 
regarding painkiller access.  
Although some results regarding accessibility are consistent with previous 
studies (e.g. Sallam et al., 2009), others were contradictory. The contradictory 
findings were because accessibility mostly did not predict dependence except 
for the UK and USA, which is unexpected because the previous results 
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showed accessibility has been linked to more use of painkillers (e.g. Hanoch 
et al., 2007; Sallam et al., 2009). Since accessibility mostly did not predict 
dependence, this would suggest that accessibility may not alone explain 
problematic painkiller use unless other factors are considered, for example 
psychological factors, as discussed in section 7.1.1. 
Regarding psychological factors, some results found were consistent with 
previous literature (e.g. Jensen & Karoly, 2008), while others were 
contradictory (e.g. Christiaens et al., 2010). A summary of factors that were 
significant predictors of dependence is provided in Table 49. 
Table 49. Summary of final Beta values for accessibility and psychological factors that 
were significant predictors of dependence, and total R2 for each country and over time 
in the UK longitudinal study. 
 
 UK Egypt Germany USA Australia China Over 
time 
Accessibility 
OTC from internet -0.08*       
Strong painkillers from 
“other” source 
   0.18*    
Psychological factors 
PMAQ Need 0.59**  0.24** 0.20* 0.35* 0.46**  
PMAQ Side Effects 0.18**       
PMAQ Withdrawal   0.21** 0.31**   0.12** 
PMAQ Tolerance     0.23*   
SOPA-B Control 0.13**       
SOPA-B Medical Cure 0.09*       
SOPA-B Solicitude  0.25**      
SOPA-B Medication   0.16*  0.19*   
SMS Run its Course    -0.19*    
HCAMQ HH     -0.16*   
R2 0.61 0.13 0.67 0.50 0.57 0.75 0.57 
 
Note: 
*p ≤ 0.05 
**p ≤ 0.001 
As shown in Table 49, there were differences between countries regarding 
psychological factors that were significant predictors. For example, PMAQ 
Side Effects predicted dependence in the UK only, whereas PMAQ Tolerance 
predicted dependence in Australia only, and SOPA-B Solicitude predicted 
dependence in Egypt only.  
The differences suggest that there might be cultural reasons, which is 
supporting Jensen and Karoly (2008) about what may be adaptive for some 
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people might not be adaptive for others. Meanwhile, the contradictory results 
to the literature were the psychological factors with no role in dependence or 
the opposite role to the predictions, as discussed in section 7.1.2. For 
example, SOPA-B Control predicted increased dependence in the UK, which 
is unexpected because this subscale is considered as adaptive attitudes and 
beliefs towards pain, which have previously been associated with less 
painkiller use, therefore expected to predict decreased dependence (e.g. 
Callister et al., 2003; James & French, 2008; Christiaens et al., 2010).  
However, the findings on the roles of PMAQ subscales, including Withdrawal, 
Need, and Side-Effects, were consistent with previous research using the 
PMAQ (McCracken et al., 2006). 
The contradictory results for the SOPA-B scores mean that further research is 
needed to clarify the role of such psychological factors. However, the reason 
for contradictory results may be due to differences with the literature; the 
thesis focused on problematic painkiller use in the general population 
whereas the literature focused on clinical samples (e.g. Cogan et al., 2014) or 
childbirth pain (e.g. Callister et al., 2003; Christiaens et al., 2010) and other 
outcomes than problematic painkiller use (e.g. El Rasheed, 2003; Petit et al., 
2015). Also, the longitudinal study was different from the literature about 
psychological factors in the general population because the focus was 
problematic painkiller use over time, rather than cross-sectional research (e.g. 
Elander et al., 2014). Therefore, further understanding has been added to the 
literature by clarifying over time the role of psychological factors, specifically 
showing that PMAQ Withdrawal predicted dependence over time. 
As mentioned in the beginning of this section, there are also important 
implications concerning results in respect to the general population. This 
means that the findings can be translated into public health and health 
promotion interventions, designed to be delivered outside clinical settings. 
Specifically, based on the factors that were significant predictors of 
dependence shown in Table 49, interventions can be developed to reduce or 
prevent this problem among the general population. Additionally, the 
differences between countries regarding the significant predictors of 
 227 
dependence means that interventions should be tailored for different 
countries. For example, as shown in Table 49, Side Effects predicted more 
dependence in the UK only. This means that interventions should be 
developed to change attitudes and beliefs towards side effects of painkillers in 
the UK, but these interventions might not be useful for the other countries. 
These might take the form of public health education, in the form of leaflets, 
posters, or perhaps even including television health campaigns, to alert 
people to pay greater attention to symptoms like withdrawal, tolerance and 
side effects, and to treat these as warnings of potential painkiller dependence. 
Another intervention to help the general population is educating healthcare 
professionals to spot the warning signs for risk of dependence. Again, the 
differences between countries for significant predictors of dependence means 
that interventions should be tailored for different countries. For example, 
regarding attitudes and beliefs towards pain, Control predicted more 
dependence in the UK only whereas Solicitude predicted more dependence in 
Egypt only. Due to this, healthcare professionals in the UK should be 
educated that attitudes and beliefs towards control of pain may be a warning 
sign for more dependence, but this would not be useful for Egypt. Instead, 
healthcare professionals in Egypt should be educated that attitudes and 
beliefs towards solicitude from others may be a warning sign for more 
dependence. The implications of these findings are that different screening 
tools should be used in different countries, including those used by health 
professionals, clinical staff, and also prescribers and dispensers of painkillers 
at pharmacies, as the study of international differences showed differences in 
risk factors for painkiller dependence in different countries.  
Longitudinal research would be useful to investigate these factors over time to 
be more confident if these are warning signs. In the longitudinal study of the 
UK, Withdrawal predicted more dependence, so we can be more confident 
that this is a risk factor for more dependence. Healthcare professionals in the 
UK should be educated therefore that attitudes and beliefs towards withdrawal 
might be useful warning signs for dependence.  
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The PMAQ-14 that was developed in this thesis is a brief measure that can be 
used by healthcare professionals to identify attitudes and beliefs towards 
withdrawal easily. Specifically, the Withdrawal subscale can be used for this 
purpose, and consists of two items; these items are “I am afraid that stopping 
my pain medication/s will cause me to feel ill” and “I worry that withdrawal 
from my pain medication/s will cause me some harm”. These items can also 
be used as a brief self-help tool to help members of the public identify risk of 
dependence, and make better judgments about whether they should seek 
help or take steps to change their painkiller use. Further, the results have 
implications for preventing or reducing dependence over time in the UK by 
developing interventions based on changing attitudes and beliefs towards 
withdrawal. The PMAQ-14 can also be useful for researchers to measure 
attitudes and beliefs towards painkillers easily than the full version.  
7.3. Future research 
There are a number of future research studies that could be conducted to 
provide more understanding regarding the role of accessibility and 
psychological factors in dependence. Since there were differences between 
countries with respect to what predicted dependence, future research should 
investigate more countries internationally. This is especially important when 
considering countries with high prevalence of pain or prescriptions of 
painkillers because there might be a higher risk of using painkillers in 
problematic ways. For example, surveys in developing countries such as 
Lebanon and Pakistan have shown high rates of painkiller use (e.g. Mumtaz 
et al., 2011; Ghandour et al., 2012), and further surveys showed rates of 
painkiller use vary considerably in European countries such as France, 
Norway, Sweden and Finland (e.g. Casati et al., 2012). It would therefore be 
useful to extend the international comparison reported in this thesis, to obtain 
a more comprehensive picture of international variations in problematic 
painkiller use and the different risk factors. By investigating a greater number 
of countries, understanding can be provided to help develop ways to reduce 
and prevent painkiller use problems that can be tailored for different countries.  
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As mentioned in the implications (see section 7.2), more longitudinal research 
is needed to increase confidence about warning signs for dependence. If 
longitudinal research is conducted internationally, this understanding might 
help to develop more effective ways to reduce and prevent painkiller use 
problems. It would also be interesting to conduct research to find out more 
about populations of painkiller users such as the dropout group in the 
longitudinal study. This group appeared to have more severe problems and 
greater dependence than those who were followed-up, so future research 
could use other methods in order to include those more vulnerable and at-risk 
painkiller users in research. This might involve interview studies, or cross-
sectional methods that do not depend on participants being able to continue 
participation in a study over a period of time.  
More research should focus on Egypt to understand the reasons for such high 
levels of painkiller use problems found in this population such as misuse, 
abuse and dependence despite less pain and less painkiller use frequency. 
Here qualitative methods would be useful, such as interviews with people in 
Egypt, to explore and understand their experience of pain and reasons for 
problematic painkiller use. At the time of the data collection for the studies in 
this thesis, the social situation in Egypt was problematic. Specifically, the 
Egypt data were collected in 2012-13, shortly after the Egyptian “Arab 
Spring’”, so the country was unstable and in an unusual social situation. This 
may have affected participants’ emotional state, and it would be valuable to 
conduct a similar study in the future, during a more peaceful and stable time 
for the country, to assess risk factors for painkiller dependence in the absence 
of social upheaval. 
Additionally, to develop ways to reduce and prevent problematic painkiller 
use, future research should test how effective are these ways. In the 
implications (see section 7.2), it was suggested that interventions can be 
developed to change attitudes and beliefs towards withdrawal in the UK, since 
this predicted increased dependence over time. To progress this, an 
educational intervention might be useful to educate people about painkillers 
 230 
and withdrawal so people can understand more correctly and be less 
concerned about withdrawal.  
To expand, online interventions have been effective in several previous 
studies concerned with substance use, anxiety, depression and lifestyle 
behaviours (e.g. Newton et al., 2016; Pedersen, Neighbors, Atkins, Lee & 
Larimer, 2017). Such interventions have advantages compared to offline 
interventions (e.g. Andersson & Titov, 2014). This is because online 
interventions are useful for reaching greater numbers of people in the general 
population more easily, quickly and with less cost than offline interventions 
(e.g. Andersson & Titov, 2014). An educational video or website containing 
information can be used, or both of these methods. If the interventions are 
effective in reducing or preventing problematic painkiller use, there would be 
much benefit of this research for the general population given statistics about 
high and increasing rates of pain and painkiller prescriptions (e.g. British Pain 
Society, 2008; NSDUH, 2013).  
7.4. Conclusion 
Using online surveys, this thesis has demonstrated that accessibility of 
painkillers and psychological factors are important factors to consider to 
explain problematic painkiller use in the general population. In particular, 
scores from standardised brief scales such as the PMAQ were consistently 
predictive of painkiller dependence, and the relevant questionnaire items 
could be translated into screening tools and resources for health promotion. 
However, more research needs to be conducted concerning how these 
factors influence problematic painkiller use, and how patterns of use change 
over time. In the UK, demographic factors also influenced dependence, 
including age, socio-economic status, employment status and education level. 
More research is therefore needed to understand how those factors are 
translated into greater dependence, that is, what behavioural or psychological 
factors mediate the influence of demographic factors. This must involve 
psychological and behavioural factors other than those measured in the 
present studies.  
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In terms of psychological factors, the results showed that attitudes and beliefs 
towards pain, painkillers, self-medication and alternative methods of pain 
relief predicted problematic painkiller use. However, there were differences 
between the countries regarding the particular role of these factors. To 
summarise these differences, the following predicted more problematic 
painkiller use: SOPA-B Medical Cure and Control in the UK; SOPA-B 
Solicitude in Egypt; SOPA-B Medication in Germany and Australia; PMAQ 
Need in all the countries except Egypt; PMAQ Side Effects in the UK; PMAQ 
Withdrawal in USA and Germany; and PMAQ Tolerance in Australia. The 
following predicted less problematic painkiller use; SMS Run its Course in the 
USA; and HCAMQ HH in Australia. Therefore, interventions based on these 
factors should be tailored to the countries to decrease the attitudes and 
beliefs that were predictors of more problematic use and increase that were 
predictors of less problematic use.   
Finally, the results also showed that psychological factors predicted 
problematic painkiller use over time in the longitudinal study of the UK, but 
this was only for PMAQ Withdrawal. Because of this, decreasing negative 
attitudes and beliefs about withdrawal from painkillers might help reduce 
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Please take a few minutes to read the following information about this research before 
continuing to the questionnaire. 
You are invited to take part in this research study, which is investigating painkiller use in the 
UK. This research is being conducted by Postgraduate Researcher Omimah Said and is 
supervised by Professor James Elander (Director of Studies) and Dr Frances Maratos at the 
University of Derby. The purpose of this research is to examine the prevalence of painkiller 
use in the UK.  
Your participation will be very precious because it will help us find out how prevalent painkiller 
use is in the UK. Your participation will also help clarify how factors such as pain, beliefs 
about pain and beliefs about painkillers might influence painkiller use in the UK population. 
 
To participate in this research you must: 
• be at least 18 years old  
• have experienced any type of pain in the last month 
• have taken at least one over-the counter or prescription painkiller in the last month 
• be a UK national and resident in the UK 
If you have any questions about whether you meet these criteria, please email me 
(o.said@derby.ac.uk) or my supervisor (j.elander@derby.ac.uk) for clarification.  
 
Participating in this study is entirely voluntary and will involve answering a questionnaire 
which takes approximately 15-20 minutes to complete. The questionnaire will ask you some 
questions about your pain, how you manage your pain and your beliefs and attitudes about 
pain and painkillers. You will also be asked some general information about yourself such as 
your age and gender but you will not be asked to give any personal identity information like 
your name or address; all of the information you give will be anonymous. In addition, the 
information you give will be kept confidential and will not be shared or accessed by anyone 
except my supervisors and myself at the University of Derby.  
All information collected through the questionnaire will be stored securely for up to five years 
after the research has been completed. While the data is stored, it will be analysed 
statistically and the results of this analysis will be written up in a research thesis, presented in 
conferences and published in academic journals. After this time, the questionnaire data will 
be deleted. 
You may withdraw from this research without giving any reason at any time during or up to 
four weeks after completing the questionnaire. Withdrawal will result in your questionnaire 
data being deleted. To withdraw you will need to email me (o.said@derby.ac.uk) or my 
supervisor (j.elander@derby.ac.uk), giving your unique identification code (this is a code 
which you will be asked to create before beginning the questionnaire because it allows your 
data to be identified anonymously in case you want to withdraw). To make yourself a unique 
identification code, please use the first three letters of your mother’s maiden name followed 
by the day you were born. For example, if your mother’s maiden name is Taylor and you were 
born on the 17th June your unique identification number would be TAY17.  
As a thank you for your time completing the questionnaire, you will be given the chance to 
enter a prize draw for Amazon e-vouchers worth £70. If you want to enter the draw you will be 
asked to provide your email address so that the e-vouchers can be emailed to you if you win. 
Your email address will only be used to send you the e-vouchers if you win.  
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This study has been approved by the Psychology Research Ethics Committee at the 
University of Derby (reference number 071-13-OS). If you have any questions about this 
please contact the chair of the ethics committee (f.maratos@derby.ac.uk). 
Please feel free to send me or my supervisor any questions about this invitation by emailing: 
 
Postgraduate Researcher 
Mrs O Said 
Centre for Psychological Research 
Faculty of Education, Health and Sciences 
University of Derby  
o.said@derby.ac.uk 
Supervisor  
Professor J Elander 
Head of Centre for Psychological Research  
Centre for Psychological Research 
Faculty of Education, Health and Sciences 
University of Derby 
j.elander@derby.ac.uk 
Yours faithfully,  
Mrs O Said 
Consent 
If you have read the invitation to participate and would like to take part in the research, please 
read the declaration below and enter your unique identification code. By entering this code 
you are providing your consent to continue.  
Declaration 
I understand that participating in this study is entirely voluntary. I understand that my 
questionnaire responses will be completely anonymous because no personal identifying 
information will be required from me. I understand that my responses will be kept confidential 
and will not be shared or accessed by anyone except the researcher and supervisors of the 
research at the University of Derby. I understand that I have the right to withdraw from the 
study without giving any reason and I may withdraw by providing the researcher or supervisor 
with my unique identification number up to four weeks after completing the questionnaire. I 
am aware that my data will be deleted if I withdraw from the study. I confirm that I have been 
given the opportunity to ask the researcher or supervisor questions about this research (via e-
mail). I confirm that I would like to take part in this research.  
Please enter your unique identification code (first three letters of your mother’s maiden name 
followed by the day you were born):  
For example, if your mother’s maiden name is Taylor and you were born on the 17th June 
your unique identification number would be TAY17. 
 
Prize draw entry 
To thank you for your time and effort completing the questionnaire, I would like to give you the 
opportunity to enter a prize draw and win a £70 Amazon e-voucher. If you would like to enter 
the prize draw you will need to provide your email address in the space below. The winner of 
the prize draw will be emailed their e-voucher shortly after 31/07/13.  
Please note that entry into the prize draw is conditional upon completing the questionnaire.  




If yes, please provide the email address you would like the e-voucher sent to below. Your 
email address will only be used to send you the e-vouchers if you win.  
 
About yourself (page 1 of 10)  
Please complete the following questions about yourself by placing a tick in the appropriate 
boxes or writing your response in the space provided. Please answer all of the questions. 
 
1. What is your gender?  
Male 
Female 
2. What is your age?  
 
 
3. What is your current marital status?  
Married / Co-habiting  
Single 
Widowed 
Divorced / Separated 
4. What is your nationality?  
 
 
5. What language do you speak at home?  
 
 
6. How long have you been living in the United Kingdom?  
Since birth 
Other 
If other, please specify the year when you arrived in the UK  
 
 
7. What is your highest education level?  
No qualifications 
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If other, please specify.  
 
 









If other, please specify.  
 
 















I don't have any religion 
Other 
If other, please specify.  
 
 
11. How religious would you describe yourself?  
 1 2 3 4 5  
Not at all religious  
     
Extremely religious 
12. What is your ethnic origin?  
White 
Mixed 
Asian or Asian British 
Black or Black British 
Any other ethnic group 
If you selected any other ethnic group, please specify below.  
 
 
13. How would you describe your financial status?  
A little or a lot poorer than most 
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About the same as most 
A little or a lot richer than most 
 
About your pain (page 2 of 10) 
 
Please complete the following questions about your pain by placing a tick in the appropriate 
boxes or writing your response in the space provided. Please answer all of the questions.  
 
1. How long have you been experiencing pain?  





Longer than 12 months 
If longer than 12 months, please specify how long you have been experiencing pain.  
 
 
2. In the last month, how many days have you experienced pain?  
 
 
3. Please rate your pain by choosing the number that best describes your pain at its 
WORST in the last month.  
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as 
you can imagine 
 
4. Please rate your pain by choosing the number that best describes your pain at its 
LEAST in the last month.  
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as 
you can imagine 
 
5. Please rate your pain by choosing the number that best describes your pain on the 
AVERAGE.  
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as 
you can imagine 
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6. Please rate your pain by choosing the number that tells how much pain you have 
RIGHT NOW.  
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as 
you can imagine 
 
7. What pain have you experienced in the last month?  














If other, please specify what pain you have experienced.  
Please write as many as applicable. 
 
 




If yes, what condition have you been diagnosed with?  
 
 
About your painkillers (page 3 of 10) 
 
Please complete the following questions about your painkillers by placing a tick in the 
appropriate boxes or writing your response in the space provided. Please answer all of the 
questions.  
 
1. In the last month, what kind of medication have you taken for your pain?  
Prescription medication only (please answer question 2 and continue from question 5) 
Over-the-counter medication only (please continue from question 3) 
Both prescription and over-the-counter medication (please continue from question 2) 
2. What prescription medication/s have you taken for your pain?  
Please specify the name/s of your prescription medication/s below. 
 
 
3. What over-the-counter medication/s have you taken for your pain?  
Please specify the name/s of your over-the-counter medication/s below. 
 
 
4. Where did you obtain your over-the-counter medication/s from?  
Pharmacy 
Supermarket shelf 
Family member who IS a medical professional 
Family member who is NOT a medical professional 
Friend who IS a medical professional 
Friend who is NOT a medical professional 
Internet 
Other  




5. How difficult would you say it is for you to get some strong painkillers without a 
prescription if you wanted some?  
'Strong painkillers' refers to any painkillers which are used for moderate to severe pain e.g. 
Tramadol.  
 1 2 3 4 5  
Probably impossible 
     
Very easy 
6. Have you ever used any strong painkillers without a prescription?  
Yes 
No 
If yes, please specify where you obtained the strong painkillers?  
Pharmacy 
Family member who IS a medical professional  
Family member who is NOT a medical professional 
Friend who IS a medical professional  
Friend who is NOT a medical professional 
Other 
If other, please specify.  
 
 
7. In the last month, how many days have you used painkillers?  
 
 
8. What dosage of painkillers did you take each day?  
1-2 tablets once 
1-2 tablets every 4 hours 
More than 1-2 tablets every 4 hours 
Other 
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If other, please specify.  
 
 
9. In the last month, how often have you taken more than the recommended dose of 





10. In the last month, how often have you taken painkillers for longer than the 










12. Did you try anything else to relieve your symptoms?  
You may tick or write as many responses as applicable. 
Nothing 
Hot water bottle 
















Ointments / creams / gels 
Laser therapy 
Other  









About your painkiller use (page 4 of 10) 
Please read each statement and chose the response which is the most applicable to you. 
Please answer all questions. 
 Never Sometimes Often Nearly always 
1. Do you find 
yourself thinking 
about when you 
will next be able 
to take 
painkillers? 
    




you might do 
during the day? 
    
3. Do you feel 
your need for 
painkillers is too 
strong to 
control?  
    




    
5. Do you take 
painkillers in a 
particular way in 
order to increase 
the effect it gives 
you? 
    





    
7. Do you feel 





    
8. Is getting the 






    
9. Do you want 
to take more 
painkillers when 
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Your thoughts about your pain (page 5 of 10) 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions.  
the effect starts 
to wear off? 
10. Do you find it 
difficult to cope 
with life without 
painkillers?  
    










1. There are 
many times 
when I can 
influence the 
amount of pain I 
feel 
     
2. I will probably 
always have to 
take pain 
medications  
     
3. When I hurt, I 
want my family 
to treat me better 
     
4. I do not expect 
a medical cure 
for my pain 
     
5. I have had the 
most relief from 
the pain with the 
use of 
medications 
     
6. Anxiety 
increases the 
pain I feel 
     
7. When I am 
hurting, people 
should treat me 
with care and 
concern 
     
8. I have given 
up my search for 
the complete 
elimination of my 
pain through the 
work of the 
medical 
profession 




Your thoughts about your pain (page 6 of 10) 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions.  
 
16. If I exercise, I 
could make my 
pain problem 
much worse 
     
17. I believe that 
I can control how 
much pain I feel 
by changing my 
thoughts 
     
18. Often I need 
more tender 
loving care than I 
am now getting 
when I am in 
pain 
     
19. Something is 
     
9. It is the 
responsibility of 
my loved ones to 
help me when I 
feel pain 
     
10. Stress in my 
life increases my 
pain 
     
11. Exercise and 
movement are 
good for my pain 
problem 
     
12. Just by 
concentrating or 
relaxing, I can 
'take the edge' 
off my pain 
     
13. Medicine is 
one of the best 
treatments for 
chronic pain 
     
14. My family 
needs to learn 
how to take 
better care of me 
when I am in 
pain 
     
15. Depression 
increases the 
pain I feel 
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20. I have 
learned to 
control my pain 
     
21. I trust that 
the medical 
profession can 
cure my pain 
     
22. I know for 
sure I can learn 
to manage my 
pain 
     
23. My pain does 




     
24. My physical 
pain will never 
be cured 
     




emotions and my 
pain level 
     
26. I can do 
nearly everything 
as well as I could 
before I had a 
pain problem 
     
27. If I do not 
exercise 
regularly, my 
pain problem will 
continue to get 
worse  
     
28. Exercise can 
decrease the 
amount of pain I 
experience 
     
29. I'm 
convinced that 
there is no 
medical 
procedure that 
will help my pain 
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30. My pain 
would stop 
anyone from 
leading an active 
life  
     
How you feel about your painkiller use (page 7 of 10) 
 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions.  
















      
2. I rely on 
my pain 
medication/s  
      
3. I worry 
about how 
other people 
view my use 
of pain 
medication/s  
      




from my pain 
medication/s  
      
5. I worry 
that over 




      
6. I worry 









      
7. I worry 
that I will 
have some 
withdrawal 
symptoms if I 
stop my 
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medication 




for a long 
time will lead 
to addiction 
      
9. I fear that I 
may run out 
of pain 
medication/s 
      
10. I try to 
hide the fact 
that I use 
pain 
medication/s 
      
11. I worry 
that my pain 
medication/s 
have an 
effect on my 
ability to 
think 
      
12. I worry 










      





will cause me 
to feel ill 
      




      
16. I would 
be unwilling 
to reduce my 
pain 
medication/s 




      
 282 
How you feel about your painkiller use (page 8 of 10) 
 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions.  
 
25. I find it 
hard to put 
up with the 
side effects 
from my pain 
medication/s 
      
use of pain 
medication/s 
18. I am 
afraid that I 




      
19. I feel that 
I will 
eventually 
run out of 
pain 
medication/s 
that will help 
with the pain 
      
20. I trust my 
doctor to give 
me the 
correct dose 
      
21. I worry 
that 
withdrawal 
from my pain 
medication/s 
will cause me 
some harm  
      
22. I am 





      




      




see me as an 
'addict'  
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26. It worries 
me that I 
have to 
increase the 
dose to get 
the same 
pain relief 








      








      
29. I worry 




      
30. I feel that 










for my pain 
embarrasses 
me 




want to stop 
taking pain 
medication/s 
      
33. I need to 
limit my use 
of pain 
medication/s 
in case my 
pain gets 
worse in the 
future 
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34. I am 






      





      
36. I want to 
take my pain 
medication/s 
more often 
than they are 
prescribed 
      
37. I worry 
what others 
think about 
my use of 
pain 
medication/s  
      







      
39. 
Eventually I 
will run out of 
pain 
medication/s 
that I can use 
to relieve my 
pain 
      





of my pain 
medication/s 
      




      
42. I depend 
on my pain 
medication/s 





my use of 
pain 
medication/s 
      






      













      
47. People 
accept that I 
need to take 
pain 
medication/s  
      
About your painkiller use (page 9 of 10) 
 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions.  
 Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
1. I take tablets 
only when I'm in 
a lot of pain 
     
2. I only take 
something if it's 
really bad 
     




     
4. I always take 
something if I'm 
in pain 
     
5. If I'm in pain I 
need medication 
to fix it  
     
6. I don't hesitate 









7. I prefer to let 
my body fight it 
out 
     
8. I do nothing 
just let it pass      
9. I try to ignore 
it and get on with 
it 
 
   
  
How you feel about holistic, complementary and alternative medicine (page 10 of 10) 
 
Please read each statement and choose the response which is the most applicable to you. 













help you fight 
off a minor 
illness  





subject to more 
scientific testing 




      
3. When people 
are stressed it 
is important 
that they are 
careful about 
other aspects 
of their lifestyle 
as their body 
already has 
enough to cope 
with 
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5. The 
symptoms of an 
illness can be 
made worse by 
depression 




should only be 




nothing to offer  
      




events they are 
more likely to 
become ill 
      





before going to 
the doctor 
      
9. Conflict with 
others has no 
effect on your 
health 




should only be 
used in minor 
ailments and 




      
11. It is 
important to 
find a balance 
between work 
and relaxation 
in order to stay 
healthy 




up the body's 
own defenses, 
so leading to a 
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If there is any additional information you would like to share about your pain or 
painkiller use which you feel is important or you feel you have not been asked about, 
please comment below.  
 
 
Thank you for your participation and for your time answering the questionnaire. Please 
read the following information and then click "submit".  
Your participation will allow us to improve understanding of painkiller use in the UK. Previous 
research has shown that factors such as people’s beliefs and attitudes about pain influence 
their painkiller use. Generally, positive beliefs and attitudes about pain are associated with 
less painkiller use but negative beliefs and attitudes about pain are associated with more 
painkiller use (Christiaens et al., 2010). Also, beliefs and attitudes about painkillers can 
influence use (Abe et al., 2008). As an example, people who believe that painkillers have 
negative side effects for their health avoid using painkillers and prefer to use alternative 
methods for pain relief (Abe et al., 2008). Although these researches have investigated the 
role of beliefs and attitudes in painkiller use, more research is needed which investigates 
further how these factors influences painkiller use. Please remember that you may withdraw 
from the study up to four weeks after completing the questionnaire. To do this you will need to 
email me or my supervisor, giving your unique identification code (the first three letters of your 
mother’s maiden name followed by the day you were born). If you know anyone who might 
like to take part in this research, feel free to forward this link: 
https://docs.google.com/forms/d/1jNHkxihlTEZnPL01oCTFK8tWmQylgKpWbnif-
oaqlTo/viewform Your help will be greatly appreciated. To find out about the results of this 
research or to ask any questions, please send an email to either of the contacts below. 
Also, there will be further research on painkiller use following up this study. If you wish to be 
contacted about taking part in this research with us, please enter your email address below.  
 
Thank you again for your participation. Postgraduate Researcher Mrs O Said Centre for 
Psychological Research Faculty of Education, Health and Sciences University of Derby 
o.said@derby.ac.uk Supervisor Professor J Elander Head of Centre for Psychological 
Research Centre for Psychological Research Faculty of Education, Health and Sciences 
University of Derby j.elander@derby.ac.uk  
 
Useful addresses 
If you are interested in reading more about pain or painkiller use, please see the links below 
for more information. Always remember to talk to your doctor if you are worried about your 
pain or painkiller use.  
• British Pain Society – http://www.britishpainsociety.org/   
• NHS Living with Pain – http://www.nhs.uk/Livewell/Pain/Pages/Painhome.aspx   
• NHS Which Painkiller? – http://www.nhs.uk/Livewell/Pain/Pages/Whichpainkiller.aspx   
• Pain – http://www.patient.co.uk/directory/pain     
• Painkillers – http://www.patient.co.uk/health/painkillers   
• Painkillers video – http://www.youtube.com/watch?v=mqOwSnwtQkU  
Please print or save this page for your records. 
Appendix B: Egypt questionnaire 
 
 دعوة للمشاركة






  السكان في المملكة المتحدة و مصردور العوامل الثقافية في إنتشار إستعمال مسكنات األلم و االعتماد عليها. مقارنه بين عامه 
أنتم مدعوون للمشاركة في هذا البحث الدراسي وهو عباره عن التحقيق عبر الثقافه في إستخدام مسكنات األلم و االعتماد عليها . و 
 في الدراسات العليا و المشرف جميس األندر ينفذ هذا البحث بواسطة أميمة سعيد الباحثة 
 لدكتوراه فرنسيس مارتوس من جامعة دربي .) مدير الدراسات ( و ا
الغرض من هذا البحث هو المقارنة و كيف توثر الثقافة على إنتشار إستخدم مسكنات األالم و االعتماد عليها . سوف تكون مشاركتكم 
المتحدة و مصر إيضا  ذات قيمة النها سوف تساعدنا على معرفة كيفيه إنتشار إستعمال مسكنات األالم و االعتماد عليها في الملكة
مشاركتكم ستساعد في توضيح كيفيه تاثير العوامل الحضاريه أو الثقافية في إنتشار إستعمال مسكنات األالم و االعتماد عليها في 
 المملكه المتحدة و مصر.
اهم في تحسين فهم هذه االعتماد علي مسكنات األالم هو مسالة خطرة ذات عواقب وخيمة علي الصحة و لذلك فباالمكان مشاركتكم تس
 . القضية و الحد منها
 لكي تكون مناسب لالشتراك في هذا البحث يجب عليك األتي:
 سنة 18أن تكون علي األقل 
 شعرت بألم خالل الشهر الماضي
مثال) أبر علي األقل أخذت حبة مسكن دون وصفة طبية أو بوصفة طبية في الشهر الماضي أو استخدمت طريقه بديلة لتخفيف األلم 
 صينيه، أو مساج (
 مقيم في مصر
االعتماد علي مسكنات األالم هو مسالة خطرة ذات عواقب وخيمة علي الصحة و لذلك فباالمكان مشاركتكم تساهم في تحسين فهم هذه 
 . القضية و الحد منها
 لكي تكون مناسب لالشتراك في هذا البحث يجب عليك األتي:
 سنة 18أن تكون علي األقل 
 رت بألم خالل الشهر الماضيشع
علي األقل أخذت حبة مسكن دون وصفة طبية أو بوصفة طبية في الشهر الماضي أو استخدمت طريقه بديلة لتخفيف األلم مثال) أبر 
 صينيه، أو مساج (
  مقيم في مصر
 أو إلي  )o.said@derby.ac.uk (إذا كان لديك أي اسلة حول إذا كنت مناسب لهذه المعايير الرجاء بعث رساله الكترونيه إلى
)j.elander@derby.ac.uk(المشرف علي البحث الي توضيح.  
دقيقه الكماله. هناك أسئلة  المشاركة في هذه البحث هو عمعل تطوعي تماما وسيشمل االجابة علي اإلستبيان الذي سيستغرق حوالي 
وايضا سوف يطلب منك بعض المعلومات . تجاه األلم والمسكنات ،وعن معتقداتك، و أخالقك معه تتعامل وكيف تسألك عن ألمك
العامة عنك مثل عمرك، و نوع الجنس و لكن لن يطلب منك إعطاء اى معلومات شخصية مثل اسمك أو عنوان منزلك. كل 
طيها ستكون مجهولة. باإلضافة ، جميع معلوماتك المعطاه منك ستبقي سريه و لن يسمح بمشاركتها أو الوصول المعلومات التي ستع
إليها من قبل أي شخص بإستثنائ شخصياً أو المشرفين بجامعة دربي. كافه المعلومات التي تم جمعها سيتم تخزينها من خالل 
 عد االنتهاء من البحث. اإلستبيان بشكل أمن لمدة تصل إلي خمس سنوات وذلك ب
في حين تخزين البيانات يتم تحليلها إحصائياً و نتائج هذا التحليل سيتم كتابتها في أطروحة البحث المقدمة في المؤتمرات و المنشوره   
سبب في  بيانات اإلستبيان. من الممكن إن تنسحب من هذا البحث دون إعطاء أي في المجالت األكاديمية بعد ذلك سيتم حذف جميع 
 أي وقت أثناء أو بعد اإلجابه علي اإلستبيان حتى.
جميع البيانات الخاصه بك سوف تحذف نتيجه انسحابك. في حاله رغبتك في االنسحاب عليك أن تبعث إلي رساله الكترونيه علي 
بإعطاء الرمز الخاص بك ) )j.elander@derby.ac.uk (البحثأو إلي مشرف  )o.said@derby.ac.uk (العنوان التالي
هذا الرمز الذي سوف يطلب منك أن تخلقه قبل البدء في اإلستبيان ألنه يسمح لنا بالتعرف علي البيانات الخاصة بك بشكل مجهول في 
 الرجاء إستخدام األحرف الثالثه االولي من إسم والدتك يعقبها يوم ميالدك . حاله رغبتك في اإلنسحاب(. لعمل هذا الرمز
  .17مثال إذا كان إسم والدتك تايلور و تاريخ ميالدك يونيو سيكون رمزك كالتي تاي
 
لشكركم علي المشاركة سيتم منحك فرصة للدخول في السحب علي الجائزه وهي عباره عن  جنيه مصري إن كنت ترغب لدخول 
االلكتروني في حالة فوزك . ال تترد في ارسالي  البريد عبر نرسلك الجائزه أن لنا لسحب سوف نحتاج بريدك االلكتروني بحيث يمكنا
  أو إرسال مشرفي أي اسئله حول هذة الدعوة علي العنوان التالي. 
 
 السيدة اميمة سعيد 
 باحثة في الدراسات العليا
 يم و الصحة و العلومكليه التعل -مركز البحوث النفسية 




  بروفسور جيمس األندر
 رئيس مركز البحوث النفسيه




 تفضلوا بقبول فائق االحترام
 اميمه سعيد
 
  موافقة: 
، يرجي قراءة التالي أدناه وإدخال رمزك الشخصي الخاص. بأدخال هذا الرمز  إذا قرأت دعوة المشاركة و تود أن تشارك في البحث
 سيتوفر لنا موافقتك إلكمال البحث.
 
 تصريح.
 في هذا البحث هو أمر تطوعي أنا أدرك تماما إن المشاركة •
 أنا أدرك أن اإلجابة علي اإلستبيان الخاص بي سيكون مجهول تماما ألنه لن يكون هناك حاجة تتطلب مني تحديد شخصي •
و ادرك أنه سيتم االحتفاظ بجميع اجاباتي و التعامل معها في سريه تامه و لن يتم مقاسمتها أو الوصول إليها من قبل أي  •
 .الباحثة، أو المشرفين علي البحث من جامعه دربيشخص بإستثناء 
أنا أفهم أن لي الحق في االنسحاب من البحث دون إعطاء أي سبب.وذلك بإعطاء الباحث أو المشرفين الرمز الرقمي  •
  الشخصي قبل. وبذلك أودرك أن جميع معلوماتي ستلغي في حال االنسحاب
 المشرف عن هذه الدراسة أو البحثأؤكد أنه قد اعطيت لي الفرصه لسؤال الباحث أو  •
 أؤكد أنني أود إن اشارك في هذا البحث •
 الرجاء أدخال الرمز الشخصي ألفريد ) أول ثالثة أحرف من إسم والدتك يليها يوم تاريخ ميالدك(: 
 17مثال اذا كان إسم والدتك تيلر، و تاريخ ميالدك  يونيو سيكون رمزك التالي تي 
  دخول السحب علي الجائزه
 
جنيه كقسائم  70لشكرك علي وقتك و جهدك للمشاركة في هذا البحث. أود أن أعطيك الفرصه لدخول السحب علي الجائزة و الفوز ب
 شراء
 













لمساحة المتوفرة. الرجاء اإلجابة على األسئلة التالية حول نفسك عن طريق وضع عالمة في المربعات المناسبة أو كتابة ردكم في ا
 الرجاء اإلجابة على جميع األسئلة
 




....................................ما هو عمرك؟  .2 
 
 3. ما هو الوضع العائلي الحالي الخاص بك؟
 متزوج / عشير •
 واحدة •
 ارمل •
 مطلق / منفصل •
 4. ما هي جنسيتك؟
  
المنزل؟ما هي اللغة التي تتكلم بها في   .5 
  
 6. منذ متى وأنت تعيش في المملكة المتحدة؟
 منذ الوالدة •
 أخرى •
 أخرى )يرجى تحديد سنة دخول المملكة المتحدة(:
 
 ..........................................................................................................................................  
 
 7. ما هو أعلى مستوى تعليم خاص بك؟ 
 ال مؤهالت •
 متوسط •
 ثانوي •
 شهادة البكالوريوس •
 دبلوم الدراسات العليا •
…………………………………………. أخرى يرجى التحديد()  
 
 8. ما هو نظام العمل الحالي الخاص بك؟
 رعاية الطفل •
 عمل بدوام كامل •
 عمل بدوام جزئي •
 متقاعد •
 لحسابهم الخاص •
 عاطل عن العمل •
 دراسة •
 أخرى •
 إذا كان غير ذلك، يرجى التحدي………………………
  
 9. هل نظام العمل الحالي له أية عالقة مع األلم التي تواجهك؟
 نعم •
 ال •







 ليس لدي أي دين •
 أخرى •
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 إذا كان غير ذلك، يرجى التحديد
 
بالديانة؟كيف تصف مدى التزامك   .11 
1  2  3  4  5 
 متدين متدينة         لست متدين متدينة 
 
للغاية   
 
 12. ما هو أصلك العرقي ؟
 أبيض •
 مختلط •
 آسيوي أو بريطاني آسيوي •
 أسود أو أسود بريطاني •
 أي مجموعة عرقية أخرى •




...............................................................................................................................   
 
 13. كيف تصف وضعك المالي؟
 قليال أو أكثر فقرا بكثير من البعض •
 كباقي الناس •




المساحة المتوفرة.  الرجاء اإلجابة على األسئلة التالية حول ألمك عن طريق وضع عالمة في المربعات المناسبة أو كتابة ردكم في
 الرجاء اإلجابة على جميع األسئلة
 1. منذ متى وأنت تعاني من آالم تم؟
 أقل من شهر •
 3-1أشهر •
  6-4 أشهر •
  9-7 أشهر •
 12-10 شهرا •
 شهرا 12أكثر من  •






 2. في الشهر الماضي، كم يوما قد واجهت األلم؟
 يرجى تقييم معدل األلم الخاص بك عن طريق اختيار الرقم الذي يصف أفضل ألمك في أسوأ حاالته في الشهر الماضي 
0    1    2    3    4    5    6    7    8    9    10 
األلم سيئ كما يمكنك أن تتخيل          ال ألم  
 
 3. يرجى تقييم معدل األلم الخاص بك عن طريق اختيار الرقم الذي يصف أفضل ألمك على األقل في الشهر الماضي
0    1    2    3    4    5    6    7    8    9    10 
األلم سيئ كما يمكنك أن تتخيل         ال ألم  
معدل األلم الخاص بك عن طريق اختيار الرقم الذي يصف أفضل ألمك في المتوسطيرجى تقييم   .4 
0    1    2    3    4    5    6    7    8    9    10 
 األلم سيئ كما يمكنك أن تتخيل        ال ألم 
لديك في الوقت الحالييرجى تقييم معدل األلم الخاص بك عن طريق اختيار الرقم الذي يروي كيف الكثير من األلم   .5 
0    1    2    3    4    5    6    7    8    9    10 
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 األلم سيئ كما يمكنك أن تتخيل        ال ألم 
 
 6. أي نوع من األلم قد واجهت في الشهر الماضي؟
 )يرجى وضع عالمة أو أكثر إن وجد(
 الصداع •
 الصداع النصفي •
 ألم الفترة •
 وجع األسنان •
 ألم في البطن •
 ألم في الصدر •
 ألم في القدم •
 التهاب الحلق •
 آالم الظهر •
 آالم المفاصل •
 وجع األذن •
 ألم في العضالت •
 أخرى •




................................................................................................................................   
 
 7. هل تم التشخيص على أسباب األلم؟
 نعم •
 ال •






 حول المسكنات الخاصة بك
 
التالية حول المسكنات الخاصة بك عن طريق وضع عالمة في المربعات المناسبة أو كتابة ردكم في الرجاء اإلجابة على األسئلة 
 المساحة المتوفرة. الرجاء اإلجابة على جميع األسئلة
 1. في الشهر الماضي، أي نوع من األدوية التي أخذتها أللمك؟
 )5واستمر من السؤال  2وصفة الدواء فقط )يرجى إجابة السؤال  •
 )3ء أكثر من دون وصفة طبية فقط )الرجاء االستمرار من السؤال الدوا •
 )2كل وصفة الدواء، وأكثر من وصفة طبية )الرجاء االستمرار من السؤال  •
 2. ما صفة الدواء / األدوية التي أخذتها أللمك من الوصفة الطبية؟
 يرجى تحديد اسم / أسماء األدوية في الوصفة طبية أدناه
 
 ...................................................................................................................................................  
 
 3. ما صفة الدواء / األدوية التي أخذتها أللمك من غير وصفة الطبية؟






 4. من أين حصلت على األدوية من غير وصفة طبية؟
 صيدلية •
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 سوبر ماركت •
 عضو في األسرة الذي لديه مهنية طبية •
 عضو في األسرة الذي ليس لديه مهنية طبية  •
 صديق لديه مهنية طبية •
 صديق ليس لديه مهنية طبية •
 تاإلنترن •
 أخرى •






 5. ما مدى صعوبتها عليك للحصول على مسكن ألم قوي بدون وصفة طبية إذا أردت ذلك؟
' امادولالمسكنات القوية "يشير إلى أي المسكنات التي تستخدم لمتوسطة الىقوية االم مثل تر  
1  2  3  4  5 
 من السهل جدا      من المستحيل ربما
 
 6. هل سبق لك استخدام أي المسكنات القوية دون وصفة طبية؟
 نعم •
 ال •
 إذا كانت اإلجابة بنعم، يرجى تحديد المكان الذي حصل على مسكنات قوية؟
 صيدلية •
 عضو في األسرة الذي لديه مهنية طبية •
 عضو في األسرة الذي ليس لديه مهنية طبية  •
 صديق لديه مهنية طبية •
 صديق والمنظمة ليست المهنية الطبية •
 أخرى •










 8. ما جرعة من المسكنات تأخذها في كل يوم؟
 مرة واحدة أقراص 1-2  •
 ساعات 4أقراص كل  1-2  •
 ساعات 4كل  أقراص 2-1 أكثر من  •
 أخرى •






ضي، كم مرة أخذت فيها أكثر من الجرعة الموصى بها من المسكنات الخاصة بك؟في الشهر الما  .9 
 أبدا •




 10. في الشهر الماضي، كم مرة أخذت المسكنات لمدة أطول من المدة الموصى بها؟
 أبدا •
 في بعض األحيان •
 عادة  •
 دائما •
عند عدم وجود ألم؟في الشهر الماضي، كم مرة أخذت فيها مسكنات األلم   .11 
 أبدا •
 في بعض األحيان •
 عادة •
 دائما •
 12. هل جربت أي شيء آخر لتخفيف األعراض الخاصة بك؟      
 (تستطيع وضع عالمة أو كتابة العديد من االستجابات حسب مقتضى الحال) 
 ال شيء •
 زجاجة مياه ساخنة •




 العالج الطبيعي •
 الوخز باإلبر •
 العالج الطبيعي •
 العالج بالتنويم المغناطيسي •
 التمرين •
 الشفاء الروحي •
 الطب الصيني التقليدي •
 العالج المائي •
 العالج المغناطيسي •
 الروائح •
 الريكي •
 المراهم / كريمات / المواد الهالمية •
 العالج بالليزر •
 أخرى •






 حول استخدام مسكن لأللم الخاص بك
 يرجى قراءة كل عبارة واختيار اإلجابة التي هي األكثر انطباقا عليك. الرجاء اإلجابة على جميع األسئلة
 
دائما  غالبا أحيانا أبدا
 تقريبا
 
 تكون المرة المقبلة قادرا على تناول المسكنات؟هل تجد نفسك تفكر حول متى سوف  .1
 هو أخذ المسكنات أكثر أهمية من أي شيء آخر كنت قد تفعل خالل النهار؟ .2
 هل تشعر الحاجة للحصول على مسكنات قوية جدا للسيطرة؟ .3
 هل تخطط أيامك حول أخذ مسكنات األلم؟ .4
 وفرها لك؟هل تناول المسكنات بطريقة معينة من أجل زيادة التأثير التي ت .5
 هل تأخذ المسكنات الصباح وبعد الظهر والمساء؟ .6
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 هل تشعر أنك يجب أن تستمرفي أخذ المسكنات عندنا بدأت بأخذها؟ .7
 هل الحصول على التأثير الذي تريده أكثر أهمية من نوع المسكن الذي تستخدمه؟ .8
 هل تريد أن تأخذ مسكنات األلم أكثر عندما يبدأ زوال تأثيرها؟ .9
 في التكيف مع الحياة بدون مسكنات األلم؟ هل تجد صعوبة .10
 
 أفكارك حول ألمك
 











ال تنطبق(  
   
صحيحا   




 هناك العديد من األوقات عندما يمكن أن أشعر بكمية األلم .1
 أنا على األرجح يجب أن اخذ أدوية األلم  .2
 عندما أتألم، أريد معاملة أفضل من عائلتي .3
 ال أتوقع عالج طبي أللمي .4
 لقد شعرت بارتياح من األلم مع استخدام األدوية .5
 القلق يزيد من األلم الذي أشعر به .6
 ب على الناس أن يعاملونني مع الرعاية واالهتماموأنا عندما أتألم، يج .7
 لقد تخليت بحثي عن القضاء التام على ألمي من خالل العمل في مهنة الطب .8
 يقع على عاتق األحباء مساعدتي عندما أشعر باأللم .9
 التوتر في حياتي يزيد ألمي .10
 ممارسة الرياضة والحركة هي جيدة لمشكلة ألمي .11
 االسترخاء، ويمكنني 'اتخاذ حافة' قبالة ألميفقط عن طريق التركيز أو  .12
 الطب هو واحد من أفضل العالجات لأللم المزمن .13
 تحتاج عائلتي لمعرفة كيفية اتخاذ رعاية أفضل لي عندما أشعر في األلم .14
  االكتئاب يزيد من األلم الذي أشعر به .15
 إذا كنت أمارس الرياضة، فأنا يمكني أن أجعل مشكلة ألمي أسوأ بكثير  .16
 أعتقد أنه يمكن التحكم في مقدار األلم الذي أشعر به من خالل تغيير أفكاري .17
 كثيرا ما كنت أحتاج إلى مزيد من الرعاية والعطاء والمحبة أكثر مما أحصل عليه عندما أكون في األلم .18
 هناك شيء خاطئ مع جسدي الذي يمنع الكثير من الحركة أو ممارسة الرياضة .19
 ميلقد تعلمت السيطرة على أل .20
 وأنا على ثقة أن مهنة الطب يمكن أن يشفي ألمي .21
 وأنا أعلم يقينا أنني يمكن أن أتعلم إلدارة ألمي .22
 ألمي ال يمنعني من عيش حياة نشطة بدنيا .23
 ألمي الجسدي لن يشفى .24
 هناك عالقة قوية بين مشاعري ومستوى ألمي .25
 أستطيع أن أفعل كل شيء تقريبا كما كان قبل مشكلة األلم .26
 مارس الرياضة بانتظام، مشكلة ألمي سوف تزداد سوءاإذا كنت ال أ .27
 ممارسة الرياضة يمكن أن تقلل من كمية األلم  .28
 أنا مقتنع أنه ال يوجد أي إجراء طبي من شأنها أن تساعد ألمي .29
 ألمي يمنع أي شخص من قيادة الحياة النشطة .30
 
 كيف تشعر حيال استخدام مسكن لأللم الخاص بك
 
























 أنا قلق بشأن أصبح مدمنا على دواء ألمي .1
 أنا أعتمد على دواء ألمي .2
 أنا قلق حول كيفية عرض اآلخرين استخدامي لعالج األلم  .3
 لدي مخاوف حول اآلثار الجانبية من دواء ألمي .4
 أنا قلق أنه بمرور الوقت سوف أحتاج المزيد من دواء األلم .5
 أنا قلق من اختالف المعلومات التي أعطيت لي حول األلم عن طريق أطباء مختلفين .6
 نسحاب إذا توقفت عن الدواءأخشى أن سوف يكون لي بعض أعراض اال .7
 أشعر بالقلق من أن تناول الدواء لفترة طويلة سوف يؤدي إلى اإلدمان .8
 أخشى من نفاد دواء األلم .9
 أنا أحاول أن أخفي حقيقة أني أستخدم دواء األلم .10
 أخشى أن دواء ألمي يكون له تأثير على قدرتي على التفكير .11
 أخشى أن دواء ألمي يتوقف عن العمل .12
 طبيبي متفهم تماماعن دواء ألمي  .13
 أخشى أن وقف دواء ألمي سوف يسبب لي أن أشعر بالمرض .14
 أخشى أنني أصبحت مدمنا .15
 أنا غير مستعد للحد من دواء ألمي  .16
 أشخاص آخرين يدعمون استخدامي لعالج األلم .17
 أخشى أنني ال أعرف ما يكفي عن اآلثار الجانبية .18
 سوف يساعدني على األلمأشعر بأن دواء األلم سوف ينفد الذي  .19
 أنا على ثقة أن طبيبي يعطيني الجرعة الصحيحة .20
 أنا قلق من أن االنسحاب من دواء ألمي سوف يسبب لي بعض الضرر .21
 أخشى أنني سوف يفقد السيطرة على دواء ألمي .22
 أنا يمكنني التعامل دون دواء ألمي  .23
 'أشعر بالقلق من أن الناس اآلخرين سوف يرونني مدمنا .24
 من الصعب أن أتكيف مع اآلثار الجانبية من دواء ألمي أجد أنه  .25
 يقلقني أن أكون قد أحتاج لزيادة الجرعة للحصول على تخفيف األلم نفسه .26
 طبيبي يقول لي كل شيء عن دواء ألمي .27
 أنا أفضل أن أبقى مع دواء ألمي بدال من تجربة االنسحاب .28
 أنا قلق بأنني قد أكون مدمنا على دواء ألمي  .29
 ي بحاجة الى مزيد من دواء األلمأشعر بأنن .30
 الحاجة إلى تناول دواء ألمي تحرجني  .31
 اآلثار الجانبية جعلتني أريد أن أتوقف عن أخذ دواء األلم .32
 في حالة زاد ألمي سوءا في المستقبلأحتاج إلؤ الحد من استخدام دواء األلم  .33
 أخشى أنني وصف لي الدواء الخطأ .34
 جداأخشى من تقليل دوائي بسرعة كبيرة  .35
 أود أن أخذ الدواء أكثر من األحيان التي وصفت لي .36
 أنا قلق ما يرى آخرون حول استخدامي لعالج األلم .37
 أنا قلق حول األضرار التي لحقت األجهزة الداخلية من دواء ألمي .38
 أخشى من نفاد دواء األلم الذي يمكن استخدامه لتخفيف ألمي .39
 أشعر واثقا من إدارة طبيبي لدواء ألمي .40
 اض االنسحاب ال يطاقأجد أعر .41
 اعتمادي األول هو على الدواء .42
 الناس اآلخرين يفهمون استخدامي لعالج األلم .43
 أجد أنه من الصعب على تحمل اآلثار الجانبية للدواء .44
 أشعر بالرضى حول المعلومات التي أعطيت لي عن الدواء .45
 دون دواء ألمي سيصبح ال يطاق .46
 يقبل الناس أنني بحاجة ألخذ دواء األلم .47
 حول استخدام مسكن لأللم الخاص بك
 
 298 




 أوافق بشدة أوافق غير متأكد ال أوافق
 
 أخذ حبة فقط عندما أشعر في الكثير من األلم .1
 الحالة سيئة جداأنا فقط أخذ شيئا إذا كانت  .2
 أنا فقط أتناول المسكنات عندما يكون ذلك ضروريا جدا .3
 أنا دائما أخذ شيئا إذا شعرت في األلم .4
 إذا شعرت في األلم فأنا بحاجة إلى الدواء .5
 أنا ال أتردد في تناول المسكنات .6
 أنا أفضل أن تدع جسدي يحارب األلم .7
 أنا ال أفعل شيأ مجرد السماح لها بالمرور .8
 أن أتجاهله والتعايش معه أنا أحاول .9
 
 كيف تشعر حيال كلية الطب، البديل والتكاملي
 












 محاربة المرض البسيطالتفكير اإليجابي يمكن أن يساعدك على  .1
 الطب التكميلي ينبغي أن يخضع لمزيد من االختبارات العلمية قبل أن يكون مقبوال من قبل األطباء التقليدية .2
عندمايشعر الناس بالضغط فإنه من المهم أن يكونوا حذرين حول الجوانب األخرى من نمط حياتهم وأجسامهم ويكون لديهم  .3
 بالفعل ما يكفي للتعامل معه
 طب التكميلي يمكن أن يكون خطرا ألنه قد يمنع الناس الحصول على العالج المناسبال .4
 أعراض المرض يمكن أن تزداد سوءا بسبب االكتئاب .5
 الطب التكميلي يجب أن يستخدم كمالذ أخير عندما يعجز الطب التقليدي  .6
 رضإذا كان الشخص يواجه سلسلة من األحداث المجهدة في الحياة هم أكثر عرضة للم .7
 إنه من المفيد محاولة الطب التكميلي قبل الذهاب إلى الطبيب .8
 الصراع مع اآلخرين ليس له تأثير على صحتك .9
 الطب التكميلي يجب أن يستخدم في األمراض البسيطة، وليس في عالج مرض أكثر خطورة .10
 من المهم إيجاد توازن بين العمل واالسترخاء من أجل البقاء في صحة جيدة .11
 ي يبني دفاعات الجسم الخاصة، مما يأدى إلى عالج دائمالطب التكميل .12
 
إذا كان هناك أي معلومات إضافية كنت تود أن تدلي بها حول األلم الخاص بك أو حول استخدام مسكن لأللم الذي تشعر أنه مهم أو 






 .على مشاركتك وعلى وقتك في اإلجابة على االستبيان أشكرك
 
وسلوكهم  األبحاث السابقه اظهرت أن معتقدات الناس .تحسين فهم إستخدام مسكن األلم في مصر لنا تتيح سوف مشاركتكم
لكن  ,في إستخدام أقل لمسكن األلم األلم عموما، ترتبط المعتقدات والسلوك اإليجابية نحو . له تأثير في إستخدام مسكن األلم األلم تجاه
أيضا المعتقدات  . )(Christiaens et al., 2010 نحو إستخدم أكثر لمسكن األلم تجاه األلم ترتبط السلبية والسلوك المعتقدات
وكمثال على ذلك، الناس الذين يعتقدون أن مسكنات   .(Abe et al., 2008) تؤثرعلي االستخدام أن المسكنات ممكنوالسلوك تجاه 
  .األلم لها آثار جانبية سلبية على صحتهم ويتجنبوا استخدام مسكنات األلم يفضلون استخدام الطرق البديلة لتخفيف األلم
(Abe et al., 2008)  حققت في دور المعتقدات والسلوك في استخدام مسكن األلم، هناك حاجة للمزيد من ورغم أن هذه األبحاث قد
 .على استخدام مسكن األلم هذه العوامل تأثير كيفيه البحث الذي يحقق أكثر في
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     ١٣/ ٦/ ٣٠الرجاء تذكر أنه بإمكانك االنسحاب من الدراسه حتي 
ثم أول ثالثه   (ي أو مشرفي، وإعطاء التعليمات البرمجية لهويتك الفريدةلعمل ذلك سوف تحتاج إلى البريد االلكتروني الخاص ب 
  )أحرف من أسم والدتك يتبعها يوم والدتك
إذا كنت  .١٣/  ٦/  ٣٠الفائز بجائزه السحب سوف ترسل له القسيمه الخاصه بأمازون عبر البريد االلكتروني بعد وقت قصير من 
 هذا البحث، ال تتردد في إرسال هذا الرابطتعرف أي شخص قد يرغب في المشاركة في 
 مساعدتكم ستكون موضع تقدير كبير
لمعرفة نتائج هذا البحث أو إذا كان لديكم اسئله ، يرجى إرسال رسالة إلكترونية إلى أي من جهات االتصال أدناه. أيضا، سيكون  
نت ترغب في أن يتم االتصال بك الجل المشاركة في هذا هناك مزيد من االبحاث على استخدام مسكن األلم تتبع هذه الدراسة. إذا ك
 .البحث لدينا، من فضلك ادخل بريدك اإللكتروني
 
 أشكركم مرة أخرى على مشاركتكم. 
 تفضلوا بقبول فائق االحترام،
 
 اميمة سعيد
 باحثة في الدراسات العليا
 كليه التعليم و الصحة و العلوم -مركز البحوث النفسية 
  جامعة دربي
 o.said@derby.ac.uk 
 
  بروفسور جيمس األندر
 رئيس مركز البحوث النفسيه




 من مزيد على للحصول أدناه الروابط على االطالع يرجى األلم، مسكن استخدام أو األلم عن المزيد قراءة في ترغب كنت لو
 .األلم مسكن استخدام أو األلم بشأن قلقا كنت إذا طبيبك مع نتحدث أن دائما تذكر. المعلومات
 
 الجمعية المصرية إلدارة األلم
http://www.egyptianpainsociety.com 
 
 الجمعية الدولية لدراسة األلم في المؤتمر، مص
http://www.iasp-pain.org//AM/Template.cfm؟Section=Home 
 
    إدارة األلم
http://www.mhcs.health.nsw.gov.au/publication_pdfs/9025/NGO-9025-ARA.pdf 
 






 .لسجالتكيرجى طباعة أو حفظ هذه الصفحات 
 
 






Please take a few minutes to read the following information about this research before 
continuing to the questionnaire. 
 
You are invited to take part in this research study, which is investigating painkiller use in the 
USA, Canada and Australia. The purpose of this research is to examine the prevalence of 
painkiller use in these countries and clarify how factors such as pain, beliefs about pain and 
beliefs about painkillers might influence painkiller use. Additionally, this research has recently 
been conducted in the UK and is now being extended to these countries in order to increase 
understanding of painkiller use. 
   
To participate in this research you must: 
• be at least 18 years old  
• have experienced any type of pain in the last month 
• have taken at least one over-the counter or prescription painkiller in the last month 
• be a resident in the USA or Canada or Australia. 
 
If you have any questions about whether you meet these criteria, please email me 
(o.said@derby.ac.uk) or my supervisor (j.elander@derby.ac.uk) for clarification.  
   
Participating in this study is entirely voluntary and will involve answering a questionnaire 
which takes approximately 15-20 minutes to complete. The questionnaire will ask you some 
questions about your pain, how you manage your pain and your beliefs and attitudes about 
pain and painkillers. You will also be asked for some general information about yourself such 
as your age, gender, nationality etc. but you will not be asked to give any personal identity 
information like your name or address; all of the information you give will be anonymous. In 
addition, the information you give will be kept confidential and will not be shared or accessed 
by anyone except my supervisors and myself at the University of Derby.  
 
All information collected through the questionnaire will be stored securely for up to five years 
after the research has been completed. While the data is stored, it will be analysed 
statistically and the results of this analysis will be written up in a research thesis, presented in 
conferences and likely published in academic journals. After this time, the questionnaire data 
will be deleted. 
 
You may withdraw from this research without giving any reason at any time during the 
process of completing the questionnaire or up to four weeks after completing the 
questionnaire. Withdrawal will result in your questionnaire data being deleted. To withdraw 
you will need to email me (o.said@derby.ac.uk) or my supervisor (j.elander@derby.ac.uk), 
giving your unique identification code (this is a code which you will be asked to create before 
beginning the questionnaire because it allows your data to be identified anonymously in case 
you want to withdraw). To make yourself a unique identification code, please use the first 
three letters of your mother’s maiden name followed by the day you were born. For example, 
if your mother’s maiden name is Taylor and you were born on the 17th June your unique 
identification code would be TAY17.  
 
As a thank you for your time completing the questionnaire, you will be given the chance to 
enter a prize draw for Amazon e-vouchers worth $70. If you want to enter the draw you will be 
asked to provide your email address so that the e-vouchers can be emailed to you if you win. 
Your email address will only be used to send you the e-vouchers if you win.  
 
This study has been approved by the Psychology Research Ethics Committee at the 
University of Derby (reference number 071-13-OS). If you have any questions about this 
please contact the chair of the ethics committee (f.maratos@derby.ac.uk).  
Please feel free to send me or my supervisor any questions about this invitation by emailing: 
Postgraduate Researcher 
Mrs O Said 
Centre for Psychological Research 
Faculty of Education, Health and Sciences 
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University of Derby  
o.said@derby.ac.uk 
Supervisor  
Professor J Elander 
Head of Centre for Psychological Research  
Centre for Psychological Research 
Faculty of Education, Health and Sciences 
University of Derby 
j.elander@derby.ac.uk 
Yours faithfully,  
Mrs O Said 
Consent  
If you have read the information in the previous page and would like to take part in the 
research, please read the declaration below and enter your unique identification code. By 
entering this code you are providing your consent to continue. 
Declaration 
I understand that participating in this study is entirely voluntary. I understand that my 
questionnaire responses will be completely anonymous because no personal identifying 
information will be required from me. I understand that my responses will be kept confidential 
and will not be shared or accessed by anyone except the researcher and supervisors of the 
research at the University of Derby. I understand that I have the right to withdraw from the 
study without giving any reason and I may withdraw by providing the researcher or supervisor 
with my unique identification code up to four weeks after completing the questionnaire. I am 
aware that my data will be deleted if I withdraw from the study. I confirm that I have been 
given the opportunity to ask the researcher or supervisor questions about this research (via e-
mail). I confirm that I would like to take part in this research. 
Please enter your unique identification code (first three letters of your mother’s maiden name 
followed by the day you were born): 
For example, if your mother’s maiden name is Taylor and you were born on the 17th June 
your unique identification code would be TAY17. 
 
Prize draw entry 
To thank you for your time and effort completing the questionnaire, I would like to give you the 
opportunity to enter a prize draw to win a $100 Amazon e-voucher. If you would like to enter 
the prize draw you will need to provide your email address in the space below. The winner of 
the prize draw will be emailed their e-voucher shortly after 31/05/14.  
Please note that entry into the prize draw is conditional upon fully completing the 
questionnaire.   




If yes, please provide the email address you would like the e-voucher sent to below. Your 
email address will only be used to send you the e-vouchers if you win. 
 
About yourself (1 of 10) 
Please complete the following questions about yourself by placing a tick in the appropriate 
boxes or writing your response in the space provided. Please answer all of the questions. 
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1. What is your gender?  
Male  
Female  




3. What is your current marital status?  
Married / Co-habiting  
Single  
Widowed  
Divorced / Separated  








6. How long have you been living in the [country name]?  
Since birth  
Other  







7. What is your highest education level?  
No qualifications  
Secondary 
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Undergraduate degree  
Postgraduate degree  
Other  




8. What is your current employment status?  
Child care  
Employed full-time  






















I don't have any religion  
Other  




11. How religious would you describe yourself?  
 
 1 2 3 4 5  
Not at all religious 
     
Extremely religious 
 





Any other ethnic group  






13. How would you describe your financial status?  
A little or a lot poorer than most  
About the same as most  
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A little or a lot richer than most  
About your pain (2 of 10) 
Please complete the following questions about your pain by placing a tick in the appropriate 
boxes or writing your response in the space provided. Please answer all of the questions.  
 
1. How long have you been experiencing pain?  
Less than 1 month  
1-3 months  
4-6 months  
7-9 months  
10-12 months  
Longer than 12 months  








3. Please rate your pain by choosing the number that best describes your pain at its 
WORST in the last month.  
 
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad 








4. Please rate your pain by choosing the number that best describes your pain at its 
LEAST in the last month.  
 
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad 
as you can 
imagine 
 




 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad 
as you can 
imagine 
 
6. Please rate your pain by choosing the number that tells how much pain you have 
RIGHT NOW.  
 
 0 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad 
as you can 
imagine 
 
7. What pain have you experienced in the last month?  
Please tick as many as applicable.  
Headache  
Migraine  
Period pain  
Toothache  
Abdominal pain  
Chest pain  
Foot pain  
Sore throat  
Back pain  
Joint pain  
Earache  
Muscle pain  
Other  
If other, please specify what pain you have experienced.  





8. Have you been diagnosed with a condition that causes your pain?  
Yes  
No  
If yes, what condition have you been diagnosed with? 
 
  
About your painkillers (3 of 10) 
Please complete the following questions about your painkillers by placing a tick in the 
appropriate boxes or writing your response in the space provided. Please answer all of the 
questions.  
 
1. In the last month, what kind of medication have you taken for your pain?  
Prescription medication only (please answer question 2 and continue from question 
5)  
Over-the-counter medication only (please continue from question 3)  
Both prescription and over-the-counter medication (please continue from question 2)  
2. What prescription medication/s have you taken for your pain?  




3. What over-the-counter medication/s have you taken for your pain?  




4. Where did you obtain your over-the-counter medication/s from?  
Pharmacy  
Supermarket shelf  
Family member who IS a medical professional  
Family member who is NOT a medical professional  
 308 
Friend who IS a medical professional  
Friend who is NOT a medical professional  
Internet  
Other  




5. How difficult would you say it is for you to get some strong painkillers without a 
prescription if you wanted some?  
'Strong painkillers' refers to any painkillers which are used for moderate to severe pain e.g. 
Tramadol.  
 
 1 2 3 4 5  
Probably 
impossible      
Very easy 
 
6. Have you ever used any strong painkillers without a prescription?  
Yes  
No  
If yes, please specify where you obtained the strong painkillers.  
Pharmacy  
Family member who IS a medical professional  
Family member who is NOT a medical professional  
Friend who IS a medical professional  
Friend who is NOT a medical professional  
Other  









8. What dosage of painkillers did you take each day?  
1-2 tablets once  
1-2 tablets every 4 hours  
More than 1-2 tablets every 4 hours  
Other  




9. In the last month, how often have you taken more than the recommended dose of 





10. In the last month, how often have you taken painkillers for longer than the 











12. Did you try anything else to relieve your symptoms?  
You may tick or write as many responses as applicable. 
Nothing  
Hot water bottle  









Spiritual healing  
Traditional Chinese medicine  
Aquatherapy  




Ointments/ creams/ gels  
Laser therapy  
Other  




About your painkiller use (4 of 10) 
Please read each statement and chose the response which is the most applicable to you. 




Sometimes Often Nearly always 
1. Do you find 
yourself thinking 
about when you 
will next be able 
to take 
painkillers? 
    




you might do 
during the day? 
    
3. Do you feel your 
need for 
painkillers is too 
strong to 
control?  
    




    
5. Do you take 
painkillers in a 
particular way in 
order to increase 
the effect it gives 
you? 
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evening? 
7. Do you feel you 
have to carry on 
taking painkillers 
once you have 
started? 
    
8. Is getting the 






    
9. Do you want to 
take more 
painkillers when 
the effect starts 
to wear off? 
    
10. Do you find it 
difficult to cope 
with life without 
painkillers? 
    
 
Your thoughts about your pain (5 of 10) 
Please read each statement and choose the response which is the most applicable to you. 



















1. There are 
many times 
when I can 
influence the 
amount of pain 
I feel 
     
2. I will probably 
always have to 
take pain 
medication 
     
3. When I hurt, I 
want my family 
to treat me 
better 
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4. I have had the 
most relief 
from the pain 
with the use of 
medications 
     
5. Anxiety 
increases the 
pain I feel 
     
6. I have given 






work of the 
medical 
profession 
     
7. Just by 
concentrating 
or relaxing, I 
can 'take the 
edge' off my 
pain 
     
8. By 
concentrating 
or relaxing, I 
can 'take the 
edge' off my 
pain 
     
9. Depression 
increases the 
pain I feel 







Your thoughts about your pain (6 of 10) 
Please read each statement and choose the response which is the most applicable to you. 




















10. Often I need 
more tender 
loving care 
than I am now 
getting when I 
am in pain 
     
11. Something is 





     
12. My pain does 
not stop me 
from leading a 
physically 
active life 
     
13. I'm convinced 
that there is no 
medical 
procedure that 
will help my 
pain 
     
14. My pain would 
stop anyone 
from leading 
an active life 
     
  
How you feel about your painkiller use (7 of 10) 
Please read each statement and choose the response which is the most applicable to you. 


















1. I am 
concerned that 
taking 
medication for a 
long time will 
lead to addiction 
      




      
3. I am afraid 




cause me to feel 
ill 
4. I fear that I 
am becoming an 
addict 
      
5. I would be 
unwilling to 
reduce my pain 
medication/s 
      
6. I feel that I will 
eventually run 
out of pain 
medication/s 
that will help 
with the pain 
      




cause me some 
harm 
      
 
How you feel about your painkiller use (8 of 10) 
Please read each statement and choose the response which is the most applicable to you. 


















1. I find it hard to 
put up with the 
side effects 
from my pain 
medication/s 
      






      
3. I worry what 
others think 
about my use 
of pain 
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medication/s 
4. I worry about 
damage to 
internal organs 
from my pain 
medication/s 
      




of my pain 
medication/s 
      
6. I depend on 
my pain 
medication/s 
      






      
 
About your painkiller use (9 of 10) 
Please read each statement and choose the response which is the most applicable to you. 





Agree Uncertain Disagree Strongly 
disagree 
1. I take 
tablets only 
when I'm in 
a lot of pain 
     
2. I only take 
something 
if it's really 
bad 
     





     
4. I always 
take 
something 
if I'm in pain 
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5. If I'm in 
pain I need 
medication 
to fix it 
     




     
7. I prefer to 
let my body 
fight it out 
     
8. I do nothing 
just let it 
pass 
     
9. I try to 
ignore it 
and get on 
with it 
     
 
How you feel about holistic, complementary and alternative medicine (10 of 10) 
Please read each statement and choose the response which is the most applicable to you. 
















help you fight off 
a minor illness 




be subject to 
more scientific 
testing before it 
can be accepted 
by conventional 
doctors 
      
3. When people 
are stressed it is 
important that 
they are careful 
about other 
aspects of their 
lifestyle as their 
body already 
has enough to 





medicine can be 
dangerous in 




      
5. The 
symptoms of an 
illness can be 
made worse by 
depression 




only be used as 




nothing to offer 
      




events they are 
more likely to 
become ill 
      





going to the 
doctor 
      
9. Conflict with 
others has no 
effect on your 
health 




only be used in 
minor ailments 
and not in the 





11. It is 
important to find 
a balance 
between work 
and relaxation in 
order to stay 
healthy 




up the body's 
own defenses, 
so leading to a 
permanent cure 
      
 
 
If there is any additional information you would like to share about your pain or painkiller use 





Thank you for your participation and for your time answering the questionnaire. Please 
read the following information and then click "submit". 
Your participation will allow us to improve understanding of painkiller use in the USA, Canada 
and Australia. Previous research has shown that factors such as people’s beliefs and 
attitudes about pain influence their painkiller use. Generally, positive beliefs and attitudes 
about pain are associated with less painkiller use but negative beliefs and attitudes about 
pain are associated with more painkiller use (Christiaens et al., 2010). Also, beliefs and 
attitudes about painkillers can influence use (Abe et al., 2008). As an example, people who 
believe that painkillers have negative side effects for their health avoid using painkillers and 
prefer to use alternative methods for pain relief (Abe et al., 2008). Although these researches 
have investigated the role of beliefs and attitudes in painkiller use, more research is needed 
which investigates further how these factors influences painkiller use. Please remember that 
you may withdraw from the study up to four weeks after completing the questionnaire. To do 
this you will need to email me or my supervisor, giving your unique identification code (the 
first three letters of your mother’s maiden name followed by the day you were born). If you 
know anyone who might like to take part in this research, feel free to forward this link:  
https://docs.google.com/forms/d/1YZcVDOyZ2jvgkzWYoxnqrBq2WEYkpDPcCoGhE76_Y-
8/viewform. Your help will be greatly appreciated. To find out about the results of this 
research or to ask any questions, please send an email to either o.said@derby.ac.uk or 
j.elander@derby.ac.uk. Also, there will be further research on painkiller use following up this 
study. If you wish to be contacted about taking part in this research with us, please enter your 






If you are interested in reading more about pain or painkiller use, please see the links below 
for more information. Always remember to talk to your doctor if you are worried about your 
pain or painkiller use. 
 
• American Pain Society – http://www.americanpainsociety.org/resources/content/for-
people-in-pain.html  
• American Chronic Pain Association – http://theacpa.org/   
• Canadian Pain Society – http://www.canadianpainsociety.ca/en/index.html  
• Canadian Pain Coalition – http://www.canadianpaincoalition.ca/  
• Australian Pain Society – http://www.apsoc.org.au/useful-links   
• Chronic Pain Australia – http://www.chronicpainaustralia.org.au/   
• Australian Pain Management Association – http://www.painmanagement.org.au/   
• Living with Pain – http://www.nhs.uk/Livewell/Pain/Pages/Painhome.aspx    
• Which Painkiller? – http://www.nhs.uk/Livewell/Pain/Pages/Whichpainkiller.aspx  
• Painkillers – Youtube http://www.youtube.com/watch?v=mqOwSnwtQkU      















Einladung zur Teilnahme 
Wir möchten Sie einladen, an einer interkulturellen Studie zum Thema Nutzung von 
Schmerzmitteln und Schmerzmittelabhängigkeit teilzunehmen. Die Studie wird durchgeführt 
von Doktorandin Omimah Said, betreut von Professor James Elander und Dr Frances 
Maratos an der Universität von Derby, England. Diese Studie erforscht vergleichend, wie 
unterschiedliche nationale Kulturen die Verbreitung von Schmerzmittelnutzung und 
Schmerzmittelabhängigkeit beeinflussen.  
 
Wir würden Ihre Teilnahme sehr zu schätzen wissen, da sie uns helfen wird zu erforschen, 
wie verbreitet die Nutzung von Schmerzmitteln und die Abhängigkeit von Schmerzmitteln im 
deutschsprachigen Raum ist. Ihre Teilnahme wird uns helfen klarzustellen, inwiefern 
kulturelle Faktoren die Verbreitung von Schmerzmittelnutzung und 
Schmerzmittelabhängigkeit im deutschsprachigen Raum beeinflussen.  
 
Um an dieser Studie teilzunehmen, müssen Sie:  
-mindestens 18 Jahre alt sein  
-innerhalb des vergangenen Monats an Schmerzen gelitten haben 
-innerhalb des vergangenen Monats mindestens ein nicht-verschreibungspflichtiges oder 
verschreibungspflichtiges Schmerzmittel oder eine alternative Methode zur Schmerzlinderung 
(z.B. Akkupunktur, Massage usw.) benutzt haben 
-in Deutschland, Österreich oder der Schweiz leben und ein/e Staatsbürger/in von 
Deutschland, Österreich oder der Schweiz sein 
  
Sollten Sie Fragen zu diesen Eignungskriterien haben, können Sie uns per Email erreichen: 
f.uhlenbruch@derby.ac.uk   
 
Die Teilnahme an dieser Studie ist vollkommen freiwillig und wird die Beantwortung eines 
Fragebogen beinhalten, für die etwa 20-25 Minuten Zeit aufgewendet werden müsste. Der 
Fragebogen wird Ihnen Fragen über Ihren Schmerz stellen, darüber wie sie mit Ihrem 
Schmerz umgehen und zu Ihrer Einstellung und Ihren Ansichten zum Thema Schmerz und 
Schmerzmittel. Es werden Ihnen einige allgemeine Fragen zur Person gestellt, wie z.B. zu 
Alter und Geschlecht. Sie werden nicht nach Ihrem Namen oder Ihrer Adresse gefragt: alle 
Informationen, die Sie angeben bleiben anonym. Außerdem werden Ihre Angaben vertraulich 
behandelt, mit niemandem außer mir selbst und den Betreuern meiner Doktorarbeit an der 
Universität Derby geteilt und niemandem zugänglich gemacht.  
 
Alle Informationen, die wir durch den Fragebogen sammeln, werden bis zu 5 Jahre nach 
Abschluss der Studie sicher verwahrt. Während die gesammelten Daten verwahrt werden, 
werden wir die Daten statistisch analysieren. Die Ergebnisse der statistische Analyse werden 
in einer Doktorarbeit zusammengetragen, auf Konferenzen präsentiert und in akademischen 
Fachzeitschriften veröffentlicht. Nach Ablauf dieser Zeit werden die Daten vernichtet. 
  
Sie können Ihre Teilnahme an dieser Studie ohne einen Grund zu nennen zurückziehen 
(innerhalb von vier Wochen nach Teilnahme). Sollten Sie Ihre Teilnahme zurückziehen, 
würden Ihre Angaben im Fragebogen gelöscht werden. Um Ihre Teilnahme zurückzuziehen 
schicken Sie eine Email an mich (o.said@derby.ac.uk) oder meinen Betreuer 
(j.elander@derby.ac.uk), in der Sie Ihren einzigartigen Identifikationscode angeben (Sie 
werden diesen Code selbst bestimmen bevor Sie den Fragebogen beantworten, da dies uns 
erlaubt Ihre Daten anonym zu identifizieren falls Sie sich entschließen Ihre Teilnahme 
zurückzuziehen). Um Ihren persönlichen einzigartigen Identifikationscode zu erstellen, 
benutzen Sie bitte die ersten 3 Buchstaben des Mädchennamens Ihrer Mutter, gefolgt vom 
Tag Ihres Geburtstages. Zum Beispiel, falls der Mädchenname Ihrer Mutter Meier is und Sie 
am 17. Juni Geburtstag haben, so ist Ihr einzigartiger Identifikationscode MEI17.  
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Als Dankeschön für Ihre Teilnahme haben Sie die Möglichkeit an einer Verlosung eines 
Amazon Gutscheins im Wert von 80 Euro teilnzunehmen. Wenn Sie an der Verlosung 
teilnehmen möchten, würden wir Sie um die Angabe Ihrer Emailadresse bitten, so dass Ihnen 
der Gutschein auf elektronischem Wege zugestellt werden kann.  
 
Diese Studie wurde von der Ethik-Kommission Psychologie an der Universität Derby 
genehmigt (Referenznummer 071-13-OS). Wenn Sie Fragen zur ethischen Genehmigung 
haben, setzten Sie sich bitte mit der Vorsitzenden der Ethik-Kommisson in Verbindung: 
f.maratos@derby.ac.uk  
 
Sollten Sie noch Fragen zu dieser Einladung haben, schicken Sie eine Email mit Ihrer Frage 
an folgende Adressen:  
 
Hilfskraft  
Frau Frauke Uhlenbruch  
Centre for Psychological Research  
Faculty of Education, Health and Sciences  
University of Derby  
f.uhlenbruch@derby.ac.uk   
 
Doktorandin  
Frau O Said  
Centre for Psychological Research  
Faculty of Education, Health and Sciences  
University of Derby  
o.said@derby.ac.uk   
 
Betreuer  
Professor J Elander  
Head of Centre for Psychological Research 
Faculty of Education, Health and Sciences  
University of Derby  
j.elander@derby.ac.uk   
 




Wenn Sie die Einladung zur Teilnahme gelesen haben und an der Studie teilnehmen 
möchten, lesen Sie untenstehende Erklärung und geben Sie Ihren einzigartigen 
Identifikationscode ein. Durch die Eingabe Ihres Identifikationscodes erklären Sie sich damit 
einverstanden, fortzufahren.  
 
Einverständniserklärung:  
Ich habe verstanden, dass die Teilname an dieser Studie vollkommen freiwillig ist.  
 
Ich habe verstanden, dass meine Antworten im Fragebogen vollkommen anonym bleiben, da 
keine persönlichen Daten die mich identifizieren könnten erfragt werden.  
 
Ich habe verstanden, dass meine Antworten vertraulich behandelt werden, sie mit 
niemandem geteilt werden und niemand auf sie zugreifen wird, außer der Doktorandin und 
den akademischen Betreuern an der Universität Derby.  
 
Ich habe verstanden, dass ich das Recht habe jederzeit von der Studie zurückzutreten ohne 
einen Grund nennen zu müssen und dass ich Zurücktreten kann, indem ich der Hilfskraft, der 
Doktorandin oder ihrem Betreuer meinen einzigartigen Identifikationscode innerhalb von vier 
Wochen nach Teilnahme an der Studie nenne. Ich bin mir bewusst, dass meine Daten 
gelöscht werden, wenn ich von der Studie zurücktrete.  
 
Ich bestätige, dass ich die Möglichkeit hatte, der Doktorandin oder dem Betreuer Fragen zu 
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dieser Studie zu stellen.  
 
Ich bestätige, dass ich an dieser Studie teilnehmen möchte.  
 
Bitte geben Sie Ihren einzigartigen Identifikationscode ein (die ersten drei Buchstaben des 
Mädchennamens Ihrer Mutter, gefolgt von dem Tag Ihres Geburtstages):  
 
 
Beispiel: wenn der Mädchenname Ihrer Mutter Meier is und Sie am 17. Juni Geburtstag 
haben, so ist Ihr einzigartiger Identifikationscode MEI17. 
  
Teilnahme an der Verlosung 
Als Dankeschön für Ihre Zeit und Mühe, möchte ich Ihnen die Möglichkeit geben, an der 
Verlosung eines Amazon E-Gutscheines im Wert von 80 Euro teilzunehmen. Wenn Sie an 
der Verlosung teilnehmen möchten, tragen Sie bitte Ihre Emailadresse in das Feld ein. Der 
Gewinner des Gutscheines wird kurz nach Ende Februar 2014 per Email benachrichtigt.  
 
Nehmen Sie bitte zur Kenntnis, dass die Teilnahme an der Verlosung nur möglich ist, wenn 
Sie den Fragebogen komplett ausfüllen.  





Falls ja, geben Sie bitte hier die Emailadresse ein, an die der Gutschein geschickt 
werden soll. Ihre Emailadresse wird ausschliesslich dazu benutzt, Ihnen den Gutschein 
zuzustellen, falls Sie gewinnen. 
 
 
   
 
Zu Ihrer Person (1 von 10) 
Bitte füllen Sie den folgenden Fragebogen zu demografischen Angaben aus, indem Sie die 
zutreffenden Kästchen ankreuzen oder Ihre Antwort in das Feld eintragen. Bitte beantworten 
Sie alle Fragen.  
 









 .Was ist Ihr momentaner Familienstand?3  
 

















6. Wie lange wohnen Sie bereits in dem Land, in dem Sie jetzt leben? * 
 
Seit meiner Geburt 
Andere Antwort 
  





7. Was ist Ihr Bildungsgrad? * 
 
Kein Abschluss  
Realschulabschluss / Hauptschulabschluss  
Abitur/Fachabitur/Matura 
Abgeschlossene Ausbildung  
Abgeschlossenes Hochschulstudium  
Andere 
  




8. Was ist Ihre derzeite Tätigkeit? * 
 
Elternzeit 


























Keine Religion  
Andere Antwort (bitte angeben)  
  




11. Als wie gläubig würden Sie sich beschreiben? 
 
 1 2 3 4 5  
Gar nicht gläubig 








12. Wie würden Sie Ihr Vermögensverhältnis beschreiben? * 
 
Ein wenig oder viel ärmer als die meisten  
In etwa so vermögend wie die meisten  
Ein wenig oder viel reicher als die meisten  
  
 
Zu Ihren Schmerzen (2 von 10) 
Füllen Sie bitte den folgenden Schmerz-Fragebogen aus, indem Sie ein Häkchen in das 
entsprechende Kästchen eintragen oder Ihre Antwort in das Feld schreiben. Bitte 
beantworten Sie alle Fragen.  
 
1. Wie lange leiden Sie bereits an Schmerzen? * 
 
Weniger als 1 Monat  
1-3 Monate  
3-6 Monate  
6-9 Monate  
9-12 Monate  
Länger als 12 Monate (bitte angeben) 
  









3. Bitte stufen Sie Ihre Schmerzen ein, indem Sie die Zahl auswählen, die am besten 
Ihre SCHLIMMSTEN Schmerzen im vergangenen Monat beschreibt* 
 
 1 2 3 4 5 6 7 8 9 10  
Keine 





4. Bitte stufen Sie Ihre Schmerzen ein, indem Sie die Zahl auswählen, die am besten 
Ihre WENIGSTEN Schmerzen im vergangenen Monat beschreibt* 
 
 1 2 3 4 5 6 7 8 9 10  
Keine 












5. Bitte stufen Sie Ihre Schmerzen ein, indem Sie die Zahl auswählen, die Ihre 
DURCHSCHNITTLICHEN Schmerzen beschreibt* 
 
 1 2 3 4 5 6 7 8 9 10  
Keine 





6. Bitte stufen Sie Ihre Schmerzen ein, indem Sie die Zahl auswählen, die Ihre 
Schmerzen in DIESEM MOMENT beschreibt* 
 
 1 2 3 4 5 6 7 8 9 10  
Keine 





7. Welche Art Schmerz haben Sie im vergangenen Monat erlebt? * 






Schmerzen in der Brust  








Falls "andere Antwort", geben Sie bitte an, welche Art von Schmerzen Sie hatten. 















Ihre Schmerzmittel (3 von 10) 
Bitte beantworten Sie die folgenden Fragen über Ihre Schmerzmittel indem Sie ein Häkchen 
in das entsprechende Kästchen setzen oder Ihre Antwort in das Feld eintragen. Bitte 
beantworten Sie alle Fragen.  
1. Im vergangenen Monat, welche Arten von Medikamenten haben Sie gegen Ihre 
Schmerz genommen? * 
 
Nur verschreibungspflichtige Medikamente (bitte beantworten Sie Frage 2 und fahren 
Sie dann mit Frage 5 fort)  
Nur rezeptfreie Medikamente (fahren Sie bitte mit Frage 3 fort)  
Sowohl verschreibungspflichtige als auch rezeptfreie Medikamente (fahren Sie bitte 
mit Frage 2 fort)  
 
2. Welche/s verschreibungspflichtige/n Medikament/e haben Sie gegen Ihre Schmerzen 
eingenommen? 




3. Welche/s rezeptfreie/n Medikament/e haben Sie gegen Ihre Schmerzen 
eingenommen? 








Familienmitgleid (medizinischen Beruf ausübend) 
Familienmitgleid (KEINEN medizinischen Beruf ausübend) 
Bekannte/r (medizinischen Beruf ausübend)  








5. Wie schwierig würden Sie es einschätzen starke Schmerzmittel ohne Rezept zu 
erhalten, wenn Sie welche haben wollen würden? * 
„starke Schmerzmittel“ bezieht sich auf Schmerzmittel, die für mittlere bis starke Schmerzen 
verwendet werden, z.B. Tramadol 
 
 1 2 3 4 5  
So gut wie 










Falls ja, wo haben Sie das starke Schmerzmittel bekommen? 
 
Apotheke  
Familienmitglied (medizinischen Beruf ausübend)  
Familienmitgleid (KEINEN medizinischen Beruf ausübend) 
Bekannte/r (medizinischen Beruf ausübend)  
Bekannte/r (KEINEN medizinischen Beruf ausübend) 
Andere  
 









8. Welche Dosierung an Schmerzmitteln haben Sie an einem dieser Tage 
eingenommen? * 
 
1-2 Tabletten ein Mal  
1-2 Tabletten alle 4 Stunden  
Mehr als 1-2 Tabletten alle 4 Stunden  
Andere Antwort 
  




9. Im vergagenen Monat, wie oft haben Sie mehr als die empfohlene Dosierung Ihres 











10. Im vergangenen Monat, wie oft haben Sie Schmerzmittel für längere Zeit als 







11. Im vergangenen Monat, wie oft haben Sie Schmerzmittel eingenommen wenn Sie 







12. Haben Sie andere Methoden zur Schmerzlinderung probiert? * 
 (Sie können so viele Antworten anklicken, wie zutreffen) 
Keine 
Wärmflasche  























Zu Ihrer Nutzung von Schmerzmitteln (4 von 10) 
Lesen Sie bitte jede Aussage und wählen Sie die Antwort, die am ehesten auf Sie zutrifft. 
Bitte beantworten Sie alle Fragen.  
* 
 
 Niemals Manchmal Oft Fast immer 
1. Bemerken Sie, wie Sie darüber nachdenken, 
wann Sie zum nächsten Mal Schmerzmittel 
einnehmen können? 
    
2. Ist die Einnahme von Schmerzmitteln wichtiger 
als alles andere, was Sie tagsüber machen?     
3. Fühlen Sie sich, als ob Ihr Bedürfnis nach 
Schmerzmitteln zu stark ist, um es zu kontrollieren?     
4. Planen Sie Ihren Tagesablauf um die Einnahme 
von Schmerzmitteln herum?     
5. Nehmen Sie Schmerzmittel auf eine bestimmte 
Art und Weise ein, um ihre Wirkung bei Ihnen zu 
verstärken? 
    
6. Nehmen Sie Schmerzmittel morgens, 
nachmittags und abends ein?     
7. Fühlen Sie sich, als ob Sie fortfahren müssen, 
Schmerzmittel zu nehmen wenn sie einmal 
angefangen haben? 
    
8. Ist die Wirkung, die Sie erzielen wichtiger als 
welches bestimmtes Schmerzmittel sie benutzen?     
9. Wollen Sie weitere Schmerzmittel einnehmen 
wenn die Wirkung nachlässt?     
10. Finden Sie es schwierig, ohne Schmerzmittel 
im Leben zurechtzukommen?     
  
 
Ihre Gedanken zu Ihrem Schmerz (5 von 10) 
Bitte lesen Sie jede Aussage und wählen Sie die Antwort, die am ehesten auf Sie zutrifft. 














Trifft voll zu 
1. Es gibt viele 
Momente, in denen 
ich beeinflussen 
kann, wie starke 
Schmerzen ich fühle 
     




     
3. Wenn ich 
Schmerzen habe 
möchte ich, dass 
meine Familie mich 
besser behandelt 
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4. Die beste 
Linderung meiner 
Schmerzen habe ich 
durch die Nutzung 
von Medikamenten 
erfahren 
     
5. Sorgen verstärken 
meine Schmerzen      
6. Ich habe meine 
Suche nach der 
vollkommenen 
Beseitigung meines 
Schmerzes durch die 
Medizinerschaft 
aufgegeben 
     






     
8. Depression 
verstärkt den 
Schmerz, den ich 
fühle 
     
  
 
Ihre Gedanken zu Ihrem Schmerz (6 von 10) 
Bitte lesen Sie jede Aussage und wählen Sie die Antwort, die am ehesten auf Sie zutrifft. 














Trifft voll zu 
9. Oft brauche ich 
mehr liebevolle 




     
10. Ich habe ein 
körperliches 
Problem, das mich 
davon abhält, mich 
zu bewegen oder 
Sport zu treiben 
     
11. Meine 
Schmerzen halten 
mich nicht davon 
ab, ein körperlich 
aktives Leben zu 
führen 
     
12. Sport kann die 
Schmerzen die ich 
empfinde lindern 
     
13. Ich bin 
überzeugt, dass es 
keinen 
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medizinischen 








aktives Leben zu 
führen 
     
  
 
Ihre Gedanken zu Ihrer Nutzung von Schmerzmitteln (7 von 10) 
Bitte lesen Sie jede Aussage und wählen Sie die Antwort, die am ehesten auf Sie zutrifft. 















1. Ich bin 




Zeitraum zu einer 
Sucht führen könnte 
      
2. Ich mache mir 
Sorgen, dass mein/e 
Schmerzmittel 
aufhören werden zu 
wirken 
      
3. Ich habe Angst, 
dass die Absetzung 
meines/r 
Schmerzmittel/s 
mich mich krank 
fühlen lassen wird 
      
4. Ich fürchte, dass 
ich abhängig werde       
5. Ich würde mein/e 
Schmerzmittel nicht 
reduzieren wollen 
      
6. Ich denke, dass 
ich irgendwann 
kein/e Schmerzmittel 
mehr haben werde, 
die den Schmerz 
lindern können 
      
7. Ich mache mir 




      
  
 
Ihre Gedanken zu Ihrer Nutzung von Schmerzmitteln (8 von 10) 
Bitte lesen Sie jede Aussage und wählen Sie die Antwort, die am ehesten auf Sie zutrifft. 
















8. Ich finde es 





      
9. Es ist mir peinlich, 
Schmerzmittel gegen 
meinen Schmerz 
nehmen zu müssen 
      
10. Ich bin beunruhigt 
darüber, was andere 
von meiner Nutzung 
von Schmerzmitteln 
halten 
      
11. Ich mache mir 
Sorgen, dass innere 




      
12. Ich habe Vertrauen 




      
13. Ich bin auf mein/e 
Schmerzmittel 
angewiesen 
      
14. Ich bin zufrieden 
mit Informationen, die 
mein Arzt mir über 
Medikamente gibt 
      
  
 
Zu Ihrer Nutzung von Schmerzmitteln (9 von 10) 
Bitte lesen Sie jede Aussage durch und wählen Sie die Antwort, die am ehesten auf Sie 
zutrifft. Bitte beantworten Sie alle Fragen. 
* 
 





1. Ich nehme nur 
Tabletten, wenn ich 
große Schmerzen 
habe 
     
2. Ich nehme nur 
etwas ein, wenn es 
richtig schlimm ist 
     
3. Ich nehme 
Schmerzmittel nur 
wenn es absolut 
notwendig ist 
     
4. Immer wenn ich 
Schmerzen habe, 
nehme ich etwas 
ein 
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5. Wenn ich 
Schmerzen habe, 
brauche ich ein 
Medikament um sie 
zu beheben 
     
6. Ich zögere nicht, 
Schmerzmittel zu 
nehmen 
     
7. Ich ziehe es vor, 
meinen Körper es 
bekämpfen zu 
lassen 
     
8. Ich tue nichts, 
lasse es einfach 
vorbeigehen 
     
9. Ich versuche es 
zu ignorieren und 
mache einfach 
weiter 
     
  
 
Ihre Gedanken zu ganzheitlicher Medizin, Komplementärmedizin und Alternativmedizin 
(10 von 10) 
Bitte lesen Sie jede Aussage durch und wählen Sie die Antwort, die am ehesten auf Sie 

















1. Positives Denken kann 
einem helfen, eine leichte 
Krankheit abzuwehren 
      
2. Komplementärmedizin 
sollte wissenschaftlich 
besser geprüft werden, 
bevor sie von 
Schulmedizinern 
akzeptiert wird 
      
3. Wenn jemand im 
Stress ist, ist es wichtig, 
dass er/sie sich in 
anderen Bereichen des 
Lebens vorsichtig verhält, 
da der Körper schon 
genug zu tun hat 
      
4. Komplementärmedizin 
kann gefährlich sein, da 
jemand deswegen 
vielleicht keine richtige 
Behandlung bekommt 
      
5. Die Symptome einer 
Krankheit können sich 
durch Depression 
verschlimmern 
      
6. Auf 
Komplementärmedizin 
sollte nur als letzte 
Möglichkeit 
zurückgegriffen werden, 
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wenn die Schulmedizin 
nichts mehr bieten kann 
7. Wenn jemand viele 
stressige 
Lebenssituationen 
durchlebt, ist es 
wahrscheinlicher, dass 
er/sie krank wird 
      
8. Es lohnt sich, 
Komplementärmedizin 
auszuprobieren, bevor 
man zum Arzt geht 
      
9. Konflikte mit Anderen 
haben keine 
Auswirkungen auf die 
Gesundheit 
      
10. 
Komplementärmedizin 
sollte nur zur Behandlung 
von geringeren Leiden 
benutzt werden und nicht 
zur Behandlung 
schwererer Krankheiten 
      
11. Es ist wichtig, ein 
ausgewogenes Verhältnis 
zwischen Arbeit und 
Entspannung zu finden 
um gesund zu bleiben 
      
12. 
Komplementärmedizin 
baut das körpereigene 
Abwehrsystem auf und 
führt so zu einer 
dauerhaften Heilung 
      
 
Wenn Sie weitere Informationen zu ihren Schmerzen oder ihrer Nutzung von 
Schmerzmitteln haben, die sie für wichtig halten oder finden, dass Sie nicht dazu 






Vielen Dank für Ihre Teilnahme und dass Sie sich die Zeit genommen haben, den 
Fragebogen auszufüllen. Bitte lesen Sie die folgenden Informationen und klicken Sie 
dann auf „Senden“. 
Ihre Teilnahme wird uns erlauben, unser Verständnis der Nutzung von Schmerzmitteln im 
deutschsprachigen Raum zu verbessern. Vorhergehende Studien haben gezeigt, dass 
Faktoren wie die Einstellung oder Ansichten zu Schmerzen die Nutzung von Schmerzmitteln 
beeinflussen. Im Allgemeinen werden positive Einstellungen und Ansichten zu Schmerzen mit 
vermehrter Nutzung von Schmerzmitteln in Zusammenhang gebracht, wohingegen negative 
Ansichten und Einstellungen zu Schmerzen mit geringerer Nutzung von Schmerzmitteln in 
Zusammenhang gebracht werden (Christiaens u.a. 2010). Auch können Ansichten und 
Einstellungen zu Schmerzmitteln die Nutzung beeinflussen (Abe u.a. 2008). Als Beispiel: 
Menschen, die glauben, dass Schmerzmittel negative Nebenwirkungen auf die Gesundheit 
haben, vermeiden die Nutzung von Schmerzmitteln und ziehen alternative Methoden zur 
Schmerzbekämpfung vor (Abe u.a., 2008). Obwohl diese Studien die Rolle die Ansichten und 
Einstellungen bei der Nutzung von Schmerzmitteln spielen erforscht haben, ist weitere 
Forschung nötig, die weiter herausarbeitet, wie diese Faktoren die Nutzung von 
Schmerzmitteln beeinflussen.  
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Wir möchten Sie daran erinnern, dass Sie innerhalb von vier Wochen nach Beantwortung des 
Fragebogen von dieser Studie zurücktreten können. Um zurückzutreten, müssten Sie mir 
oder meinem Betreuer eine Email schicken, in der Sie Ihren einzigartigen Identifikationscode 
angeben (die erstern drei Buchstaben des Mädchennamens Ihrer Mutter gefolgt von dem Tag 
ihre Geburtsdatums).  
 
Falls Sie jemanden kennen, der auch an dieser Studie teilnehmen möchte, schicken Sie doch 





Ihre Hilfe wissen wir sehr zu schätzen. 
  
Wenn Sie über die Ergebnisse dieser Studie informiert werden wollen oder noch 
irgendwelche Fragen haben, schicken Sie eine Email an eine der untenstehenden Adressen.  
 
Es wird noch eine weitere Studie geben, die an diese Studie anschließt. Falls Sie kontaktiert 
werden möchten, um auch an der folgenden Studie teilzunehmen, geben Sie bitte hier Ihre 
Emailadresse ein:  
 
Vielen Dank für Ihre Teilnahme.  
 
Assistentin  
Frauke Uhlenbruch  
Centre for Psychological Research  
Faculty of Education Health and Sciences 




Omimah Said  
Centre for Psychological Research  
Faculty of Education Health and Sciences 




Professor J Elander  
Head of Centre for Psychological Research  
Centre for Psychological Research  
Faculty of Education, Health and Sciences  
University of Derby  
j.elander@derby.ac.uk  
 
Wenn Sie Interesse daran haben, mehr über Schmerzmittel und Nutzung von Schmerzmitteln 
zu erfahren, folgen Sie untenstehenden Links. Denken Sie daran, sich immer mit Ihrem Arzt 
in Verbindung zu setzen, wenn Sie sich Sorgen um Ihren Schmerz oder Ihre Nutzung von 
Schmerzmitteln machen.  
 




Deutsche Gesellschaft fuer psychologische Schmerztherapie und -Forschung e.V.: 
http://www.dgpsf.de/fuerpatienten.html  
 








Deutsche Schmerzliga e.V.:  
http://www.schmerzliga.de/  
 
















































Appendix F: Longitudinal 
questionnaire 
 
Pain and painkiller use questionnaire  
Please take a few minutes to read the following information about this research before 
continuing to the questionnaire. 
You are invited to take part in this longitudinal research study, which is investigating the role 
of pain medication beliefs, pain acceptance and emotions in painkiller use among the UK 
population. Your participation will be very precious because it will help us clarify how these 
factors might influence painkiller use and painkiller use problems over time. 
To participate in this research you must: 
• be at least 18 years old 
• have experienced any type of pain in the last month 
• have taken at least one over-the counter or prescription painkiller in the last month 
• be resident citizens in the UK  
If you have any questions about whether you meet these criteria, please email me 
(o.said@derby.ac.uk) or my supervisors (j.elander@derby.ac.uk; f.maratos@derby.ac.uk) for 
clarification. 
Participating in this study is entirely voluntary and will involve answering a questionnaire 
which takes approximately 15-20 minutes to complete. The questionnaire will ask you some 
questions about your pain, how you manage your pain, how you feel about your pain and how 
you feel about your painkillers. You will also be asked some general information about 
yourself such as your age and gender but you will not be asked to give any personal identity 
information like your name or address; all of the information you give will be anonymous. In 
addition, the information you give will be kept confidential and will not be shared or accessed 
by anyone except my supervisors and myself at the University of Derby.  
In order to investigate painkiller use over time, we will repeat the survey after 3 months. 
Please note that you will need to provide your email address to take part in these future 
surveys so we can contact you regarding these future surveys. Your email address will be 
kept confidential and will not be used for any other purposes. 
All information collected through the questionnaire will be stored securely for up to five years 
after the research has been completed. While the data is stored, it will be analysed 
statistically and the results of this analysis will be written up in a research thesis, presented in 
conferences and likely published in academic journals. After this time, the questionnaire data 
will be deleted. 
You may withdraw from this research without giving any reason at any time during the 
process of completing the questionnaire or up to four weeks after completing the 
questionnaire. Withdrawal will result in your questionnaire data being deleted. To withdraw 
you will need to email me (o.said@derby.ac.uk) or my supervisors (j.elander@derby.ac.uk; 
f.maratos@derby.ac.uk), giving your unique identification code (this is a code which you will 
be asked to create before beginning the questionnaire because it allows your data to be 
identified anonymously in case you want to withdraw). To make yourself a unique 
identification code, please use the first three letters of your mother’s maiden name followed 
by the last two digits of your telephone number. For example, if your mother’s maiden name 
is Taylor and the last two digits of your telephone number are 17, your unique identification 
code would be TAY17.  
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As a thank you for your time completing the questionnaire, you will be given the chance to 
enter a prize draw for an Amazon e-voucher worth £20. If you want to enter the draw you will 
be asked to provide your email address so that the e-vouchers can be emailed to you if you 
win. There will be another prize draw for an Amazon e-voucher worth £50 to thank you for 
your time completing the follow-up questionnaire in 3 months time.  
This study has been approved by the Psychology Research Ethics Committee at the 
University of Derby [17-14-OS]. If you have any questions about this please contact the 
deputy chair of the ethics committee (c.barnes1@derby.ac.uk).  






Professor J Elander 
j.elander@derby.ac.uk  
 




Centre for Psychological Research 
Department of Life and Natural Sciences 
University of Derby 
Consent 
If you have read the information in the previous page and would like to take part in the 
research, please read the declaration below and enter your unique identification code. By 
entering this code you are providing your consent to continue.  
Declaration 
I understand that participating in this study is entirely voluntary. 
 
I understand that my questionnaire responses will be completely anonymous because no 
personal identifying information will be required from me.  
 
I understand that my responses will be kept confidential and will not be shared or accessed 
by anyone except the researcher and supervisors of the research at the University of Derby.  
 
I understand that the researcher will contact me via email when the survey is repeated after 3 
months. 
 
I understand that I have the right to withdraw from the study without giving any reason and I 
may withdraw by providing the researcher or supervisor with my unique identification code up 
to four weeks after completing the questionnaire. I am aware that my data will be deleted if I 
withdraw from the study.  
 
I confirm that I have been given the opportunity to ask the researcher or supervisor questions 
about this research (via e-mail).  
 
I confirm that I would like to take part in this research.  
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Please enter your unique identification code (first three letters of your mother’s maiden name 
followed by the last two digits of your telephone number): 
 
For example, if your mother’s maiden name is Taylor and the last two digits of your telephone 
number are 17, your unique identification code would be TAY17. 
 
 
Prize draw entry 
To thank you for your time and effort completing this questionnaire, I would like to give you 
the opportunity to enter a prize draw to win a £20 Amazon e-voucher. If you would like to 
enter the prize draw you will need to provide your email address in the space below.  
 
Would you like to be entered into the prize draw?  
Yes  
No  
If yes, please provide the email address you would like the e-voucher sent to below. Your 




3 month follow-up 
 
Please enter your email address below to allow us to contact you when the survey is 




Please complete the following questions about yourself by placing a tick in the appropriate 
boxes or writing your response in the space provided. Please answer all of the questions. 
 
1. What is your gender?  
Male  
Female  




3. What is your current marital status?  




Divorced / Separated  












6. What is your highest education level?  
No qualifications  
GCSE / O level  
A level  
Undergraduate degree  
Postgraduate degree  
Other  




7. What is your current employment status?  
Child care  
Employed full-time  
















9. How would you describe your financial status?  
A little or a lot poorer than most  
About the same as most  
A little or a lot richer than most  









About your pain  
Please complete the following questions about your pain by placing a tick in the appropriate 
boxes or writing your response in the space provided. Please answer all of the questions.  
 
1. How long have you been experiencing pain?  
Less than 1 month  
1-3 months  
4-6 months  
7-9 months  
10-12 months  
Longer than 12 months  








3. Please rate your pain by choosing the number that best describes your pain at its 
WORST in the last month.  
 
 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as you 
can imagine 
4. Please rate your pain by choosing the number that best describes your pain at its 
LEAST in the last month.  
 
 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as you 
can imagine 
5. Please rate your pain by choosing the number that best describes your pain on the 
AVERAGE.  
 
 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as you 
can imagine 
6. Please rate your pain by choosing the number that tells how much pain you have 
RIGHT NOW.  
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 1 2 3 4 5 6 7 8 9 10  
No 
pain            
Pain as bad as you 
can imagine 
7. What pain have you experienced in the last month?  
Please tick as many as applicable.  
Headache  
Migraine  
Period pain  
Toothache  
Abdominal pain  
Chest pain  
Foot pain  
Sore throat  
Back pain  
Joint pain  
Earache  
Muscle pain  
Other  
If other, please specify what pain you have experienced.  












If yes, what condition have you been diagnosed with? 
 
 
About your painkillers  
Please complete the following questions about your painkillers by placing a tick in the 
appropriate boxes or writing your response in the space provided. Please answer all of the 
questions.  
 
1. In the last month, what kind of medication have you taken for your pain?  
Prescription medication only (please answer question 2 and continue from question 
4)  
Over-the-counter medication only (please continue from question 3)  
Both prescription and over-the-counter medication (please continue from question 2)  
2. What prescription medication/s have you taken for your pain?  




3. What over-the-counter medication/s have you taken for your pain?  








5. What dosage of painkillers did you take each day?  
1-2 tablets once  
1-2 tablets every 4 hours  
More than 1-2 tablets every 4 hours  
Other  





6. In the last month, how often have you taken more than the recommended dose of 





7. In the last month, how often have you taken painkillers for longer than the 










9. Did you try anything else to relieve your symptoms?  
You may tick or write as many responses as applicable. 
Nothing  
Hot water bottle  










Spiritual healing  
Traditional Chinese medicine  
Aquatherapy  
Magnetic therapy  
Aromatherapy  
Reiki  
Ointments/ creams/ gels  
Laser therapy  
Other  






About your painkiller use  
 
Please read each statement and chose the response which is the most applicable to you. 
Please answer all questions. 
 
 Never  
 
Sometimes Often Nearly 
always 
 
1. Do you find yourself thinking about 
when you will next be able to take 
painkillers? 
    
2. Is taking painkillers more important 
than anything else you might do 
during the day? 
    
3. Do you feel your need for 
painkillers is too strong to control?      
4. Do you plan your days around 
taking painkillers?     
5. Do you take painkillers in a 
particular way in order to increase 
the effect it gives you? 
    
6. Do you take painkillers morning, 
afternoon and evening?     
7. Do you feel you have to carry on 
taking painkillers once you have 
started? 
    
8. Is getting the effect you want more 
important than the particular 
painkiller you use? 
    
9. Do you want to take more 
painkillers when the effect starts to 
wear off? 
    
10. Do you find it difficult to cope with 
life without painkillers?     
 
How you feel about your painkiller use  
 
Please read each statement and choose the response which is the most applicable to you. 


















1. I am 
concerned that 
taking 
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medication for 
a long time will 
lead to 
addiction 





      




will cause me 
to feel ill 
      
4. I fear that I am 
becoming an 
addict 
      





      
6. I feel that I will 
eventually run 
out of pain 
medication/s 
that will help 
with the pain 
      
7. I worry that 
withdrawal 
from my pain 
medication/s 
will cause me 
some harm 
      
8. I find it hard to 
put up with the 
side effects 
from my pain 
medication/s 
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me 
10. I worry what 
others think 
about my use 
of pain 
medication/s 
      
11. I worry about 
damage to 
internal organs 
from my pain 
medication/s 
      




of my pain 
medication/s 
      
13. I depend on 
my pain 
medication/s 
      






      
 
How you feel about your pain 
 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions. 
 
When I am in pain…. 
 
 Not at 
all 
 












1. I become 
afraid that 
the pain will 
get worse. 
 
      
2. I anxiously 
want the 
pain to go 
away. 
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3. I keep 
thinking 
about how 
badly I want 
the pain to 
stop. 
      
How you feel about your pain 
 
Please read each statement and choose the response which is the most applicable to you. 


















1. I am getting 




my level of 
pain is. 
      

















      








      





      
6. When my 
pain 
increases, I 
can still take 
care of my 











      
8. My worries 
and fears 
about what 
pain will do 
to me are 
true 
      
 
How you feel about your pain  
 
Please read each statement and choose the response which is the most applicable to you. 
Please answer all questions. 
 
1. I can still accomplish most of my goals in life, despite the pain. 
 1 2 3 4 5 6  
Not at all confident  
      
Completely confident 
 
2. I can live a normal lifestyle, despite the pain.  
 1 2 3 4 5 6  
Not at all confident  
      
Completely confident 
 
About your emotions 
 
Please read each statement and choose the response which is the most applicable to you. 
















     
2. It is difficult 





     
3. I have 











     







     
6. When I am 
upset, I 
don’t know 
if I am sad, 
frightened 
or angry. 
     
7. I am often 
puzzled by 
sensations 
in my body.  
     









that way.  
     
9. I have 
feelings that 
I can’t quite 
identify. 
     




     
11. I find it hard 
to describe      
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how I feel 
about 
people. 





     




     
14. I often don’t 
know why I 
am angry. 
     









     







     
17. It is difficult 







     






     
19. I find 

















     
 
If there is any additional information you would like to share about your pain or painkiller use 
which you feel is important or you feel you have not been asked about, please comment 
below.  
 
Thank you for your participation and for your time answering the questionnaire. Please 
read the following information and then click "submit".  
 
Your participation will allow us to improve understanding of painkiller use. Previous research 
has shown that factors such as people’s beliefs and attitudes about painkillers influence their 
painkiller use. Generally, positive beliefs and attitudes about painkillers are associated with 
less painkiller use but negative beliefs and attitudes about painkillers are associated with 
more painkiller use (Abe et al., 2008). As an example, people who believe that painkillers 
have negative side effects for their health avoid using painkillers and prefer to use alternative 
methods for pain relief (Abe et al., 2008). 
 
It has also been found that greater pain catastrophising increases painkiller use whereas 
greater pain self-efficacy and pain acceptance decrease painkiller use (Christiaens et al., 
2010; Jacobsen and Butler, 1995). More research is needed which investigates further how 
these factors influences painkiller use, in order to increase our understanding of painkiller 
use. 
  
Please remember that you may withdraw from the study up to four weeks after completing the 
questionnaire. To do this you will need to email me or my supervisor, giving your unique 
identification code (the first three letters of your mother’s maiden name followed by the last 
two digits of your telephone number).  
 
In 3 months time, we will be sending an email with information about the follow-up survey of 
this study to the email address you have provided. Please keep a note of your unique 
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identification code, as you will be asked for this in the follow-up survey. This will allow us to 
match the responses from both surveys to help us assess painkiller use over time. You will 
have the opportunity to enter a prize draw for a £50 Amazon voucher to thank you for your 
time completing the follow-up questionnaire.   
 




Your help will be greatly appreciated. 
To find out about the results of this research or to ask any questions, please send an email to 
any of the contacts below. 





Professor J Elander 
j.elander@derby.ac.uk  
 
Dr Frances Maratos 
f.maratos@derby.ac.uk  
 
Centre for Psychological Research 
Department of Life and Natural Sciences 




If you are interested in reading more about pain or painkiller use, please see the links below 
for more information. Always remember to talk to your doctor if you are worried about your 
pain or painkiller use.  
British Pain Society – http://www.britishpainsociety.org/  
NHS Living with Pain – http://www.nhs.uk/Livewell/Pain/Pages/Painhome.aspx 
NHS Which Painkiller? – http://www.nhs.uk/Livewell/Pain/Pages/Whichpainkiller.aspx  
Pain – http://www.patient.co.uk/directory/pain  
Painkillers – http://www.patient.co.uk/health/painkillers  
Painkillers video – http://www.youtube.com/watch?v=mqOwSnwtQkU  
 
 





Appendix G: Tables from Chapter 3 
Table 50. A comparison of demographic variables for the UK sample and Egypt sample 
before binary recoding. 




Marital status    
Married/co-habiting 197 (66.8%) 240 (57.3%) 
Single 73 (24.7%) 145 (34.6%) 
Widowed 2 (0.7%) 26 (6.2%) 
Divorced/separated 23 (7.8%) 8 (1.9%) 
Nationality   
British 274 (92.9%) 0 (0.0%) 
Egyptian 0 (0.0%) 420 (100.0%) 
Albanian 1 (0.3%) 0 (0.0%) 
American 2 (0.7%) 0 (0.0%) 
Cofe 1 (0.3%) 0 (0.0%) 
Czech 1 (0.3%) 0 (0.0%) 
Dutch 2 (0.7%) 0 (0.0%) 
French 1 (0.3%) 0 (0.0%) 
German 2 (0.7%) 0 (0.0%) 
Hungarian 1 (0.3%) 0 (0.0%) 
Irish 5 (1.7%) 0 (0.0%) 
Italian 1 (0.3%) 0 (0.0%) 
Maltese 1 (0.3%) 0 (0.0%) 
New Zealander 1 (0.3%) 0 (0.0%) 
Polish 2 (0.7%) 0 (0.0%) 
Language spoken at home   
English 289 (98.0%) 0 (0.0%) 
Arabic 1 (0.3%) 420 (100.0%) 
Hungarian 1 (0.3%) 0 (0.0%) 
Kurdish 1 (0.3%) 0 (0.0%) 
Maltese 1 (0.3%) 0 (0.0%) 
Spanish 1 (0.3%) 0 (0.0%) 
Welsh 2 (0.7%) 0 (0.0%) 
Ethnic origin   
White 281 (95.3%) 0 (0.0%) 
Egyptian 0 (0.0%) 414 (98.6%) 
Mixed 6 (2.0%) 0 (0.0%) 
Asian or Asian British 3 (1.0%) 0 (0.0%) 
Black or Black British 1 (0.3%) 0 (0.0%) 
Nubian 0 (0.0%) 2 (0.5%) 
Bedouin 0 (0.0%) 4 (1.0%) 
Any other ethnic group 4 (1.4%) 0 (0.0%) 
Highest education level   
No qualifications 9 (3.1%) 0 (0.0%) 
Secondary school (Egypt only) - 157 (37.4%) 
GCSE/O level (UK only) 52 (17.6%) - 
A level (UK only) 39 (13.2%) - 
Undergraduate degree 74 (25.1%) 114 (27.1%) 
Postgraduate degree 75 (25.4%) 62 (14.8%) 
Other 46 (15.6%) 87 (20.7%) 
Employment status   
Child care 13 (4.4%) 89 (21.2%) 
Employed full-time 98 (33.2%) 108 (25.7%) 
Employed part-time 47 (15.9%) 59 (14.0%) 
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Retired 29 (9.8%) 18 (4.3%) 
Self-employed 12 (4.1%) 40 (9.5%) 
Unemployed 44 (14.9%) 63 (15.0%) 
Studying 17 (5.8%) 43 (10.2%) 
Other 35 (11.9%) 0 (0.0%) 
Religion   
Buddhism 3 (1.0%) 0 (0.0%) 
Christianity 133 (45.1%) 137 (32.6%) 
Hinduism 1 (0.3%) 0 (0.0%) 
Islam 4 (1.4%) 282 (67.1%) 
Judaism 1 (0.3%) 0 (0.0%) 
I don't have any religion 136 (46.1%) 0 (0.0%) 
Other 17 (5.8%) 1 (0.2%) 
 
 
Table 51. A comparison of pain variables for the UK sample 
and Egypt sample before binary recoding. 




Pain duration   
Less than 1 month 14 (4.7%) 126 (30.0%) 
1-3 months 4 (1.4%) 97 (23.1%) 
4-6 months 6 (2.0%) 92 (21.9%) 
7-9 months 4 (1.4%) 64 (15.2%) 
10-12 months 8 (2.7%) 19 (4.5%) 
Longer than 12 months 259 (87.8%) 22 (5.2%) 
 
 
Table 52. A comparison of painkiller use variables for the UK sample and Egypt 
sample before binary recoding. 




Type of painkillers taken in the last month   
Prescription only 112 (38.0%) 183 (43.6%) 
Over-the-counter only 56 (19.0%) 150 (35.7%) 
Both prescription and over-the-counter  127 (43.1%) 87 (20.7%) 
Using more than the recommended dose of 
painkillers in the last month 
  
Never 207 (70.2%) 68 (16.2%) 
Sometimes 79 (26.8%) 193 (46.0%) 
Usually 6 (2.0%) 109 (26.0%) 
Always 3 (1.0%) 50 (11.9%) 
Using painkillers for longer than the 
recommended duration in the last month 
  
Never 207 (70.2%) 61 (14.5%) 
Sometimes 44 (14.9%) 179 (42.6%) 
Usually 14 (4.7%) 129 (30.7%) 
Always 30 (10.2%) 51 (12.1%) 
Using painkillers when not in pain   
Never 268 (90.8%) 82 (19.5%) 
Sometimes 21 (7.1%) 146 (34.8%) 




4 (1.4%) 62 (14.8%) 
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Alternatives to painkillers used in the last 
month 
  
Nothing 20 (6.8%) 197 (46.9%) 
Hot water bottle 169 (57.3%) 42 (10.0%) 
A drink of water 65 (22.0%) 31 (7.4%) 
Ice 72 (24.4%) 16 (3.8%) 
Osteopathy 28 (9.5%) 27 (6.4%) 
Massage 126 (42.7%) 83 (19.8%) 
Physiotherapy 83 (28.1%) 71 (16.9%) 
Acupuncture 59 (20.0%) 18 (4.3%) 
Naturopathy 5 (1.7%) 36 (8.6%) 
Hypnotherapy 12 (4.1%) 9 (2.1%) 
Exercise 163 (55.3%) 9 (2.1%) 
Spiritual healing 18 (6.1%) 9 (2.1%) 
Traditional Chinese medicine 12 (4.1%) 4 (1.0%) 
Aquatherapy 28 (9.5%) 6 (1.4%) 
Magnetic therapy 22 (7.5%) 3 (0.7%) 
Aromatherapy 41 (13.9%) 4 (1.0%) 
Reiki 31 (10.5%) 2 (0.5%) 
Ointments, creams or gels 104 (35.3%) 25 (6.0%) 
Laser therapy 2 (0.7%) 4 (1.0%) 































Appendix H: Tables from Chapter 5 
Table 53. A comparison of demographic variables between the countries before binary 
recoding. 
 UK Egypt Germany USA Australia China 

























Widowed 2 (0.7%) 26 (6.2%) 0 (0.0%) 3 (2.1%) 2 (2.2%) 0 (0.0%) 
Divorced/separated 23 
(7.8%) 





Nationality       
British 274 
(92.9%) 
0 (0.0%) 0 (0.0%) 4 (2.7%) 5 (5.4%) 0 (0.0%) 
Egyptian 0 (0.0%) 420 
(100.0%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Albanian 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
American 2 (0.7%) 0 (0.0%) 2 (0.9%) 122 
(83.6%) 
0 (0.0%) 0 (0.0%) 
Cofe 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Czech 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Dutch 2 (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
French 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.1%) 0 (0.0%) 
German 2 (0.7%) 0 (0.0%) 173 
(79.7%) 
1 (0.7%) 0 (0.0%) 0 (0.0%) 
Hungarian 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Irish 5 (1.7%) 0 (0.0%) 0 (0.0%) 2 (1.4%) 0 (0.0%) 0 (0.0%) 
Italian 1 (0.3%) 0 (0.0%) 1 (0.5%) 2 (1.4%) 0 (0.0%) 0 (0.0%) 
Maltese 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
New Zealander 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (3.2%) 0 (0.0%) 
Polish 2 (0.7%) 0 (0.0%) 0 (0.0%) 1 (0.7%) 0 (0.0%) 0 (0.0%) 
Austrian 0 (0.0%) 0 (0.0%) 19 (8.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Belgian 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Luxembourgian 0 (0.0%) 0 (0.0%) 2 (0.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Swiss 0 (0.0%) 0 (0.0%) 19 (8.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Canadian 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 
(6.8%) 
0 (0.0%) 0 (0.0%) 
Australian 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 83 
(89.2%) 
0 (0.0%) 
Chinese 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 74 
(97.4%) 
Portuguese 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (2.6%) 
Language spoken 
at home 
      
English 289 
(98.0%) 





Arabic 1 (0.3%) 420 
(100.0%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Hungarian 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Kurdish 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Maltese 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Spanish 1 (0.3%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Welsh 2 (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Arabic 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
French 
 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.1%) 0 (0.0%) 
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Cantonese 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 49 
(64.5%) 
Mandarin 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 27 
(35.5%) 
German 0 (0.0%) 0 (0.0%) 209 
(96.3%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 
Luxembourgish 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Swiss German 0 (0.0%) 0 (0.0%) 3 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Ethnic origin       
White 281 
(95.3%) 





Egyptian 0 (0.0%) 414 
(98.6%) 
– 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Mixed 6 (2.0%) 0 (0.0%) – 5 (3.4%) 2 (2.2%) 0 (0.0%) 
Asian or Asian 
British 
3 (1.0%) 0 (0.0%) – 0 (0.0%) 0 (0.0%) 76 
(100%) 
Black or Black 
British 
1 (0.3%) 0 (0.0%) – 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Nubian 0 (0.0%) 2 (0.5%) – 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Bedouin 0 (0.0%) 4 (1.0%) – 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Any other ethnic 
group 
4 (1.4%) 0 (0.0%) – 6 (4.1%) 2 (2.2%) 0 (0.0%) 
Highest education 
level 
      


















– – – – – 
A level (UK only) 39 
(13.2%) 































39 (18%) 13 
(8.9%) 
8 (8.6%) 6 (7.9%) 
Employment 
status 
      




2 (0.9%) 6 (4.1%) 3 (3.2%) 2 (2.6%) 



































7  (3.2%) 22 
(15.1%) 


















      














Hinduism 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Islam 4 (1.4%) 282 
(67.1%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Judaism 1 (0.3%) 0 (0.0%) 0 (0.0%) 2 (1.4%) 0 (0.0%) 0 (0.0%) 














1 (0.2%) 3 (1.4%) 10 
(6.8%) 





























Table 54. A comparison of pain duration between the countries before binary recoding. 
 UK Egypt Germany USA Australia China 
Pain duration       
Less than 1 month 14 (4.7%) 126 (30.0%) 60 (27.6%) 2 (1.4%) 0 (0.0%) 37 (48.7%) 
1-3 months 4 (1.4%) 97 (23.1%) 19 (8.8%) 3 (2.1%) 3 (3.2%) 6 (7.9%) 
4-6 months 6 (2.0%) 92 (21.9%) 8 (3.7%) 2 (1.4%) 2 (2.2%) 4 (5.3%) 
7-9 months 4 (1.4%) 64 (15.2%) 5 (2.3%) 2 (1.4%) 4 (4.3%) 3 (3.9%) 
10-12 months 8 (2.7%) 19 (4.5%) 11 (5.1%) 5 (3.4%) 2 (2.2%) 7 (9.2%) 























Table 55. A comparison of painkiller use variables between the countries before binary recoding.  
 UK Egypt Germany USA Australia China 
Type of painkillers taken in the last month       
Prescription only 112 (38.0%) 183 (43.6%) 39 (18%) 37 (25.3%) 29 (31.2%) 17 (22.4%) 
Over-the-counter only 56 (19.0%) 150 (35.7%) 125 (57.6%) 14 (9.6%) 12 (12.9%) 50 (65.8%) 
Both prescription and over-the-counter  127 (43.1%) 87 (20.7%) 53 (24.4%) 95 (65.1%) 52 (55.9%) 9 (11.8%) 
Using more than the recommended dose of 
painkillers in the last month 
      
Never 207 (70.2%) 68 (16.2%) 181 (83.4%) 106 (72.6%) 52 (55.9%) 66 (86.8%) 
Sometimes 79 (26.8%) 193 (46.0%) 33 (15.2%) 34 (23.3%) 37 (39.8%) 8 (10.5%) 
Usually 6 (2.0%) 109 (26.0%) 0 (0.0%) 5 (8.4%) 1 (1.1%) 0 (0.0%) 
Always 3 (1.0%) 50 (11.9%) 3 (1.4%) 1 (0.7%) 3 (3.2%) 2 (2.6%) 
Using painkillers for longer than the recommended 
duration in the last month 
      
Never 207 (70.2%) 61 (14.5%) 182 (83.9%) 125 (85.6%) 62 (66.7%) 63 (82.9%) 
Sometimes 44 (14.9%) 179 (42.6%) 27 (12.4%) 17 (11.6%) 17 (18.3%) 11 (14.5%) 
Usually 14 (4.7%) 129 (30.7%) 3 (1.4%) 4 (2.7%) 7 (7.5%) 2 (2.6%) 
Always 30 (10.2%) 51 (12.1%) 5 (2.3%) 0 (0.0%) 7 (7.5%) 0 (0.0%) 
Using painkillers when not in pain       
Never 268 (90.8%) 82 (19.5%) 205 (94.5%) 139 (95.2%) 76 (81.7%) 61 (80.3%) 
Sometimes 21 (7.1%) 146 (34.8%) 11 (5.1%) 4 (2.7%) 12 (12.9%) 12 (15.8%) 
Usually 2 (0.7%) 130 (31.0%) 0 (0.0%) 1 (0.7%) 2 (2.2%) 2 (2.6%) 
Always 4 (1.4%) 62 (14.8%) 1 (0.5%) 2 (1.4%) 3 (3.2%) 1 (1.3%) 
Alternatives to painkillers used in the last month       
Nothing 20 (6.8%) 197 (46.9%) 11 (5.1%) 7 (4.8%) 4 (4.3%) 8 (10.5%) 
Hot water bottle 169 (57.3%) 42 (10.0%) 124 (57.1%) 56 (38.4%) 51 (54.8%) 36 (47.4%) 
A drink of water 65 (22.0%) 31 (7.4%) 99 (45.6%) 39 (26.7%) 24 (25.8%) 22 (28.9%) 
Ice 72 (24.4%) 16 (3.8%) 38 (17.5%) 61 (41.8%) 31 (33.3%) 3 (3.9%) 
Osteopathy 28 (9.5%) 27 (6.4%) 0 (0.0%) 7 (4.8%) 6 (6.5%) 5 (6.6%) 
Massage 126 (42.7%) 83 (19.8%) 0 (0.0%) 66 (45.2%) 48 (51.6%) 39 (51.3%) 
Physiotherapy 83 (28.1%) 71 (16.9%) 55 (25.3%) 23 (15.8%) 36 (38.7%) 11 (14.5%) 
Acupuncture 59 (20.0%) 18 (4.3%) 26 (12%) 21 (14.4%) 24 (25.8%) 6 (7.9%) 
Naturopathy 5 (1.7%) 36 (8.6%) 32 (14.7%) 15 (10.3%) 6 (6.5%) 2 (2.6%) 
Hypnotherapy 12 (4.1%) 9 (2.1%) 0 (0.0%) 9 (6.2%) 7 (7.5%) 4 (5.3%) 
Exercise 163 (55.3%) 9 (2.1%) 138 (63.6%) 80 (54.8%) 63 (67.7%) 17 (22.4%) 
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Spiritual healing 18 (6.1%) 9 (2.1%) 6 (2.8%) 18 (12.3%) 4 (4.3%) 1 (1.3%) 
Traditional Chinese medicine 12 (4.1%) 4 (1.0%) 11 (5.1%) 10 (6.8%) 5 (5.4%) 10 (13.2%) 
Aquatherapy 28 (9.5%) 6 (1.4%) 6 (2.8%) 27 (18.5%) 18 (19.4%) 0 (0.0%) 
Magnetic therapy 22 (7.5%) 3 (0.7%) 4 (1.8%) 5 (3.4%) 10 (10.8%) 1 (1.3%) 
Aromatherapy 41 (13.9%) 4 (1.0%) 0 (0.0%) 20 (13.7%) 6 (6.5%) 3 (3.9%) 
Reiki 31 (10.5%) 2 (0.5%) 0 (0.0%) 7 (4.8%) 1 (1.1%) 0 (0.0%) 
Ointments, creams or gels 104 (35.3%) 25 (6.0%) 86 (39.6%) 64 (43.8%) 41 (44.1%) 10 (13.2%) 
Laser therapy 2 (0.7%) 4 (1.0%) 2 (0.9%) 5 (3.4%) 1 (1.1%) 0 (0.0%) 
Other 92 (31.2%) 7 (1.7%) 46 (21.2%) 55 (37.7%) 33 (35.5%) 4 (5.3%) 
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Appendix I: Tables from Chapter 6 
Table 56. Baseline demographic variables for the non-dropout sample and the dropout 
sample before binary recoding. 
 Non-dropout sample Dropout sample 
Marital status   
Married/co-habiting 353 (69.2%) 167 (69.9%) 
Single 91 (17.8%) 47 (19.7%) 
Widowed 8 (1.6%) 2 (0.8%) 
Divorced/separated 58 (11.4%) 23 (9.6%) 
Education level   
No qualification 18 (3.5%) 18 (7.5%) 
GCSE/ O level 108 (21.2%) 67 (28.0%) 
A level 72 (14.1%) 31 (13.0%) 
Undergraduate degree 137 (26.9%) 54 (22.6%) 
Postgraduate degree 119 (23.3%) 39 (16.3%) 
Other 56 (11.0%) 30 (12.6%) 
Employment status   
Child care 8 (1.6%) 7 (2.9%) 
Employed full-time 150 (29.4%)  69 (28.9%) 
Employed part-time 94 (18.4%) 43 (18.0%) 
Retired  87 (17.1%) 25 (10.5%) 
Self-employed 33 (6.5%) 13 (5.4%) 
Unemployed 50 (9.8%) 37 (15.5%) 
Studying 13 (2.5%) 10 (4.2%) 
Other 75 (14.7%) 35 (14.6%) 
 
Table 57. Baseline pain variables for the non-dropout sample and the dropout sample 
before binary recoding. 
 Non-dropout sample Dropout sample 
Pain duration   
Less than 1 month 8 (1.6%) 7 (2.9%) 
1 – 3 months 5 (1.0%) 3 (1.3%) 
4 – 6 months 4 (0.8%) 2 (0.8%) 
7 – 9 months 0 (0.0%) 1 (0.4%) 








Table 58. Baseline painkiller use variables for the non-dropout sample and the dropout 
sample before binary recoding. 
 Non-dropout sample Dropout sample 
Type of painkillers taken 
in the last month 
  
Prescription only 186 (36.5%) 78 (32.6%) 
Over-the-counter only 69 (13.5%) 37 (15.5%) 
Both prescription and over-
the-counter  
255 (50.0%) 124 (51.9%) 
Using more than the 
recommended dose of 
painkillers in the last 
month 
  
Never 392 (76.9%) 159 (66.5%) 
Sometimes 97 (19.0%) 64 (26.8%) 
Usually 12 (2.4%) 9 (3.8%) 
Always 9 (1.8%) 7 (2.9%) 
Using painkillers for 
longer than the 
recommended duration 
in the last month 
  
Never 357 (70.0%) 150 (62.8%) 
Sometimes 98 (19.2%) 53 (22.2%) 
Usually 23 (4.5%) 18 (7.5%) 
Always 32 (6.3%) 18 (7.5%) 
Using painkillers when 
not in pain 
  
Never 433 (84.9%) 191 (79.9%) 
Sometimes 54 (10.6%) 32 (13.4%) 
Usually 7 (1.4%) 7 (2.9%) 
Always 16 (3.1%) 9 (3.8%) 
Alternatives to painkillers 
used in the last month 
  
Nothing 35 (6.9%) 28 (11.7%) 
Hot water bottle 280 (54.9%) 145 (60.7%) 
A drink of water 118 (23.1%) 51 (21.3%) 
Ice 97 (19.0%) 39 (16.3%) 
Osteopathy 36 (7.1%) 12 (5.0%) 
Massage 199 (39.0%) 93 (38.9%) 
Physiotherapy 109 (21.4%) 49 (20.5%) 
Acupuncture 60 (11.8%) 29 (12.1%) 
Naturopathy 7 (1.4%) 4 (1.7%) 
Hypnotherapy 16 (3.1%) 10 (4.2%) 
Exercise 276 (54.1%) 109 (45.6%) 
Spiritual healing 20 (3.9%) 14 (5.9%) 
Traditional Chinese 
medicine 
5 (1.0%) 5 (2.1%) 
Aquatherapy 35 (6.9%) 24 (10.0%) 
Magnetic therapy 27 (5.3%) 11 (4.6%) 
Aromatherapy 32 (6.3%) 15 (6.3%) 
Reiki 29 (5.7%) 15 (6.3%) 
Ointments, creams or gels 175 (34.3%) 91 (38.1%) 
Laser therapy 3 (0.6%) 2 (0.8%) 




Table 59. Pain variables at baseline and follow-up before binary recoding. 
 Baseline Follow-up 
Pain duration   
Less than 1 month 8 (1.6%) 2 (0.4%) 
1 – 3 months 5 (1.0%) 5 (1.0%) 
4 – 6 months 4 (0.8%) 5 (1.0%) 
7 – 9 months 0 (0.0%) 3 (0.6%) 
10 – 12 months 14 (2.7%) 10 (2.0%) 
Longer than 12 months  479 (93.9%) 485 (95.1%) 
 
Table 60. Painkiller use variables at baseline and follow-up before binary recoding. 
 Baseline Follow-up 
Type of painkillers taken 
in the last month 
  
Prescription only 186 (36.5%) 197 (38.6%) 
Over-the-counter only 69 (13.5%) 81 (15.9%) 
Both prescription and 
over-the-counter  
255 (50.0%) 232 (45.5%) 
Alternatives to 
painkillers used in the 
last month 
  
Nothing 35 (6.9%) 36 (7.1%) 
Hot water bottle 280 (54.9%) 288 (56.5%) 
A drink of water 118 (23.1%) 120 (23.5%) 
Ice 97 (19.0%) 88 (17.3%) 
Osteopathy 36 (7.1%) 29 (5.7%) 
Massage 199 (39.0%) 177 (34.7%) 
Physiotherapy 109 (21.4%) 94 (18.4%) 
Acupuncture 60 (11.8%) 49 (9.6%) 
Naturopathy 7 (1.4%) 5 (1.0%) 
Hypnotherapy 16 (3.1%) 14 (2.7%) 
Exercise 276 (54.1%) 278 (54.5%) 
Spiritual healing 20 (3.9%) 12 (2.4%) 
Traditional Chinese 
medicine 
5 (1.0%) 3 (0.6%) 
Aquatherapy 35 (6.9%) 40 (7.8%) 
Magnetic therapy 27 (5.3%) 15 (2.9%) 
Aromatherapy 32 (6.3%) 29 (5.7%) 
Reiki 29 (5.7%) 24 (4.7%) 
Ointments, creams or gels 175 (34.3%) 176 (34.5%) 
Laser therapy 3 (0.6%) 1 (0.2%) 








Appendix J: Published paper on the 
development and validation of a short-
form Pain Medication Attitudes 
Questionnaire (PMAQ-14). 
 
 
 
